<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230000970</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>143</s160></s100><s200><s210>1</s210><s211>47</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 1gggaaauaag agagaaaaga agaguaagaa gaaauauaag agccacc                   47</s400><s200><s210>2</s210><s211>57</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 2gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccacc        57</s400><s200><s210>3</s210><s211>119</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 3ugauaauagg cuggagccuc gguggccaug cuucuugccc cuugggccuc cccccagccc     60cuccuccccu uccugcaccc guacccccgu ggucuuugaa uaaagucuga gugggcggc     119</s400><s200><s210>4</s210><s211>119</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 4ugauaauagg cuggagccuc gguggccuag cuucuugccc cuugggccuc cccccagccc     60cuccuccccu uccugcaccc guacccccgu ggucuuugaa uaaagucuga gugggcggc     119</s400><s200><s210>5</s210><s211>1874</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 5gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaggccaucc uggucgugcu gcuguacacc uucaccaccg ccaacgccga cacccugugc    120aucggcuacc acgccaacaa cagcaccgac accguggaca ccgugcugga gaagaacgug    180accgugaccc acagcgugaa ccugcuggag gacaagcaca acggcaagcu gugcaagcug    240aggggagugg caccccugca ccugggcaag ugcaacaucg ccggcuggau ccugggcaac    300cccgagugcg agagccugag cacagcccgg agcuggagcu acaucgugga gaccagcaac    360agcgacaacg gcaccuguua ccccggcgac uucaucaacu acgaggagcu gcgggagcag    420cugagcagcg ugagcagcuu cgagcgguuc gagaucuucc ccaagaccag cagcuggccc    480aaccacgaca gcgacaaggg cgugacagca gccuguccac acgccggagc caagagcuuc    540uacaagaacc ugaucuggcu ggugaagaag ggcaacagcu accccaaacu gaaccagacc    600uacaucaacg acaagggcaa ggaggugcug gugcuguggg gcauccacca cccaccuacc    660aucgccgccc aggagagccu guaccagaac gccgacgccu acguguucgu gggcaccagc    720cgguacagca agaaguucaa gccagagauc gccacccggc ccaaggugag agaccaggag    780ggccggauga acuacuacug gacccuggug gagcccggag acaagauuac cuucgaggcc    840accggcaacc ugguggugcc ccgguacgcc uucaccaugg aacgggacgc uggcagcggc    900aucaucauca gcgacacucc cgugcacgac ugcaacacca ccugccagac ucccgagggc    960gcuaucaaca ccagccugcc cuuccagaac gugcacccca ucaccaucgg caagugcccc   1020aaguacguaa agagcaccaa auugcggcug gccaccggac ucaggaacgu gcccagcauc   1080caaagccggg gccuguuugg cgcaaucgcc ggcuucaucg agggcggcug gacuggcaug   1140guggacggcu gguacggcua ccaccaccag aacgaacagg ggagcggcua cgcagcugac   1200cugaagagca cccagaacgc caucgacaag aucaccaaca aggugaacag cgugaucgag   1260aagaugaaca cccaguucac cgccgugggc aaggaguuca accaccugga gaagcggauc   1320gagaaccuga acaagaaggu ggacgacggc uuccuggaca ucuggaccua caacgccgag   1380cugcugguuc ugcuggagaa cgagcggacc cuggacuauc acgacagcaa cgugaagaac   1440cuguacgaga aggugcggaa ccagcugaag aacaacgcca aggagaucgg caacggcugc   1500uucgaguucu accacaagug cgacaacacc ugcauggaga gcgugaagaa cggcaccuac   1560gacuacccca aguacagcga ggaggccaag cugaaccggg agaagaucga cggcgugaag   1620cuggagagca cccggaucua ccagauccug gccaucuaca gcaccguggc cagcagccug   1680gugcuggugg ugagccuggg cgccaucagc uucuggaugu gcagcaacgg cagccugcag   1740ugccggaucu gcaucugaua auaggcugga gccucggugg ccuagcuucu ugccccuugg   1800gccucccccc agccccuccu ccccuuccug cacccguacc cccguggucu uugaauaaag   1860ucugaguggg cggc                                                     1874</s400><s200><s210>6</s210><s211>1698</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 6augaaggcca uccuggucgu gcugcuguac accuucacca ccgccaacgc cgacacccug     60ugcaucggcu accacgccaa caacagcacc gacaccgugg acaccgugcu ggagaagaac    120gugaccguga cccacagcgu gaaccugcug gaggacaagc acaacggcaa gcugugcaag    180cugaggggag uggcaccccu gcaccugggc aagugcaaca ucgccggcug gauccugggc    240aaccccgagu gcgagagccu gagcacagcc cggagcugga gcuacaucgu ggagaccagc    300aacagcgaca acggcaccug uuaccccggc gacuucauca acuacgagga gcugcgggag    360cagcugagca gcgugagcag cuucgagcgg uucgagaucu uccccaagac cagcagcugg    420cccaaccacg acagcgacaa gggcgugaca gcagccuguc cacacgccgg agccaagagc    480uucuacaaga accugaucug gcuggugaag aagggcaaca gcuaccccaa acugaaccag    540accuacauca acgacaaggg caaggaggug cuggugcugu ggggcaucca ccacccaccu    600accaucgccg cccaggagag ccuguaccag aacgccgacg ccuacguguu cgugggcacc    660agccgguaca gcaagaaguu caagccagag aucgccaccc ggcccaaggu gagagaccag    720gagggccgga ugaacuacua cuggacccug guggagcccg gagacaagau uaccuucgag    780gccaccggca accugguggu gccccgguac gccuucacca uggaacggga cgcuggcagc    840ggcaucauca ucagcgacac ucccgugcac gacugcaaca ccaccugcca gacucccgag    900ggcgcuauca acaccagccu gcccuuccag aacgugcacc ccaucaccau cggcaagugc    960cccaaguacg uaaagagcac caaauugcgg cuggccaccg gacucaggaa cgugcccagc   1020auccaaagcc ggggccuguu uggcgcaauc gccggcuuca ucgagggcgg cuggacuggc   1080augguggacg gcugguacgg cuaccaccac cagaacgaac aggggagcgg cuacgcagcu   1140gaccugaaga gcacccagaa cgccaucgac aagaucacca acaaggugaa cagcgugauc   1200gagaagauga acacccaguu caccgccgug ggcaaggagu ucaaccaccu ggagaagcgg   1260aucgagaacc ugaacaagaa gguggacgac ggcuuccugg acaucuggac cuacaacgcc   1320gagcugcugg uucugcugga gaacgagcgg acccuggacu aucacgacag caacgugaag   1380aaccuguacg agaaggugcg gaaccagcug aagaacaacg ccaaggagau cggcaacggc   1440ugcuucgagu ucuaccacaa gugcgacaac accugcaugg agagcgugaa gaacggcacc   1500uacgacuacc ccaaguacag cgaggaggcc aagcugaacc gggagaagau cgacggcgug   1560aagcuggaga gcacccggau cuaccagauc cuggccaucu acagcaccgu ggccagcagc   1620cuggugcugg uggugagccu gggcgccauc agcuucugga ugugcagcaa cggcagccug   1680cagugccgga ucugcauc                                                 1698</s400><s200><s210>7</s210><s211>566</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 7Met Lys Ala Ile Leu Val Val Leu Leu Tyr Thr Phe Thr Thr Ala Asn1               5                   10                  15Ala Asp Thr Leu Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr            20                  25                  30Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn        35                  40                  45Leu Leu Glu Asp Lys His Asn Gly Lys Leu Cys Lys Leu Arg Gly Val    50                  55                  60Ala Pro Leu His Leu Gly Lys Cys Asn Ile Ala Gly Trp Ile Leu Gly65                  70                  75                  80Asn Pro Glu Cys Glu Ser Leu Ser Thr Ala Arg Ser Trp Ser Tyr Ile                85                  90                  95Val Glu Thr Ser Asn Ser Asp Asn Gly Thr Cys Tyr Pro Gly Asp Phe            100                 105                 110Ile Asn Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe        115                 120                 125Glu Arg Phe Glu Ile Phe Pro Lys Thr Ser Ser Trp Pro Asn His Asp    130                 135                 140Ser Asp Lys Gly Val Thr Ala Ala Cys Pro His Ala Gly Ala Lys Ser145                 150                 155                 160Phe Tyr Lys Asn Leu Ile Trp Leu Val Lys Lys Gly Asn Ser Tyr Pro                165                 170                 175Lys Leu Asn Gln Thr Tyr Ile Asn Asp Lys Gly Lys Glu Val Leu Val            180                 185                 190Leu Trp Gly Ile His His Pro Pro Thr Ile Ala Ala Gln Glu Ser Leu        195                 200                 205Tyr Gln Asn Ala Asp Ala Tyr Val Phe Val Gly Thr Ser Arg Tyr Ser    210                 215                 220Lys Lys Phe Lys Pro Glu Ile Ala Thr Arg Pro Lys Val Arg Asp Gln225                 230                 235                 240Glu Gly Arg Met Asn Tyr Tyr Trp Thr Leu Val Glu Pro Gly Asp Lys                245                 250                 255Ile Thr Phe Glu Ala Thr Gly Asn Leu Val Val Pro Arg Tyr Ala Phe            260                 265                 270Thr Met Glu Arg Asp Ala Gly Ser Gly Ile Ile Ile Ser Asp Thr Pro        275                 280                 285Val His Asp Cys Asn Thr Thr Cys Gln Thr Pro Glu Gly Ala Ile Asn    290                 295                 300Thr Ser Leu Pro Phe Gln Asn Val His Pro Ile Thr Ile Gly Lys Cys305                 310                 315                 320Pro Lys Tyr Val Lys Ser Thr Lys Leu Arg Leu Ala Thr Gly Leu Arg                325                 330                 335Asn Val Pro Ser Ile Gln Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly            340                 345                 350Phe Ile Glu Gly Gly Trp Thr Gly Met Val Asp Gly Trp Tyr Gly Tyr        355                 360                 365His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Leu Lys Ser    370                 375                 380Thr Gln Asn Ala Ile Asp Lys Ile Thr Asn Lys Val Asn Ser Val Ile385                 390                 395                 400Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu Phe Asn His                405                 410                 415Leu Glu Lys Arg Ile Glu Asn Leu Asn Lys Lys Val Asp Asp Gly Phe            420                 425                 430Leu Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu Glu Asn        435                 440                 445Glu Arg Thr Leu Asp Tyr His Asp Ser Asn Val Lys Asn Leu Tyr Glu    450                 455                 460Lys Val Arg Asn Gln Leu Lys Asn Asn Ala Lys Glu Ile Gly Asn Gly465                 470                 475                 480Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Thr Cys Met Glu Ser Val                485                 490                 495Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ala Lys Leu            500                 505                 510Asn Arg Glu Lys Ile Asp Gly Val Lys Leu Glu Ser Thr Arg Ile Tyr        515                 520                 525Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Val    530                 535                 540Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu545                 550                 555                 560Gln Cys Arg Ile Cys Ile                565</s400><s200><s210>8</s210><s211>1583</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 8gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaccccaacc agaagaucau caccaucggc agcaucugca ugaccaucgg cauggccaac    120cugauccugc aaaucggcaa caucaucagc aucuggguga gccacagcau ccagaucggc    180aaccagagcc agaucgagac cugcaacaag aacgugauca ccuacgagaa caacaccugg    240gugaaccaga ccuacgugaa caucagcaac accaacagcg ccgcucggca gucaguggcc    300agcgugaagc uggccggcaa cagcagccug ugccccguua guggcugggc caucuacagc    360aaggacaaca gcgugcggau cggcagcaag ggcgacgugu ucgugauccg ggagcccuuc    420aucagcugca gcccgcuuga gugccgcacc uucuuccuga cccagggcgc ucugcugaac    480gacaagcaca gcaacggcac caucaaggac cggagccccu aucggacccu gaugagcugc    540cccauuggcg aggugcccag ccccuacaac agccgguucg agucuguggc cuggagcgcc    600ucugccugcc acgacggcac caacuggcug accaucggga ucagcggacc cgauagcgga    660gcaguggccg ugcugaagua caacggcauc aucaccgaca ccaucaagag cuggcggaac    720aacauccugc ggacccagga gagcgagugc gccugcguga acggcagcug cuucaccauc    780augaccgacg gcccuagcga cggacaggcc agcuacaaga ucuuccggau cgagaagggc    840aagaucauca agagcgugga gaugaaggca cccaacuacc acuacgagga gugcagcugc    900uaccccgaca gcagcgagau caccugcgug ugccgggaca acuggcacgg gagcaacagg    960cccuggguga gcuucaacca gaaccuggag uaccagaugg gcuacaucug cagcggcgug   1020uucggcgaca acccacggcc caacgacaag acuggcagcu gcgguccggu gagcagcaac   1080ggcgccaacg gcgugaaggg cuucagcuuc aaguacggca acggcgugug gaucggccgg   1140accaagagca ucagcagccg gaagggcuuc gagaugaucu gggaccccaa cggcuggacc   1200ggcaccgaca acaaguucag caagaagcag gacaucgugg gcaucaacga guggagcggc   1260uacagcggca gcuucgugca gcaccccgag cugacuggcc ugaacugcau ccggcccugc   1320uucugggugg aacugauacg gggacggccc gaggagaaca ccaucuggac cagcggcagc   1380agcaucagcu ucugcggcgu ggacagcgau aucgugggcu ggagcuggcc agacggagcc   1440gagcugcccu ucaccaucga caagugauaa uaggcuggag ccucgguggc cuagcuucuu   1500gccccuuggg ccucccccca gccccuccuc cccuuccugc acccguaccc ccguggucuu   1560ugaauaaagu cugagugggc ggc                                           1583</s400><s200><s210>9</s210><s211>1407</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 9augaacccca accagaagau caucaccauc ggcagcaucu gcaugaccau cggcauggcc     60aaccugaucc ugcaaaucgg caacaucauc agcaucuggg ugagccacag cauccagauc    120ggcaaccaga gccagaucga gaccugcaac aagaacguga ucaccuacga gaacaacacc    180ugggugaacc agaccuacgu gaacaucagc aacaccaaca gcgccgcucg gcagucagug    240gccagcguga agcuggccgg caacagcagc cugugccccg uuaguggcug ggccaucuac    300agcaaggaca acagcgugcg gaucggcagc aagggcgacg uguucgugau ccgggagccc    360uucaucagcu gcagcccgcu ugagugccgc accuucuucc ugacccaggg cgcucugcug    420aacgacaagc acagcaacgg caccaucaag gaccggagcc ccuaucggac ccugaugagc    480ugccccauug gcgaggugcc cagccccuac aacagccggu ucgagucugu ggccuggagc    540gccucugccu gccacgacgg caccaacugg cugaccaucg ggaucagcgg acccgauagc    600ggagcagugg ccgugcugaa guacaacggc aucaucaccg acaccaucaa gagcuggcgg    660aacaacaucc ugcggaccca ggagagcgag ugcgccugcg ugaacggcag cugcuucacc    720aucaugaccg acggcccuag cgacggacag gccagcuaca agaucuuccg gaucgagaag    780ggcaagauca ucaagagcgu ggagaugaag gcacccaacu accacuacga ggagugcagc    840ugcuaccccg acagcagcga gaucaccugc gugugccggg acaacuggca cgggagcaac    900aggcccuggg ugagcuucaa ccagaaccug gaguaccaga ugggcuacau cugcagcggc    960guguucggcg acaacccacg gcccaacgac aagacuggca gcugcggucc ggugagcagc   1020aacggcgcca acggcgugaa gggcuucagc uucaaguacg gcaacggcgu guggaucggc   1080cggaccaaga gcaucagcag ccggaagggc uucgagauga ucugggaccc caacggcugg   1140accggcaccg acaacaaguu cagcaagaag caggacaucg ugggcaucaa cgaguggagc   1200ggcuacagcg gcagcuucgu gcagcacccc gagcugacug gccugaacug cauccggccc   1260ugcuucuggg uggaacugau acggggacgg cccgaggaga acaccaucug gaccagcggc   1320agcagcauca gcuucugcgg cguggacagc gauaucgugg gcuggagcug gccagacgga   1380gccgagcugc ccuucaccau cgacaag                                       1407</s400><s200><s210>10</s210><s211>469</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 10Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Ile Cys Met Thr1               5                   10                  15Ile Gly Met Ala Asn Leu Ile Leu Gln Ile Gly Asn Ile Ile Ser Ile            20                  25                  30Trp Val Ser His Ser Ile Gln Ile Gly Asn Gln Ser Gln Ile Glu Thr        35                  40                  45Cys Asn Lys Asn Val Ile Thr Tyr Glu Asn Asn Thr Trp Val Asn Gln    50                  55                  60Thr Tyr Val Asn Ile Ser Asn Thr Asn Ser Ala Ala Arg Gln Ser Val65                  70                  75                  80Ala Ser Val Lys Leu Ala Gly Asn Ser Ser Leu Cys Pro Val Ser Gly                85                  90                  95Trp Ala Ile Tyr Ser Lys Asp Asn Ser Val Arg Ile Gly Ser Lys Gly            100                 105                 110Asp Val Phe Val Ile Arg Glu Pro Phe Ile Ser Cys Ser Pro Leu Glu        115                 120                 125Cys Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His    130                 135                 140Ser Asn Gly Thr Ile Lys Asp Arg Ser Pro Tyr Arg Thr Leu Met Ser145                 150                 155                 160Cys Pro Ile Gly Glu Val Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser                165                 170                 175Val Ala Trp Ser Ala Ser Ala Cys His Asp Gly Thr Asn Trp Leu Thr            180                 185                 190Ile Gly Ile Ser Gly Pro Asp Ser Gly Ala Val Ala Val Leu Lys Tyr        195                 200                 205Asn Gly Ile Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Asn Ile Leu    210                 215                 220Arg Thr Gln Glu Ser Glu Cys Ala Cys Val Asn Gly Ser Cys Phe Thr225                 230                 235                 240Ile Met Thr Asp Gly Pro Ser Asp Gly Gln Ala Ser Tyr Lys Ile Phe                245                 250                 255Arg Ile Glu Lys Gly Lys Ile Ile Lys Ser Val Glu Met Lys Ala Pro            260                 265                 270Asn Tyr His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ser Ser Glu Ile        275                 280                 285Thr Cys Val Cys Arg Asp Asn Trp His Gly Ser Asn Arg Pro Trp Val    290                 295                 300Ser Phe Asn Gln Asn Leu Glu Tyr Gln Met Gly Tyr Ile Cys Ser Gly305                 310                 315                 320Val Phe Gly Asp Asn Pro Arg Pro Asn Asp Lys Thr Gly Ser Cys Gly                325                 330                 335Pro Val Ser Ser Asn Gly Ala Asn Gly Val Lys Gly Phe Ser Phe Lys            340                 345                 350Tyr Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser Ile Ser Ser Arg        355                 360                 365Lys Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Gly Thr Asp    370                 375                 380Asn Lys Phe Ser Lys Lys Gln Asp Ile Val Gly Ile Asn Glu Trp Ser385                 390                 395                 400Gly Tyr Ser Gly Ser Phe Val Gln His Pro Glu Leu Thr Gly Leu Asn                405                 410                 415Cys Ile Arg Pro Cys Phe Trp Val Glu Leu Ile Arg Gly Arg Pro Glu            420                 425                 430Glu Asn Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly Val        435                 440                 445Asp Ser Asp Ile Val Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu Pro    450                 455                 460Phe Thr Ile Asp Lys465</s400><s200><s210>11</s210><s211>1583</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 11gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaccccaacc agaagaucau caccaucggc agcaucugca ugaccaucgg cauggccaac    120cugauccugc aaaucggcaa caucaucagc aucuggguga gccacagcau ccagaucggc    180aaccagagcc agaucgagac cugcaacaag aacgugauca ccuacgagaa caacaccugg    240gugaaccaga ccuacgugaa caucagcaac accaacagcg ccgcucggca gucaguggcc    300agcgugaagc uggccggcaa cagcagccug ugccccguua guggcugggc caucuacagc    360aaggacaaca gcgugcggau cggcagcaag ggcgacgugu ucgugauccg ggagcccuuc    420aucagcugca gcccgcuuga gugccgcacc uucuuccuga cccagggcgc ucugcugaac    480gacaagcaca gcaacggcac caucaagggc cggagccccu aucggacccu gaugagcugc    540cccauuggcg aggugcccag ccccuacaac agccgguucg agucuguggc cuggagcgcc    600ucugccugcc acgacggcac caacuggcug accaucggga ucagcggacc cgauagcgga    660gcaguggccg ugcugaagua caacggcauc aucaccgaca ccaucaagag cuggcggaac    720aacauccugc ggacccagga gagcgagugc gccugcguga acggcagcug cuucaccauc    780augaccgacg gcccuagcga cggacaggcc agcuacaaga ucuuccggau cgagaagggc    840aagaucauca agagcgugga gaugaaggca cccaacuacc acuacgagga gugcagcugc    900uaccccgaca gcagcgagau caccugcgug ugccgggaca acuggcacgg gagcaacagg    960cccuggguga gcuucaacca gaaccuggag uaccagaugg gcuacaucug cagcggcgug   1020uucggcgaca acccacggcc caacgacaag acuggcagcu gcgguccggu gagcagcaac   1080ggcgccaacg gcgugaaggg cuucagcuuc aaguacggca acggcgugug gaucggccgg   1140accaagagca ucagcagccg gaagggcuuc gagaugaucu gggaccccaa cggcuggacc   1200ggcaccgaca acaaguucag caagaagcag gacaucgugg gcaucaacga guggagcggc   1260uacagcggca gcuucgugca gcaccccgag cugacuggcc ugaacugcau ccggcccugc   1320uucugggugg aacugauacg gggacggccc gaggagaaca ccaucuggac cagcggcagc   1380agcaucagcu ucugcggcgu ggacagcgau aucgugggcu ggagcuggcc agacggagcc   1440gagcugcccu ucaccaucga caagugauaa uaggcuggag ccucgguggc cuagcuucuu   1500gccccuuggg ccucccccca gccccuccuc cccuuccugc acccguaccc ccguggucuu   1560ugaauaaagu cugagugggc ggc                                           1583</s400><s200><s210>12</s210><s211>1407</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 12augaacccca accagaagau caucaccauc ggcagcaucu gcaugaccau cggcauggcc     60aaccugaucc ugcaaaucgg caacaucauc agcaucuggg ugagccacag cauccagauc    120ggcaaccaga gccagaucga gaccugcaac aagaacguga ucaccuacga gaacaacacc    180ugggugaacc agaccuacgu gaacaucagc aacaccaaca gcgccgcucg gcagucagug    240gccagcguga agcuggccgg caacagcagc cugugccccg uuaguggcug ggccaucuac    300agcaaggaca acagcgugcg gaucggcagc aagggcgacg uguucgugau ccgggagccc    360uucaucagcu gcagcccgcu ugagugccgc accuucuucc ugacccaggg cgcucugcug    420aacgacaagc acagcaacgg caccaucaag ggccggagcc ccuaucggac ccugaugagc    480ugccccauug gcgaggugcc cagccccuac aacagccggu ucgagucugu ggccuggagc    540gccucugccu gccacgacgg caccaacugg cugaccaucg ggaucagcgg acccgauagc    600ggagcagugg ccgugcugaa guacaacggc aucaucaccg acaccaucaa gagcuggcgg    660aacaacaucc ugcggaccca ggagagcgag ugcgccugcg ugaacggcag cugcuucacc    720aucaugaccg acggcccuag cgacggacag gccagcuaca agaucuuccg gaucgagaag    780ggcaagauca ucaagagcgu ggagaugaag gcacccaacu accacuacga ggagugcagc    840ugcuaccccg acagcagcga gaucaccugc gugugccggg acaacuggca cgggagcaac    900aggcccuggg ugagcuucaa ccagaaccug gaguaccaga ugggcuacau cugcagcggc    960guguucggcg acaacccacg gcccaacgac aagacuggca gcugcggucc ggugagcagc   1020aacggcgcca acggcgugaa gggcuucagc uucaaguacg gcaacggcgu guggaucggc   1080cggaccaaga gcaucagcag ccggaagggc uucgagauga ucugggaccc caacggcugg   1140accggcaccg acaacaaguu cagcaagaag caggacaucg ugggcaucaa cgaguggagc   1200ggcuacagcg gcagcuucgu gcagcacccc gagcugacug gccugaacug cauccggccc   1260ugcuucuggg uggaacugau acggggacgg cccgaggaga acaccaucug gaccagcggc   1320agcagcauca gcuucugcgg cguggacagc gauaucgugg gcuggagcug gccagacgga   1380gccgagcugc ccuucaccau cgacaag                                       1407</s400><s200><s210>13</s210><s211>469</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 13Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Ile Cys Met Thr1               5                   10                  15Ile Gly Met Ala Asn Leu Ile Leu Gln Ile Gly Asn Ile Ile Ser Ile            20                  25                  30Trp Val Ser His Ser Ile Gln Ile Gly Asn Gln Ser Gln Ile Glu Thr        35                  40                  45Cys Asn Lys Asn Val Ile Thr Tyr Glu Asn Asn Thr Trp Val Asn Gln    50                  55                  60Thr Tyr Val Asn Ile Ser Asn Thr Asn Ser Ala Ala Arg Gln Ser Val65                  70                  75                  80Ala Ser Val Lys Leu Ala Gly Asn Ser Ser Leu Cys Pro Val Ser Gly                85                  90                  95Trp Ala Ile Tyr Ser Lys Asp Asn Ser Val Arg Ile Gly Ser Lys Gly            100                 105                 110Asp Val Phe Val Ile Arg Glu Pro Phe Ile Ser Cys Ser Pro Leu Glu        115                 120                 125Cys Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His    130                 135                 140Ser Asn Gly Thr Ile Lys Gly Arg Ser Pro Tyr Arg Thr Leu Met Ser145                 150                 155                 160Cys Pro Ile Gly Glu Val Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser                165                 170                 175Val Ala Trp Ser Ala Ser Ala Cys His Asp Gly Thr Asn Trp Leu Thr            180                 185                 190Ile Gly Ile Ser Gly Pro Asp Ser Gly Ala Val Ala Val Leu Lys Tyr        195                 200                 205Asn Gly Ile Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Asn Ile Leu    210                 215                 220Arg Thr Gln Glu Ser Glu Cys Ala Cys Val Asn Gly Ser Cys Phe Thr225                 230                 235                 240Ile Met Thr Asp Gly Pro Ser Asp Gly Gln Ala Ser Tyr Lys Ile Phe                245                 250                 255Arg Ile Glu Lys Gly Lys Ile Ile Lys Ser Val Glu Met Lys Ala Pro            260                 265                 270Asn Tyr His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ser Ser Glu Ile        275                 280                 285Thr Cys Val Cys Arg Asp Asn Trp His Gly Ser Asn Arg Pro Trp Val    290                 295                 300Ser Phe Asn Gln Asn Leu Glu Tyr Gln Met Gly Tyr Ile Cys Ser Gly305                 310                 315                 320Val Phe Gly Asp Asn Pro Arg Pro Asn Asp Lys Thr Gly Ser Cys Gly                325                 330                 335Pro Val Ser Ser Asn Gly Ala Asn Gly Val Lys Gly Phe Ser Phe Lys            340                 345                 350Tyr Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser Ile Ser Ser Arg        355                 360                 365Lys Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Gly Thr Asp    370                 375                 380Asn Lys Phe Ser Lys Lys Gln Asp Ile Val Gly Ile Asn Glu Trp Ser385                 390                 395                 400Gly Tyr Ser Gly Ser Phe Val Gln His Pro Glu Leu Thr Gly Leu Asn                405                 410                 415Cys Ile Arg Pro Cys Phe Trp Val Glu Leu Ile Arg Gly Arg Pro Glu            420                 425                 430Glu Asn Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly Val        435                 440                 445Asp Ser Asp Ile Val Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu Pro    450                 455                 460Phe Thr Ile Asp Lys465</s400><s200><s210>14</s210><s211>1874</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 14gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aagaccauca ucgcccugag cuacauccug ugccugggcu ucacccagaa gauccccggc    120aacgauaaca gcaccgccac ccugugucug ggacaccacg ccgugcccaa cggcaccauc    180gugaagacua ucaccaacga ccggaucgag gugaccaacg ccaccgagcu ggugcagaac    240agcagcaucg gcgagaucug cgacagcccu caccagaucc uggacggcgg caacugcacc    300cugaucgacg cacugcuggg cgacccucag ugcgacggcu uucagaacaa gaagugggac    360cuguucgugg agagaucgcg ggccuacagc aacugcuacc ccuacgacgu ccccgacuac    420gcaagccuga gaagccucgu ggccucaagc ggcacccugg aguucaagaa cgagagcuuc    480aacugggccg gcgugaccca gaacggcaag ucauucagcu gcauccgggg cuccagcagc    540agcuucuucu cacggcugaa cuggcugacc caccugaacu acaccuaccc cgcccugaac    600gugaccaugc ccaacaagga gcaguucgac aagcuguaca ucuggggagu gcaccauccc    660ggcaccgaca aggaccagau uagccuguac gcccagucua gcggccggau caccgugagc    720accaagcgga gccagcaggc cgugaucccc aacaucggcu cucggcccag aauccgggac    780auccccagcc ggaucagcau cuacuggacc auugugaagc ccggcgacau ccugcugauc    840aacuccaccg gcaaccugau cgccccucgg ggcuauuuca agauccggag cggcaagagc    900agcaucaugc ggagcgacgc cccuaucggc aagugcaaga gcgagugcau cacacccaac    960ggaagcaucc ccaacgacaa gcccuuccag aacgugaacc ggauaaccua cggcgccugc   1020ccuagauacg ugaagcagaa cacccugaag cuggccaccg gcaugcggaa cgugcccgag   1080aagcagacuc ggggcaucuu cggcgccauc gccggcuuca ucgagaacgg cugggagggc   1140augguggacg gcugguacgg cuuccggcac cagaacucug agggcagagg acaggccgca   1200gaccugaaga gcacccaggc cgccaucgac cagaucaacg gcaagcugaa ccggcugauc   1260ggcaagacca acgagaaguu ccaccagauc gagaaggagu ucagcgaggu ggagggcagg   1320guacaggacc uggagaagua cguggaggac accaagaucg accuguggag cuacaacgcc   1380gagcugcugg uagcccugga gaaccagcac accaucgacc ugaccgacag cgagaugaac   1440aagcuguucg agaagaccaa gaagcagcug cgggagaacg ccgaggacau gggcaacggc   1500ugcuucaaga ucuaccacaa gugcgacaac gccugcaucg gcagcauccg gaacgagacc   1560uacgaccaca acguguaccg ggacgaggcc cugaacaacc gguuccagau caagggcgug   1620gagcugaaga gcggcuacaa ggacuggauc cuguggauca gcuucgccau cuccugcuuc   1680cugcugugcg uggcccugcu ggguuucauc augugggccu gccagaaggg caacauccgg   1740ugcaacaucu gcaucugaua auaggcugga gccucggugg ccuagcuucu ugccccuugg   1800gccucccccc agccccuccu ccccuuccug cacccguacc cccguggucu uugaauaaag   1860ucugaguggg cggc                                                     1874</s400><s200><s210>15</s210><s211>1698</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 15augaagacca ucaucgcccu gagcuacauc cugugccugg gcuucaccca gaagaucccc     60ggcaacgaua acagcaccgc cacccugugu cugggacacc acgccgugcc caacggcacc    120aucgugaaga cuaucaccaa cgaccggauc gaggugacca acgccaccga gcuggugcag    180aacagcagca ucggcgagau cugcgacagc ccucaccaga uccuggacgg cggcaacugc    240acccugaucg acgcacugcu gggcgacccu cagugcgacg gcuuucagaa caagaagugg    300gaccuguucg uggagagauc gcgggccuac agcaacugcu accccuacga cguccccgac    360uacgcaagcc ugagaagccu cguggccuca agcggcaccc uggaguucaa gaacgagagc    420uucaacuggg ccggcgugac ccagaacggc aagucauuca gcugcauccg gggcuccagc    480agcagcuucu ucucacggcu gaacuggcug acccaccuga acuacaccua ccccgcccug    540aacgugacca ugcccaacaa ggagcaguuc gacaagcugu acaucugggg agugcaccau    600cccggcaccg acaaggacca gauuagccug uacgcccagu cuagcggccg gaucaccgug    660agcaccaagc ggagccagca ggccgugauc cccaacaucg gcucucggcc cagaauccgg    720gacaucccca gccggaucag caucuacugg accauuguga agcccggcga cauccugcug    780aucaacucca ccggcaaccu gaucgccccu cggggcuauu ucaagauccg gagcggcaag    840agcagcauca ugcggagcga cgccccuauc ggcaagugca agagcgagug caucacaccc    900aacggaagca uccccaacga caagcccuuc cagaacguga accggauaac cuacggcgcc    960ugcccuagau acgugaagca gaacacccug aagcuggcca ccggcaugcg gaacgugccc   1020gagaagcaga cucggggcau cuucggcgcc aucgccggcu ucaucgagaa cggcugggag   1080ggcauggugg acggcuggua cggcuuccgg caccagaacu cugagggcag aggacaggcc   1140gcagaccuga agagcaccca ggccgccauc gaccagauca acggcaagcu gaaccggcug   1200aucggcaaga ccaacgagaa guuccaccag aucgagaagg aguucagcga gguggagggc   1260aggguacagg accuggagaa guacguggag gacaccaaga ucgaccugug gagcuacaac   1320gccgagcugc ugguagcccu ggagaaccag cacaccaucg accugaccga cagcgagaug   1380aacaagcugu ucgagaagac caagaagcag cugcgggaga acgccgagga caugggcaac   1440ggcugcuuca agaucuacca caagugcgac aacgccugca ucggcagcau ccggaacgag   1500accuacgacc acaacgugua ccgggacgag gcccugaaca accgguucca gaucaagggc   1560guggagcuga agagcggcua caaggacugg auccugugga ucagcuucgc caucuccugc   1620uuccugcugu gcguggcccu gcuggguuuc aucauguggg ccugccagaa gggcaacauc   1680cggugcaaca ucugcauc                                                 1698</s400><s200><s210>16</s210><s211>566</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 16Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys Leu Gly Phe Thr1               5                   10                  15Gln Lys Ile Pro Gly Asn Asp Asn Ser Thr Ala Thr Leu Cys Leu Gly            20                  25                  30His His Ala Val Pro Asn Gly Thr Ile Val Lys Thr Ile Thr Asn Asp        35                  40                  45Arg Ile Glu Val Thr Asn Ala Thr Glu Leu Val Gln Asn Ser Ser Ile    50                  55                  60Gly Glu Ile Cys Asp Ser Pro His Gln Ile Leu Asp Gly Gly Asn Cys65                  70                  75                  80Thr Leu Ile Asp Ala Leu Leu Gly Asp Pro Gln Cys Asp Gly Phe Gln                85                  90                  95Asn Lys Lys Trp Asp Leu Phe Val Glu Arg Ser Arg Ala Tyr Ser Asn            100                 105                 110Cys Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Arg Ser Leu Val        115                 120                 125Ala Ser Ser Gly Thr Leu Glu Phe Lys Asn Glu Ser Phe Asn Trp Ala    130                 135                 140Gly Val Thr Gln Asn Gly Lys Ser Phe Ser Cys Ile Arg Gly Ser Ser145                 150                 155                 160Ser Ser Phe Phe Ser Arg Leu Asn Trp Leu Thr His Leu Asn Tyr Thr                165                 170                 175Tyr Pro Ala Leu Asn Val Thr Met Pro Asn Lys Glu Gln Phe Asp Lys            180                 185                 190Leu Tyr Ile Trp Gly Val His His Pro Gly Thr Asp Lys Asp Gln Ile        195                 200                 205Ser Leu Tyr Ala Gln Ser Ser Gly Arg Ile Thr Val Ser Thr Lys Arg    210                 215                 220Ser Gln Gln Ala Val Ile Pro Asn Ile Gly Ser Arg Pro Arg Ile Arg225                 230                 235                 240Asp Ile Pro Ser Arg Ile Ser Ile Tyr Trp Thr Ile Val Lys Pro Gly                245                 250                 255Asp Ile Leu Leu Ile Asn Ser Thr Gly Asn Leu Ile Ala Pro Arg Gly            260                 265                 270Tyr Phe Lys Ile Arg Ser Gly Lys Ser Ser Ile Met Arg Ser Asp Ala        275                 280                 285Pro Ile Gly Lys Cys Lys Ser Glu Cys Ile Thr Pro Asn Gly Ser Ile    290                 295                 300Pro Asn Asp Lys Pro Phe Gln Asn Val Asn Arg Ile Thr Tyr Gly Ala305                 310                 315                 320Cys Pro Arg Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr Gly Met                325                 330                 335Arg Asn Val Pro Glu Lys Gln Thr Arg Gly Ile Phe Gly Ala Ile Ala            340                 345                 350Gly Phe Ile Glu Asn Gly Trp Glu Gly Met Val Asp Gly Trp Tyr Gly        355                 360                 365Phe Arg His Gln Asn Ser Glu Gly Arg Gly Gln Ala Ala Asp Leu Lys    370                 375                 380Ser Thr Gln Ala Ala Ile Asp Gln Ile Asn Gly Lys Leu Asn Arg Leu385                 390                 395                 400Ile Gly Lys Thr Asn Glu Lys Phe His Gln Ile Glu Lys Glu Phe Ser                405                 410                 415Glu Val Glu Gly Arg Val Gln Asp Leu Glu Lys Tyr Val Glu Asp Thr            420                 425                 430Lys Ile Asp Leu Trp Ser Tyr Asn Ala Glu Leu Leu Val Ala Leu Glu        435                 440                 445Asn Gln His Thr Ile Asp Leu Thr Asp Ser Glu Met Asn Lys Leu Phe    450                 455                 460Glu Lys Thr Lys Lys Gln Leu Arg Glu Asn Ala Glu Asp Met Gly Asn465                 470                 475                 480Gly Cys Phe Lys Ile Tyr His Lys Cys Asp Asn Ala Cys Ile Gly Ser                485                 490                 495Ile Arg Asn Glu Thr Tyr Asp His Asn Val Tyr Arg Asp Glu Ala Leu            500                 505                 510Asn Asn Arg Phe Gln Ile Lys Gly Val Glu Leu Lys Ser Gly Tyr Lys        515                 520                 525Asp Trp Ile Leu Trp Ile Ser Phe Ala Ile Ser Cys Phe Leu Leu Cys    530                 535                 540Val Ala Leu Leu Gly Phe Ile Met Trp Ala Cys Gln Lys Gly Asn Ile545                 550                 555                 560Arg Cys Asn Ile Cys Ile                565</s400><s200><s210>17</s210><s211>1583</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 17gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aacccgaacc agaagaucau caccaucggc agcgugagcc ugaccaucag caccaucugc    120uucuucaugc agaucgccau ccugaucacc accgugaccc ugcacuucaa gcaguacgag    180uucaacagcc ugcccaacaa ccaggugaug cugugcgagc ccaccaucau cgagcggaac    240aucaccgaga ucguguaccu gaccaacacc accaucgaga aggagaucug ccccaagccc    300gccgaguacc ggaacuggag caagccccag ugcggcauca ccggcuucgc cccauucagc    360aaggacaaca gcaucagacu gagugccggc ggcgacaucu gggugacccg ggagcccuac    420gugagcugcg accuggacaa gugcuaccag uucgcccugg gacagggcac cacccugaac    480aacgugcaca gcaacaacac ugugcgggac cggaccccau accggacccu gcugaugaac    540gagcugggcg ugcccuucca ccugggcacc aagcaggugu gcaucgccug gagcagcagc    600agcugccacg acggcaaggc cuggcugcac gugugcauua ccggcgacga caagaacgcc    660accgccagcu ucaucuacaa cggcaggcug guggacagcg uggugagcug gagcaacgac    720auccugcgga cccaggagag cgagugcgug ugcaucaacg gcaccugcac cguggugaug    780acugacggca acgccaccgg caaggccgac accaagaucc uguucaucga ggaggggaag    840aucgugcaca ccagcaagcu gucuggcagc gcccagcacg uggaggagug cagcugcuac    900ccucgguacc ccggcgugag gugcgugugc cgggacaacu ggaagggcag caaccggccc    960aucaucgaca ucaacaucaa ggaccacagc auagugagca gcuacgugug cagcggucug   1020gugggcgaca cuccccggaa gagcgacagc agcuccagca gccacugccu gaaccccaac   1080aacgaggagg guggucacgg cgugaagggc ugggccuucg acgacggcaa cgacgugugg   1140augggccgga ccaucaacga gaccagcaga cugggcuacg agaccuucaa ggugguggag   1200ggcuggagca aucccaagag caagcugcag aucaaccggc aggugaucgu cgaucggggc   1260gaucggagcg gcuacagcgg caucuucagc guggagggca agagcugcau caaccggugc   1320uucuacgugg agcugauccg gggccggaag gaggagaccg aggugcugug gaccagcaac   1380agcaucgugg uguucugcgg caccagcggc accuacggca ccggauccug gccagacggc   1440gccgaucuga accugaugca caucugauaa uaggcuggag ccucgguggc cuagcuucuu   1500gccccuuggg ccucccccca gccccuccuc cccuuccugc acccguaccc ccguggucuu   1560ugaauaaagu cugagugggc ggc                                           1583</s400><s200><s210>18</s210><s211>1407</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 18augaacccga accagaagau caucaccauc ggcagcguga gccugaccau cagcaccauc     60ugcuucuuca ugcagaucgc cauccugauc accaccguga cccugcacuu caagcaguac    120gaguucaaca gccugcccaa caaccaggug augcugugcg agcccaccau caucgagcgg    180aacaucaccg agaucgugua ccugaccaac accaccaucg agaaggagau cugccccaag    240cccgccgagu accggaacug gagcaagccc cagugcggca ucaccggcuu cgccccauuc    300agcaaggaca acagcaucag acugagugcc ggcggcgaca ucugggugac ccgggagccc    360uacgugagcu gcgaccugga caagugcuac caguucgccc ugggacaggg caccacccug    420aacaacgugc acagcaacaa cacugugcgg gaccggaccc cauaccggac ccugcugaug    480aacgagcugg gcgugcccuu ccaccugggc accaagcagg ugugcaucgc cuggagcagc    540agcagcugcc acgacggcaa ggccuggcug cacgugugca uuaccggcga cgacaagaac    600gccaccgcca gcuucaucua caacggcagg cugguggaca gcguggugag cuggagcaac    660gacauccugc ggacccagga gagcgagugc gugugcauca acggcaccug caccguggug    720augacugacg gcaacgccac cggcaaggcc gacaccaaga uccuguucau cgaggagggg    780aagaucgugc acaccagcaa gcugucuggc agcgcccagc acguggagga gugcagcugc    840uacccucggu accccggcgu gaggugcgug ugccgggaca acuggaaggg cagcaaccgg    900cccaucaucg acaucaacau caaggaccac agcauaguga gcagcuacgu gugcagcggu    960cuggugggcg acacuccccg gaagagcgac agcagcucca gcagccacug ccugaacccc   1020aacaacgagg agggugguca cggcgugaag ggcugggccu ucgacgacgg caacgacgug   1080uggaugggcc ggaccaucaa cgagaccagc agacugggcu acgagaccuu caagguggug   1140gagggcugga gcaaucccaa gagcaagcug cagaucaacc ggcaggugau cgucgaucgg   1200ggcgaucgga gcggcuacag cggcaucuuc agcguggagg gcaagagcug caucaaccgg   1260ugcuucuacg uggagcugau ccggggccgg aaggaggaga ccgaggugcu guggaccagc   1320aacagcaucg ugguguucug cggcaccagc ggcaccuacg gcaccggauc cuggccagac   1380ggcgccgauc ugaaccugau gcacauc                                       1407</s400><s200><s210>19</s210><s211>469</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 19Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Val Ser Leu Thr1               5                   10                  15Ile Ser Thr Ile Cys Phe Phe Met Gln Ile Ala Ile Leu Ile Thr Thr            20                  25                  30Val Thr Leu His Phe Lys Gln Tyr Glu Phe Asn Ser Leu Pro Asn Asn        35                  40                  45Gln Val Met Leu Cys Glu Pro Thr Ile Ile Glu Arg Asn Ile Thr Glu    50                  55                  60Ile Val Tyr Leu Thr Asn Thr Thr Ile Glu Lys Glu Ile Cys Pro Lys65                  70                  75                  80Pro Ala Glu Tyr Arg Asn Trp Ser Lys Pro Gln Cys Gly Ile Thr Gly                85                  90                  95Phe Ala Pro Phe Ser Lys Asp Asn Ser Ile Arg Leu Ser Ala Gly Gly            100                 105                 110Asp Ile Trp Val Thr Arg Glu Pro Tyr Val Ser Cys Asp Leu Asp Lys        115                 120                 125Cys Tyr Gln Phe Ala Leu Gly Gln Gly Thr Thr Leu Asn Asn Val His    130                 135                 140Ser Asn Asn Thr Val Arg Asp Arg Thr Pro Tyr Arg Thr Leu Leu Met145                 150                 155                 160Asn Glu Leu Gly Val Pro Phe His Leu Gly Thr Lys Gln Val Cys Ile                165                 170                 175Ala Trp Ser Ser Ser Ser Cys His Asp Gly Lys Ala Trp Leu His Val            180                 185                 190Cys Ile Thr Gly Asp Asp Lys Asn Ala Thr Ala Ser Phe Ile Tyr Asn        195                 200                 205Gly Arg Leu Val Asp Ser Val Val Ser Trp Ser Asn Asp Ile Leu Arg    210                 215                 220Thr Gln Glu Ser Glu Cys Val Cys Ile Asn Gly Thr Cys Thr Val Val225                 230                 235                 240Met Thr Asp Gly Asn Ala Thr Gly Lys Ala Asp Thr Lys Ile Leu Phe                245                 250                 255Ile Glu Glu Gly Lys Ile Val His Thr Ser Lys Leu Ser Gly Ser Ala            260                 265                 270Gln His Val Glu Glu Cys Ser Cys Tyr Pro Arg Tyr Pro Gly Val Arg        275                 280                 285Cys Val Cys Arg Asp Asn Trp Lys Gly Ser Asn Arg Pro Ile Ile Asp    290                 295                 300Ile Asn Ile Lys Asp His Ser Ile Val Ser Ser Tyr Val Cys Ser Gly305                 310                 315                 320Leu Val Gly Asp Thr Pro Arg Lys Ser Asp Ser Ser Ser Ser Ser His                325                 330                 335Cys Leu Asn Pro Asn Asn Glu Glu Gly Gly His Gly Val Lys Gly Trp            340                 345                 350Ala Phe Asp Asp Gly Asn Asp Val Trp Met Gly Arg Thr Ile Asn Glu        355                 360                 365Thr Ser Arg Leu Gly Tyr Glu Thr Phe Lys Val Val Glu Gly Trp Ser    370                 375                 380Asn Pro Lys Ser Lys Leu Gln Ile Asn Arg Gln Val Ile Val Asp Arg385                 390                 395                 400Gly Asp Arg Ser Gly Tyr Ser Gly Ile Phe Ser Val Glu Gly Lys Ser                405                 410                 415Cys Ile Asn Arg Cys Phe Tyr Val Glu Leu Ile Arg Gly Arg Lys Glu            420                 425                 430Glu Thr Glu Val Leu Trp Thr Ser Asn Ser Ile Val Val Phe Cys Gly        435                 440                 445Thr Ser Gly Thr Tyr Gly Thr Gly Ser Trp Pro Asp Gly Ala Asp Leu    450                 455                 460Asn Leu Met His Ile465</s400><s200><s210>20</s210><s211>1583</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 20gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aacccgaacc agaagaucau caccaucggc agcgugagcc ugaccaucag caccaucugc    120uucuucaugc agaucgccau ccugaucacc accgugaccc ugcacuucaa gcaguacgag    180uucaacagcc ugcccaacaa ccaggugaug cugugcgagc ccaccaucau cgagcggaac    240aucaccgaga ucguguaccu gaccaacacc accaucgaga aggagaucug ccccaagccc    300gccgaguacc ggaacuggag caagccccag ugcggcauca ccggcuucgc cccauucagc    360aaggacaaca gcaucagacu gagugccggc ggcgacaucu gggugacccg ggagcccuac    420gugagcugcg accuggacaa gugcuaccag uucgcccugg gacagggcac cacccugaac    480aacgugcaca gcaacaacac ugugcggggc cggaccccau accggacccu gcugaugaac    540gagcugggcg ugcccuucca ccugggcacc aagcaggugu gcaucgccug gagcagcagc    600agcugccacg acggcaaggc cuggcugcac gugugcauua ccggcgacga caagaacgcc    660accgccagcu ucaucuacaa cggcaggcug guggacagcg uggugagcug gagcaacgac    720auccugcgga cccaggagag cgagugcgug ugcaucaacg gcaccugcac cguggugaug    780acugacggca acgccaccgg caaggccgac accaagaucc uguucaucga ggaggggaag    840aucgugcaca ccagcaagcu gucuggcagc gcccagcacg uggaggagug cagcugcuac    900ccucgguacc ccggcgugag gugcgugugc cgggacaacu ggaagggcag caaccggccc    960aucaucgaca ucaacaucaa ggaccacagc auagugagca gcuacgugug cagcggucug   1020gugggcgaca cuccccggaa gagcgacagc agcuccagca gccacugccu gaaccccaac   1080aacgaggagg guggucacgg cgugaagggc ugggccuucg acgacggcaa cgacgugugg   1140augggccgga ccaucaacga gaccagcaga cugggcuacg agaccuucaa ggugguggag   1200ggcuggagca aucccaagag caagcugcag aucaaccggc aggugaucgu cgaucggggc   1260gaucggagcg gcuacagcgg caucuucagc guggagggca agagcugcau caaccggugc   1320uucuacgugg agcugauccg gggccggaag gaggagaccg aggugcugug gaccagcaac   1380agcaucgugg uguucugcgg caccagcggc accuacggca ccggauccug gccagacggc   1440gccgaucuga accugaugca caucugauaa uaggcuggag ccucgguggc cuagcuucuu   1500gccccuuggg ccucccccca gccccuccuc cccuuccugc acccguaccc ccguggucuu   1560ugaauaaagu cugagugggc ggc                                           1583</s400><s200><s210>21</s210><s211>1407</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 21augaacccga accagaagau caucaccauc ggcagcguga gccugaccau cagcaccauc     60ugcuucuuca ugcagaucgc cauccugauc accaccguga cccugcacuu caagcaguac    120gaguucaaca gccugcccaa caaccaggug augcugugcg agcccaccau caucgagcgg    180aacaucaccg agaucgugua ccugaccaac accaccaucg agaaggagau cugccccaag    240cccgccgagu accggaacug gagcaagccc cagugcggca ucaccggcuu cgccccauuc    300agcaaggaca acagcaucag acugagugcc ggcggcgaca ucugggugac ccgggagccc    360uacgugagcu gcgaccugga caagugcuac caguucgccc ugggacaggg caccacccug    420aacaacgugc acagcaacaa cacugugcgg ggccggaccc cauaccggac ccugcugaug    480aacgagcugg gcgugcccuu ccaccugggc accaagcagg ugugcaucgc cuggagcagc    540agcagcugcc acgacggcaa ggccuggcug cacgugugca uuaccggcga cgacaagaac    600gccaccgcca gcuucaucua caacggcagg cugguggaca gcguggugag cuggagcaac    660gacauccugc ggacccagga gagcgagugc gugugcauca acggcaccug caccguggug    720augacugacg gcaacgccac cggcaaggcc gacaccaaga uccuguucau cgaggagggg    780aagaucgugc acaccagcaa gcugucuggc agcgcccagc acguggagga gugcagcugc    840uacccucggu accccggcgu gaggugcgug ugccgggaca acuggaaggg cagcaaccgg    900cccaucaucg acaucaacau caaggaccac agcauaguga gcagcuacgu gugcagcggu    960cuggugggcg acacuccccg gaagagcgac agcagcucca gcagccacug ccugaacccc   1020aacaacgagg agggugguca cggcgugaag ggcugggccu ucgacgacgg caacgacgug   1080uggaugggcc ggaccaucaa cgagaccagc agacugggcu acgagaccuu caagguggug   1140gagggcugga gcaaucccaa gagcaagcug cagaucaacc ggcaggugau cgucgaucgg   1200ggcgaucgga gcggcuacag cggcaucuuc agcguggagg gcaagagcug caucaaccgg   1260ugcuucuacg uggagcugau ccggggccgg aaggaggaga ccgaggugcu guggaccagc   1320aacagcaucg ugguguucug cggcaccagc ggcaccuacg gcaccggauc cuggccagac   1380ggcgccgauc ugaaccugau gcacauc                                       1407</s400><s200><s210>22</s210><s211>469</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 22Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Val Ser Leu Thr1               5                   10                  15Ile Ser Thr Ile Cys Phe Phe Met Gln Ile Ala Ile Leu Ile Thr Thr            20                  25                  30Val Thr Leu His Phe Lys Gln Tyr Glu Phe Asn Ser Leu Pro Asn Asn        35                  40                  45Gln Val Met Leu Cys Glu Pro Thr Ile Ile Glu Arg Asn Ile Thr Glu    50                  55                  60Ile Val Tyr Leu Thr Asn Thr Thr Ile Glu Lys Glu Ile Cys Pro Lys65                  70                  75                  80Pro Ala Glu Tyr Arg Asn Trp Ser Lys Pro Gln Cys Gly Ile Thr Gly                85                  90                  95Phe Ala Pro Phe Ser Lys Asp Asn Ser Ile Arg Leu Ser Ala Gly Gly            100                 105                 110Asp Ile Trp Val Thr Arg Glu Pro Tyr Val Ser Cys Asp Leu Asp Lys        115                 120                 125Cys Tyr Gln Phe Ala Leu Gly Gln Gly Thr Thr Leu Asn Asn Val His    130                 135                 140Ser Asn Asn Thr Val Arg Gly Arg Thr Pro Tyr Arg Thr Leu Leu Met145                 150                 155                 160Asn Glu Leu Gly Val Pro Phe His Leu Gly Thr Lys Gln Val Cys Ile                165                 170                 175Ala Trp Ser Ser Ser Ser Cys His Asp Gly Lys Ala Trp Leu His Val            180                 185                 190Cys Ile Thr Gly Asp Asp Lys Asn Ala Thr Ala Ser Phe Ile Tyr Asn        195                 200                 205Gly Arg Leu Val Asp Ser Val Val Ser Trp Ser Asn Asp Ile Leu Arg    210                 215                 220Thr Gln Glu Ser Glu Cys Val Cys Ile Asn Gly Thr Cys Thr Val Val225                 230                 235                 240Met Thr Asp Gly Asn Ala Thr Gly Lys Ala Asp Thr Lys Ile Leu Phe                245                 250                 255Ile Glu Glu Gly Lys Ile Val His Thr Ser Lys Leu Ser Gly Ser Ala            260                 265                 270Gln His Val Glu Glu Cys Ser Cys Tyr Pro Arg Tyr Pro Gly Val Arg        275                 280                 285Cys Val Cys Arg Asp Asn Trp Lys Gly Ser Asn Arg Pro Ile Ile Asp    290                 295                 300Ile Asn Ile Lys Asp His Ser Ile Val Ser Ser Tyr Val Cys Ser Gly305                 310                 315                 320Leu Val Gly Asp Thr Pro Arg Lys Ser Asp Ser Ser Ser Ser Ser His                325                 330                 335Cys Leu Asn Pro Asn Asn Glu Glu Gly Gly His Gly Val Lys Gly Trp            340                 345                 350Ala Phe Asp Asp Gly Asn Asp Val Trp Met Gly Arg Thr Ile Asn Glu        355                 360                 365Thr Ser Arg Leu Gly Tyr Glu Thr Phe Lys Val Val Glu Gly Trp Ser    370                 375                 380Asn Pro Lys Ser Lys Leu Gln Ile Asn Arg Gln Val Ile Val Asp Arg385                 390                 395                 400Gly Asp Arg Ser Gly Tyr Ser Gly Ile Phe Ser Val Glu Gly Lys Ser                405                 410                 415Cys Ile Asn Arg Cys Phe Tyr Val Glu Leu Ile Arg Gly Arg Lys Glu            420                 425                 430Glu Thr Glu Val Leu Trp Thr Ser Asn Ser Ile Val Val Phe Cys Gly        435                 440                 445Thr Ser Gly Thr Tyr Gly Thr Gly Ser Trp Pro Asp Gly Ala Asp Leu    450                 455                 460Asn Leu Met His Ile465</s400><s200><s210>23</s210><s211>1921</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 23gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaggccauca ucgugcuguu aaugguggug accagcaacg ccgaccggau cugcaccggc    120aucaccucua gcaacagccc ucacguggug aagaccgcca cacagggcga ggugaacgug    180accggcguga uuccccugac caccaccccu accaagagcc acuucgccaa ccugaaggga    240accgagaccc ggggcaagcu gugucccaag ugccugaacu gcaccgaccu ggacguggcc    300cugggcagac ccaagugcac cggcaagauc cccagcgccc gggugucuau ccugcacgaa    360gugcggcccg ugacuagcgg cugcuucccc aucaugcacg accggaccaa gauccggcag    420cugcccaacc ugcugcgggg cuacgagcac gugcggcuga gcacccacaa cgugaucaac    480gccgaagacg cacccgggag accauacgag aucggcacca gcggcucuug ccccaacauc    540accaacggca acggcuucuu cgcuaccaug gccugggccg ugccaaagaa caagacugcc    600accaacccuc ugaccaucga ggugcccuac aucugcaccg agggcgagga ccagaucacc    660guguggggcu uccacagcga cagcgagacc cagauggcca agcuguacgg cgacagcaag    720ccccagaagu ucaccagcag cgccaacggc gugaccaccc acuacgugag ccagaucggc    780ggcuucccca accagaccga ggacggcggc uuaccccaga gcggccggau cgugguggac    840uacauggugc agaagagcgg caagaccggc accaucaccu accagcgggg cauccugcug    900ccacagaagg uguggugcgc cucagggcgg ucaaagguga ucaagggcag ccugccacug    960auuggcgagg ccgacugccu gcacgagaag uacggcggcc ugaacaagag caagcccuac   1020uacaccggcg agcacgccaa ggcaaucggc aacugcccca ucugggugaa gacaccccug   1080aagcuggcca acggcaccaa guaccggcca cccgccaaac ugcugaagga gcggggcuuc   1140uucggcgcca uugccggcuu ccucgaaggc gguugggagg gcaugaucgc cggcuggcac   1200ggcuacacua gccacggcgc acacggagua gcaguggccg ccgaccugaa gagcacccag   1260gaggccauca acaagaucac caagaaccug aacagccuga gcgagcugga ggugaagaau   1320cugcagcggc ugucuggcgc uauggacgag cugcacaacg agauccugga gcuggacgag   1380aagguggacg acuuacgggc cgacaccauc agcagccaga ucgagcuggc cgugcugcug   1440agcaacgagg gcaucaucaa cagcgaggac gagcaccugc uggcccugga gggaagcuga   1500agaagaugcu gggcccuucu gccguggaga ucgguaacgg cugcuucgag accaagcaca   1560agugcaacca gaccugccug gaucggaucg cagccggcac cuuugacgcc ggggaguuca   1620gccugcccac cuucgacagc cugaacauca ccgccgccag ccugaacgac gacggccugg   1680acaaccacac cauccugcug uacuacucua cagccgcuag cagccuggcc gugacccuga   1740ugaucgccau cuucguggug uacaugguga gccgggacaa cgugagcugc agcaucugcc   1800ugugauaaua ggcuggagcc ucgguggccu agcuucuugc cccuugggcc uccccccagc   1860cccuccuccc cuuccugcac ccguaccccc guggucuuug aauaaagucu gagugggcgg   1920c                                                                   1921</s400><s200><s210>24</s210><s211>1745</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 24augaaggcca ucaucgugcu guuaauggug gugaccagca acgccgaccg gaucugcacc     60ggcaucaccu cuagcaacag cccucacgug gugaagaccg ccacacaggg cgaggugaac    120gugaccggcg ugauuccccu gaccaccacc ccuaccaaga gccacuucgc caaccugaag    180ggaaccgaga cccggggcaa gcuguguccc aagugccuga acugcaccga ccuggacgug    240gcccugggca gacccaagug caccggcaag auccccagcg cccggguguc uauccugcac    300gaagugcggc ccgugacuag cggcugcuuc cccaucaugc acgaccggac caagauccgg    360cagcugccca accugcugcg gggcuacgag cacgugcggc ugagcaccca caacgugauc    420aacgccgaag acgcacccgg gagaccauac gagaucggca ccagcggcuc uugccccaac    480aucaccaacg gcaacggcuu cuucgcuacc auggccuggg ccgugccaaa gaacaagacu    540gccaccaacc cucugaccau cgaggugccc uacaucugca ccgagggcga ggaccagauc    600accguguggg gcuuccacag cgacagcgag acccagaugg ccaagcugua cggcgacagc    660aagccccaga aguucaccag cagcgccaac ggcgugacca cccacuacgu gagccagauc    720ggcggcuucc ccaaccagac cgaggacggc ggcuuacccc agagcggccg gaucguggug    780gacuacaugg ugcagaagag cggcaagacc ggcaccauca ccuaccagcg gggcauccug    840cugccacaga agguguggug cgccucaggg cggucaaagg ugaucaaggg cagccugcca    900cugauuggcg aggccgacug ccugcacgag aaguacggcg gccugaacaa gagcaagccc    960uacuacaccg gcgagcacgc caaggcaauc ggcaacugcc ccaucugggu gaagacaccc   1020cugaagcugg ccaacggcac caaguaccgg ccacccgcca aacugcugaa ggagcggggc   1080uucuucggcg ccauugccgg cuuccucgaa ggcgguuggg agggcaugau cgccggcugg   1140cacggcuaca cuagccacgg cgcacacgga guagcagugg ccgccgaccu gaagagcacc   1200caggaggcca ucaacaagau caccaagaac cugaacagcc ugagcgagcu ggaggugaag   1260aaucugcagc ggcugucugg cgcuauggac gagcugcaca acgagauccu ggagcuggac   1320gagaaggugg acgacuuacg ggccgacacc aucagcagcc agaucgagcu ggccgugcug   1380cugagcaacg agggcaucau caacagcgag gacgagcacc ugcuggcccu ggagggaagc   1440ugaagaagau gcugggcccu ucugccgugg agaucgguaa cggcugcuuc gagaccaagc   1500acaagugcaa ccagaccugc cuggaucgga ucgcagccgg caccuuugac gccggggagu   1560ucagccugcc caccuucgac agccugaaca ucaccgccgc cagccugaac gacgacggcc   1620uggacaacca caccauccug cuguacuacu cuacagccgc uagcagccug gccgugaccc   1680ugaugaucgc caucuucgug guguacaugg ugagccggga caacgugagc ugcagcaucu   1740gccug                                                               1745</s400><s200><s210>25</s210><s211>582</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 25Met Lys Ala Ile Ile Val Leu Leu Met Val Val Thr Ser Asn Ala Asp1               5                   10                  15Arg Ile Cys Thr Gly Ile Thr Ser Ser Asn Ser Pro His Val Val Lys            20                  25                  30Thr Ala Thr Gln Gly Glu Val Asn Val Thr Gly Val Ile Pro Leu Thr        35                  40                  45Thr Thr Pro Thr Lys Ser His Phe Ala Asn Leu Lys Gly Thr Glu Thr    50                  55                  60Arg Gly Lys Leu Cys Pro Lys Cys Leu Asn Cys Thr Asp Leu Asp Val65                  70                  75                  80Ala Leu Gly Arg Pro Lys Cys Thr Gly Lys Ile Pro Ser Ala Arg Val                85                  90                  95Ser Ile Leu His Glu Val Arg Pro Val Thr Ser Gly Cys Phe Pro Ile            100                 105                 110Met His Asp Arg Thr Lys Ile Arg Gln Leu Pro Asn Leu Leu Arg Gly        115                 120                 125Tyr Glu His Val Arg Leu Ser Thr His Asn Val Ile Asn Ala Glu Asp    130                 135                 140Ala Pro Gly Arg Pro Tyr Glu Ile Gly Thr Ser Gly Ser Cys Pro Asn145                 150                 155                 160Ile Thr Asn Gly Asn Gly Phe Phe Ala Thr Met Ala Trp Ala Val Pro                165                 170                 175Lys Asn Lys Thr Ala Thr Asn Pro Leu Thr Ile Glu Val Pro Tyr Ile            180                 185                 190Cys Thr Glu Gly Glu Asp Gln Ile Thr Val Trp Gly Phe His Ser Asp        195                 200                 205Ser Glu Thr Gln Met Ala Lys Leu Tyr Gly Asp Ser Lys Pro Gln Lys    210                 215                 220Phe Thr Ser Ser Ala Asn Gly Val Thr Thr His Tyr Val Ser Gln Ile225                 230                 235                 240Gly Gly Phe Pro Asn Gln Thr Glu Asp Gly Gly Leu Pro Gln Ser Gly                245                 250                 255Arg Ile Val Val Asp Tyr Met Val Gln Lys Ser Gly Lys Thr Gly Thr            260                 265                 270Ile Thr Tyr Gln Arg Gly Ile Leu Leu Pro Gln Lys Val Trp Cys Ala        275                 280                 285Ser Gly Arg Ser Lys Val Ile Lys Gly Ser Leu Pro Leu Ile Gly Glu    290                 295                 300Ala Asp Cys Leu His Glu Lys Tyr Gly Gly Leu Asn Lys Ser Lys Pro305                 310                 315                 320Tyr Tyr Thr Gly Glu His Ala Lys Ala Ile Gly Asn Cys Pro Ile Trp                325                 330                 335Val Lys Thr Pro Leu Lys Leu Ala Asn Gly Thr Lys Tyr Arg Pro Pro            340                 345                 350Ala Lys Leu Leu Lys Glu Arg Gly Phe Phe Gly Ala Ile Ala Gly Phe        355                 360                 365Leu Glu Gly Gly Trp Glu Gly Met Ile Ala Gly Trp His Gly Tyr Thr    370                 375                 380Ser His Gly Ala His Gly Val Ala Val Ala Ala Asp Leu Lys Ser Thr385                 390                 395                 400Gln Glu Ala Ile Asn Lys Ile Thr Lys Asn Leu Asn Ser Leu Ser Glu                405                 410                 415Leu Glu Val Lys Asn Leu Gln Arg Leu Ser Gly Ala Met Asp Glu Leu            420                 425                 430His Asn Glu Ile Leu Glu Leu Asp Glu Lys Val Asp Asp Leu Arg Ala        435                 440                 445Asp Thr Ile Ser Ser Gln Ile Glu Leu Ala Val Leu Leu Ser Asn Glu    450                 455                 460Gly Ile Ile Asn Ser Glu Asp Glu His Leu Leu Ala Leu Glu Arg Lys465                 470                 475                 480Leu Lys Lys Met Leu Gly Pro Ser Ala Val Glu Ile Gly Asn Gly Cys                485                 490                 495Phe Glu Thr Lys His Lys Cys Asn Gln Thr Cys Leu Asp Arg Ile Ala            500                 505                 510Ala Gly Thr Phe Asp Ala Gly Glu Phe Ser Leu Pro Thr Phe Asp Ser        515                 520                 525Leu Asn Ile Thr Ala Ala Ser Leu Asn Asp Asp Gly Leu Asp Asn His    530                 535                 540Thr Ile Leu Leu Tyr Tyr Ser Thr Ala Ala Ser Ser Leu Ala Val Thr545                 550                 555                 560Leu Met Ile Ala Ile Phe Val Val Tyr Met Val Ser Arg Asp Asn Val                565                 570                 575Ser Cys Ser Ile Cys Leu            580</s400><s200><s210>26</s210><s211>1574</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 26gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60cugcccagca ccauccagac ccugacccug uuucugacca gcggaggcgu gcugcugagc    120cuguacguga gcgccagccu gagcuaccug cuguacagcg acauccugcu gaaguucagc    180cccaccgaga ucaccgcacc caccaugccc cuggacugcg ccaacgccag caacgugcag    240gccgugaacc ggagcgccac aaagggcgug acccugcugc ugcccgagcc agaguggaca    300uauccucggc ugagcugccc uggcagcacc uuccagaagg cccugcugau cagcccacac    360cgguucggcg agaccaaggg caacagcgca ccccugauca uccgggagcc cuucguggcc    420uguggcccca acgagugcaa gcacuucgcc cugacacacu acgcugcuca gcccgguggc    480uacuacaacg gcacccgggg ugaucggaac aagcugcggc accugaucag cgugaagcug    540ggcaagaucc ccaccgugga gaacagcauc uuccacaugg ccgccugguc aggaagcgcc    600ugccacgacg gcaaggagug gaccuacauc ggcguggacg gcccugacaa caacgcccug    660cugaagguga aguacggcga ggccuacacc gacaccuacc acagcuacgc caacaacauc    720cugcggaccc aggagagcgc cugcaacugc aucggcggca acugcuaccu gaugaucacc    780gacggcagcg cuucuggcgu gagcgagugc cgguuccuga agauccggga gggccggauc    840aucaaggaga ucuuucccac cggccgggug aagcacaccg aggagugcac cugcggcuuc    900gccagcaaca agaccaucga gugcgccugc cgggacaauc gguacaccgc caagcggccc    960uucgugaagc ugaacgugga gaccgacacc gccgagaucc ggcugaugug caccgacacu   1020uaucuggaca ccccucggcc uaacgacggc agcaucaccg gcccuugcga gagcgacggc   1080gacaagggaa gcggcggcau caagggcggu uucgugcacc agcggaugaa gagcaagauc   1140ggccgguggu acagccggac caugagcaag accgagcgga ugggcauggg ccuguacgua   1200aaguacggag gggaucccug ggcugacagc gacgcccuga ccuucagcgg cgugauggug   1260agcaugaagg agcccggcug guacagcuuc ggcuucgaga ucaaggacaa gaagugcgac   1320gugcccugca ucggcaucga gauggugcac gacggcggca aggagaccug gcacucugcc   1380gccacugcca ucuacugccu gaugggcagc ggccagcugc ugugggacac cgugaccggc   1440guggacaugg cccugugaua auaggcugga gccucggugg ccuagcuucu ugccccuugg   1500gccucccccc agccccuccu ccccuuccug cacccguacc cccguggucu uugaauaaag   1560ucugaguggg cggc                                                     1574</s400><s200><s210>27</s210><s211>1398</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 27augcugccca gcaccaucca gacccugacc cuguuucuga ccagcggagg cgugcugcug     60agccuguacg ugagcgccag ccugagcuac cugcuguaca gcgacauccu gcugaaguuc    120agccccaccg agaucaccgc acccaccaug ccccuggacu gcgccaacgc cagcaacgug    180caggccguga accggagcgc cacaaagggc gugacccugc ugcugcccga gccagagugg    240acauauccuc ggcugagcug cccuggcagc accuuccaga aggcccugcu gaucagccca    300caccgguucg gcgagaccaa gggcaacagc gcaccccuga ucauccggga gcccuucgug    360gccuguggcc ccaacgagug caagcacuuc gcccugacac acuacgcugc ucagcccggu    420ggcuacuaca acggcacccg gggugaucgg aacaagcugc ggcaccugau cagcgugaag    480cugggcaaga uccccaccgu ggagaacagc aucuuccaca uggccgccug gucaggaagc    540gccugccacg acggcaagga guggaccuac aucggcgugg acggcccuga caacaacgcc    600cugcugaagg ugaaguacgg cgaggccuac accgacaccu accacagcua cgccaacaac    660auccugcgga cccaggagag cgccugcaac ugcaucggcg gcaacugcua ccugaugauc    720accgacggca gcgcuucugg cgugagcgag ugccgguucc ugaagauccg ggagggccgg    780aucaucaagg agaucuuucc caccggccgg gugaagcaca ccgaggagug caccugcggc    840uucgccagca acaagaccau cgagugcgcc ugccgggaca aucgguacac cgccaagcgg    900cccuucguga agcugaacgu ggagaccgac accgccgaga uccggcugau gugcaccgac    960acuuaucugg acaccccucg gccuaacgac ggcagcauca ccggcccuug cgagagcgac   1020ggcgacaagg gaagcggcgg caucaagggc gguuucgugc accagcggau gaagagcaag   1080aucggccggu gguacagccg gaccaugagc aagaccgagc ggaugggcau gggccuguac   1140guaaaguacg gaggggaucc cugggcugac agcgacgccc ugaccuucag cggcgugaug   1200gugagcauga aggagcccgg cugguacagc uucggcuucg agaucaagga caagaagugc   1260gacgugcccu gcaucggcau cgagauggug cacgacggcg gcaaggagac cuggcacucu   1320gccgccacug ccaucuacug ccugaugggc agcggccagc ugcuguggga caccgugacc   1380ggcguggaca uggcccug                                                 1398</s400><s200><s210>28</s210><s211>466</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 28Met Leu Pro Ser Thr Ile Gln Thr Leu Thr Leu Phe Leu Thr Ser Gly1               5                   10                  15Gly Val Leu Leu Ser Leu Tyr Val Ser Ala Ser Leu Ser Tyr Leu Leu            20                  25                  30Tyr Ser Asp Ile Leu Leu Lys Phe Ser Pro Thr Glu Ile Thr Ala Pro        35                  40                  45Thr Met Pro Leu Asp Cys Ala Asn Ala Ser Asn Val Gln Ala Val Asn    50                  55                  60Arg Ser Ala Thr Lys Gly Val Thr Leu Leu Leu Pro Glu Pro Glu Trp65                  70                  75                  80Thr Tyr Pro Arg Leu Ser Cys Pro Gly Ser Thr Phe Gln Lys Ala Leu                85                  90                  95Leu Ile Ser Pro His Arg Phe Gly Glu Thr Lys Gly Asn Ser Ala Pro            100                 105                 110Leu Ile Ile Arg Glu Pro Phe Val Ala Cys Gly Pro Asn Glu Cys Lys        115                 120                 125His Phe Ala Leu Thr His Tyr Ala Ala Gln Pro Gly Gly Tyr Tyr Asn    130                 135                 140Gly Thr Arg Gly Asp Arg Asn Lys Leu Arg His Leu Ile Ser Val Lys145                 150                 155                 160Leu Gly Lys Ile Pro Thr Val Glu Asn Ser Ile Phe His Met Ala Ala                165                 170                 175Trp Ser Gly Ser Ala Cys His Asp Gly Lys Glu Trp Thr Tyr Ile Gly            180                 185                 190Val Asp Gly Pro Asp Asn Asn Ala Leu Leu Lys Val Lys Tyr Gly Glu        195                 200                 205Ala Tyr Thr Asp Thr Tyr His Ser Tyr Ala Asn Asn Ile Leu Arg Thr    210                 215                 220Gln Glu Ser Ala Cys Asn Cys Ile Gly Gly Asn Cys Tyr Leu Met Ile225                 230                 235                 240Thr Asp Gly Ser Ala Ser Gly Val Ser Glu Cys Arg Phe Leu Lys Ile                245                 250                 255Arg Glu Gly Arg Ile Ile Lys Glu Ile Phe Pro Thr Gly Arg Val Lys            260                 265                 270His Thr Glu Glu Cys Thr Cys Gly Phe Ala Ser Asn Lys Thr Ile Glu        275                 280                 285Cys Ala Cys Arg Asp Asn Arg Tyr Thr Ala Lys Arg Pro Phe Val Lys    290                 295                 300Leu Asn Val Glu Thr Asp Thr Ala Glu Ile Arg Leu Met Cys Thr Asp305                 310                 315                 320Thr Tyr Leu Asp Thr Pro Arg Pro Asn Asp Gly Ser Ile Thr Gly Pro                325                 330                 335Cys Glu Ser Asp Gly Asp Lys Gly Ser Gly Gly Ile Lys Gly Gly Phe            340                 345                 350Val His Gln Arg Met Lys Ser Lys Ile Gly Arg Trp Tyr Ser Arg Thr        355                 360                 365Met Ser Lys Thr Glu Arg Met Gly Met Gly Leu Tyr Val Lys Tyr Gly    370                 375                 380Gly Asp Pro Trp Ala Asp Ser Asp Ala Leu Thr Phe Ser Gly Val Met385                 390                 395                 400Val Ser Met Lys Glu Pro Gly Trp Tyr Ser Phe Gly Phe Glu Ile Lys                405                 410                 415Asp Lys Lys Cys Asp Val Pro Cys Ile Gly Ile Glu Met Val His Asp            420                 425                 430Gly Gly Lys Glu Thr Trp His Ser Ala Ala Thr Ala Ile Tyr Cys Leu        435                 440                 445Met Gly Ser Gly Gln Leu Leu Trp Asp Thr Val Thr Gly Val Asp Met    450                 455                 460Ala Leu465</s400><s200><s210>29</s210><s211>1574</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 29gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60cugcccagca ccauccagac ccugacccug uuucugacca gcggaggcgu gcugcugagc    120cuguacguga gcgccagccu gagcuaccug cuguacagcg acauccugcu gaaguucagc    180cccaccgaga ucaccgcacc caccaugccc cuggacugcg ccaacgccag caacgugcag    240gccgugaacc ggagcgccac aaagggcgug acccugcugc ugcccgagcc agaguggaca    300uauccucggc ugagcugccc uggcagcacc uuccagaagg cccugcugau cagcccacac    360cgguucggcg agaccaaggg caacagcgca ccccugauca uccgggagcc cuucguggcc    420uguggcccca acgagugcaa gcacuucgcc cugacacacu acgcugcuca gcccgguggc    480uacuacaacg gcacccgggg uggccggaac aagcugcggc accugaucag cgugaagcug    540ggcaagaucc ccaccgugga gaacagcauc uuccacaugg ccgccugguc aggaagcgcc    600ugccacgacg gcaaggagug gaccuacauc ggcguggacg gcccugacaa caacgcccug    660cugaagguga aguacggcga ggccuacacc gacaccuacc acagcuacgc caacaacauc    720cugcggaccc aggagagcgc cugcaacugc aucggcggca acugcuaccu gaugaucacc    780gacggcagcg cuucuggcgu gagcgagugc cgguuccuga agauccggga gggccggauc    840aucaaggaga ucuuucccac cggccgggug aagcacaccg aggagugcac cugcggcuuc    900gccagcaaca agaccaucga gugcgccugc cgggacaauc gguacaccgc caagcggccc    960uucgugaagc ugaacgugga gaccgacacc gccgagaucc ggcugaugug caccgacacu   1020uaucuggaca ccccucggcc uaacgacggc agcaucaccg gcccuugcga gagcgacggc   1080gacaagggaa gcggcggcau caagggcggu uucgugcacc agcggaugaa gagcaagauc   1140ggccgguggu acagccggac caugagcaag accgagcgga ugggcauggg ccuguacgua   1200aaguacggag gggaucccug ggcugacagc gacgcccuga ccuucagcgg cgugauggug   1260agcaugaagg agcccggcug guacagcuuc ggcuucgaga ucaaggacaa gaagugcgac   1320gugcccugca ucggcaucga gauggugcac gacggcggca aggagaccug gcacucugcc   1380gccacugcca ucuacugccu gaugggcagc ggccagcugc ugugggacac cgugaccggc   1440guggacaugg cccugugaua auaggcugga gccucggugg ccuagcuucu ugccccuugg   1500gccucccccc agccccuccu ccccuuccug cacccguacc cccguggucu uugaauaaag   1560ucugaguggg cggc                                                     1574</s400><s200><s210>30</s210><s211>1398</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 30augcugccca gcaccaucca gacccugacc cuguuucuga ccagcggagg cgugcugcug     60agccuguacg ugagcgccag ccugagcuac cugcuguaca gcgacauccu gcugaaguuc    120agccccaccg agaucaccgc acccaccaug ccccuggacu gcgccaacgc cagcaacgug    180caggccguga accggagcgc cacaaagggc gugacccugc ugcugcccga gccagagugg    240acauauccuc ggcugagcug cccuggcagc accuuccaga aggcccugcu gaucagccca    300caccgguucg gcgagaccaa gggcaacagc gcaccccuga ucauccggga gcccuucgug    360gccuguggcc ccaacgagug caagcacuuc gcccugacac acuacgcugc ucagcccggu    420ggcuacuaca acggcacccg ggguggccgg aacaagcugc ggcaccugau cagcgugaag    480cugggcaaga uccccaccgu ggagaacagc aucuuccaca uggccgccug gucaggaagc    540gccugccacg acggcaagga guggaccuac aucggcgugg acggcccuga caacaacgcc    600cugcugaagg ugaaguacgg cgaggccuac accgacaccu accacagcua cgccaacaac    660auccugcgga cccaggagag cgccugcaac ugcaucggcg gcaacugcua ccugaugauc    720accgacggca gcgcuucugg cgugagcgag ugccgguucc ugaagauccg ggagggccgg    780aucaucaagg agaucuuucc caccggccgg gugaagcaca ccgaggagug caccugcggc    840uucgccagca acaagaccau cgagugcgcc ugccgggaca aucgguacac cgccaagcgg    900cccuucguga agcugaacgu ggagaccgac accgccgaga uccggcugau gugcaccgac    960acuuaucugg acaccccucg gccuaacgac ggcagcauca ccggcccuug cgagagcgac   1020ggcgacaagg gaagcggcgg caucaagggc gguuucgugc accagcggau gaagagcaag   1080aucggccggu gguacagccg gaccaugagc aagaccgagc ggaugggcau gggccuguac   1140guaaaguacg gaggggaucc cugggcugac agcgacgccc ugaccuucag cggcgugaug   1200gugagcauga aggagcccgg cugguacagc uucggcuucg agaucaagga caagaagugc   1260gacgugcccu gcaucggcau cgagauggug cacgacggcg gcaaggagac cuggcacucu   1320gccgccacug ccaucuacug ccugaugggc agcggccagc ugcuguggga caccgugacc   1380ggcguggaca uggcccug                                                 1398</s400><s200><s210>31</s210><s211>466</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 31Met Leu Pro Ser Thr Ile Gln Thr Leu Thr Leu Phe Leu Thr Ser Gly1               5                   10                  15Gly Val Leu Leu Ser Leu Tyr Val Ser Ala Ser Leu Ser Tyr Leu Leu            20                  25                  30Tyr Ser Asp Ile Leu Leu Lys Phe Ser Pro Thr Glu Ile Thr Ala Pro        35                  40                  45Thr Met Pro Leu Asp Cys Ala Asn Ala Ser Asn Val Gln Ala Val Asn    50                  55                  60Arg Ser Ala Thr Lys Gly Val Thr Leu Leu Leu Pro Glu Pro Glu Trp65                  70                  75                  80Thr Tyr Pro Arg Leu Ser Cys Pro Gly Ser Thr Phe Gln Lys Ala Leu                85                  90                  95Leu Ile Ser Pro His Arg Phe Gly Glu Thr Lys Gly Asn Ser Ala Pro            100                 105                 110Leu Ile Ile Arg Glu Pro Phe Val Ala Cys Gly Pro Asn Glu Cys Lys        115                 120                 125His Phe Ala Leu Thr His Tyr Ala Ala Gln Pro Gly Gly Tyr Tyr Asn    130                 135                 140Gly Thr Arg Gly Gly Arg Asn Lys Leu Arg His Leu Ile Ser Val Lys145                 150                 155                 160Leu Gly Lys Ile Pro Thr Val Glu Asn Ser Ile Phe His Met Ala Ala                165                 170                 175Trp Ser Gly Ser Ala Cys His Asp Gly Lys Glu Trp Thr Tyr Ile Gly            180                 185                 190Val Asp Gly Pro Asp Asn Asn Ala Leu Leu Lys Val Lys Tyr Gly Glu        195                 200                 205Ala Tyr Thr Asp Thr Tyr His Ser Tyr Ala Asn Asn Ile Leu Arg Thr    210                 215                 220Gln Glu Ser Ala Cys Asn Cys Ile Gly Gly Asn Cys Tyr Leu Met Ile225                 230                 235                 240Thr Asp Gly Ser Ala Ser Gly Val Ser Glu Cys Arg Phe Leu Lys Ile                245                 250                 255Arg Glu Gly Arg Ile Ile Lys Glu Ile Phe Pro Thr Gly Arg Val Lys            260                 265                 270His Thr Glu Glu Cys Thr Cys Gly Phe Ala Ser Asn Lys Thr Ile Glu        275                 280                 285Cys Ala Cys Arg Asp Asn Arg Tyr Thr Ala Lys Arg Pro Phe Val Lys    290                 295                 300Leu Asn Val Glu Thr Asp Thr Ala Glu Ile Arg Leu Met Cys Thr Asp305                 310                 315                 320Thr Tyr Leu Asp Thr Pro Arg Pro Asn Asp Gly Ser Ile Thr Gly Pro                325                 330                 335Cys Glu Ser Asp Gly Asp Lys Gly Ser Gly Gly Ile Lys Gly Gly Phe            340                 345                 350Val His Gln Arg Met Lys Ser Lys Ile Gly Arg Trp Tyr Ser Arg Thr        355                 360                 365Met Ser Lys Thr Glu Arg Met Gly Met Gly Leu Tyr Val Lys Tyr Gly    370                 375                 380Gly Asp Pro Trp Ala Asp Ser Asp Ala Leu Thr Phe Ser Gly Val Met385                 390                 395                 400Val Ser Met Lys Glu Pro Gly Trp Tyr Ser Phe Gly Phe Glu Ile Lys                405                 410                 415Asp Lys Lys Cys Asp Val Pro Cys Ile Gly Ile Glu Met Val His Asp            420                 425                 430Gly Gly Lys Glu Thr Trp His Ser Ala Ala Thr Ala Ile Tyr Cys Leu        435                 440                 445Met Gly Ser Gly Gln Leu Leu Trp Asp Thr Val Thr Gly Val Asp Met    450                 455                 460Ala Leu465</s400><s200><s210>32</s210><s211>1928</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 32gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaggccauca ucgugcuacu gaugguggug accagcaacg ccgaccggau cugcaccggc    120aucaccagca gcaacagccc gcacguggug aagaccgcca cccaaggcga ggugaacgug    180accggcguga ucccacugac caccacuccc accaagagcu acuucgccaa ccugaagggc    240acacggacuc ggggcaagcu gugccccgac ugccugaacu gcaccgaccu ggacguggcc    300cugggcagac ccaugugcgu gggcaccacc ccuucugcca aggccagcau ccugcacgag    360gugagacccg ugaccagcgg gugcuucccc aucaugcacg accggaccaa gauccggcag    420cugcccaacc ugcugcgggg cuacgagaag auccggcuga gcacccagaa cgugaucgac    480gccgagaagg ccccuggagg ucccuaccgg cugggcacca gcggaagcug ccccaacgcc    540accagcaaga ucggcuucuu cgccaccaug gccugggcug ugcccaagga caacuacaag    600aacgccacca auccccugac cguggaggug cccuacaucu gcaccgaggg cgaggaccag    660aucaccgugu ggggcuucca cagcgacaac aagacccaga ugaagagccu guacggcgac    720agcaaucccc agaaguucac aagcagcgcc aacggcguga ccacccacua cgugagccag    780aucggcgacu uccccgacca gaccgaggac ggagggcugc cucagagugg ccggaucgug    840guggacuaca ugaugcagaa gcccggcaag accggcacca ucguguacca gcggggcgug    900cuguugccuc agaaaguuug gugugccagc ggcaggagca aggugaucaa gggcagccug    960ccccugaucg gcgaggcaga cugccuccac gaggaguacg gcggccugaa caagagcaag   1020cccuacuaca ccggcaagca cgccaaggcc aucggcaacu gccccaucug ggugaagacc   1080ccucugaagc uggccaacgg caccaaguac cggccaccag ccaagcugcu gaaggagcgg   1140ggcuucuuug gcgccauugc cggcuuccuc gagggaggcu gggagggcau gaucgccggc   1200uggcacggcu acacaagcca cggcgcacac ggaguggcug uggcugccga ccugaagagc   1260acccaggagg ccaucaacaa gaucaccaag aaccugaaca gccugagcga gcuggaggug   1320aagaaccugc agcggcuguc aggcgccaug gacgagcugc acaacgagau ccuggagcug   1380gacgagaagg uggacgaccu gcgugccgac accaucagca gccagaucga gcuggccgug   1440cugcugagca acgagggcau caucaacagc gaggacgagc accugcuggc ccuggagcgg   1500aaacugaaga agaugcuggg acccucugcc guggacaucg gcaacggcug cuucgagacc   1560aagcacaagu gcaaccagac cugccuggau cggaucgccg ccggaaccuu caacgccggc   1620gaguucagcc ugcccaccuu cgacagccug aacaucaccg ccgccagccu gaacgacgac   1680ggccuggaca accacaccau ccugcuguac uacagcacug ccgccucaag ccuggccgug   1740acccugaugc uggccaucuu caucguguac auggugagcc gggacaacgu gagcugcagc   1800aucugccugu gauaauaggc uggagccucg guggccuagc uucuugcccc uugggccucc   1860ccccagcccc uccuccccuu ccugcacccg uacccccgug gucuuugaau aaagucugag   1920ugggcggc                                                            1928</s400><s200><s210>33</s210><s211>1752</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 33augaaggcca ucaucgugcu acugauggug gugaccagca acgccgaccg gaucugcacc     60ggcaucacca gcagcaacag cccgcacgug gugaagaccg ccacccaagg cgaggugaac    120gugaccggcg ugaucccacu gaccaccacu cccaccaaga gcuacuucgc caaccugaag    180ggcacacgga cucggggcaa gcugugcccc gacugccuga acugcaccga ccuggacgug    240gcccugggca gacccaugug cgugggcacc accccuucug ccaaggccag cauccugcac    300gaggugagac ccgugaccag cgggugcuuc cccaucaugc acgaccggac caagauccgg    360cagcugccca accugcugcg gggcuacgag aagauccggc ugagcaccca gaacgugauc    420gacgccgaga aggccccugg aggucccuac cggcugggca ccagcggaag cugccccaac    480gccaccagca agaucggcuu cuucgccacc auggccuggg cugugcccaa ggacaacuac    540aagaacgcca ccaauccccu gaccguggag gugcccuaca ucugcaccga gggcgaggac    600cagaucaccg uguggggcuu ccacagcgac aacaagaccc agaugaagag ccuguacggc    660gacagcaauc cccagaaguu cacaagcagc gccaacggcg ugaccaccca cuacgugagc    720cagaucggcg acuuccccga ccagaccgag gacggagggc ugccucagag uggccggauc    780gugguggacu acaugaugca gaagcccggc aagaccggca ccaucgugua ccagcggggc    840gugcuguugc cucagaaagu uuggugugcc agcggcagga gcaaggugau caagggcagc    900cugccccuga ucggcgaggc agacugccuc cacgaggagu acggcggccu gaacaagagc    960aagcccuacu acaccggcaa gcacgccaag gccaucggca acugccccau cugggugaag   1020accccucuga agcuggccaa cggcaccaag uaccggccac cagccaagcu gcugaaggag   1080cggggcuucu uuggcgccau ugccggcuuc cucgagggag gcugggaggg caugaucgcc   1140ggcuggcacg gcuacacaag ccacggcgca cacggagugg cuguggcugc cgaccugaag   1200agcacccagg aggccaucaa caagaucacc aagaaccuga acagccugag cgagcuggag   1260gugaagaacc ugcagcggcu gucaggcgcc auggacgagc ugcacaacga gauccuggag   1320cuggacgaga agguggacga ccugcgugcc gacaccauca gcagccagau cgagcuggcc   1380gugcugcuga gcaacgaggg caucaucaac agcgaggacg agcaccugcu ggcccuggag   1440cggaaacuga agaagaugcu gggacccucu gccguggaca ucggcaacgg cugcuucgag   1500accaagcaca agugcaacca gaccugccug gaucggaucg ccgccggaac cuucaacgcc   1560ggcgaguuca gccugcccac cuucgacagc cugaacauca ccgccgccag ccugaacgac   1620gacggccugg acaaccacac cauccugcug uacuacagca cugccgccuc aagccuggcc   1680gugacccuga ugcuggccau cuucaucgug uacaugguga gccgggacaa cgugagcugc   1740agcaucugcc ug                                                       1752</s400><s200><s210>34</s210><s211>584</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 34Met Lys Ala Ile Ile Val Leu Leu Met Val Val Thr Ser Asn Ala Asp1               5                   10                  15Arg Ile Cys Thr Gly Ile Thr Ser Ser Asn Ser Pro His Val Val Lys            20                  25                  30Thr Ala Thr Gln Gly Glu Val Asn Val Thr Gly Val Ile Pro Leu Thr        35                  40                  45Thr Thr Pro Thr Lys Ser Tyr Phe Ala Asn Leu Lys Gly Thr Arg Thr    50                  55                  60Arg Gly Lys Leu Cys Pro Asp Cys Leu Asn Cys Thr Asp Leu Asp Val65                  70                  75                  80Ala Leu Gly Arg Pro Met Cys Val Gly Thr Thr Pro Ser Ala Lys Ala                85                  90                  95Ser Ile Leu His Glu Val Arg Pro Val Thr Ser Gly Cys Phe Pro Ile            100                 105                 110Met His Asp Arg Thr Lys Ile Arg Gln Leu Pro Asn Leu Leu Arg Gly        115                 120                 125Tyr Glu Lys Ile Arg Leu Ser Thr Gln Asn Val Ile Asp Ala Glu Lys    130                 135                 140Ala Pro Gly Gly Pro Tyr Arg Leu Gly Thr Ser Gly Ser Cys Pro Asn145                 150                 155                 160Ala Thr Ser Lys Ile Gly Phe Phe Ala Thr Met Ala Trp Ala Val Pro                165                 170                 175Lys Asp Asn Tyr Lys Asn Ala Thr Asn Pro Leu Thr Val Glu Val Pro            180                 185                 190Tyr Ile Cys Thr Glu Gly Glu Asp Gln Ile Thr Val Trp Gly Phe His        195                 200                 205Ser Asp Asn Lys Thr Gln Met Lys Ser Leu Tyr Gly Asp Ser Asn Pro    210                 215                 220Gln Lys Phe Thr Ser Ser Ala Asn Gly Val Thr Thr His Tyr Val Ser225                 230                 235                 240Gln Ile Gly Asp Phe Pro Asp Gln Thr Glu Asp Gly Gly Leu Pro Gln                245                 250                 255Ser Gly Arg Ile Val Val Asp Tyr Met Met Gln Lys Pro Gly Lys Thr            260                 265                 270Gly Thr Ile Val Tyr Gln Arg Gly Val Leu Leu Pro Gln Lys Val Trp        275                 280                 285Cys Ala Ser Gly Arg Ser Lys Val Ile Lys Gly Ser Leu Pro Leu Ile    290                 295                 300Gly Glu Ala Asp Cys Leu His Glu Glu Tyr Gly Gly Leu Asn Lys Ser305                 310                 315                 320Lys Pro Tyr Tyr Thr Gly Lys His Ala Lys Ala Ile Gly Asn Cys Pro                325                 330                 335Ile Trp Val Lys Thr Pro Leu Lys Leu Ala Asn Gly Thr Lys Tyr Arg            340                 345                 350Pro Pro Ala Lys Leu Leu Lys Glu Arg Gly Phe Phe Gly Ala Ile Ala        355                 360                 365Gly Phe Leu Glu Gly Gly Trp Glu Gly Met Ile Ala Gly Trp His Gly    370                 375                 380Tyr Thr Ser His Gly Ala His Gly Val Ala Val Ala Ala Asp Leu Lys385                 390                 395                 400Ser Thr Gln Glu Ala Ile Asn Lys Ile Thr Lys Asn Leu Asn Ser Leu                405                 410                 415Ser Glu Leu Glu Val Lys Asn Leu Gln Arg Leu Ser Gly Ala Met Asp            420                 425                 430Glu Leu His Asn Glu Ile Leu Glu Leu Asp Glu Lys Val Asp Asp Leu        435                 440                 445Arg Ala Asp Thr Ile Ser Ser Gln Ile Glu Leu Ala Val Leu Leu Ser    450                 455                 460Asn Glu Gly Ile Ile Asn Ser Glu Asp Glu His Leu Leu Ala Leu Glu465                 470                 475                 480Arg Lys Leu Lys Lys Met Leu Gly Pro Ser Ala Val Asp Ile Gly Asn                485                 490                 495Gly Cys Phe Glu Thr Lys His Lys Cys Asn Gln Thr Cys Leu Asp Arg            500                 505                 510Ile Ala Ala Gly Thr Phe Asn Ala Gly Glu Phe Ser Leu Pro Thr Phe        515                 520                 525Asp Ser Leu Asn Ile Thr Ala Ala Ser Leu Asn Asp Asp Gly Leu Asp    530                 535                 540Asn His Thr Ile Leu Leu Tyr Tyr Ser Thr Ala Ala Ser Ser Leu Ala545                 550                 555                 560Val Thr Leu Met Leu Ala Ile Phe Ile Val Tyr Met Val Ser Arg Asp                565                 570                 575Asn Val Ser Cys Ser Ile Cys Leu            580</s400><s200><s210>35</s210><s211>1574</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 35gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60cugcccagca ccauccagac ccugacccug uuccugacca gcggaggcgu gcugcugagc    120cuguacguca gcgccagccu gagcuaccug cuguacagcg acauccugcu gaaguucagc    180cggaccgagg ugaccgcucc caucaugccc cuggacugcg ccaacgccag caacgugcag    240gccgugaauc ggagcgccac caagggcgug acuccccugc ugcccgagcc ugaguggacu    300uauccucggc ugagcugccc aggcagcacc uuccagaagg cccugcugau cagcccacac    360cgguucggcg agaccaaggg caacagcgcu ccccugauca uccgggagcc cuucaucgcc    420ugcggcccca aggagugcaa gcacuucgcc cugacccacu acgcugccca acccggaggc    480uacuacaacg gcaccagaga ggaccggaac aagcugcggc accugaucag cgugaagcug    540ggcaagaucc ccaccgugga gaacagcauc uuccacaugg cugcuugguc uggaagugcu    600ugucacgacg gccgggagug gaccuacauc ggcguggacg gcccagacag caacgcccug    660cugaagauca aguacggcga ggccuacacc gacaccuacc acagcuacgc caagaacauc    720cugcggaccc aggagagcgc cugcaacugc aucggcggcg acugcuaccu gaugaucacc    780gacggcccag caucuggcau cagcgagugc cgguuccuga agauccggga gggccggauc    840aucaaggaga ucuuccccac cgggagagug aagcacaccg aggagugcac cugcggcuuc    900gccagcaaca agaccaucga gugcgccugc cgggacaaca gcuacaccgc caagcggccc    960uucgugaagc ugaacgugga gaccgacacc gccgagaucc ggcugaugug caccaagacc   1020uaccuggaca ccccucggcc caacgacgga agcaucaccg gacccugcga gagcgacggg   1080gacgaaggaa gcggcggaau caagggcggc uucgugcacc agcggauggc cagcaagauc   1140ggccgguggu acagccggac caugagcaag accaagcgga ugggcauggg ccuguacgug   1200aaguacgacg gcgaccccug gacagacagc gaagcccugg cccugucugg cgugauggug   1260agcauggagg agcccggcug guacagcuuc ggcuucgaga ucaaggacaa gaagugcgac   1320gugcccugca ucggcaucga gauggugcac gacggcggca agaccaccug gcauagcgcc   1380gcaaccgcga ucuacugccu gaugggcagc ggccagcugc ugugggacac cgugaccggc   1440gugaacauga cccugugaua auaggcugga gccucggugg ccuagcuucu ugccccuugg   1500gccucccccc agccccuccu ccccuuccug cacccguacc cccguggucu uugaauaaag   1560ucugaguggg cggc                                                     1574</s400><s200><s210>36</s210><s211>1398</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 36augcugccca gcaccaucca gacccugacc cuguuccuga ccagcggagg cgugcugcug     60agccuguacg ucagcgccag ccugagcuac cugcuguaca gcgacauccu gcugaaguuc    120agccggaccg aggugaccgc ucccaucaug ccccuggacu gcgccaacgc cagcaacgug    180caggccguga aucggagcgc caccaagggc gugacucccc ugcugcccga gccugagugg    240acuuauccuc ggcugagcug cccaggcagc accuuccaga aggcccugcu gaucagccca    300caccgguucg gcgagaccaa gggcaacagc gcuccccuga ucauccggga gcccuucauc    360gccugcggcc ccaaggagug caagcacuuc gcccugaccc acuacgcugc ccaacccgga    420ggcuacuaca acggcaccag agaggaccgg aacaagcugc ggcaccugau cagcgugaag    480cugggcaaga uccccaccgu ggagaacagc aucuuccaca uggcugcuug gucuggaagu    540gcuugucacg acggccggga guggaccuac aucggcgugg acggcccaga cagcaacgcc    600cugcugaaga ucaaguacgg cgaggccuac accgacaccu accacagcua cgccaagaac    660auccugcgga cccaggagag cgccugcaac ugcaucggcg gcgacugcua ccugaugauc    720accgacggcc cagcaucugg caucagcgag ugccgguucc ugaagauccg ggagggccgg    780aucaucaagg agaucuuccc caccgggaga gugaagcaca ccgaggagug caccugcggc    840uucgccagca acaagaccau cgagugcgcc ugccgggaca acagcuacac cgccaagcgg    900cccuucguga agcugaacgu ggagaccgac accgccgaga uccggcugau gugcaccaag    960accuaccugg acaccccucg gcccaacgac ggaagcauca ccggacccug cgagagcgac   1020ggggacgaag gaagcggcgg aaucaagggc ggcuucgugc accagcggau ggccagcaag   1080aucggccggu gguacagccg gaccaugagc aagaccaagc ggaugggcau gggccuguac   1140gugaaguacg acggcgaccc cuggacagac agcgaagccc uggcccuguc uggcgugaug   1200gugagcaugg aggagcccgg cugguacagc uucggcuucg agaucaagga caagaagugc   1260gacgugcccu gcaucggcau cgagauggug cacgacggcg gcaagaccac cuggcauagc   1320gccgcaaccg cgaucuacug ccugaugggc agcggccagc ugcuguggga caccgugacc   1380ggcgugaaca ugacccug                                                 1398</s400><s200><s210>37</s210><s211>466</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 37Met Leu Pro Ser Thr Ile Gln Thr Leu Thr Leu Phe Leu Thr Ser Gly1               5                   10                  15Gly Val Leu Leu Ser Leu Tyr Val Ser Ala Ser Leu Ser Tyr Leu Leu            20                  25                  30Tyr Ser Asp Ile Leu Leu Lys Phe Ser Arg Thr Glu Val Thr Ala Pro        35                  40                  45Ile Met Pro Leu Asp Cys Ala Asn Ala Ser Asn Val Gln Ala Val Asn    50                  55                  60Arg Ser Ala Thr Lys Gly Val Thr Pro Leu Leu Pro Glu Pro Glu Trp65                  70                  75                  80Thr Tyr Pro Arg Leu Ser Cys Pro Gly Ser Thr Phe Gln Lys Ala Leu                85                  90                  95Leu Ile Ser Pro His Arg Phe Gly Glu Thr Lys Gly Asn Ser Ala Pro            100                 105                 110Leu Ile Ile Arg Glu Pro Phe Ile Ala Cys Gly Pro Lys Glu Cys Lys        115                 120                 125His Phe Ala Leu Thr His Tyr Ala Ala Gln Pro Gly Gly Tyr Tyr Asn    130                 135                 140Gly Thr Arg Glu Asp Arg Asn Lys Leu Arg His Leu Ile Ser Val Lys145                 150                 155                 160Leu Gly Lys Ile Pro Thr Val Glu Asn Ser Ile Phe His Met Ala Ala                165                 170                 175Trp Ser Gly Ser Ala Cys His Asp Gly Arg Glu Trp Thr Tyr Ile Gly            180                 185                 190Val Asp Gly Pro Asp Ser Asn Ala Leu Leu Lys Ile Lys Tyr Gly Glu        195                 200                 205Ala Tyr Thr Asp Thr Tyr His Ser Tyr Ala Lys Asn Ile Leu Arg Thr    210                 215                 220Gln Glu Ser Ala Cys Asn Cys Ile Gly Gly Asp Cys Tyr Leu Met Ile225                 230                 235                 240Thr Asp Gly Pro Ala Ser Gly Ile Ser Glu Cys Arg Phe Leu Lys Ile                245                 250                 255Arg Glu Gly Arg Ile Ile Lys Glu Ile Phe Pro Thr Gly Arg Val Lys            260                 265                 270His Thr Glu Glu Cys Thr Cys Gly Phe Ala Ser Asn Lys Thr Ile Glu        275                 280                 285Cys Ala Cys Arg Asp Asn Ser Tyr Thr Ala Lys Arg Pro Phe Val Lys    290                 295                 300Leu Asn Val Glu Thr Asp Thr Ala Glu Ile Arg Leu Met Cys Thr Lys305                 310                 315                 320Thr Tyr Leu Asp Thr Pro Arg Pro Asn Asp Gly Ser Ile Thr Gly Pro                325                 330                 335Cys Glu Ser Asp Gly Asp Glu Gly Ser Gly Gly Ile Lys Gly Gly Phe            340                 345                 350Val His Gln Arg Met Ala Ser Lys Ile Gly Arg Trp Tyr Ser Arg Thr        355                 360                 365Met Ser Lys Thr Lys Arg Met Gly Met Gly Leu Tyr Val Lys Tyr Asp    370                 375                 380Gly Asp Pro Trp Thr Asp Ser Glu Ala Leu Ala Leu Ser Gly Val Met385                 390                 395                 400Val Ser Met Glu Glu Pro Gly Trp Tyr Ser Phe Gly Phe Glu Ile Lys                405                 410                 415Asp Lys Lys Cys Asp Val Pro Cys Ile Gly Ile Glu Met Val His Asp            420                 425                 430Gly Gly Lys Thr Thr Trp His Ser Ala Ala Thr Ala Ile Tyr Cys Leu        435                 440                 445Met Gly Ser Gly Gln Leu Leu Trp Asp Thr Val Thr Gly Val Asn Met    450                 455                 460Thr Leu465</s400><s200><s210>38</s210><s211>1574</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 38gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60cugcccagca ccauccagac ccugacccug uuccugacca gcggaggcgu gcugcugagc    120cuguacguca gcgccagccu gagcuaccug cuguacagcg acauccugcu gaaguucagc    180cggaccgagg ugaccgcucc caucaugccc cuggacugcg ccaacgccag caacgugcag    240gccgugaauc ggagcgccac caagggcgug acuccccugc ugcccgagcc ugaguggacu    300uauccucggc ugagcugccc aggcagcacc uuccagaagg cccugcugau cagcccacac    360cgguucggcg agaccaaggg caacagcgcu ccccugauca uccgggagcc cuucaucgcc    420ugcggcccca aggagugcaa gcacuucgcc cugacccacu acgcugccca acccggaggc    480uacuacaacg gcaccagaga gggccggaac aagcugcggc accugaucag cgugaagcug    540ggcaagaucc ccaccgugga gaacagcauc uuccacaugg cugcuugguc uggaagugcu    600ugucacgacg gccgggagug gaccuacauc ggcguggacg gcccagacag caacgcccug    660cugaagauca aguacggcga ggccuacacc gacaccuacc acagcuacgc caagaacauc    720cugcggaccc aggagagcgc cugcaacugc aucggcggcg acugcuaccu gaugaucacc    780gacggcccag caucuggcau cagcgagugc cgguuccuga agauccggga gggccggauc    840aucaaggaga ucuuccccac cgggagagug aagcacaccg aggagugcac cugcggcuuc    900gccagcaaca agaccaucga gugcgccugc cgggacaaca gcuacaccgc caagcggccc    960uucgugaagc ugaacgugga gaccgacacc gccgagaucc ggcugaugug caccaagacc   1020uaccuggaca ccccucggcc caacgacgga agcaucaccg gacccugcga gagcgacggg   1080gacgaaggaa gcggcggaau caagggcggc uucgugcacc agcggauggc cagcaagauc   1140ggccgguggu acagccggac caugagcaag accaagcgga ugggcauggg ccuguacgug   1200aaguacgacg gcgaccccug gacagacagc gaagcccugg cccugucugg cgugauggug   1260agcauggagg agcccggcug guacagcuuc ggcuucgaga ucaaggacaa gaagugcgac   1320gugcccugca ucggcaucga gauggugcac gacggcggca agaccaccug gcauagcgcc   1380gcaaccgcga ucuacugccu gaugggcagc ggccagcugc ugugggacac cgugaccggc   1440gugaacauga cccugugaua auaggcugga gccucggugg ccuagcuucu ugccccuugg   1500gccucccccc agccccuccu ccccuuccug cacccguacc cccguggucu uugaauaaag   1560ucugaguggg cggc                                                     1574</s400><s200><s210>39</s210><s211>1398</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 39augcugccca gcaccaucca gacccugacc cuguuccuga ccagcggagg cgugcugcug     60agccuguacg ucagcgccag ccugagcuac cugcuguaca gcgacauccu gcugaaguuc    120agccggaccg aggugaccgc ucccaucaug ccccuggacu gcgccaacgc cagcaacgug    180caggccguga aucggagcgc caccaagggc gugacucccc ugcugcccga gccugagugg    240acuuauccuc ggcugagcug cccaggcagc accuuccaga aggcccugcu gaucagccca    300caccgguucg gcgagaccaa gggcaacagc gcuccccuga ucauccggga gcccuucauc    360gccugcggcc ccaaggagug caagcacuuc gcccugaccc acuacgcugc ccaacccgga    420ggcuacuaca acggcaccag agagggccgg aacaagcugc ggcaccugau cagcgugaag    480cugggcaaga uccccaccgu ggagaacagc aucuuccaca uggcugcuug gucuggaagu    540gcuugucacg acggccggga guggaccuac aucggcgugg acggcccaga cagcaacgcc    600cugcugaaga ucaaguacgg cgaggccuac accgacaccu accacagcua cgccaagaac    660auccugcgga cccaggagag cgccugcaac ugcaucggcg gcgacugcua ccugaugauc    720accgacggcc cagcaucugg caucagcgag ugccgguucc ugaagauccg ggagggccgg    780aucaucaagg agaucuuccc caccgggaga gugaagcaca ccgaggagug caccugcggc    840uucgccagca acaagaccau cgagugcgcc ugccgggaca acagcuacac cgccaagcgg    900cccuucguga agcugaacgu ggagaccgac accgccgaga uccggcugau gugcaccaag    960accuaccugg acaccccucg gcccaacgac ggaagcauca ccggacccug cgagagcgac   1020ggggacgaag gaagcggcgg aaucaagggc ggcuucgugc accagcggau ggccagcaag   1080aucggccggu gguacagccg gaccaugagc aagaccaagc ggaugggcau gggccuguac   1140gugaaguacg acggcgaccc cuggacagac agcgaagccc uggcccuguc uggcgugaug   1200gugagcaugg aggagcccgg cugguacagc uucggcuucg agaucaagga caagaagugc   1260gacgugcccu gcaucggcau cgagauggug cacgacggcg gcaagaccac cuggcauagc   1320gccgcaaccg cgaucuacug ccugaugggc agcggccagc ugcuguggga caccgugacc   1380ggcgugaaca ugacccug                                                 1398</s400><s200><s210>40</s210><s211>466</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 40Met Leu Pro Ser Thr Ile Gln Thr Leu Thr Leu Phe Leu Thr Ser Gly1               5                   10                  15Gly Val Leu Leu Ser Leu Tyr Val Ser Ala Ser Leu Ser Tyr Leu Leu            20                  25                  30Tyr Ser Asp Ile Leu Leu Lys Phe Ser Arg Thr Glu Val Thr Ala Pro        35                  40                  45Ile Met Pro Leu Asp Cys Ala Asn Ala Ser Asn Val Gln Ala Val Asn    50                  55                  60Arg Ser Ala Thr Lys Gly Val Thr Pro Leu Leu Pro Glu Pro Glu Trp65                  70                  75                  80Thr Tyr Pro Arg Leu Ser Cys Pro Gly Ser Thr Phe Gln Lys Ala Leu                85                  90                  95Leu Ile Ser Pro His Arg Phe Gly Glu Thr Lys Gly Asn Ser Ala Pro            100                 105                 110Leu Ile Ile Arg Glu Pro Phe Ile Ala Cys Gly Pro Lys Glu Cys Lys        115                 120                 125His Phe Ala Leu Thr His Tyr Ala Ala Gln Pro Gly Gly Tyr Tyr Asn    130                 135                 140Gly Thr Arg Glu Gly Arg Asn Lys Leu Arg His Leu Ile Ser Val Lys145                 150                 155                 160Leu Gly Lys Ile Pro Thr Val Glu Asn Ser Ile Phe His Met Ala Ala                165                 170                 175Trp Ser Gly Ser Ala Cys His Asp Gly Arg Glu Trp Thr Tyr Ile Gly            180                 185                 190Val Asp Gly Pro Asp Ser Asn Ala Leu Leu Lys Ile Lys Tyr Gly Glu        195                 200                 205Ala Tyr Thr Asp Thr Tyr His Ser Tyr Ala Lys Asn Ile Leu Arg Thr    210                 215                 220Gln Glu Ser Ala Cys Asn Cys Ile Gly Gly Asp Cys Tyr Leu Met Ile225                 230                 235                 240Thr Asp Gly Pro Ala Ser Gly Ile Ser Glu Cys Arg Phe Leu Lys Ile                245                 250                 255Arg Glu Gly Arg Ile Ile Lys Glu Ile Phe Pro Thr Gly Arg Val Lys            260                 265                 270His Thr Glu Glu Cys Thr Cys Gly Phe Ala Ser Asn Lys Thr Ile Glu        275                 280                 285Cys Ala Cys Arg Asp Asn Ser Tyr Thr Ala Lys Arg Pro Phe Val Lys    290                 295                 300Leu Asn Val Glu Thr Asp Thr Ala Glu Ile Arg Leu Met Cys Thr Lys305                 310                 315                 320Thr Tyr Leu Asp Thr Pro Arg Pro Asn Asp Gly Ser Ile Thr Gly Pro                325                 330                 335Cys Glu Ser Asp Gly Asp Glu Gly Ser Gly Gly Ile Lys Gly Gly Phe            340                 345                 350Val His Gln Arg Met Ala Ser Lys Ile Gly Arg Trp Tyr Ser Arg Thr        355                 360                 365Met Ser Lys Thr Lys Arg Met Gly Met Gly Leu Tyr Val Lys Tyr Asp    370                 375                 380Gly Asp Pro Trp Thr Asp Ser Glu Ala Leu Ala Leu Ser Gly Val Met385                 390                 395                 400Val Ser Met Glu Glu Pro Gly Trp Tyr Ser Phe Gly Phe Glu Ile Lys                405                 410                 415Asp Lys Lys Cys Asp Val Pro Cys Ile Gly Ile Glu Met Val His Asp            420                 425                 430Gly Gly Lys Thr Thr Trp His Ser Ala Ala Thr Ala Ile Tyr Cys Leu        435                 440                 445Met Gly Ser Gly Gln Leu Leu Trp Asp Thr Val Thr Gly Val Asn Met    450                 455                 460Thr Leu465</s400><s200><s210>41</s210><s211>1874</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 41gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaggccaucc uggucgugau gcuguacacc uucaccaccg ccaacgccga cacccugugc    120aucggcuacc acgccaacaa cagcaccgac accguggaca ccgugcugga gaagaacgug    180accgugaccc acagcgugaa ccugcuggag gacaagcaca acggcaagcu gugcaagcug    240aggggagugg caccccugca ccugggcaag ugcaacaucg ccggcuggau ccugggcaac    300cccgagugcg agagccugag cacagcccgg agcuggagcu acaucgugga gaccagcaac    360agcgacaacg gcaccuguua ccccggcgac uucaucaacu acgaggagcu gcgggagcag    420cugagcagcg ugagcagcuu cgagcgguuc gagaucuucc ccaagaccag cagcuggccc    480aaccacgaca gcgacaacgg cgugacagca gccuguccac acgccggagc caagagcuuc    540uacaagaacc ugaucuggcu ggugaagaag ggcaagagcu accccaagau caaccagacc    600uacaucaacg acaagggcaa ggaggugcug gugcuguggg gcauccacca cccaccuacc    660aucgccgacc agcagagccu guaccagaac gccgacgccu acguguucgu gggcaccagc    720cgguacagca agaaguucaa gccagagauc gccacccggc ccaaggugag agaccaggag    780ggccggauga acuacuacug gacccuggug gagcccggag acaagauuac cuucgaggcc    840accggcaacc ugguggcccc ucgguacgcc uucaccaugg aacgggacgc uggcagcggc    900aucaucauca gcgacacucc cgugcacgac ugcaacacca ccugccagac ucccgagggc    960gcuaucaaca ccagccugcc cuuccagaac gugcacccca ucaccaucgg caagugcccc   1020aaguacguaa agagcaccaa auugcggcug gccaccggac ucaggaacgu gcccagcauc   1080caaagccggg gccuguuugg cgcaaucgcc ggcuucaucg agggcggcug gacuggcaug   1140guggacggcu gguacggcua ccaccaccag aacgaacagg ggagcggcua cgcagcugac   1200cugaagagca cccagaacgc caucgacaag aucaccaaca aggugaacag cgugaucgag   1260aagaugaaca cccaguucac cgccgugggc aaggaguuca accaccugga gaagcggauc   1320gagaaccuga acaagaaggu ggacgacggc uuccuggaca ucuggaccua caacgccgag   1380cugcugguuc ugcuggagaa cgagcggacc cuggacuauc acgacagcaa cgugaagaac   1440cuguacgaga aggugcggaa ccagcugaag aacaacgcca aggagaucgg caacggcugc   1500uucgaguucu accacaagug cgacaacacc ugcauggaga gcgugaagaa cggcaccuac   1560gacuacccca aguacagcga ggaggccaag cugaaccggg agaagaucga cggcgugaag   1620cuggacagca cccggaucua ccagauccug gccaucuaca gcaccguggc cagcagccug   1680gugcuggugg ugagccuggg cgccaucagc uucuggaugu gcagcaacgg cagccugcag   1740ugccggaucu gcaucugaua auaggcugga gccucggugg ccuagcuucu ugccccuugg   1800gccucccccc agccccuccu ccccuuccug cacccguacc cccguggucu uugaauaaag   1860ucugaguggg cggc                                                     1874</s400><s200><s210>42</s210><s211>1698</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 42augaaggcca uccuggucgu gaugcuguac accuucacca ccgccaacgc cgacacccug     60ugcaucggcu accacgccaa caacagcacc gacaccgugg acaccgugcu ggagaagaac    120gugaccguga cccacagcgu gaaccugcug gaggacaagc acaacggcaa gcugugcaag    180cugaggggag uggcaccccu gcaccugggc aagugcaaca ucgccggcug gauccugggc    240aaccccgagu gcgagagccu gagcacagcc cggagcugga gcuacaucgu ggagaccagc    300aacagcgaca acggcaccug uuaccccggc gacuucauca acuacgagga gcugcgggag    360cagcugagca gcgugagcag cuucgagcgg uucgagaucu uccccaagac cagcagcugg    420cccaaccacg acagcgacaa cggcgugaca gcagccuguc cacacgccgg agccaagagc    480uucuacaaga accugaucug gcuggugaag aagggcaaga gcuaccccaa gaucaaccag    540accuacauca acgacaaggg caaggaggug cuggugcugu ggggcaucca ccacccaccu    600accaucgccg accagcagag ccuguaccag aacgccgacg ccuacguguu cgugggcacc    660agccgguaca gcaagaaguu caagccagag aucgccaccc ggcccaaggu gagagaccag    720gagggccgga ugaacuacua cuggacccug guggagcccg gagacaagau uaccuucgag    780gccaccggca accugguggc cccucgguac gccuucacca uggaacggga cgcuggcagc    840ggcaucauca ucagcgacac ucccgugcac gacugcaaca ccaccugcca gacucccgag    900ggcgcuauca acaccagccu gcccuuccag aacgugcacc ccaucaccau cggcaagugc    960cccaaguacg uaaagagcac caaauugcgg cuggccaccg gacucaggaa cgugcccagc   1020auccaaagcc ggggccuguu uggcgcaauc gccggcuuca ucgagggcgg cuggacuggc   1080augguggacg gcugguacgg cuaccaccac cagaacgaac aggggagcgg cuacgcagcu   1140gaccugaaga gcacccagaa cgccaucgac aagaucacca acaaggugaa cagcgugauc   1200gagaagauga acacccaguu caccgccgug ggcaaggagu ucaaccaccu ggagaagcgg   1260aucgagaacc ugaacaagaa gguggacgac ggcuuccugg acaucuggac cuacaacgcc   1320gagcugcugg uucugcugga gaacgagcgg acccuggacu aucacgacag caacgugaag   1380aaccuguacg agaaggugcg gaaccagcug aagaacaacg ccaaggagau cggcaacggc   1440ugcuucgagu ucuaccacaa gugcgacaac accugcaugg agagcgugaa gaacggcacc   1500uacgacuacc ccaaguacag cgaggaggcc aagcugaacc gggagaagau cgacggcgug   1560aagcuggaca gcacccggau cuaccagauc cuggccaucu acagcaccgu ggccagcagc   1620cuggugcugg uggugagccu gggcgccauc agcuucugga ugugcagcaa cggcagccug   1680cagugccgga ucugcauc                                                 1698</s400><s200><s210>43</s210><s211>566</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 43Met Lys Ala Ile Leu Val Val Met Leu Tyr Thr Phe Thr Thr Ala Asn1               5                   10                  15Ala Asp Thr Leu Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr            20                  25                  30Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn        35                  40                  45Leu Leu Glu Asp Lys His Asn Gly Lys Leu Cys Lys Leu Arg Gly Val    50                  55                  60Ala Pro Leu His Leu Gly Lys Cys Asn Ile Ala Gly Trp Ile Leu Gly65                  70                  75                  80Asn Pro Glu Cys Glu Ser Leu Ser Thr Ala Arg Ser Trp Ser Tyr Ile                85                  90                  95Val Glu Thr Ser Asn Ser Asp Asn Gly Thr Cys Tyr Pro Gly Asp Phe            100                 105                 110Ile Asn Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe        115                 120                 125Glu Arg Phe Glu Ile Phe Pro Lys Thr Ser Ser Trp Pro Asn His Asp    130                 135                 140Ser Asp Asn Gly Val Thr Ala Ala Cys Pro His Ala Gly Ala Lys Ser145                 150                 155                 160Phe Tyr Lys Asn Leu Ile Trp Leu Val Lys Lys Gly Lys Ser Tyr Pro                165                 170                 175Lys Ile Asn Gln Thr Tyr Ile Asn Asp Lys Gly Lys Glu Val Leu Val            180                 185                 190Leu Trp Gly Ile His His Pro Pro Thr Ile Ala Asp Gln Gln Ser Leu        195                 200                 205Tyr Gln Asn Ala Asp Ala Tyr Val Phe Val Gly Thr Ser Arg Tyr Ser    210                 215                 220Lys Lys Phe Lys Pro Glu Ile Ala Thr Arg Pro Lys Val Arg Asp Gln225                 230                 235                 240Glu Gly Arg Met Asn Tyr Tyr Trp Thr Leu Val Glu Pro Gly Asp Lys                245                 250                 255Ile Thr Phe Glu Ala Thr Gly Asn Leu Val Ala Pro Arg Tyr Ala Phe            260                 265                 270Thr Met Glu Arg Asp Ala Gly Ser Gly Ile Ile Ile Ser Asp Thr Pro        275                 280                 285Val His Asp Cys Asn Thr Thr Cys Gln Thr Pro Glu Gly Ala Ile Asn    290                 295                 300Thr Ser Leu Pro Phe Gln Asn Val His Pro Ile Thr Ile Gly Lys Cys305                 310                 315                 320Pro Lys Tyr Val Lys Ser Thr Lys Leu Arg Leu Ala Thr Gly Leu Arg                325                 330                 335Asn Val Pro Ser Ile Gln Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly            340                 345                 350Phe Ile Glu Gly Gly Trp Thr Gly Met Val Asp Gly Trp Tyr Gly Tyr        355                 360                 365His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Leu Lys Ser    370                 375                 380Thr Gln Asn Ala Ile Asp Lys Ile Thr Asn Lys Val Asn Ser Val Ile385                 390                 395                 400Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu Phe Asn His                405                 410                 415Leu Glu Lys Arg Ile Glu Asn Leu Asn Lys Lys Val Asp Asp Gly Phe            420                 425                 430Leu Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu Glu Asn        435                 440                 445Glu Arg Thr Leu Asp Tyr His Asp Ser Asn Val Lys Asn Leu Tyr Glu    450                 455                 460Lys Val Arg Asn Gln Leu Lys Asn Asn Ala Lys Glu Ile Gly Asn Gly465                 470                 475                 480Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Thr Cys Met Glu Ser Val                485                 490                 495Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ala Lys Leu            500                 505                 510Asn Arg Glu Lys Ile Asp Gly Val Lys Leu Asp Ser Thr Arg Ile Tyr        515                 520                 525Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Val    530                 535                 540Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu545                 550                 555                 560Gln Cys Arg Ile Cys Ile                565</s400><s200><s210>44</s210><s211>1583</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 44gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaccccaacc agaagaucau caccaucggc agcaucugca ugaccaucgg caccgccaac    120cugauccugc aaaucggcaa caucaucagc aucuggguga gccacagcau ccagaucggc    180aaccagagcc agaucgagac cugcaacaag agcgugauca ccuacgagaa caacaccugg    240gugaaccaga ccuucgugaa caucagcaac accaacagcg ccgcucggca gucaguggcc    300agcgugaagc uggccggcaa cagcagccug ugccccguua guggcugggc caucuacagc    360aaggacaaca gcgugcggau cggcagcaag ggcgacgugu ucgugauccg ggagcccuuc    420aucagcugca gcccgcuuga gugccgcacc uucuuccuga cccagggcgc ucugcugaac    480gacaagcaca gcaacggcac caucaaggac cggagccccu aucggacccu gaugagcugc    540cccauuggcg aggugcccag ccccuacaac agccgguucg agucuguggc cuggagcgcc    600ucugccugcc acgacggcac caacuggcug accaucggga ucagcggacc cgauagcgga    660gcaguggccg ugcugaagua caacggcauc aucaccgaca ccaucaagag cuggcggaac    720aagauccugc ggacccagga gagcgagugc gccugcguga acggcagcug cuucaccauc    780augaccgacg gcccuagcga cggacaggcc agcuacaaga ucuuccggau cgagaagggc    840aagaucauca agagcgugga gaugaaggca cccaacuacc acuacgagga gugcagcugc    900uaccccgaca gcagcgagau caccugcgug ugccgggaca acuggcacgg gagcaacagg    960cccuggguga gcuucaacca gaaccuggag uaccagaugg gcuacaucug cagcggcgug   1020uucggcgaca acccacggcc caacgacaag acuggcagcu gcgguccggu gagcagcaac   1080ggcgccaacg gcgugaaggg cuucagcuuc aaguacggca acggcgugug gaucggccgg   1140accaagagca ucagcagccg gaagggcuuc gagaugaucu gggaccccaa cggcuggacc   1200ggcaccgaca acaaguucag caagaagcag gacaucgugg gcaucaacga guggagcggc   1260uacagcggca gcuucgugca gcaccccgag cugacuggcc ugaacugcau ccggcccugc   1320uucugggugg aacugauacg gggacggccc gaggagaaca ccaucuggac cagcggcagc   1380agcaucagcu ucugcggcgu ggacagcgau aucgugggcu ggagcuggcc agacggagcc   1440gagcugcccu ucaccaucga caagugauaa uaggcuggag ccucgguggc cuagcuucuu   1500gccccuuggg ccucccccca gccccuccuc cccuuccugc acccguaccc ccguggucuu   1560ugaauaaagu cugagugggc ggc                                           1583</s400><s200><s210>45</s210><s211>1407</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 45augaacccca accagaagau caucaccauc ggcagcaucu gcaugaccau cggcaccgcc     60aaccugaucc ugcaaaucgg caacaucauc agcaucuggg ugagccacag cauccagauc    120ggcaaccaga gccagaucga gaccugcaac aagagcguga ucaccuacga gaacaacacc    180ugggugaacc agaccuucgu gaacaucagc aacaccaaca gcgccgcucg gcagucagug    240gccagcguga agcuggccgg caacagcagc cugugccccg uuaguggcug ggccaucuac    300agcaaggaca acagcgugcg gaucggcagc aagggcgacg uguucgugau ccgggagccc    360uucaucagcu gcagcccgcu ugagugccgc accuucuucc ugacccaggg cgcucugcug    420aacgacaagc acagcaacgg caccaucaag gaccggagcc ccuaucggac ccugaugagc    480ugccccauug gcgaggugcc cagccccuac aacagccggu ucgagucugu ggccuggagc    540gccucugccu gccacgacgg caccaacugg cugaccaucg ggaucagcgg acccgauagc    600ggagcagugg ccgugcugaa guacaacggc aucaucaccg acaccaucaa gagcuggcgg    660aacaagaucc ugcggaccca ggagagcgag ugcgccugcg ugaacggcag cugcuucacc    720aucaugaccg acggcccuag cgacggacag gccagcuaca agaucuuccg gaucgagaag    780ggcaagauca ucaagagcgu ggagaugaag gcacccaacu accacuacga ggagugcagc    840ugcuaccccg acagcagcga gaucaccugc gugugccggg acaacuggca cgggagcaac    900aggcccuggg ugagcuucaa ccagaaccug gaguaccaga ugggcuacau cugcagcggc    960guguucggcg acaacccacg gcccaacgac aagacuggca gcugcggucc ggugagcagc   1020aacggcgcca acggcgugaa gggcuucagc uucaaguacg gcaacggcgu guggaucggc   1080cggaccaaga gcaucagcag ccggaagggc uucgagauga ucugggaccc caacggcugg   1140accggcaccg acaacaaguu cagcaagaag caggacaucg ugggcaucaa cgaguggagc   1200ggcuacagcg gcagcuucgu gcagcacccc gagcugacug gccugaacug cauccggccc   1260ugcuucuggg uggaacugau acggggacgg cccgaggaga acaccaucug gaccagcggc   1320agcagcauca gcuucugcgg cguggacagc gauaucgugg gcuggagcug gccagacgga   1380gccgagcugc ccuucaccau cgacaag                                       1407</s400><s200><s210>46</s210><s211>469</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 46Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Ile Cys Met Thr1               5                   10                  15Ile Gly Thr Ala Asn Leu Ile Leu Gln Ile Gly Asn Ile Ile Ser Ile            20                  25                  30Trp Val Ser His Ser Ile Gln Ile Gly Asn Gln Ser Gln Ile Glu Thr        35                  40                  45Cys Asn Lys Ser Val Ile Thr Tyr Glu Asn Asn Thr Trp Val Asn Gln    50                  55                  60Thr Phe Val Asn Ile Ser Asn Thr Asn Ser Ala Ala Arg Gln Ser Val65                  70                  75                  80Ala Ser Val Lys Leu Ala Gly Asn Ser Ser Leu Cys Pro Val Ser Gly                85                  90                  95Trp Ala Ile Tyr Ser Lys Asp Asn Ser Val Arg Ile Gly Ser Lys Gly            100                 105                 110Asp Val Phe Val Ile Arg Glu Pro Phe Ile Ser Cys Ser Pro Leu Glu        115                 120                 125Cys Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His    130                 135                 140Ser Asn Gly Thr Ile Lys Asp Arg Ser Pro Tyr Arg Thr Leu Met Ser145                 150                 155                 160Cys Pro Ile Gly Glu Val Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser                165                 170                 175Val Ala Trp Ser Ala Ser Ala Cys His Asp Gly Thr Asn Trp Leu Thr            180                 185                 190Ile Gly Ile Ser Gly Pro Asp Ser Gly Ala Val Ala Val Leu Lys Tyr        195                 200                 205Asn Gly Ile Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Lys Ile Leu    210                 215                 220Arg Thr Gln Glu Ser Glu Cys Ala Cys Val Asn Gly Ser Cys Phe Thr225                 230                 235                 240Ile Met Thr Asp Gly Pro Ser Asp Gly Gln Ala Ser Tyr Lys Ile Phe                245                 250                 255Arg Ile Glu Lys Gly Lys Ile Ile Lys Ser Val Glu Met Lys Ala Pro            260                 265                 270Asn Tyr His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ser Ser Glu Ile        275                 280                 285Thr Cys Val Cys Arg Asp Asn Trp His Gly Ser Asn Arg Pro Trp Val    290                 295                 300Ser Phe Asn Gln Asn Leu Glu Tyr Gln Met Gly Tyr Ile Cys Ser Gly305                 310                 315                 320Val Phe Gly Asp Asn Pro Arg Pro Asn Asp Lys Thr Gly Ser Cys Gly                325                 330                 335Pro Val Ser Ser Asn Gly Ala Asn Gly Val Lys Gly Phe Ser Phe Lys            340                 345                 350Tyr Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser Ile Ser Ser Arg        355                 360                 365Lys Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Gly Thr Asp    370                 375                 380Asn Lys Phe Ser Lys Lys Gln Asp Ile Val Gly Ile Asn Glu Trp Ser385                 390                 395                 400Gly Tyr Ser Gly Ser Phe Val Gln His Pro Glu Leu Thr Gly Leu Asn                405                 410                 415Cys Ile Arg Pro Cys Phe Trp Val Glu Leu Ile Arg Gly Arg Pro Glu            420                 425                 430Glu Asn Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly Val        435                 440                 445Asp Ser Asp Ile Val Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu Pro    450                 455                 460Phe Thr Ile Asp Lys465</s400><s200><s210>47</s210><s211>1583</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 47gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaccccaacc agaagaucau caccaucggc agcaucugca ugaccaucgg caccgccaac    120cugauccugc aaaucggcaa caucaucagc aucuggguga gccacagcau ccagaucggc    180aaccagagcc agaucgagac cugcaacaag agcgugauca ccuacgagaa caacaccugg    240gugaaccaga ccuucgugaa caucagcaac accaacagcg ccgcucggca gucaguggcc    300agcgugaagc uggccggcaa cagcagccug ugccccguua guggcugggc caucuacagc    360aaggacaaca gcgugcggau cggcagcaag ggcgacgugu ucgugauccg ggagcccuuc    420aucagcugca gcccgcuuga gugccgcacc uucuuccuga cccagggcgc ucugcugaac    480gacaagcaca gcaacggcac caucaagggc cggagccccu aucggacccu gaugagcugc    540cccauuggcg aggugcccag ccccuacaac agccgguucg agucuguggc cuggagcgcc    600ucugccugcc acgacggcac caacuggcug accaucggga ucagcggacc cgauagcgga    660gcaguggccg ugcugaagua caacggcauc aucaccgaca ccaucaagag cuggcggaac    720aagauccugc ggacccagga gagcgagugc gccugcguga acggcagcug cuucaccauc    780augaccgacg gcccuagcga cggacaggcc agcuacaaga ucuuccggau cgagaagggc    840aagaucauca agagcgugga gaugaaggca cccaacuacc acuacgagga gugcagcugc    900uaccccgaca gcagcgagau caccugcgug ugccgggaca acuggcacgg gagcaacagg    960cccuggguga gcuucaacca gaaccuggag uaccagaugg gcuacaucug cagcggcgug   1020uucggcgaca acccacggcc caacgacaag acuggcagcu gcgguccggu gagcagcaac   1080ggcgccaacg gcgugaaggg cuucagcuuc aaguacggca acggcgugug gaucggccgg   1140accaagagca ucagcagccg gaagggcuuc gagaugaucu gggaccccaa cggcuggacc   1200ggcaccgaca acaaguucag caagaagcag gacaucgugg gcaucaacga guggagcggc   1260uacagcggca gcuucgugca gcaccccgag cugacuggcc ugaacugcau ccggcccugc   1320uucugggugg aacugauacg gggacggccc gaggagaaca ccaucuggac cagcggcagc   1380agcaucagcu ucugcggcgu ggacagcgau aucgugggcu ggagcuggcc agacggagcc   1440gagcugcccu ucaccaucga caagugauaa uaggcuggag ccucgguggc cuagcuucuu   1500gccccuuggg ccucccccca gccccuccuc cccuuccugc acccguaccc ccguggucuu   1560ugaauaaagu cugagugggc ggc                                           1583</s400><s200><s210>48</s210><s211>1407</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 48augaacccca accagaagau caucaccauc ggcagcaucu gcaugaccau cggcaccgcc     60aaccugaucc ugcaaaucgg caacaucauc agcaucuggg ugagccacag cauccagauc    120ggcaaccaga gccagaucga gaccugcaac aagagcguga ucaccuacga gaacaacacc    180ugggugaacc agaccuucgu gaacaucagc aacaccaaca gcgccgcucg gcagucagug    240gccagcguga agcuggccgg caacagcagc cugugccccg uuaguggcug ggccaucuac    300agcaaggaca acagcgugcg gaucggcagc aagggcgacg uguucgugau ccgggagccc    360uucaucagcu gcagcccgcu ugagugccgc accuucuucc ugacccaggg cgcucugcug    420aacgacaagc acagcaacgg caccaucaag ggccggagcc ccuaucggac ccugaugagc    480ugccccauug gcgaggugcc cagccccuac aacagccggu ucgagucugu ggccuggagc    540gccucugccu gccacgacgg caccaacugg cugaccaucg ggaucagcgg acccgauagc    600ggagcagugg ccgugcugaa guacaacggc aucaucaccg acaccaucaa gagcuggcgg    660aacaagaucc ugcggaccca ggagagcgag ugcgccugcg ugaacggcag cugcuucacc    720aucaugaccg acggcccuag cgacggacag gccagcuaca agaucuuccg gaucgagaag    780ggcaagauca ucaagagcgu ggagaugaag gcacccaacu accacuacga ggagugcagc    840ugcuaccccg acagcagcga gaucaccugc gugugccggg acaacuggca cgggagcaac    900aggcccuggg ugagcuucaa ccagaaccug gaguaccaga ugggcuacau cugcagcggc    960guguucggcg acaacccacg gcccaacgac aagacuggca gcugcggucc ggugagcagc   1020aacggcgcca acggcgugaa gggcuucagc uucaaguacg gcaacggcgu guggaucggc   1080cggaccaaga gcaucagcag ccggaagggc uucgagauga ucugggaccc caacggcugg   1140accggcaccg acaacaaguu cagcaagaag caggacaucg ugggcaucaa cgaguggagc   1200ggcuacagcg gcagcuucgu gcagcacccc gagcugacug gccugaacug cauccggccc   1260ugcuucuggg uggaacugau acggggacgg cccgaggaga acaccaucug gaccagcggc   1320agcagcauca gcuucugcgg cguggacagc gauaucgugg gcuggagcug gccagacgga   1380gccgagcugc ccuucaccau cgacaag                                       1407</s400><s200><s210>49</s210><s211>469</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 49Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Ile Cys Met Thr1               5                   10                  15Ile Gly Thr Ala Asn Leu Ile Leu Gln Ile Gly Asn Ile Ile Ser Ile            20                  25                  30Trp Val Ser His Ser Ile Gln Ile Gly Asn Gln Ser Gln Ile Glu Thr        35                  40                  45Cys Asn Lys Ser Val Ile Thr Tyr Glu Asn Asn Thr Trp Val Asn Gln    50                  55                  60Thr Phe Val Asn Ile Ser Asn Thr Asn Ser Ala Ala Arg Gln Ser Val65                  70                  75                  80Ala Ser Val Lys Leu Ala Gly Asn Ser Ser Leu Cys Pro Val Ser Gly                85                  90                  95Trp Ala Ile Tyr Ser Lys Asp Asn Ser Val Arg Ile Gly Ser Lys Gly            100                 105                 110Asp Val Phe Val Ile Arg Glu Pro Phe Ile Ser Cys Ser Pro Leu Glu        115                 120                 125Cys Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His    130                 135                 140Ser Asn Gly Thr Ile Lys Gly Arg Ser Pro Tyr Arg Thr Leu Met Ser145                 150                 155                 160Cys Pro Ile Gly Glu Val Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser                165                 170                 175Val Ala Trp Ser Ala Ser Ala Cys His Asp Gly Thr Asn Trp Leu Thr            180                 185                 190Ile Gly Ile Ser Gly Pro Asp Ser Gly Ala Val Ala Val Leu Lys Tyr        195                 200                 205Asn Gly Ile Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Lys Ile Leu    210                 215                 220Arg Thr Gln Glu Ser Glu Cys Ala Cys Val Asn Gly Ser Cys Phe Thr225                 230                 235                 240Ile Met Thr Asp Gly Pro Ser Asp Gly Gln Ala Ser Tyr Lys Ile Phe                245                 250                 255Arg Ile Glu Lys Gly Lys Ile Ile Lys Ser Val Glu Met Lys Ala Pro            260                 265                 270Asn Tyr His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ser Ser Glu Ile        275                 280                 285Thr Cys Val Cys Arg Asp Asn Trp His Gly Ser Asn Arg Pro Trp Val    290                 295                 300Ser Phe Asn Gln Asn Leu Glu Tyr Gln Met Gly Tyr Ile Cys Ser Gly305                 310                 315                 320Val Phe Gly Asp Asn Pro Arg Pro Asn Asp Lys Thr Gly Ser Cys Gly                325                 330                 335Pro Val Ser Ser Asn Gly Ala Asn Gly Val Lys Gly Phe Ser Phe Lys            340                 345                 350Tyr Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser Ile Ser Ser Arg        355                 360                 365Lys Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Gly Thr Asp    370                 375                 380Asn Lys Phe Ser Lys Lys Gln Asp Ile Val Gly Ile Asn Glu Trp Ser385                 390                 395                 400Gly Tyr Ser Gly Ser Phe Val Gln His Pro Glu Leu Thr Gly Leu Asn                405                 410                 415Cys Ile Arg Pro Cys Phe Trp Val Glu Leu Ile Arg Gly Arg Pro Glu            420                 425                 430Glu Asn Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly Val        435                 440                 445Asp Ser Asp Ile Val Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu Pro    450                 455                 460Phe Thr Ile Asp Lys465</s400><s200><s210>50</s210><s211>1874</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 50gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aagaccauca ucgcccugag cuacauccug ugccugggcu ucacccagaa gauccccggc    120aacgauaaca gcaccgccac ccugugucug ggacaccacg ccgugcccaa cggcaccauc    180gugaagacua ucaccaacga ccggaucgag gugaccaacg ccaccgagcu ggugcagaac    240agcagcaucg gcgagaucug cgacagcccu caccagaucc uggacggcgg caacugcacc    300cugaucgacg cacugcuggg cgacccucag ugcgacggcu uucagaacaa gaagugggac    360cuguucgugg agagaucgcg ggccuacagc aacugcuacc ccuacgacgu ccccgacuac    420gcaagccuga gaagccucgu ggccucaagc ggcacccugg aguucaagaa cgagagcuuc    480aacugggccg gcgugaccca gaacggcaag ucauucagcu gcauccgggg cuccagcagc    540agcuucuucu cacggcugaa cuggcugacc caccugaacu acaccuaccc cgcccugaac    600gugaccaugc ccaacaagga gcaguucgac aagcuguaca ucuggggagu gcaccauccc    660ggcaccgaca aggaccagau uagccuguac gcccagucua gcggccggau caccgugagc    720accaagcgga gccagcaggc cgugaucccc aacaucggcu cucggcccag aauccgggac    780auccccagcc ggaucagcau cuacuggacc auugugaagc ccggcgacau ccugcugauc    840aacuccaccg gcaaccugau cgccccucgg ggcuauuuca agauccggag cggcaagagc    900agcaucaugc ggagcgacgc cccuaucggc aagugcaaga gcgagugcau cacacccaac    960ggaagcaucc ccaacgacaa gcccuuccag aacgugaacc ggauaaccua cggcgccugc   1020ccuagauacg ugaagcagaa cacccugaag cuggccaccg gcaugcggaa cgugcccgag   1080aagcagacuc ggggcaucuu cggcgccauc gccggcuuca ucgagaacgg cugggagggc   1140augguggacg gcugguacgg cuuccggcac cagaacucug agggcagagg acaggccgca   1200gaccugaaga gcacccaggc cgccaucgac cagaucaacg gcaagcugaa ccggcugauc   1260ggcaagacca acgagaaguu ccaccagauc gagaaggagu ucagcgaggu ggagggcagg   1320guacaggacc uggagaagua cguggaggac accaagaucg accuguggag cuacaacgcc   1380gagcugcugg uagcccugga gaaccagcac accaucgacc ugaccgacag cgagaugaac   1440aagcuguucg agaagaccaa gaagcagcug cgggagaacg ccgaggacau gggcaacggc   1500ugcuucaaga ucuaccacaa gugcgacaac gccugcaucg gcagcauccg gaacgagacc   1560uacgaccaca acguguaccg ggacgaggcc cugaacaacc gguuccagau caagggcgug   1620gagcugaaga gcggcuacaa ggacuggauc cuguggauca gcuucgccau cuccugcuuc   1680cugcugugcg uggcccugcu ggguuucauc augugggccu gccagaaggg caacauccgg   1740ugcaacaucu gcaucugaua auaggcugga gccucggugg ccuagcuucu ugccccuugg   1800gccucccccc agccccuccu ccccuuccug cacccguacc cccguggucu uugaauaaag   1860ucugaguggg cggc                                                     1874</s400><s200><s210>51</s210><s211>1698</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 51augaagacca ucaucgcccu gagcuacauc cugugccugg gcuucaccca gaagaucccc     60ggcaacgaua acagcaccgc cacccugugu cugggacacc acgccgugcc caacggcacc    120aucgugaaga cuaucaccaa cgaccggauc gaggugacca acgccaccga gcuggugcag    180aacagcagca ucggcgagau cugcgacagc ccucaccaga uccuggacgg cggcaacugc    240acccugaucg acgcacugcu gggcgacccu cagugcgacg gcuuucagaa caagaagugg    300gaccuguucg uggagagauc gcgggccuac agcaacugcu accccuacga cguccccgac    360uacgcaagcc ugagaagccu cguggccuca agcggcaccc uggaguucaa gaacgagagc    420uucaacuggg ccggcgugac ccagaacggc aagucauuca gcugcauccg gggcuccagc    480agcagcuucu ucucacggcu gaacuggcug acccaccuga acuacaccua ccccgcccug    540aacgugacca ugcccaacaa ggagcaguuc gacaagcugu acaucugggg agugcaccau    600cccggcaccg acaaggacca gauuagccug uacgcccagu cuagcggccg gaucaccgug    660agcaccaagc ggagccagca ggccgugauc cccaacaucg gcucucggcc cagaauccgg    720gacaucccca gccggaucag caucuacugg accauuguga agcccggcga cauccugcug    780aucaacucca ccggcaaccu gaucgccccu cggggcuauu ucaagauccg gagcggcaag    840agcagcauca ugcggagcga cgccccuauc ggcaagugca agagcgagug caucacaccc    900aacggaagca uccccaacga caagcccuuc cagaacguga accggauaac cuacggcgcc    960ugcccuagau acgugaagca gaacacccug aagcuggcca ccggcaugcg gaacgugccc   1020gagaagcaga cucggggcau cuucggcgcc aucgccggcu ucaucgagaa cggcugggag   1080ggcauggugg acggcuggua cggcuuccgg caccagaacu cugagggcag aggacaggcc   1140gcagaccuga agagcaccca ggccgccauc gaccagauca acggcaagcu gaaccggcug   1200aucggcaaga ccaacgagaa guuccaccag aucgagaagg aguucagcga gguggagggc   1260aggguacagg accuggagaa guacguggag gacaccaaga ucgaccugug gagcuacaac   1320gccgagcugc ugguagcccu ggagaaccag cacaccaucg accugaccga cagcgagaug   1380aacaagcugu ucgagaagac caagaagcag cugcgggaga acgccgagga caugggcaac   1440ggcugcuuca agaucuacca caagugcgac aacgccugca ucggcagcau ccggaacgag   1500accuacgacc acaacgugua ccgggacgag gcccugaaca accgguucca gaucaagggc   1560guggagcuga agagcggcua caaggacugg auccugugga ucagcuucgc caucuccugc   1620uuccugcugu gcguggcccu gcuggguuuc aucauguggg ccugccagaa gggcaacauc   1680cggugcaaca ucugcauc                                                 1698</s400><s200><s210>52</s210><s211>566</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 52Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys Leu Gly Phe Thr1               5                   10                  15Gln Lys Ile Pro Gly Asn Asp Asn Ser Thr Ala Thr Leu Cys Leu Gly            20                  25                  30His His Ala Val Pro Asn Gly Thr Ile Val Lys Thr Ile Thr Asn Asp        35                  40                  45Arg Ile Glu Val Thr Asn Ala Thr Glu Leu Val Gln Asn Ser Ser Ile    50                  55                  60Gly Glu Ile Cys Asp Ser Pro His Gln Ile Leu Asp Gly Gly Asn Cys65                  70                  75                  80Thr Leu Ile Asp Ala Leu Leu Gly Asp Pro Gln Cys Asp Gly Phe Gln                85                  90                  95Asn Lys Lys Trp Asp Leu Phe Val Glu Arg Ser Arg Ala Tyr Ser Asn            100                 105                 110Cys Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Arg Ser Leu Val        115                 120                 125Ala Ser Ser Gly Thr Leu Glu Phe Lys Asn Glu Ser Phe Asn Trp Ala    130                 135                 140Gly Val Thr Gln Asn Gly Lys Ser Phe Ser Cys Ile Arg Gly Ser Ser145                 150                 155                 160Ser Ser Phe Phe Ser Arg Leu Asn Trp Leu Thr His Leu Asn Tyr Thr                165                 170                 175Tyr Pro Ala Leu Asn Val Thr Met Pro Asn Lys Glu Gln Phe Asp Lys            180                 185                 190Leu Tyr Ile Trp Gly Val His His Pro Gly Thr Asp Lys Asp Gln Ile        195                 200                 205Ser Leu Tyr Ala Gln Ser Ser Gly Arg Ile Thr Val Ser Thr Lys Arg    210                 215                 220Ser Gln Gln Ala Val Ile Pro Asn Ile Gly Ser Arg Pro Arg Ile Arg225                 230                 235                 240Asp Ile Pro Ser Arg Ile Ser Ile Tyr Trp Thr Ile Val Lys Pro Gly                245                 250                 255Asp Ile Leu Leu Ile Asn Ser Thr Gly Asn Leu Ile Ala Pro Arg Gly            260                 265                 270Tyr Phe Lys Ile Arg Ser Gly Lys Ser Ser Ile Met Arg Ser Asp Ala        275                 280                 285Pro Ile Gly Lys Cys Lys Ser Glu Cys Ile Thr Pro Asn Gly Ser Ile    290                 295                 300Pro Asn Asp Lys Pro Phe Gln Asn Val Asn Arg Ile Thr Tyr Gly Ala305                 310                 315                 320Cys Pro Arg Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr Gly Met                325                 330                 335Arg Asn Val Pro Glu Lys Gln Thr Arg Gly Ile Phe Gly Ala Ile Ala            340                 345                 350Gly Phe Ile Glu Asn Gly Trp Glu Gly Met Val Asp Gly Trp Tyr Gly        355                 360                 365Phe Arg His Gln Asn Ser Glu Gly Arg Gly Gln Ala Ala Asp Leu Lys    370                 375                 380Ser Thr Gln Ala Ala Ile Asp Gln Ile Asn Gly Lys Leu Asn Arg Leu385                 390                 395                 400Ile Gly Lys Thr Asn Glu Lys Phe His Gln Ile Glu Lys Glu Phe Ser                405                 410                 415Glu Val Glu Gly Arg Val Gln Asp Leu Glu Lys Tyr Val Glu Asp Thr            420                 425                 430Lys Ile Asp Leu Trp Ser Tyr Asn Ala Glu Leu Leu Val Ala Leu Glu        435                 440                 445Asn Gln His Thr Ile Asp Leu Thr Asp Ser Glu Met Asn Lys Leu Phe    450                 455                 460Glu Lys Thr Lys Lys Gln Leu Arg Glu Asn Ala Glu Asp Met Gly Asn465                 470                 475                 480Gly Cys Phe Lys Ile Tyr His Lys Cys Asp Asn Ala Cys Ile Gly Ser                485                 490                 495Ile Arg Asn Glu Thr Tyr Asp His Asn Val Tyr Arg Asp Glu Ala Leu            500                 505                 510Asn Asn Arg Phe Gln Ile Lys Gly Val Glu Leu Lys Ser Gly Tyr Lys        515                 520                 525Asp Trp Ile Leu Trp Ile Ser Phe Ala Ile Ser Cys Phe Leu Leu Cys    530                 535                 540Val Ala Leu Leu Gly Phe Ile Met Trp Ala Cys Gln Lys Gly Asn Ile545                 550                 555                 560Arg Cys Asn Ile Cys Ile                565</s400><s200><s210>53</s210><s211>1874</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 53gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aagaccauca ucgcccugag cuacauccug ugccugggcu ucacccagaa gauccccggc    120aacgauaaca ugaccgccac ccugugucug ggacaccacg ccgugcccaa cggcaccauc    180gugaagacua ucaccaacga ccggaucgag gugaccaacg ccaccgagcu ggugcagaac    240agcagcaucg gcgagaucug cgacagcccu caccagaucc uggacggcgg caacugcacc    300cugaucgacg cacugcuggg cgacccucag ugcgacggcu uucagaacaa gaagugggac    360cuguucgugg agagaucgcg ggccuacagc aacugcuacc ccuacgacgu ccccgacuac    420gcaagccuga gaagccucgu ggccucaagc ggcacccugg aguucaagaa cgagagcuuc    480aacugggccg gcgugaccca gaacggcaag ucauucagcu gcauccgggg cuccagcagc    540agcuucuucu cacggcugaa cuggcugacc caccugaacu acaccuaccc cgcccugaac    600gugaccaugc ccaacaagga gcaguucgac aagcuguaca ucuggggagu gcaccauccc    660ggcaccgaca aggaccagau uagccuguac gcccagucua gcggccggau caccgugagc    720accaagcgga gccagcaggc cgugaucccc aacaucggcu cucggcccag aauccgggac    780auccccagcc ggaucagcau cuacuggacc auugugaagc ccggcgacau ccugcugauc    840aacuccaccg gcaaccugau cgccccucgg ggcuauuuca agauccggag cggcaagagc    900agcaucaugc ggagcgacgc cccuaucggc aagugcaaga gcgagugcau cacacccaac    960ggaagcaucc ccaacgacaa gcccuuccag aacgugaacc ggauaaccua cggcgccugc   1020ccuagauacg ugaagcagaa cacccugaag cuggccaccg gcaugcggaa cgugcccgag   1080aagcagacuc ggggcaucuu cggcgccauc gccggcuuca ucgagaacgg cugggagggc   1140augguggacg gcugguacgg cuuccggcac cagaacucug agggcagagg acaggccgca   1200gaccugaaga gcacccaggc cgccaucgac cagaucaacg gcaagcugaa ccggcugauc   1260ggcaagacca acgagaaguu ccaccagauc gagaaggagu ucagcgaggu ggagggcagg   1320guacaggacc uggagaagua cguggaggac accaagaucg accuguggag cuacaacgcc   1380gagcugcugg uagcccugga gaaccagcac accaucgacc ugaccgacag cgagaugaac   1440aagcuguucg agaagaccaa gaagcagcug cgggagaacg ccgaggacau gggcaacggc   1500ugcuucaaga ucuaccacaa gugcgacaac gccugcaucg gcagcauccg gaacgagacc   1560uacgaccaca acguguaccg ggacgaggcc cugaacaacc gguuccagau caagggcgug   1620gagcugaaga gcggcuacaa ggacuggauc cuguggauca gcuucgccau cuccugcuuc   1680cugcugugcg uggcccugcu ggguuucauc augugggccu gccagaaggg caacauccgg   1740ugcaacaucu gcaucugaua auaggcugga gccucggugg ccuagcuucu ugccccuugg   1800gccucccccc agccccuccu ccccuuccug cacccguacc cccguggucu uugaauaaag   1860ucugaguggg cggc                                                     1874</s400><s200><s210>54</s210><s211>1698</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 54augaagacca ucaucgcccu gagcuacauc cugugccugg gcuucaccca gaagaucccc     60ggcaacgaua acaugaccgc cacccugugu cugggacacc acgccgugcc caacggcacc    120aucgugaaga cuaucaccaa cgaccggauc gaggugacca acgccaccga gcuggugcag    180aacagcagca ucggcgagau cugcgacagc ccucaccaga uccuggacgg cggcaacugc    240acccugaucg acgcacugcu gggcgacccu cagugcgacg gcuuucagaa caagaagugg    300gaccuguucg uggagagauc gcgggccuac agcaacugcu accccuacga cguccccgac    360uacgcaagcc ugagaagccu cguggccuca agcggcaccc uggaguucaa gaacgagagc    420uucaacuggg ccggcgugac ccagaacggc aagucauuca gcugcauccg gggcuccagc    480agcagcuucu ucucacggcu gaacuggcug acccaccuga acuacaccua ccccgcccug    540aacgugacca ugcccaacaa ggagcaguuc gacaagcugu acaucugggg agugcaccau    600cccggcaccg acaaggacca gauuagccug uacgcccagu cuagcggccg gaucaccgug    660agcaccaagc ggagccagca ggccgugauc cccaacaucg gcucucggcc cagaauccgg    720gacaucccca gccggaucag caucuacugg accauuguga agcccggcga cauccugcug    780aucaacucca ccggcaaccu gaucgccccu cggggcuauu ucaagauccg gagcggcaag    840agcagcauca ugcggagcga cgccccuauc ggcaagugca agagcgagug caucacaccc    900aacggaagca uccccaacga caagcccuuc cagaacguga accggauaac cuacggcgcc    960ugcccuagau acgugaagca gaacacccug aagcuggcca ccggcaugcg gaacgugccc   1020gagaagcaga cucggggcau cuucggcgcc aucgccggcu ucaucgagaa cggcugggag   1080ggcauggugg acggcuggua cggcuuccgg caccagaacu cugagggcag aggacaggcc   1140gcagaccuga agagcaccca ggccgccauc gaccagauca acggcaagcu gaaccggcug   1200aucggcaaga ccaacgagaa guuccaccag aucgagaagg aguucagcga gguggagggc   1260aggguacagg accuggagaa guacguggag gacaccaaga ucgaccugug gagcuacaac   1320gccgagcugc ugguagcccu ggagaaccag cacaccaucg accugaccga cagcgagaug   1380aacaagcugu ucgagaagac caagaagcag cugcgggaga acgccgagga caugggcaac   1440ggcugcuuca agaucuacca caagugcgac aacgccugca ucggcagcau ccggaacgag   1500accuacgacc acaacgugua ccgggacgag gcccugaaca accgguucca gaucaagggc   1560guggagcuga agagcggcua caaggacugg auccugugga ucagcuucgc caucuccugc   1620uuccugcugu gcguggcccu gcuggguuuc aucauguggg ccugccagaa gggcaacauc   1680cggugcaaca ucugcauc                                                 1698</s400><s200><s210>55</s210><s211>566</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 55Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys Leu Gly Phe Thr1               5                   10                  15Gln Lys Ile Pro Gly Asn Asp Asn Met Thr Ala Thr Leu Cys Leu Gly            20                  25                  30His His Ala Val Pro Asn Gly Thr Ile Val Lys Thr Ile Thr Asn Asp        35                  40                  45Arg Ile Glu Val Thr Asn Ala Thr Glu Leu Val Gln Asn Ser Ser Ile    50                  55                  60Gly Glu Ile Cys Asp Ser Pro His Gln Ile Leu Asp Gly Gly Asn Cys65                  70                  75                  80Thr Leu Ile Asp Ala Leu Leu Gly Asp Pro Gln Cys Asp Gly Phe Gln                85                  90                  95Asn Lys Lys Trp Asp Leu Phe Val Glu Arg Ser Arg Ala Tyr Ser Asn            100                 105                 110Cys Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Arg Ser Leu Val        115                 120                 125Ala Ser Ser Gly Thr Leu Glu Phe Lys Asn Glu Ser Phe Asn Trp Ala    130                 135                 140Gly Val Thr Gln Asn Gly Lys Ser Phe Ser Cys Ile Arg Gly Ser Ser145                 150                 155                 160Ser Ser Phe Phe Ser Arg Leu Asn Trp Leu Thr His Leu Asn Tyr Thr                165                 170                 175Tyr Pro Ala Leu Asn Val Thr Met Pro Asn Lys Glu Gln Phe Asp Lys            180                 185                 190Leu Tyr Ile Trp Gly Val His His Pro Gly Thr Asp Lys Asp Gln Ile        195                 200                 205Ser Leu Tyr Ala Gln Ser Ser Gly Arg Ile Thr Val Ser Thr Lys Arg    210                 215                 220Ser Gln Gln Ala Val Ile Pro Asn Ile Gly Ser Arg Pro Arg Ile Arg225                 230                 235                 240Asp Ile Pro Ser Arg Ile Ser Ile Tyr Trp Thr Ile Val Lys Pro Gly                245                 250                 255Asp Ile Leu Leu Ile Asn Ser Thr Gly Asn Leu Ile Ala Pro Arg Gly            260                 265                 270Tyr Phe Lys Ile Arg Ser Gly Lys Ser Ser Ile Met Arg Ser Asp Ala        275                 280                 285Pro Ile Gly Lys Cys Lys Ser Glu Cys Ile Thr Pro Asn Gly Ser Ile    290                 295                 300Pro Asn Asp Lys Pro Phe Gln Asn Val Asn Arg Ile Thr Tyr Gly Ala305                 310                 315                 320Cys Pro Arg Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr Gly Met                325                 330                 335Arg Asn Val Pro Glu Lys Gln Thr Arg Gly Ile Phe Gly Ala Ile Ala            340                 345                 350Gly Phe Ile Glu Asn Gly Trp Glu Gly Met Val Asp Gly Trp Tyr Gly        355                 360                 365Phe Arg His Gln Asn Ser Glu Gly Arg Gly Gln Ala Ala Asp Leu Lys    370                 375                 380Ser Thr Gln Ala Ala Ile Asp Gln Ile Asn Gly Lys Leu Asn Arg Leu385                 390                 395                 400Ile Gly Lys Thr Asn Glu Lys Phe His Gln Ile Glu Lys Glu Phe Ser                405                 410                 415Glu Val Glu Gly Arg Val Gln Asp Leu Glu Lys Tyr Val Glu Asp Thr            420                 425                 430Lys Ile Asp Leu Trp Ser Tyr Asn Ala Glu Leu Leu Val Ala Leu Glu        435                 440                 445Asn Gln His Thr Ile Asp Leu Thr Asp Ser Glu Met Asn Lys Leu Phe    450                 455                 460Glu Lys Thr Lys Lys Gln Leu Arg Glu Asn Ala Glu Asp Met Gly Asn465                 470                 475                 480Gly Cys Phe Lys Ile Tyr His Lys Cys Asp Asn Ala Cys Ile Gly Ser                485                 490                 495Ile Arg Asn Glu Thr Tyr Asp His Asn Val Tyr Arg Asp Glu Ala Leu            500                 505                 510Asn Asn Arg Phe Gln Ile Lys Gly Val Glu Leu Lys Ser Gly Tyr Lys        515                 520                 525Asp Trp Ile Leu Trp Ile Ser Phe Ala Ile Ser Cys Phe Leu Leu Cys    530                 535                 540Val Ala Leu Leu Gly Phe Ile Met Trp Ala Cys Gln Lys Gly Asn Ile545                 550                 555                 560Arg Cys Asn Ile Cys Ile                565</s400><s200><s210>56</s210><s211>1874</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 56gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aagaccauca ucgcccugag cuacauccug ugccugggcu ucacccagaa gauccccggc    120aacgauaaca ugaccgccac ccugugucug ggacaccacg ccgugcccaa cggcaccauc    180gugaagacua ucaccaacga ccggaucgag gugaccaacg ccaccgagcu ggugcagaac    240agcagcaucg gcgagaucug cgacagcccu caccagaucc uggacggcgg caacugcacc    300cugaucgacg cacugcuggg cgacccucag ugcgacggcu uucagaacaa gaagugggac    360cuguucgugg agagaucgcg ggccuacagc aacugcuacc ccuacgacgu ccccgacuac    420gcaagccuga gaagccucgu ggccucaagc ggcacccugg aguucaagaa cgagagcuuc    480aacugggccg gcgugaccca gaacggcaag ucauucagcu gcauccgggg cuccagcagc    540agcuucuucu cacggcugaa cuggcugacc caccugaacu acaccuaccc cgcccugaac    600gugaccaugc ccaacaagga gcaguucgac aagcuguaca ucuggggagu gcaccauccc    660ggcaccgaca aggaccagau uagccuguac gcccagucua gcggccggau caccgugagc    720accaagcgga gccagcaggc cgugaucccc aacaucggcu cucggcccag aauccgggac    780auccccagcc ggaucagcau cuacuggacc auugugaagc ccggcgacau ccugcugauc    840aacuccaccg gcaaccugau cgccccucgg ggcuauuuca agauccggag cggcaagagc    900agcaucaugc ggagcgacgc cccuaucggc aagugcaaga gcgagugcau cacacccaac    960ggaagcaucc ccaacgacaa gcccuuccag aacgugaacc ggauaaccua cggcgccugc   1020ccuagauacg ugaagcagaa cacccugaag cuggccaccg gcaugcggaa cgugcccgag   1080aagcagacuc ggggcaucuu cggcgccauc gccggcuuca ucgagaacgg cugggagggc   1140augguggacg gcugguacgg cuuccggcac cagaacucug agggcagagg acaggccgca   1200gaccugaaga gcacccaggc cgccaucgac cagaucaacg gcaagcugaa ccggcugauc   1260ggcaagacca acgagaaguu ccaccagauc gagaaggagu ucagcgaggu ggagggcagg   1320guacaggacc uggagaagua cguggaggac accaagaucg accuguggag cuacaacgcc   1380gagcugcugg uagcccugga gaaccagcac accaucgacc ugaccgacag cgagaugaac   1440aagcuguucg agaagaccaa gaagcagcug cgggagaacg ccgaggacau gggcaacggc   1500ugcuucaaga ucuaccacaa gugcgacaac gccugcaucg gcagcauccg gaacgagacc   1560uacgaccaca acguguaccg ggacgaggcc cugaacaacc gguuccagau caagggcgug   1620gagcugaaga gcggcuacaa ggacuggauc cuguggauca gcuucgccau cuccugcuuc   1680cugcugugcg uggcccugcu ggguuucauc augugggccu gccagaaggg caacauccgg   1740ugcaacaucu gcaucugaua auaggcugga gccucggugg ccuagcuucu ugccccuugg   1800gccucccccc agccccuccu ccccuuccug cacccguacc cccguggucu uugaauaaag   1860ucugaguggg cggc                                                     1874</s400><s200><s210>57</s210><s211>1698</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 57augaagacca ucaucgcccu gagcuacauc cugugccugg gcuucaccca gaagaucccc     60ggcaacgaua acaugaccgc cacccugugu cugggacacc acgccgugcc caacggcacc    120aucgugaaga cuaucaccaa cgaccggauc gaggugacca acgccaccga gcuggugcag    180aacagcagca ucggcgagau cugcgacagc ccucaccaga uccuggacgg cggcaacugc    240acccugaucg acgcacugcu gggcgacccu cagugcgacg gcuuucagaa caagaagugg    300gaccuguucg uggagagauc gcgggccuac agcaacugcu accccuacga cguccccgac    360uacgcaagcc ugagaagccu cguggccuca agcggcaccc uggaguucaa gaacgagagc    420uucaacuggg ccggcgugac ccagaacggc aagucauuca gcugcauccg gggcuccagc    480agcagcuucu ucucacggcu gaacuggcug acccaccuga acuacaccua ccccgcccug    540aacgugacca ugcccaacaa ggagcaguuc gacaagcugu acaucugggg agugcaccau    600cccggcaccg acaaggacca gauuagccug uacgcccagu cuagcggccg gaucaccgug    660agcaccaagc ggagccagca ggccgugauc cccaacaucg gcucucggcc cagaauccgg    720gacaucccca gccggaucag caucuacugg accauuguga agcccggcga cauccugcug    780aucaacucca ccggcaaccu gaucgccccu cggggcuauu ucaagauccg gagcggcaag    840agcagcauca ugcggagcga cgccccuauc ggcaagugca agagcgagug caucacaccc    900aacggaagca uccccaacga caagcccuuc cagaacguga accggauaac cuacggcgcc    960ugcccuagau acgugaagca gaacacccug aagcuggcca ccggcaugcg gaacgugccc   1020gagaagcaga cucggggcau cuucggcgcc aucgccggcu ucaucgagaa cggcugggag   1080ggcauggugg acggcuggua cggcuuccgg caccagaacu cugagggcag aggacaggcc   1140gcagaccuga agagcaccca ggccgccauc gaccagauca acggcaagcu gaaccggcug   1200aucggcaaga ccaacgagaa guuccaccag aucgagaagg aguucagcga gguggagggc   1260aggguacagg accuggagaa guacguggag gacaccaaga ucgaccugug gagcuacaac   1320gccgagcugc ugguagcccu ggagaaccag cacaccaucg accugaccga cagcgagaug   1380aacaagcugu ucgagaagac caagaagcag cugcgggaga acgccgagga caugggcaac   1440ggcugcuuca agaucuacca caagugcgac aacgccugca ucggcagcau ccggaacgag   1500accuacgacc acaacgugua ccgggacgag gcccugaaca accgguucca gaucaagggc   1560guggagcuga agagcggcua caaggacugg auccugugga ucagcuucgc caucuccugc   1620uuccugcugu gcguggcccu gcuggguuuc aucauguggg ccugccagaa gggcaacauc   1680cggugcaaca ucugcauc                                                 1698</s400><s200><s210>58</s210><s211>566</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 58Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys Leu Gly Phe Thr1               5                   10                  15Gln Lys Ile Pro Gly Asn Asp Asn Met Thr Ala Thr Leu Cys Leu Gly            20                  25                  30His His Ala Val Pro Asn Gly Thr Ile Val Lys Thr Ile Thr Asn Asp        35                  40                  45Arg Ile Glu Val Thr Asn Ala Thr Glu Leu Val Gln Asn Ser Ser Ile    50                  55                  60Gly Glu Ile Cys Asp Ser Pro His Gln Ile Leu Asp Gly Gly Asn Cys65                  70                  75                  80Thr Leu Ile Asp Ala Leu Leu Gly Asp Pro Gln Cys Asp Gly Phe Gln                85                  90                  95Asn Lys Lys Trp Asp Leu Phe Val Glu Arg Ser Arg Ala Tyr Ser Asn            100                 105                 110Cys Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Arg Ser Leu Val        115                 120                 125Ala Ser Ser Gly Thr Leu Glu Phe Lys Asn Glu Ser Phe Asn Trp Ala    130                 135                 140Gly Val Thr Gln Asn Gly Lys Ser Phe Ser Cys Ile Arg Gly Ser Ser145                 150                 155                 160Ser Ser Phe Phe Ser Arg Leu Asn Trp Leu Thr His Leu Asn Tyr Thr                165                 170                 175Tyr Pro Ala Leu Asn Val Thr Met Pro Asn Lys Glu Gln Phe Asp Lys            180                 185                 190Leu Tyr Ile Trp Gly Val His His Pro Gly Thr Asp Lys Asp Gln Ile        195                 200                 205Ser Leu Tyr Ala Gln Ser Ser Gly Arg Ile Thr Val Ser Thr Lys Arg    210                 215                 220Ser Gln Gln Ala Val Ile Pro Asn Ile Gly Ser Arg Pro Arg Ile Arg225                 230                 235                 240Asp Ile Pro Ser Arg Ile Ser Ile Tyr Trp Thr Ile Val Lys Pro Gly                245                 250                 255Asp Ile Leu Leu Ile Asn Ser Thr Gly Asn Leu Ile Ala Pro Arg Gly            260                 265                 270Tyr Phe Lys Ile Arg Ser Gly Lys Ser Ser Ile Met Arg Ser Asp Ala        275                 280                 285Pro Ile Gly Lys Cys Lys Ser Glu Cys Ile Thr Pro Asn Gly Ser Ile    290                 295                 300Pro Asn Asp Lys Pro Phe Gln Asn Val Asn Arg Ile Thr Tyr Gly Ala305                 310                 315                 320Cys Pro Arg Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr Gly Met                325                 330                 335Arg Asn Val Pro Glu Lys Gln Thr Arg Gly Ile Phe Gly Ala Ile Ala            340                 345                 350Gly Phe Ile Glu Asn Gly Trp Glu Gly Met Val Asp Gly Trp Tyr Gly        355                 360                 365Phe Arg His Gln Asn Ser Glu Gly Arg Gly Gln Ala Ala Asp Leu Lys    370                 375                 380Ser Thr Gln Ala Ala Ile Asp Gln Ile Asn Gly Lys Leu Asn Arg Leu385                 390                 395                 400Ile Gly Lys Thr Asn Glu Lys Phe His Gln Ile Glu Lys Glu Phe Ser                405                 410                 415Glu Val Glu Gly Arg Val Gln Asp Leu Glu Lys Tyr Val Glu Asp Thr            420                 425                 430Lys Ile Asp Leu Trp Ser Tyr Asn Ala Glu Leu Leu Val Ala Leu Glu        435                 440                 445Asn Gln His Thr Ile Asp Leu Thr Asp Ser Glu Met Asn Lys Leu Phe    450                 455                 460Glu Lys Thr Lys Lys Gln Leu Arg Glu Asn Ala Glu Asp Met Gly Asn465                 470                 475                 480Gly Cys Phe Lys Ile Tyr His Lys Cys Asp Asn Ala Cys Ile Gly Ser                485                 490                 495Ile Arg Asn Glu Thr Tyr Asp His Asn Val Tyr Arg Asp Glu Ala Leu            500                 505                 510Asn Asn Arg Phe Gln Ile Lys Gly Val Glu Leu Lys Ser Gly Tyr Lys        515                 520                 525Asp Trp Ile Leu Trp Ile Ser Phe Ala Ile Ser Cys Phe Leu Leu Cys    530                 535                 540Val Ala Leu Leu Gly Phe Ile Met Trp Ala Cys Gln Lys Gly Asn Ile545                 550                 555                 560Arg Cys Asn Ile Cys Ile                565</s400><s200><s210>59</s210><s211>1568</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 59gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aucaucacca ucggcagcau cugcaugacc aucggcaccg ccaaccugau ccugcaaauc    120ggcaacauca ucagcaucug ggugagccac agcauccaga ucggcaacca gagccagauc    180gagaccugca acaagagcgu gaucaccuac gagaacaaca ccugggugaa ccagaccuuc    240gugaacauca gcaacaccaa cagcgccgcu cggcagucag uggccagcgu gaagcuggcc    300ggcaacagca gccugugccc cguuaguggc ugggccaucu acagcaagga caacagcgug    360cggaucggca gcaagggcga cguguucgug auccgggagc ccuucaucag cugcagcccg    420cuugagugcc gcaccuucuu ccugacccag ggcgcucugc ugaacgacaa gcacagcaac    480ggcaccauca aggaccggag ccccuaucgg acccugauga gcugccccau uggcgaggug    540cccagccccu acaacagccg guucgagucu guggccugga gcgccucugc cugccacgac    600ggcaccaacu ggcugaccau cgggaucagc ggacccgaua gcggagcagu ggccgugcug    660aaguacaacg gcaucaucac cgacaccauc aagagcuggc ggaacaagau ccugcggacc    720caggagagcg agugcgccug cgugaacggc agcugcuuca ccaucaugac cgacggcccu    780agcgacggac aggccagcua caagaucuuc cggaucgaga agggcaagau caucaagagc    840guggagauga aggcacccaa cuaccacuac gaggagugca gcugcuaccc cgacagcagc    900gagaucaccu gcgugugccg ggacaacugg cacgggagca acaggcccug ggugagcuuc    960aaccagaacc uggaguacca gaugggcuac aucugcagcg gcguguucgg cgacaaccca   1020cggcccaacg acaagacugg cagcugcggu ccggugagca gcaacggcgc caacggcgug   1080aagggcuuca gcuucaagua cggcaacggc guguggaucg gccggaccaa gagcaucagc   1140agccggaagg gcuucgagau gaucugggac cccaacggcu ggaccggcac cgacaacaag   1200uucagcaaga agcaggacau cgugggcauc aacgagugga gcggcuacag cggcagcuuc   1260gugcagcacc ccgagcugac uggccugaac ugcauccggc ccugcuucug gguggaacug   1320auacggggac ggcccgagga gaacaccauc uggaccagcg gcagcagcau cagcuucugc   1380ggcguggaca gcgauaucgu gggcuggagc uggccagacg gagccgagcu gcccuucacc   1440aucgacaagu gauaauaggc uggagccucg guggccuagc uucuugcccc uugggccucc   1500ccccagcccc uccuccccuu ccugcacccg uacccccgug gucuuugaau aaagucugag   1560ugggcggc                                                            1568</s400><s200><s210>60</s210><s211>1392</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 60augaucauca ccaucggcag caucugcaug accaucggca ccgccaaccu gauccugcaa     60aucggcaaca ucaucagcau cugggugagc cacagcaucc agaucggcaa ccagagccag    120aucgagaccu gcaacaagag cgugaucacc uacgagaaca acaccugggu gaaccagacc    180uucgugaaca ucagcaacac caacagcgcc gcucggcagu caguggccag cgugaagcug    240gccggcaaca gcagccugug ccccguuagu ggcugggcca ucuacagcaa ggacaacagc    300gugcggaucg gcagcaaggg cgacguguuc gugauccggg agcccuucau cagcugcagc    360ccgcuugagu gccgcaccuu cuuccugacc cagggcgcuc ugcugaacga caagcacagc    420aacggcacca ucaaggaccg gagccccuau cggacccuga ugagcugccc cauuggcgag    480gugcccagcc ccuacaacag ccgguucgag ucuguggccu ggagcgccuc ugccugccac    540gacggcacca acuggcugac caucgggauc agcggacccg auagcggagc aguggccgug    600cugaaguaca acggcaucau caccgacacc aucaagagcu ggcggaacaa gauccugcgg    660acccaggaga gcgagugcgc cugcgugaac ggcagcugcu ucaccaucau gaccgacggc    720ccuagcgacg gacaggccag cuacaagauc uuccggaucg agaagggcaa gaucaucaag    780agcguggaga ugaaggcacc caacuaccac uacgaggagu gcagcugcua ccccgacagc    840agcgagauca ccugcgugug ccgggacaac uggcacggga gcaacaggcc cugggugagc    900uucaaccaga accuggagua ccagaugggc uacaucugca gcggcguguu cggcgacaac    960ccacggccca acgacaagac uggcagcugc gguccgguga gcagcaacgg cgccaacggc   1020gugaagggcu ucagcuucaa guacggcaac ggcgugugga ucggccggac caagagcauc   1080agcagccgga agggcuucga gaugaucugg gaccccaacg gcuggaccgg caccgacaac   1140aaguucagca agaagcagga caucgugggc aucaacgagu ggagcggcua cagcggcagc   1200uucgugcagc accccgagcu gacuggccug aacugcaucc ggcccugcuu cuggguggaa   1260cugauacggg gacggcccga ggagaacacc aucuggacca gcggcagcag caucagcuuc   1320ugcggcgugg acagcgauau cgugggcugg agcuggccag acggagccga gcugcccuuc   1380accaucgaca ag                                                       1392</s400><s200><s210>61</s210><s211>464</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 61Met Ile Ile Thr Ile Gly Ser Ile Cys Met Thr Ile Gly Thr Ala Asn1               5                   10                  15Leu Ile Leu Gln Ile Gly Asn Ile Ile Ser Ile Trp Val Ser His Ser            20                  25                  30Ile Gln Ile Gly Asn Gln Ser Gln Ile Glu Thr Cys Asn Lys Ser Val        35                  40                  45Ile Thr Tyr Glu Asn Asn Thr Trp Val Asn Gln Thr Phe Val Asn Ile    50                  55                  60Ser Asn Thr Asn Ser Ala Ala Arg Gln Ser Val Ala Ser Val Lys Leu65                  70                  75                  80Ala Gly Asn Ser Ser Leu Cys Pro Val Ser Gly Trp Ala Ile Tyr Ser                85                  90                  95Lys Asp Asn Ser Val Arg Ile Gly Ser Lys Gly Asp Val Phe Val Ile            100                 105                 110Arg Glu Pro Phe Ile Ser Cys Ser Pro Leu Glu Cys Arg Thr Phe Phe        115                 120                 125Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His Ser Asn Gly Thr Ile    130                 135                 140Lys Asp Arg Ser Pro Tyr Arg Thr Leu Met Ser Cys Pro Ile Gly Glu145                 150                 155                 160Val Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser Val Ala Trp Ser Ala                165                 170                 175Ser Ala Cys His Asp Gly Thr Asn Trp Leu Thr Ile Gly Ile Ser Gly            180                 185                 190Pro Asp Ser Gly Ala Val Ala Val Leu Lys Tyr Asn Gly Ile Ile Thr        195                 200                 205Asp Thr Ile Lys Ser Trp Arg Asn Lys Ile Leu Arg Thr Gln Glu Ser    210                 215                 220Glu Cys Ala Cys Val Asn Gly Ser Cys Phe Thr Ile Met Thr Asp Gly225                 230                 235                 240Pro Ser Asp Gly Gln Ala Ser Tyr Lys Ile Phe Arg Ile Glu Lys Gly                245                 250                 255Lys Ile Ile Lys Ser Val Glu Met Lys Ala Pro Asn Tyr His Tyr Glu            260                 265                 270Glu Cys Ser Cys Tyr Pro Asp Ser Ser Glu Ile Thr Cys Val Cys Arg        275                 280                 285Asp Asn Trp His Gly Ser Asn Arg Pro Trp Val Ser Phe Asn Gln Asn    290                 295                 300Leu Glu Tyr Gln Met Gly Tyr Ile Cys Ser Gly Val Phe Gly Asp Asn305                 310                 315                 320Pro Arg Pro Asn Asp Lys Thr Gly Ser Cys Gly Pro Val Ser Ser Asn                325                 330                 335Gly Ala Asn Gly Val Lys Gly Phe Ser Phe Lys Tyr Gly Asn Gly Val            340                 345                 350Trp Ile Gly Arg Thr Lys Ser Ile Ser Ser Arg Lys Gly Phe Glu Met        355                 360                 365Ile Trp Asp Pro Asn Gly Trp Thr Gly Thr Asp Asn Lys Phe Ser Lys    370                 375                 380Lys Gln Asp Ile Val Gly Ile Asn Glu Trp Ser Gly Tyr Ser Gly Ser385                 390                 395                 400Phe Val Gln His Pro Glu Leu Thr Gly Leu Asn Cys Ile Arg Pro Cys                405                 410                 415Phe Trp Val Glu Leu Ile Arg Gly Arg Pro Glu Glu Asn Thr Ile Trp            420                 425                 430Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly Val Asp Ser Asp Ile Val        435                 440                 445Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu Pro Phe Thr Ile Asp Lys    450                 455                 460</s400><s200><s210>62</s210><s211>1538</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 62gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaccccaacc agaagaucau caccaucggc agcaucugca ugaccaucgg caccgccaac    120cugauccugc aaaucggcaa caucaucagc aucuggguga gccacagcau ccagaccggc    180agccagagcc agaucgagac cugcaaccag agcauuauca ccuacgagaa uaacaccugg    240gugaaggaca ccaccagcgu gauccugacc ggcaacagca gccugugccc cguuaguggc    300ugggccaucu acagcaagga caacagcgug cggaucggca gcaagggcga cguguucgug    360auccgggagc ccuucaucag cugcagcccg cuugagugcc gcaccuucuu ccugacccag    420ggcgcucugc ugaacgacaa gcacagcaac ggcaccauca aggaccggag ccccuaucgg    480acccugauga gcugccccau uggcgaggug cccagccccu acaacagccg guucgagucu    540guggccugga gcgccucugc cugccacgac ggcaccaacu ggcugaccau cgggaucagc    600ggacccgaua gcggagcagu ggccgugcug aaguacaacg gcaucaucac cgacaccauc    660aagagcuggc ggaacaagau ccugcggacc caggagagcg agugcgccug cgugaacggc    720agcugcuuca ccaucaugac cgacggcccu agcgacggac aggccagcua caagaucuuc    780cggaucgaga agggcaagau caucaagagc guggagauga aggcacccaa cuaccacuac    840gaggagugca gcugcuaccc cgacagcagc gagaucaccu gcgugugccg ggacaacugg    900cacgggagca acaggcccug ggugagcuuc aaccagaacc uggaguacca gaugggcuac    960aucugcagcg gcguguucgg cgacaaccca cggcccaacg acaagacugg cagcugcggu   1020ccggugagca gcaacggcgc caacggcgug aagggcuuca gcuucaagua cggcaacggc   1080guguggaucg gccggaccaa gagcaucagc agccggaagg gcuucgagau gaucugggac   1140cccaacggcu ggaccggcac cgacaacaag uucagcaaga agcaggacau cgugggcauc   1200aacgagugga gcggcuacag cggcagcuuc gugcagcacc ccgagcugac uggccugaac   1260ugcauccggc ccugcuucug gguggaacug auacggggac ggcccgagga gaacaccauc   1320uggaccagcg gcagcagcau cagcuucugc ggcguggaca gcgauaucgu gggcuggagc   1380uggccagacg gagccgagcu gcccuucacc aucgacaagu gauaauaggc uggagccucg   1440guggccuagc uucuugcccc uugggccucc ccccagcccc uccuccccuu ccugcacccg   1500uacccccgug gucuuugaau aaagucugag ugggcggc                           1538</s400><s200><s210>63</s210><s211>1362</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 63augaacccca accagaagau caucaccauc ggcagcaucu gcaugaccau cggcaccgcc     60aaccugaucc ugcaaaucgg caacaucauc agcaucuggg ugagccacag cauccagacc    120ggcagccaga gccagaucga gaccugcaac cagagcauua ucaccuacga gaauaacacc    180ugggugaagg acaccaccag cgugauccug accggcaaca gcagccugug ccccguuagu    240ggcugggcca ucuacagcaa ggacaacagc gugcggaucg gcagcaaggg cgacguguuc    300gugauccggg agcccuucau cagcugcagc ccgcuugagu gccgcaccuu cuuccugacc    360cagggcgcuc ugcugaacga caagcacagc aacggcacca ucaaggaccg gagccccuau    420cggacccuga ugagcugccc cauuggcgag gugcccagcc ccuacaacag ccgguucgag    480ucuguggccu ggagcgccuc ugccugccac gacggcacca acuggcugac caucgggauc    540agcggacccg auagcggagc aguggccgug cugaaguaca acggcaucau caccgacacc    600aucaagagcu ggcggaacaa gauccugcgg acccaggaga gcgagugcgc cugcgugaac    660ggcagcugcu ucaccaucau gaccgacggc ccuagcgacg gacaggccag cuacaagauc    720uuccggaucg agaagggcaa gaucaucaag agcguggaga ugaaggcacc caacuaccac    780uacgaggagu gcagcugcua ccccgacagc agcgagauca ccugcgugug ccgggacaac    840uggcacggga gcaacaggcc cugggugagc uucaaccaga accuggagua ccagaugggc    900uacaucugca gcggcguguu cggcgacaac ccacggccca acgacaagac uggcagcugc    960gguccgguga gcagcaacgg cgccaacggc gugaagggcu ucagcuucaa guacggcaac   1020ggcgugugga ucggccggac caagagcauc agcagccgga agggcuucga gaugaucugg   1080gaccccaacg gcuggaccgg caccgacaac aaguucagca agaagcagga caucgugggc   1140aucaacgagu ggagcggcua cagcggcagc uucgugcagc accccgagcu gacuggccug   1200aacugcaucc ggcccugcuu cuggguggaa cugauacggg gacggcccga ggagaacacc   1260aucuggacca gcggcagcag caucagcuuc ugcggcgugg acagcgauau cgugggcugg   1320agcuggccag acggagccga gcugcccuuc accaucgaca ag                      1362</s400><s200><s210>64</s210><s211>454</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 64Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Ile Cys Met Thr1               5                   10                  15Ile Gly Thr Ala Asn Leu Ile Leu Gln Ile Gly Asn Ile Ile Ser Ile            20                  25                  30Trp Val Ser His Ser Ile Gln Thr Gly Ser Gln Ser Gln Ile Glu Thr        35                  40                  45Cys Asn Gln Ser Ile Ile Thr Tyr Glu Asn Asn Thr Trp Val Lys Asp    50                  55                  60Thr Thr Ser Val Ile Leu Thr Gly Asn Ser Ser Leu Cys Pro Val Ser65                  70                  75                  80Gly Trp Ala Ile Tyr Ser Lys Asp Asn Ser Val Arg Ile Gly Ser Lys                85                  90                  95Gly Asp Val Phe Val Ile Arg Glu Pro Phe Ile Ser Cys Ser Pro Leu            100                 105                 110Glu Cys Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys        115                 120                 125His Ser Asn Gly Thr Ile Lys Asp Arg Ser Pro Tyr Arg Thr Leu Met    130                 135                 140Ser Cys Pro Ile Gly Glu Val Pro Ser Pro Tyr Asn Ser Arg Phe Glu145                 150                 155                 160Ser Val Ala Trp Ser Ala Ser Ala Cys His Asp Gly Thr Asn Trp Leu                165                 170                 175Thr Ile Gly Ile Ser Gly Pro Asp Ser Gly Ala Val Ala Val Leu Lys            180                 185                 190Tyr Asn Gly Ile Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Lys Ile        195                 200                 205Leu Arg Thr Gln Glu Ser Glu Cys Ala Cys Val Asn Gly Ser Cys Phe    210                 215                 220Thr Ile Met Thr Asp Gly Pro Ser Asp Gly Gln Ala Ser Tyr Lys Ile225                 230                 235                 240Phe Arg Ile Glu Lys Gly Lys Ile Ile Lys Ser Val Glu Met Lys Ala                245                 250                 255Pro Asn Tyr His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ser Ser Glu            260                 265                 270Ile Thr Cys Val Cys Arg Asp Asn Trp His Gly Ser Asn Arg Pro Trp        275                 280                 285Val Ser Phe Asn Gln Asn Leu Glu Tyr Gln Met Gly Tyr Ile Cys Ser    290                 295                 300Gly Val Phe Gly Asp Asn Pro Arg Pro Asn Asp Lys Thr Gly Ser Cys305                 310                 315                 320Gly Pro Val Ser Ser Asn Gly Ala Asn Gly Val Lys Gly Phe Ser Phe                325                 330                 335Lys Tyr Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser Ile Ser Ser            340                 345                 350Arg Lys Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Gly Thr        355                 360                 365Asp Asn Lys Phe Ser Lys Lys Gln Asp Ile Val Gly Ile Asn Glu Trp    370                 375                 380Ser Gly Tyr Ser Gly Ser Phe Val Gln His Pro Glu Leu Thr Gly Leu385                 390                 395                 400Asn Cys Ile Arg Pro Cys Phe Trp Val Glu Leu Ile Arg Gly Arg Pro                405                 410                 415Glu Glu Asn Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly            420                 425                 430Val Asp Ser Asp Ile Val Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu        435                 440                 445Pro Phe Thr Ile Asp Lys    450</s400><s200><s210>65</s210><s211>1493</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 65gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaccccaacc agaagaucau caccaucggc agcaucugca ugaccaucgg caccgccaac    120cugauccugc aaaucggcaa caucaucagc aucuggguga gccacagcau ccagaucggc    180aaccagagcc agaucgagac cugcaaccag agcgugaucc ugaccggcaa cagcagccug    240ugccccguua guggcugggc caucuacagc aaggacaaca gcgugcggau cggcagcaag    300ggcgacgugu ucgugauccg ggagcccuuc aucagcugca gcccgcuuga gugccgcacc    360uucuuccuga cccagggcgc ucugcugaac gacaagcaca gcaacggcac caucaaggac    420cggagccccu aucggacccu gaugagcugc cccauuggcg aggugcccag ccccuacaac    480agccgguucg agucuguggc cuggagcgcc ucugccugcc acgacggcac caacuggcug    540accaucggga ucagcggacc cgauagcgga gcaguggccg ugcugaagua caacggcauc    600aucaccgaca ccaucaagag cuggcggaac aagauccugc ggacccagga gagcgagugc    660gccugcguga acggcagcug cuucaccauc augaccgacg gcccuagcga cggacaggcc    720agcuacaaga ucuuccggau cgagaagggc aagaucauca agagcgugga gaugaaggca    780cccaacuacc acuacgagga gugcagcugc uaccccgaca gcagcgagau caccugcgug    840ugccgggaca acuggcacgg gagcaacagg cccuggguga gcuucaacca gaaccuggag    900uaccagaugg gcuacaucug cagcggcgug uucggcgaca acccacggcc caacgacaag    960acuggcagcu gcgguccggu gagcagcaac ggcgccaacg gcgugaaggg cuucagcuuc   1020aaguacggca acggcgugug gaucggccgg accaagagca ucagcagccg gaagggcuuc   1080gagaugaucu gggaccccaa cggcuggacc ggcaccgaca acaaguucag caagaagcag   1140gacaucgugg gcaucaacga guggagcggc uacagcggca gcuucgugca gcaccccgag   1200cugacuggcc ugaacugcau ccggcccugc uucugggugg aacugauacg gggacggccc   1260gaggagaaca ccaucuggac cagcggcagc agcaucagcu ucugcggcgu ggacagcgau   1320aucgugggcu ggagcuggcc agacggagcc gagcugcccu ucaccaucga caagugauaa   1380uaggcuggag ccucgguggc cuagcuucuu gccccuuggg ccucccccca gccccuccuc   1440cccuuccugc acccguaccc ccguggucuu ugaauaaagu cugagugggc ggc          1493</s400><s200><s210>66</s210><s211>1317</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 66augaacccca accagaagau caucaccauc ggcagcaucu gcaugaccau cggcaccgcc     60aaccugaucc ugcaaaucgg caacaucauc agcaucuggg ugagccacag cauccagauc    120ggcaaccaga gccagaucga gaccugcaac cagagcguga uccugaccgg caacagcagc    180cugugccccg uuaguggcug ggccaucuac agcaaggaca acagcgugcg gaucggcagc    240aagggcgacg uguucgugau ccgggagccc uucaucagcu gcagcccgcu ugagugccgc    300accuucuucc ugacccaggg cgcucugcug aacgacaagc acagcaacgg caccaucaag    360gaccggagcc ccuaucggac ccugaugagc ugccccauug gcgaggugcc cagccccuac    420aacagccggu ucgagucugu ggccuggagc gccucugccu gccacgacgg caccaacugg    480cugaccaucg ggaucagcgg acccgauagc ggagcagugg ccgugcugaa guacaacggc    540aucaucaccg acaccaucaa gagcuggcgg aacaagaucc ugcggaccca ggagagcgag    600ugcgccugcg ugaacggcag cugcuucacc aucaugaccg acggcccuag cgacggacag    660gccagcuaca agaucuuccg gaucgagaag ggcaagauca ucaagagcgu ggagaugaag    720gcacccaacu accacuacga ggagugcagc ugcuaccccg acagcagcga gaucaccugc    780gugugccggg acaacuggca cgggagcaac aggcccuggg ugagcuucaa ccagaaccug    840gaguaccaga ugggcuacau cugcagcggc guguucggcg acaacccacg gcccaacgac    900aagacuggca gcugcggucc ggugagcagc aacggcgcca acggcgugaa gggcuucagc    960uucaaguacg gcaacggcgu guggaucggc cggaccaaga gcaucagcag ccggaagggc   1020uucgagauga ucugggaccc caacggcugg accggcaccg acaacaaguu cagcaagaag   1080caggacaucg ugggcaucaa cgaguggagc ggcuacagcg gcagcuucgu gcagcacccc   1140gagcugacug gccugaacug cauccggccc ugcuucuggg uggaacugau acggggacgg   1200cccgaggaga acaccaucug gaccagcggc agcagcauca gcuucugcgg cguggacagc   1260gauaucgugg gcuggagcug gccagacgga gccgagcugc ccuucaccau cgacaag      1317</s400><s200><s210>67</s210><s211>439</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 67Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Ile Cys Met Thr1               5                   10                  15Ile Gly Thr Ala Asn Leu Ile Leu Gln Ile Gly Asn Ile Ile Ser Ile            20                  25                  30Trp Val Ser His Ser Ile Gln Ile Gly Asn Gln Ser Gln Ile Glu Thr        35                  40                  45Cys Asn Gln Ser Val Ile Leu Thr Gly Asn Ser Ser Leu Cys Pro Val    50                  55                  60Ser Gly Trp Ala Ile Tyr Ser Lys Asp Asn Ser Val Arg Ile Gly Ser65                  70                  75                  80Lys Gly Asp Val Phe Val Ile Arg Glu Pro Phe Ile Ser Cys Ser Pro                85                  90                  95Leu Glu Cys Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp            100                 105                 110Lys His Ser Asn Gly Thr Ile Lys Asp Arg Ser Pro Tyr Arg Thr Leu        115                 120                 125Met Ser Cys Pro Ile Gly Glu Val Pro Ser Pro Tyr Asn Ser Arg Phe    130                 135                 140Glu Ser Val Ala Trp Ser Ala Ser Ala Cys His Asp Gly Thr Asn Trp145                 150                 155                 160Leu Thr Ile Gly Ile Ser Gly Pro Asp Ser Gly Ala Val Ala Val Leu                165                 170                 175Lys Tyr Asn Gly Ile Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Lys            180                 185                 190Ile Leu Arg Thr Gln Glu Ser Glu Cys Ala Cys Val Asn Gly Ser Cys        195                 200                 205Phe Thr Ile Met Thr Asp Gly Pro Ser Asp Gly Gln Ala Ser Tyr Lys    210                 215                 220Ile Phe Arg Ile Glu Lys Gly Lys Ile Ile Lys Ser Val Glu Met Lys225                 230                 235                 240Ala Pro Asn Tyr His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ser Ser                245                 250                 255Glu Ile Thr Cys Val Cys Arg Asp Asn Trp His Gly Ser Asn Arg Pro            260                 265                 270Trp Val Ser Phe Asn Gln Asn Leu Glu Tyr Gln Met Gly Tyr Ile Cys        275                 280                 285Ser Gly Val Phe Gly Asp Asn Pro Arg Pro Asn Asp Lys Thr Gly Ser    290                 295                 300Cys Gly Pro Val Ser Ser Asn Gly Ala Asn Gly Val Lys Gly Phe Ser305                 310                 315                 320Phe Lys Tyr Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser Ile Ser                325                 330                 335Ser Arg Lys Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Gly            340                 345                 350Thr Asp Asn Lys Phe Ser Lys Lys Gln Asp Ile Val Gly Ile Asn Glu        355                 360                 365Trp Ser Gly Tyr Ser Gly Ser Phe Val Gln His Pro Glu Leu Thr Gly    370                 375                 380Leu Asn Cys Ile Arg Pro Cys Phe Trp Val Glu Leu Ile Arg Gly Arg385                 390                 395                 400Pro Glu Glu Asn Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys                405                 410                 415Gly Val Asp Ser Asp Ile Val Gly Trp Ser Trp Pro Asp Gly Ala Glu            420                 425                 430Leu Pro Phe Thr Ile Asp Lys        435</s400><s200><s210>68</s210><s211>1628</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 68gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaccccaacc agaagaucau caccaucggc agcaucugca ugaccaucgg caccgccaac    120cugauccugc aaaucggcaa caucaucagc aucuggguga gccacagcau ccagaucggc    180aaccagagcc agaucgagac cugcaacaag agcgugauca ccuacgagaa caacaccugg    240gugaaccaga ccuucgugaa caucagcaac accaacagcg ccgcucggaa caucaccgag    300aucguguacc ugaccaacac caccaucgag aaacagucag uggccagcgu gaagcuggcc    360ggcaacagca gccugugccc cguuaguggc ugggccaucu acagcaagga caacagcgug    420cggaucggca gcaagggcga cguguucgug auccgggagc ccuucaucag cugcagcccg    480cuugagugcc gcaccuucuu ccugacccag ggcgcucugc ugaacgacaa gcacagcaac    540ggcaccauca aggaccggag ccccuaucgg acccugauga gcugccccau uggcgaggug    600cccagccccu acaacagccg guucgagucu guggccugga gcgccucugc cugccacgac    660ggcaccaacu ggcugaccau cgggaucagc ggacccgaua gcggagcagu ggccgugcug    720aaguacaacg gcaucaucac cgacaccauc aagagcuggc ggaacaagau ccugcggacc    780caggagagcg agugcgccug cgugaacggc agcugcuuca ccaucaugac cgacggcccu    840agcgacggac aggccagcua caagaucuuc cggaucgaga agggcaagau caucaagagc    900guggagauga aggcacccaa cuaccacuac gaggagugca gcugcuaccc cgacagcagc    960gagaucaccu gcgugugccg ggacaacugg cacgggagca acaggcccug ggugagcuuc   1020aaccagaacc uggaguacca gaugggcuac aucugcagcg gcguguucgg cgacaaccca   1080cggcccaacg acaagacugg cagcugcggu ccggugagca gcaacggcgc caacggcgug   1140aagggcuuca gcuucaagua cggcaacggc guguggaucg gccggaccaa gagcaucagc   1200agccggaagg gcuucgagau gaucugggac cccaacggcu ggaccggcac cgacaacaag   1260uucagcaaga agcaggacau cgugggcauc aacgagugga gcggcuacag cggcagcuuc   1320gugcagcacc ccgagcugac uggccugaac ugcauccggc ccugcuucug gguggaacug   1380auacggggac ggcccgagga gaacaccauc uggaccagcg gcagcagcau cagcuucugc   1440ggcguggaca gcgauaucgu gggcuggagc uggccagacg gagccgagcu gcccuucacc   1500aucgacaagu gauaauaggc uggagccucg guggccuagc uucuugcccc uugggccucc   1560ccccagcccc uccuccccuu ccugcacccg uacccccgug gucuuugaau aaagucugag   1620ugggcggc                                                            1628</s400><s200><s210>69</s210><s211>1452</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 69augaacccca accagaagau caucaccauc ggcagcaucu gcaugaccau cggcaccgcc     60aaccugaucc ugcaaaucgg caacaucauc agcaucuggg ugagccacag cauccagauc    120ggcaaccaga gccagaucga gaccugcaac aagagcguga ucaccuacga gaacaacacc    180ugggugaacc agaccuucgu gaacaucagc aacaccaaca gcgccgcucg gaacaucacc    240gagaucgugu accugaccaa caccaccauc gagaaacagu caguggccag cgugaagcug    300gccggcaaca gcagccugug ccccguuagu ggcugggcca ucuacagcaa ggacaacagc    360gugcggaucg gcagcaaggg cgacguguuc gugauccggg agcccuucau cagcugcagc    420ccgcuugagu gccgcaccuu cuuccugacc cagggcgcuc ugcugaacga caagcacagc    480aacggcacca ucaaggaccg gagccccuau cggacccuga ugagcugccc cauuggcgag    540gugcccagcc ccuacaacag ccgguucgag ucuguggccu ggagcgccuc ugccugccac    600gacggcacca acuggcugac caucgggauc agcggacccg auagcggagc aguggccgug    660cugaaguaca acggcaucau caccgacacc aucaagagcu ggcggaacaa gauccugcgg    720acccaggaga gcgagugcgc cugcgugaac ggcagcugcu ucaccaucau gaccgacggc    780ccuagcgacg gacaggccag cuacaagauc uuccggaucg agaagggcaa gaucaucaag    840agcguggaga ugaaggcacc caacuaccac uacgaggagu gcagcugcua ccccgacagc    900agcgagauca ccugcgugug ccgggacaac uggcacggga gcaacaggcc cugggugagc    960uucaaccaga accuggagua ccagaugggc uacaucugca gcggcguguu cggcgacaac   1020ccacggccca acgacaagac uggcagcugc gguccgguga gcagcaacgg cgccaacggc   1080gugaagggcu ucagcuucaa guacggcaac ggcgugugga ucggccggac caagagcauc   1140agcagccgga agggcuucga gaugaucugg gaccccaacg gcuggaccgg caccgacaac   1200aaguucagca agaagcagga caucgugggc aucaacgagu ggagcggcua cagcggcagc   1260uucgugcagc accccgagcu gacuggccug aacugcaucc ggcccugcuu cuggguggaa   1320cugauacggg gacggcccga ggagaacacc aucuggacca gcggcagcag caucagcuuc   1380ugcggcgugg acagcgauau cgugggcugg agcuggccag acggagccga gcugcccuuc   1440accaucgaca ag                                                       1452</s400><s200><s210>70</s210><s211>484</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 70Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Ile Cys Met Thr1               5                   10                  15Ile Gly Thr Ala Asn Leu Ile Leu Gln Ile Gly Asn Ile Ile Ser Ile            20                  25                  30Trp Val Ser His Ser Ile Gln Ile Gly Asn Gln Ser Gln Ile Glu Thr        35                  40                  45Cys Asn Lys Ser Val Ile Thr Tyr Glu Asn Asn Thr Trp Val Asn Gln    50                  55                  60Thr Phe Val Asn Ile Ser Asn Thr Asn Ser Ala Ala Arg Asn Ile Thr65                  70                  75                  80Glu Ile Val Tyr Leu Thr Asn Thr Thr Ile Glu Lys Gln Ser Val Ala                85                  90                  95Ser Val Lys Leu Ala Gly Asn Ser Ser Leu Cys Pro Val Ser Gly Trp            100                 105                 110Ala Ile Tyr Ser Lys Asp Asn Ser Val Arg Ile Gly Ser Lys Gly Asp        115                 120                 125Val Phe Val Ile Arg Glu Pro Phe Ile Ser Cys Ser Pro Leu Glu Cys    130                 135                 140Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His Ser145                 150                 155                 160Asn Gly Thr Ile Lys Asp Arg Ser Pro Tyr Arg Thr Leu Met Ser Cys                165                 170                 175Pro Ile Gly Glu Val Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser Val            180                 185                 190Ala Trp Ser Ala Ser Ala Cys His Asp Gly Thr Asn Trp Leu Thr Ile        195                 200                 205Gly Ile Ser Gly Pro Asp Ser Gly Ala Val Ala Val Leu Lys Tyr Asn    210                 215                 220Gly Ile Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Lys Ile Leu Arg225                 230                 235                 240Thr Gln Glu Ser Glu Cys Ala Cys Val Asn Gly Ser Cys Phe Thr Ile                245                 250                 255Met Thr Asp Gly Pro Ser Asp Gly Gln Ala Ser Tyr Lys Ile Phe Arg            260                 265                 270Ile Glu Lys Gly Lys Ile Ile Lys Ser Val Glu Met Lys Ala Pro Asn        275                 280                 285Tyr His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ser Ser Glu Ile Thr    290                 295                 300Cys Val Cys Arg Asp Asn Trp His Gly Ser Asn Arg Pro Trp Val Ser305                 310                 315                 320Phe Asn Gln Asn Leu Glu Tyr Gln Met Gly Tyr Ile Cys Ser Gly Val                325                 330                 335Phe Gly Asp Asn Pro Arg Pro Asn Asp Lys Thr Gly Ser Cys Gly Pro            340                 345                 350Val Ser Ser Asn Gly Ala Asn Gly Val Lys Gly Phe Ser Phe Lys Tyr        355                 360                 365Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser Ile Ser Ser Arg Lys    370                 375                 380Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Gly Thr Asp Asn385                 390                 395                 400Lys Phe Ser Lys Lys Gln Asp Ile Val Gly Ile Asn Glu Trp Ser Gly                405                 410                 415Tyr Ser Gly Ser Phe Val Gln His Pro Glu Leu Thr Gly Leu Asn Cys            420                 425                 430Ile Arg Pro Cys Phe Trp Val Glu Leu Ile Arg Gly Arg Pro Glu Glu        435                 440                 445Asn Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly Val Asp    450                 455                 460Ser Asp Ile Val Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu Pro Phe465                 470                 475                 480Thr Ile Asp Lys</s400><s200><s210>71</s210><s211>1583</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 71gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaccccaacc agaagaucau caccaucggc agcaucugca ugaccaucgg caccgccaac    120cugauccugc aaaucggcaa caucaucagc aucuggguga gccacagcau ccagaucggc    180aaccagagcc agaucgagac cugcaacaag agcgugauca ccuacgagaa caacaccugg    240gugaaccaga ccuucgugaa caucagcaac accaacagcg ccgcucggca gucaguggcc    300agcgugaagc uggccggcaa cagcagccug ugccccguua guggcugggc caucuacagc    360aaggacaaca gcgugcggau cggcagcaag ggcgacgugu ucgugaucaa ggagcccuuc    420aucagcugca gcccgcuuga gugccgcacc uucuuccuga cccagggcgc ucugcugaac    480gacaagcaca gcaacggcac caucaaggac cggagccccu aucggacccu gaugagcugc    540cccauuggcg aggugcccag ccccuacaac agccgguucg agucuguggc cuggagcgcc    600ucugccugcc acgacggcac caacuggcug accaucggga ucagcggacc cgauagcgga    660gcaguggccg ugcugaagua caacggcauc aucaccgaca ccaucaagag cuggcggaac    720aagauccugc ggacccagga gagcgagugc gccugcguga acggcagcug cuucaccauc    780augaccgacg gcccuagcga cggacaggcc agcuacaaga ucuuccggau cgagaagggc    840aagaucauca agagcgugga gaugaaggca cccaacuacc acuacgagga gugcagcugc    900uaccccgaca gcagcgagau caccugcgug ugccgggaca acuggcacgg gagcaacagg    960cccuggguga gcuucaacca gaaccuggag uaccagaugg gcuacaucug cagcggcgug   1020uucggcgaca acccacggcc caacgacaag acuggcagcu gcgguccggu gagcagcaac   1080ggcgccaacg gcgugaaggg cuucagcuuc aaguacggca acggcgugug gaucggccgg   1140accaagagca ucagcagccg gaagggcuuc gagaugaucu gggaccccaa cggcuggacc   1200ggcaccgaca acaaguucag caagaagcag gacaucgugg gcaucaacga guggagcggc   1260uacagcggca gcuucgugca gcaccccgag cugacuggcc ugaacugcau ccggcccugc   1320uucugggugg aacugauacg gggacggccc gaggagaaca ccaucuggac cagcggcagc   1380agcaucagcu ucugcggcgu ggacagcgau aucgugggcu ggagcuggcc agacggagcc   1440gagcugcccu ucaccaucga caagugauaa uaggcuggag ccucgguggc cuagcuucuu   1500gccccuuggg ccucccccca gccccuccuc cccuuccugc acccguaccc ccguggucuu   1560ugaauaaagu cugagugggc ggc                                           1583</s400><s200><s210>72</s210><s211>1407</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 72augaacccca accagaagau caucaccauc ggcagcaucu gcaugaccau cggcaccgcc     60aaccugaucc ugcaaaucgg caacaucauc agcaucuggg ugagccacag cauccagauc    120ggcaaccaga gccagaucga gaccugcaac aagagcguga ucaccuacga gaacaacacc    180ugggugaacc agaccuucgu gaacaucagc aacaccaaca gcgccgcucg gcagucagug    240gccagcguga agcuggccgg caacagcagc cugugccccg uuaguggcug ggccaucuac    300agcaaggaca acagcgugcg gaucggcagc aagggcgacg uguucgugau caaggagccc    360uucaucagcu gcagcccgcu ugagugccgc accuucuucc ugacccaggg cgcucugcug    420aacgacaagc acagcaacgg caccaucaag gaccggagcc ccuaucggac ccugaugagc    480ugccccauug gcgaggugcc cagccccuac aacagccggu ucgagucugu ggccuggagc    540gccucugccu gccacgacgg caccaacugg cugaccaucg ggaucagcgg acccgauagc    600ggagcagugg ccgugcugaa guacaacggc aucaucaccg acaccaucaa gagcuggcgg    660aacaagaucc ugcggaccca ggagagcgag ugcgccugcg ugaacggcag cugcuucacc    720aucaugaccg acggcccuag cgacggacag gccagcuaca agaucuuccg gaucgagaag    780ggcaagauca ucaagagcgu ggagaugaag gcacccaacu accacuacga ggagugcagc    840ugcuaccccg acagcagcga gaucaccugc gugugccggg acaacuggca cgggagcaac    900aggcccuggg ugagcuucaa ccagaaccug gaguaccaga ugggcuacau cugcagcggc    960guguucggcg acaacccacg gcccaacgac aagacuggca gcugcggucc ggugagcagc   1020aacggcgcca acggcgugaa gggcuucagc uucaaguacg gcaacggcgu guggaucggc   1080cggaccaaga gcaucagcag ccggaagggc uucgagauga ucugggaccc caacggcugg   1140accggcaccg acaacaaguu cagcaagaag caggacaucg ugggcaucaa cgaguggagc   1200ggcuacagcg gcagcuucgu gcagcacccc gagcugacug gccugaacug cauccggccc   1260ugcuucuggg uggaacugau acggggacgg cccgaggaga acaccaucug gaccagcggc   1320agcagcauca gcuucugcgg cguggacagc gauaucgugg gcuggagcug gccagacgga   1380gccgagcugc ccuucaccau cgacaag                                       1407</s400><s200><s210>73</s210><s211>469</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 73Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Ile Cys Met Thr1               5                   10                  15Ile Gly Thr Ala Asn Leu Ile Leu Gln Ile Gly Asn Ile Ile Ser Ile            20                  25                  30Trp Val Ser His Ser Ile Gln Ile Gly Asn Gln Ser Gln Ile Glu Thr        35                  40                  45Cys Asn Lys Ser Val Ile Thr Tyr Glu Asn Asn Thr Trp Val Asn Gln    50                  55                  60Thr Phe Val Asn Ile Ser Asn Thr Asn Ser Ala Ala Arg Gln Ser Val65                  70                  75                  80Ala Ser Val Lys Leu Ala Gly Asn Ser Ser Leu Cys Pro Val Ser Gly                85                  90                  95Trp Ala Ile Tyr Ser Lys Asp Asn Ser Val Arg Ile Gly Ser Lys Gly            100                 105                 110Asp Val Phe Val Ile Lys Glu Pro Phe Ile Ser Cys Ser Pro Leu Glu        115                 120                 125Cys Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His    130                 135                 140Ser Asn Gly Thr Ile Lys Asp Arg Ser Pro Tyr Arg Thr Leu Met Ser145                 150                 155                 160Cys Pro Ile Gly Glu Val Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser                165                 170                 175Val Ala Trp Ser Ala Ser Ala Cys His Asp Gly Thr Asn Trp Leu Thr            180                 185                 190Ile Gly Ile Ser Gly Pro Asp Ser Gly Ala Val Ala Val Leu Lys Tyr        195                 200                 205Asn Gly Ile Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Lys Ile Leu    210                 215                 220Arg Thr Gln Glu Ser Glu Cys Ala Cys Val Asn Gly Ser Cys Phe Thr225                 230                 235                 240Ile Met Thr Asp Gly Pro Ser Asp Gly Gln Ala Ser Tyr Lys Ile Phe                245                 250                 255Arg Ile Glu Lys Gly Lys Ile Ile Lys Ser Val Glu Met Lys Ala Pro            260                 265                 270Asn Tyr His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ser Ser Glu Ile        275                 280                 285Thr Cys Val Cys Arg Asp Asn Trp His Gly Ser Asn Arg Pro Trp Val    290                 295                 300Ser Phe Asn Gln Asn Leu Glu Tyr Gln Met Gly Tyr Ile Cys Ser Gly305                 310                 315                 320Val Phe Gly Asp Asn Pro Arg Pro Asn Asp Lys Thr Gly Ser Cys Gly                325                 330                 335Pro Val Ser Ser Asn Gly Ala Asn Gly Val Lys Gly Phe Ser Phe Lys            340                 345                 350Tyr Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser Ile Ser Ser Arg        355                 360                 365Lys Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Gly Thr Asp    370                 375                 380Asn Lys Phe Ser Lys Lys Gln Asp Ile Val Gly Ile Asn Glu Trp Ser385                 390                 395                 400Gly Tyr Ser Gly Ser Phe Val Gln His Pro Glu Leu Thr Gly Leu Asn                405                 410                 415Cys Ile Arg Pro Cys Phe Trp Val Glu Leu Ile Arg Gly Arg Pro Glu            420                 425                 430Glu Asn Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly Val        435                 440                 445Asp Ser Asp Ile Val Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu Pro    450                 455                 460Phe Thr Ile Asp Lys465</s400><s200><s210>74</s210><s211>1583</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 74gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaccccaacc agaagaucau caccaucggc agcaucugca ugaccaucgg caccgccaac    120cugauccugc aaaucggcaa caucaucagc aucuggguga gccacagcau ccagaucggc    180aaccagagcc agaucgagac cugcaacaag agcgugauca ccuacgagaa caacaccugg    240gugaaccaga ccuucgugaa caucagcaac accaacagcg ccgcucggca gucaguggcc    300agcgugaagc uggccggcaa cagcagccug ugccccguua guggcugggc caucuacagc    360aaggacaaca gcgugcggau cggcagcaag ggcgacgugu ucgugauccg ggagcccuuc    420aucagcugca gcccgcuuga gugccgcacc uucuuccuga cccagggcgc ucugcugaac    480gacaagcaca gcaacggcac caucaaggac cggagccccu aucggacccu gaugagcugc    540cccauuggcg aggugcccag ccccuacaac agccgguucg agucuguggc cuggagcgcc    600ucugccugcc acgacggcac caacuggcug accaucggga ucagcggacc cgauagcgga    660gcaguggccg ugcugaagua caacggcauc aucaccgaca ccaucaagag cuggcggaac    720aagauccugc ggacccagga cagcgagugc gccugcguga acggcagcug cuucaccauc    780augaccgacg gcccuagcga cggacaggcc agcuacaaga ucuuccggau cgagaagggc    840aagaucauca agagcgugga gaugaaggca cccaacuacc acuacgagga gugcagcugc    900uaccccgaca gcagcgagau caccugcgug ugccgggaca acuggcacgg gagcaacagg    960cccuggguga gcuucaacca gaaccuggag uaccagaugg gcuacaucug cagcggcgug   1020uucggcgaca acccacggcc caacgacaag acuggcagcu gcgguccggu gagcagcaac   1080ggcgccaacg gcgugaaggg cuucagcuuc aaguacggca acggcgugug gaucggccgg   1140accaagagca ucagcagccg gaagggcuuc gagaugaucu gggaccccaa cggcuggacc   1200ggcaccgaca acaaguucag caagaagcag gacaucgugg gcaucaacga guggagcggc   1260uacagcggca gcuucgugca gcaccccgag cugacuggcc ugaacugcau ccggcccugc   1320uucugggugg aacugauacg gggacggccc gaggagaaca ccaucuggac cagcggcagc   1380agcaucagcu ucugcggcgu ggacagcgau aucgugggcu ggagcuggcc agacggagcc   1440gagcugcccu ucaccaucga caagugauaa uaggcuggag ccucgguggc cuagcuucuu   1500gccccuuggg ccucccccca gccccuccuc cccuuccugc acccguaccc ccguggucuu   1560ugaauaaagu cugagugggc ggc                                           1583</s400><s200><s210>75</s210><s211>1407</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 75augaacccca accagaagau caucaccauc ggcagcaucu gcaugaccau cggcaccgcc     60aaccugaucc ugcaaaucgg caacaucauc agcaucuggg ugagccacag cauccagauc    120ggcaaccaga gccagaucga gaccugcaac aagagcguga ucaccuacga gaacaacacc    180ugggugaacc agaccuucgu gaacaucagc aacaccaaca gcgccgcucg gcagucagug    240gccagcguga agcuggccgg caacagcagc cugugccccg uuaguggcug ggccaucuac    300agcaaggaca acagcgugcg gaucggcagc aagggcgacg uguucgugau ccgggagccc    360uucaucagcu gcagcccgcu ugagugccgc accuucuucc ugacccaggg cgcucugcug    420aacgacaagc acagcaacgg caccaucaag gaccggagcc ccuaucggac ccugaugagc    480ugccccauug gcgaggugcc cagccccuac aacagccggu ucgagucugu ggccuggagc    540gccucugccu gccacgacgg caccaacugg cugaccaucg ggaucagcgg acccgauagc    600ggagcagugg ccgugcugaa guacaacggc aucaucaccg acaccaucaa gagcuggcgg    660aacaagaucc ugcggaccca ggacagcgag ugcgccugcg ugaacggcag cugcuucacc    720aucaugaccg acggcccuag cgacggacag gccagcuaca agaucuuccg gaucgagaag    780ggcaagauca ucaagagcgu ggagaugaag gcacccaacu accacuacga ggagugcagc    840ugcuaccccg acagcagcga gaucaccugc gugugccggg acaacuggca cgggagcaac    900aggcccuggg ugagcuucaa ccagaaccug gaguaccaga ugggcuacau cugcagcggc    960guguucggcg acaacccacg gcccaacgac aagacuggca gcugcggucc ggugagcagc   1020aacggcgcca acggcgugaa gggcuucagc uucaaguacg gcaacggcgu guggaucggc   1080cggaccaaga gcaucagcag ccggaagggc uucgagauga ucugggaccc caacggcugg   1140accggcaccg acaacaaguu cagcaagaag caggacaucg ugggcaucaa cgaguggagc   1200ggcuacagcg gcagcuucgu gcagcacccc gagcugacug gccugaacug cauccggccc   1260ugcuucuggg uggaacugau acggggacgg cccgaggaga acaccaucug gaccagcggc   1320agcagcauca gcuucugcgg cguggacagc gauaucgugg gcuggagcug gccagacgga   1380gccgagcugc ccuucaccau cgacaag                                       1407</s400><s200><s210>76</s210><s211>469</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 76Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Ile Cys Met Thr1               5                   10                  15Ile Gly Thr Ala Asn Leu Ile Leu Gln Ile Gly Asn Ile Ile Ser Ile            20                  25                  30Trp Val Ser His Ser Ile Gln Ile Gly Asn Gln Ser Gln Ile Glu Thr        35                  40                  45Cys Asn Lys Ser Val Ile Thr Tyr Glu Asn Asn Thr Trp Val Asn Gln    50                  55                  60Thr Phe Val Asn Ile Ser Asn Thr Asn Ser Ala Ala Arg Gln Ser Val65                  70                  75                  80Ala Ser Val Lys Leu Ala Gly Asn Ser Ser Leu Cys Pro Val Ser Gly                85                  90                  95Trp Ala Ile Tyr Ser Lys Asp Asn Ser Val Arg Ile Gly Ser Lys Gly            100                 105                 110Asp Val Phe Val Ile Arg Glu Pro Phe Ile Ser Cys Ser Pro Leu Glu        115                 120                 125Cys Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His    130                 135                 140Ser Asn Gly Thr Ile Lys Asp Arg Ser Pro Tyr Arg Thr Leu Met Ser145                 150                 155                 160Cys Pro Ile Gly Glu Val Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser                165                 170                 175Val Ala Trp Ser Ala Ser Ala Cys His Asp Gly Thr Asn Trp Leu Thr            180                 185                 190Ile Gly Ile Ser Gly Pro Asp Ser Gly Ala Val Ala Val Leu Lys Tyr        195                 200                 205Asn Gly Ile Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Lys Ile Leu    210                 215                 220Arg Thr Gln Asp Ser Glu Cys Ala Cys Val Asn Gly Ser Cys Phe Thr225                 230                 235                 240Ile Met Thr Asp Gly Pro Ser Asp Gly Gln Ala Ser Tyr Lys Ile Phe                245                 250                 255Arg Ile Glu Lys Gly Lys Ile Ile Lys Ser Val Glu Met Lys Ala Pro            260                 265                 270Asn Tyr His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ser Ser Glu Ile        275                 280                 285Thr Cys Val Cys Arg Asp Asn Trp His Gly Ser Asn Arg Pro Trp Val    290                 295                 300Ser Phe Asn Gln Asn Leu Glu Tyr Gln Met Gly Tyr Ile Cys Ser Gly305                 310                 315                 320Val Phe Gly Asp Asn Pro Arg Pro Asn Asp Lys Thr Gly Ser Cys Gly                325                 330                 335Pro Val Ser Ser Asn Gly Ala Asn Gly Val Lys Gly Phe Ser Phe Lys            340                 345                 350Tyr Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser Ile Ser Ser Arg        355                 360                 365Lys Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Gly Thr Asp    370                 375                 380Asn Lys Phe Ser Lys Lys Gln Asp Ile Val Gly Ile Asn Glu Trp Ser385                 390                 395                 400Gly Tyr Ser Gly Ser Phe Val Gln His Pro Glu Leu Thr Gly Leu Asn                405                 410                 415Cys Ile Arg Pro Cys Phe Trp Val Glu Leu Ile Arg Gly Arg Pro Glu            420                 425                 430Glu Asn Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly Val        435                 440                 445Asp Ser Asp Ile Val Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu Pro    450                 455                 460Phe Thr Ile Asp Lys465</s400><s200><s210>77</s210><s211>1583</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 77gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaccccaacc agaagaucau caccaucggc agcaucugca ugaccaucgg caccgccaac    120cugauccugc aaaucggcaa caucaucagc aucuggguga gccacagcau ccagaucggc    180aaccagagcc agaucgagac cugcaacaag agcgugauca ccuacgagaa caacaccugg    240gugaaccaga ccuucgugaa caucagcaac accaacagcg ccgcucggca gucaguggcc    300agcgugaagc uggccggcaa cagcagccug ugccccguua guggcugggc caucuacagc    360aaggacaaca gcgugcggau cggcagcaag ggcgacgugu ucgugaucaa ggagcccuuc    420aucagcugca gcccgcuuga gugccgcacc uucuuccuga cccagggcgc ucugcugaac    480gacaagcaca gcaacggcac caucaagggc cggagccccu aucggacccu gaugagcugc    540cccauuggcg aggugcccag ccccuacaac agccgguucg agucuguggc cuggagcgcc    600ucugccugcc acgacggcac caacuggcug accaucggga ucagcggacc cgauagcgga    660gcaguggccg ugcugaagua caacggcauc aucaccgaca ccaucaagag cuggcggaac    720aagauccugc ggacccagga gagcgagugc gccugcguga acggcagcug cuucaccauc    780augaccgacg gcccuagcga cggacaggcc agcuacaaga ucuuccggau cgagaagggc    840aagaucauca agagcgugga gaugaaggca cccaacuacc acuacgagga gugcagcugc    900uaccccgaca gcagcgagau caccugcgug ugccgggaca acuggcacgg gagcaacagg    960cccuggguga gcuucaacca gaaccuggag uaccagaugg gcuacaucug cagcggcgug   1020uucggcgaca acccacggcc caacgacaag acuggcagcu gcgguccggu gagcagcaac   1080ggcgccaacg gcgugaaggg cuucagcuuc aaguacggca acggcgugug gaucggccgg   1140accaagagca ucagcagccg gaagggcuuc gagaugaucu gggaccccaa cggcuggacc   1200ggcaccgaca acaaguucag caagaagcag gacaucgugg gcaucaacga guggagcggc   1260uacagcggca gcuucgugca gcaccccgag cugacuggcc ugaacugcau ccggcccugc   1320uucugggugg aacugauacg gggacggccc gaggagaaca ccaucuggac cagcggcagc   1380agcaucagcu ucugcggcgu ggacagcgau aucgugggcu ggagcuggcc agacggagcc   1440gagcugcccu ucaccaucga caagugauaa uaggcuggag ccucgguggc cuagcuucuu   1500gccccuuggg ccucccccca gccccuccuc cccuuccugc acccguaccc ccguggucuu   1560ugaauaaagu cugagugggc ggc                                           1583</s400><s200><s210>78</s210><s211>1407</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 78augaacccca accagaagau caucaccauc ggcagcaucu gcaugaccau cggcaccgcc     60aaccugaucc ugcaaaucgg caacaucauc agcaucuggg ugagccacag cauccagauc    120ggcaaccaga gccagaucga gaccugcaac aagagcguga ucaccuacga gaacaacacc    180ugggugaacc agaccuucgu gaacaucagc aacaccaaca gcgccgcucg gcagucagug    240gccagcguga agcuggccgg caacagcagc cugugccccg uuaguggcug ggccaucuac    300agcaaggaca acagcgugcg gaucggcagc aagggcgacg uguucgugau caaggagccc    360uucaucagcu gcagcccgcu ugagugccgc accuucuucc ugacccaggg cgcucugcug    420aacgacaagc acagcaacgg caccaucaag ggccggagcc ccuaucggac ccugaugagc    480ugccccauug gcgaggugcc cagccccuac aacagccggu ucgagucugu ggccuggagc    540gccucugccu gccacgacgg caccaacugg cugaccaucg ggaucagcgg acccgauagc    600ggagcagugg ccgugcugaa guacaacggc aucaucaccg acaccaucaa gagcuggcgg    660aacaagaucc ugcggaccca ggagagcgag ugcgccugcg ugaacggcag cugcuucacc    720aucaugaccg acggcccuag cgacggacag gccagcuaca agaucuuccg gaucgagaag    780ggcaagauca ucaagagcgu ggagaugaag gcacccaacu accacuacga ggagugcagc    840ugcuaccccg acagcagcga gaucaccugc gugugccggg acaacuggca cgggagcaac    900aggcccuggg ugagcuucaa ccagaaccug gaguaccaga ugggcuacau cugcagcggc    960guguucggcg acaacccacg gcccaacgac aagacuggca gcugcggucc ggugagcagc   1020aacggcgcca acggcgugaa gggcuucagc uucaaguacg gcaacggcgu guggaucggc   1080cggaccaaga gcaucagcag ccggaagggc uucgagauga ucugggaccc caacggcugg   1140accggcaccg acaacaaguu cagcaagaag caggacaucg ugggcaucaa cgaguggagc   1200ggcuacagcg gcagcuucgu gcagcacccc gagcugacug gccugaacug cauccggccc   1260ugcuucuggg uggaacugau acggggacgg cccgaggaga acaccaucug gaccagcggc   1320agcagcauca gcuucugcgg cguggacagc gauaucgugg gcuggagcug gccagacgga   1380gccgagcugc ccuucaccau cgacaag                                       1407</s400><s200><s210>79</s210><s211>469</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 79Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Ile Cys Met Thr1               5                   10                  15Ile Gly Thr Ala Asn Leu Ile Leu Gln Ile Gly Asn Ile Ile Ser Ile            20                  25                  30Trp Val Ser His Ser Ile Gln Ile Gly Asn Gln Ser Gln Ile Glu Thr        35                  40                  45Cys Asn Lys Ser Val Ile Thr Tyr Glu Asn Asn Thr Trp Val Asn Gln    50                  55                  60Thr Phe Val Asn Ile Ser Asn Thr Asn Ser Ala Ala Arg Gln Ser Val65                  70                  75                  80Ala Ser Val Lys Leu Ala Gly Asn Ser Ser Leu Cys Pro Val Ser Gly                85                  90                  95Trp Ala Ile Tyr Ser Lys Asp Asn Ser Val Arg Ile Gly Ser Lys Gly            100                 105                 110Asp Val Phe Val Ile Lys Glu Pro Phe Ile Ser Cys Ser Pro Leu Glu        115                 120                 125Cys Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His    130                 135                 140Ser Asn Gly Thr Ile Lys Gly Arg Ser Pro Tyr Arg Thr Leu Met Ser145                 150                 155                 160Cys Pro Ile Gly Glu Val Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser                165                 170                 175Val Ala Trp Ser Ala Ser Ala Cys His Asp Gly Thr Asn Trp Leu Thr            180                 185                 190Ile Gly Ile Ser Gly Pro Asp Ser Gly Ala Val Ala Val Leu Lys Tyr        195                 200                 205Asn Gly Ile Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Lys Ile Leu    210                 215                 220Arg Thr Gln Glu Ser Glu Cys Ala Cys Val Asn Gly Ser Cys Phe Thr225                 230                 235                 240Ile Met Thr Asp Gly Pro Ser Asp Gly Gln Ala Ser Tyr Lys Ile Phe                245                 250                 255Arg Ile Glu Lys Gly Lys Ile Ile Lys Ser Val Glu Met Lys Ala Pro            260                 265                 270Asn Tyr His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ser Ser Glu Ile        275                 280                 285Thr Cys Val Cys Arg Asp Asn Trp His Gly Ser Asn Arg Pro Trp Val    290                 295                 300Ser Phe Asn Gln Asn Leu Glu Tyr Gln Met Gly Tyr Ile Cys Ser Gly305                 310                 315                 320Val Phe Gly Asp Asn Pro Arg Pro Asn Asp Lys Thr Gly Ser Cys Gly                325                 330                 335Pro Val Ser Ser Asn Gly Ala Asn Gly Val Lys Gly Phe Ser Phe Lys            340                 345                 350Tyr Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser Ile Ser Ser Arg        355                 360                 365Lys Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Gly Thr Asp    370                 375                 380Asn Lys Phe Ser Lys Lys Gln Asp Ile Val Gly Ile Asn Glu Trp Ser385                 390                 395                 400Gly Tyr Ser Gly Ser Phe Val Gln His Pro Glu Leu Thr Gly Leu Asn                405                 410                 415Cys Ile Arg Pro Cys Phe Trp Val Glu Leu Ile Arg Gly Arg Pro Glu            420                 425                 430Glu Asn Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly Val        435                 440                 445Asp Ser Asp Ile Val Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu Pro    450                 455                 460Phe Thr Ile Asp Lys465</s400><s200><s210>80</s210><s211>1583</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 80gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaccccaacc agaagaucau caccaucggc agcaucugca ugaccaucgg caccgccaac    120cugauccugc aaaucggcaa caucaucagc aucuggguga gccacagcau ccagaucggc    180aaccagagcc agaucgagac cugcaacaag agcgugauca ccuacgagaa caacaccugg    240gugaaccaga ccuucgugaa caucagcaac accaacagcg ccgcucggca gucaguggcc    300agcgugaagc uggccggcaa cagcagccug ugccccguua guggcugggc caucuacagc    360aaggacaaca gcgugcggau cggcagcaag ggcgacgugu ucgugauccg ggagcccuuc    420aucagcugca gcccgcuuga gugccgcacc uucuuccuga cccagggcgc ucugcugaac    480gacaagcaca gcaacggcac caucaagggc cggagccccu aucggacccu gaugagcugc    540cccauuggcg aggugcccag ccccuacaac agccgguucg agucuguggc cuggagcgcc    600ucugccugcc acgacggcac caacuggcug accaucggga ucagcggacc cgauagcgga    660gcaguggccg ugcugaagua caacggcauc aucaccgaca ccaucaagag cuggcggaac    720aagauccugc ggacccagga cagcgagugc gccugcguga acggcagcug cuucaccauc    780augaccgacg gcccuagcga cggacaggcc agcuacaaga ucuuccggau cgagaagggc    840aagaucauca agagcgugga gaugaaggca cccaacuacc acuacgagga gugcagcugc    900uaccccgaca gcagcgagau caccugcgug ugccgggaca acuggcacgg gagcaacagg    960cccuggguga gcuucaacca gaaccuggag uaccagaugg gcuacaucug cagcggcgug   1020uucggcgaca acccacggcc caacgacaag acuggcagcu gcgguccggu gagcagcaac   1080ggcgccaacg gcgugaaggg cuucagcuuc aaguacggca acggcgugug gaucggccgg   1140accaagagca ucagcagccg gaagggcuuc gagaugaucu gggaccccaa cggcuggacc   1200ggcaccgaca acaaguucag caagaagcag gacaucgugg gcaucaacga guggagcggc   1260uacagcggca gcuucgugca gcaccccgag cugacuggcc ugaacugcau ccggcccugc   1320uucugggugg aacugauacg gggacggccc gaggagaaca ccaucuggac cagcggcagc   1380agcaucagcu ucugcggcgu ggacagcgau aucgugggcu ggagcuggcc agacggagcc   1440gagcugcccu ucaccaucga caagugauaa uaggcuggag ccucgguggc cuagcuucuu   1500gccccuuggg ccucccccca gccccuccuc cccuuccugc acccguaccc ccguggucuu   1560ugaauaaagu cugagugggc ggc                                           1583</s400><s200><s210>81</s210><s211>1407</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 81augaacccca accagaagau caucaccauc ggcagcaucu gcaugaccau cggcaccgcc     60aaccugaucc ugcaaaucgg caacaucauc agcaucuggg ugagccacag cauccagauc    120ggcaaccaga gccagaucga gaccugcaac aagagcguga ucaccuacga gaacaacacc    180ugggugaacc agaccuucgu gaacaucagc aacaccaaca gcgccgcucg gcagucagug    240gccagcguga agcuggccgg caacagcagc cugugccccg uuaguggcug ggccaucuac    300agcaaggaca acagcgugcg gaucggcagc aagggcgacg uguucgugau ccgggagccc    360uucaucagcu gcagcccgcu ugagugccgc accuucuucc ugacccaggg cgcucugcug    420aacgacaagc acagcaacgg caccaucaag ggccggagcc ccuaucggac ccugaugagc    480ugccccauug gcgaggugcc cagccccuac aacagccggu ucgagucugu ggccuggagc    540gccucugccu gccacgacgg caccaacugg cugaccaucg ggaucagcgg acccgauagc    600ggagcagugg ccgugcugaa guacaacggc aucaucaccg acaccaucaa gagcuggcgg    660aacaagaucc ugcggaccca ggacagcgag ugcgccugcg ugaacggcag cugcuucacc    720aucaugaccg acggcccuag cgacggacag gccagcuaca agaucuuccg gaucgagaag    780ggcaagauca ucaagagcgu ggagaugaag gcacccaacu accacuacga ggagugcagc    840ugcuaccccg acagcagcga gaucaccugc gugugccggg acaacuggca cgggagcaac    900aggcccuggg ugagcuucaa ccagaaccug gaguaccaga ugggcuacau cugcagcggc    960guguucggcg acaacccacg gcccaacgac aagacuggca gcugcggucc ggugagcagc   1020aacggcgcca acggcgugaa gggcuucagc uucaaguacg gcaacggcgu guggaucggc   1080cggaccaaga gcaucagcag ccggaagggc uucgagauga ucugggaccc caacggcugg   1140accggcaccg acaacaaguu cagcaagaag caggacaucg ugggcaucaa cgaguggagc   1200ggcuacagcg gcagcuucgu gcagcacccc gagcugacug gccugaacug cauccggccc   1260ugcuucuggg uggaacugau acggggacgg cccgaggaga acaccaucug gaccagcggc   1320agcagcauca gcuucugcgg cguggacagc gauaucgugg gcuggagcug gccagacgga   1380gccgagcugc ccuucaccau cgacaag                                       1407</s400><s200><s210>82</s210><s211>469</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 82Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Ile Cys Met Thr1               5                   10                  15Ile Gly Thr Ala Asn Leu Ile Leu Gln Ile Gly Asn Ile Ile Ser Ile            20                  25                  30Trp Val Ser His Ser Ile Gln Ile Gly Asn Gln Ser Gln Ile Glu Thr        35                  40                  45Cys Asn Lys Ser Val Ile Thr Tyr Glu Asn Asn Thr Trp Val Asn Gln    50                  55                  60Thr Phe Val Asn Ile Ser Asn Thr Asn Ser Ala Ala Arg Gln Ser Val65                  70                  75                  80Ala Ser Val Lys Leu Ala Gly Asn Ser Ser Leu Cys Pro Val Ser Gly                85                  90                  95Trp Ala Ile Tyr Ser Lys Asp Asn Ser Val Arg Ile Gly Ser Lys Gly            100                 105                 110Asp Val Phe Val Ile Arg Glu Pro Phe Ile Ser Cys Ser Pro Leu Glu        115                 120                 125Cys Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His    130                 135                 140Ser Asn Gly Thr Ile Lys Gly Arg Ser Pro Tyr Arg Thr Leu Met Ser145                 150                 155                 160Cys Pro Ile Gly Glu Val Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser                165                 170                 175Val Ala Trp Ser Ala Ser Ala Cys His Asp Gly Thr Asn Trp Leu Thr            180                 185                 190Ile Gly Ile Ser Gly Pro Asp Ser Gly Ala Val Ala Val Leu Lys Tyr        195                 200                 205Asn Gly Ile Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Lys Ile Leu    210                 215                 220Arg Thr Gln Asp Ser Glu Cys Ala Cys Val Asn Gly Ser Cys Phe Thr225                 230                 235                 240Ile Met Thr Asp Gly Pro Ser Asp Gly Gln Ala Ser Tyr Lys Ile Phe                245                 250                 255Arg Ile Glu Lys Gly Lys Ile Ile Lys Ser Val Glu Met Lys Ala Pro            260                 265                 270Asn Tyr His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ser Ser Glu Ile        275                 280                 285Thr Cys Val Cys Arg Asp Asn Trp His Gly Ser Asn Arg Pro Trp Val    290                 295                 300Ser Phe Asn Gln Asn Leu Glu Tyr Gln Met Gly Tyr Ile Cys Ser Gly305                 310                 315                 320Val Phe Gly Asp Asn Pro Arg Pro Asn Asp Lys Thr Gly Ser Cys Gly                325                 330                 335Pro Val Ser Ser Asn Gly Ala Asn Gly Val Lys Gly Phe Ser Phe Lys            340                 345                 350Tyr Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser Ile Ser Ser Arg        355                 360                 365Lys Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Gly Thr Asp    370                 375                 380Asn Lys Phe Ser Lys Lys Gln Asp Ile Val Gly Ile Asn Glu Trp Ser385                 390                 395                 400Gly Tyr Ser Gly Ser Phe Val Gln His Pro Glu Leu Thr Gly Leu Asn                405                 410                 415Cys Ile Arg Pro Cys Phe Trp Val Glu Leu Ile Arg Gly Arg Pro Glu            420                 425                 430Glu Asn Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly Val        435                 440                 445Asp Ser Asp Ile Val Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu Pro    450                 455                 460Phe Thr Ile Asp Lys465</s400><s200><s210>83</s210><s211>3272</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 83gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aagaccauca ucgcccugag cuacauccug ugccugggcu ucacccagaa gauccccggc    120aacgauaaca gcaccgccac ccugugucug ggacaccacg ccgugcccaa cggcaccauc    180gugaagacua ucaccaacga ccggaucgag gugaccaacg ccaccgagcu ggugcagaac    240agcagcaucg gcgagaucug cgacagcccu caccagaucc uggacggcgg caacugcacc    300cugaucgacg cacugcuggg cgacccucag ugcgacggcu uucagaacaa gaagugggac    360cuguucgugg agagaucgcg ggccuacagc aacugcuacc ccuacgacgu ccccgacuac    420gcaagccuga gaagccucgu ggccucaagc ggcacccugg aguucaagaa cgagagcuuc    480aacugggccg gcgugaccca gaacggcaag ucauucagcu gcauccgggg cuccagcagc    540agcuucuucu cacggcugaa cuggcugacc caccugaacu acaccuaccc cgcccugaac    600gugaccaugc ccaacaagga gcaguucgac aagcuguaca ucuggggagu gcaccauccc    660ggcaccgaca aggaccagau uagccuguac gcccagucua gcggccggau caccgugagc    720accaagcgga gccagcaggc cgugaucccc aacaucggcu cucggcccag aauccgggac    780auccccagcc ggaucagcau cuacuggacc auugugaagc ccggcgacau ccugcugauc    840aacuccaccg gcaaccugau cgccccucgg ggcuauuuca agauccggag cggcaagagc    900agcaucaugc ggagcgacgc cccuaucggc aagugcaaga gcgagugcau cacacccaac    960ggaagcaucc ccaacgacaa gcccuuccag aacgugaacc ggauaaccua cggcgccugc   1020ccuagauacg ugaagcagaa cacccugaag cuggccaccg gcaugcggaa cgugcccgag   1080aagcagacuc ggggcaucuu cggcgccauc gccggcuuca ucgagaacgg cugggagggc   1140augguggacg gcugguacgg cuuccggcac cagaacucug agggcagagg acaggccgca   1200gaccugaaga gcacccaggc cgccaucgac cagaucaacg gcaagcugaa ccggcugauc   1260ggcaagacca acgagaaguu ccaccagauc gagaaggagu ucagcgaggu ggagggcagg   1320guacaggacc uggagaagua cguggaggac accaagaucg accuguggag cuacaacgcc   1380gagcugcugg uagcccugga gaaccagcac accaucgacc ugaccgacag cgagaugaac   1440aagcuguucg agaagaccaa gaagcagcug cgggagaacg ccgaggacau gggcaacggc   1500ugcuucaaga ucuaccacaa gugcgacaac gccugcaucg gcagcauccg gaacgagacc   1560uacgaccaca acguguaccg ggacgaggcc cugaacaacc gguuccagau caagggcgug   1620gagcugaaga gcggcuacaa ggacuggauc cuguggauca gcuucgccau cuccugcuuc   1680cugcugugcg uggcccugcu ggguuucauc augugggccu gccagaaggg caacauccgg   1740ugcaacaucu gcaucggcuc uggcagcggc agcaccagcc ugcugggacu ggccgugcgg   1800cugcugcugu uucagccugc ccugauggug uucugggcaa gccaggugcg gcagaacugc   1860cggaacggca gcuacgagau cagcgugcug augauggaca acagcgccua caaggagccc   1920augcagaacc ugcgggaggc cguggaggag ggccuggaca ucgugcggaa gcggcugcgg   1980gaagccgacc ugaacgugac cgugaacgcc accuucaucu acagcgacgg ccugauccac   2040aagagcggcg acugccggag cagcaccugc gaggggcugg accugcugcg ggagaucacc   2100cgggaccaca agaugggcug cgcccugaug ggccccagcu gcaccuacag cacuuuccag   2160auguaccugg acaccgagcu gaacuacccc augaucagcg caggcagcua cggccugagc   2220ugcgacuaca aggagacccu gacccggauc cugccacccg cccggaagcu gauguacuuc   2280cucguggacu ucuggaaggu gaacaacgcc agcuucaagc ccuucagcug gaacagcagc   2340uacguguaca agaacggcag cgagcccgag gacugcuucu gguaccugaa cgcucuggag   2400gccgggguga gcuacuucag cgaggugcug aacuucaagg acgugcugcg gcggagcgag   2460caguuccagg agauccugac cggccacaac cggaagagca acgugaucgu gaugugcggc   2520accccggaga gcuucuacga cgugaagggc gaccugcagg uggccgagga caccguggug   2580auccuggugg accuguucag caaccacuac uucgaggaga acaccaccgc cccugaguac   2640auggacaacg ugcuggugcu gacccugccc agcgagcaga gcaccagcaa caccagcgug   2700gccgagcggu ucagcagcgg ccggagcgac uucagccugg ccuaccugga gggcacccug   2760cuguucggcc acaugcugca gaccuuccug gagaacggcg agaacguaac cggccccaag   2820uucgcccggg ccuuccggaa ccugaccuuc cagggcuucg caggccccgu gacccuggac   2880gacagcggcg acaucgacaa caucaugagc cugcuguacg ugagccugga cacccggaag   2940uacaaggugc ugaugaagua cgacacccac aagaacaaga ccauccccgu ggccgagaac   3000cccaacuuca ucuggaagaa ccacaagcug cccaacgacg ugcccggucu gggaccgcag   3060auccugauga ucgccguguu cacccugacc ggcauccugg uggugcugcu gcugaucgcc   3120cugcuggucc ugcggaagua ccggcgggac cacugauaau aggcuggagc cucgguggcc   3180uagcuucuug ccccuugggc cuccccccag ccccuccucc ccuuccugca cccguacccc   3240cguggucuuu gaauaaaguc ugagugggcg gc                                 3272</s400><s200><s210>84</s210><s211>3096</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 84augaagacca ucaucgcccu gagcuacauc cugugccugg gcuucaccca gaagaucccc     60ggcaacgaua acagcaccgc cacccugugu cugggacacc acgccgugcc caacggcacc    120aucgugaaga cuaucaccaa cgaccggauc gaggugacca acgccaccga gcuggugcag    180aacagcagca ucggcgagau cugcgacagc ccucaccaga uccuggacgg cggcaacugc    240acccugaucg acgcacugcu gggcgacccu cagugcgacg gcuuucagaa caagaagugg    300gaccuguucg uggagagauc gcgggccuac agcaacugcu accccuacga cguccccgac    360uacgcaagcc ugagaagccu cguggccuca agcggcaccc uggaguucaa gaacgagagc    420uucaacuggg ccggcgugac ccagaacggc aagucauuca gcugcauccg gggcuccagc    480agcagcuucu ucucacggcu gaacuggcug acccaccuga acuacaccua ccccgcccug    540aacgugacca ugcccaacaa ggagcaguuc gacaagcugu acaucugggg agugcaccau    600cccggcaccg acaaggacca gauuagccug uacgcccagu cuagcggccg gaucaccgug    660agcaccaagc ggagccagca ggccgugauc cccaacaucg gcucucggcc cagaauccgg    720gacaucccca gccggaucag caucuacugg accauuguga agcccggcga cauccugcug    780aucaacucca ccggcaaccu gaucgccccu cggggcuauu ucaagauccg gagcggcaag    840agcagcauca ugcggagcga cgccccuauc ggcaagugca agagcgagug caucacaccc    900aacggaagca uccccaacga caagcccuuc cagaacguga accggauaac cuacggcgcc    960ugcccuagau acgugaagca gaacacccug aagcuggcca ccggcaugcg gaacgugccc   1020gagaagcaga cucggggcau cuucggcgcc aucgccggcu ucaucgagaa cggcugggag   1080ggcauggugg acggcuggua cggcuuccgg caccagaacu cugagggcag aggacaggcc   1140gcagaccuga agagcaccca ggccgccauc gaccagauca acggcaagcu gaaccggcug   1200aucggcaaga ccaacgagaa guuccaccag aucgagaagg aguucagcga gguggagggc   1260aggguacagg accuggagaa guacguggag gacaccaaga ucgaccugug gagcuacaac   1320gccgagcugc ugguagcccu ggagaaccag cacaccaucg accugaccga cagcgagaug   1380aacaagcugu ucgagaagac caagaagcag cugcgggaga acgccgagga caugggcaac   1440ggcugcuuca agaucuacca caagugcgac aacgccugca ucggcagcau ccggaacgag   1500accuacgacc acaacgugua ccgggacgag gcccugaaca accgguucca gaucaagggc   1560guggagcuga agagcggcua caaggacugg auccugugga ucagcuucgc caucuccugc   1620uuccugcugu gcguggcccu gcuggguuuc aucauguggg ccugccagaa gggcaacauc   1680cggugcaaca ucugcaucgg cucuggcagc ggcagcacca gccugcuggg acuggccgug   1740cggcugcugc uguuucagcc ugcccugaug guguucuggg caagccaggu gcggcagaac   1800ugccggaacg gcagcuacga gaucagcgug cugaugaugg acaacagcgc cuacaaggag   1860cccaugcaga accugcggga ggccguggag gagggccugg acaucgugcg gaagcggcug   1920cgggaagccg accugaacgu gaccgugaac gccaccuuca ucuacagcga cggccugauc   1980cacaagagcg gcgacugccg gagcagcacc ugcgaggggc uggaccugcu gcgggagauc   2040acccgggacc acaagauggg cugcgcccug augggcccca gcugcaccua cagcacuuuc   2100cagauguacc uggacaccga gcugaacuac cccaugauca gcgcaggcag cuacggccug   2160agcugcgacu acaaggagac ccugacccgg auccugccac ccgcccggaa gcugauguac   2220uuccucgugg acuucuggaa ggugaacaac gccagcuuca agcccuucag cuggaacagc   2280agcuacgugu acaagaacgg cagcgagccc gaggacugcu ucugguaccu gaacgcucug   2340gaggccgggg ugagcuacuu cagcgaggug cugaacuuca aggacgugcu gcggcggagc   2400gagcaguucc aggagauccu gaccggccac aaccggaaga gcaacgugau cgugaugugc   2460ggcaccccgg agagcuucua cgacgugaag ggcgaccugc agguggccga ggacaccgug   2520gugauccugg uggaccuguu cagcaaccac uacuucgagg agaacaccac cgccccugag   2580uacauggaca acgugcuggu gcugacccug cccagcgagc agagcaccag caacaccagc   2640guggccgagc gguucagcag cggccggagc gacuucagcc uggccuaccu ggagggcacc   2700cugcuguucg gccacaugcu gcagaccuuc cuggagaacg gcgagaacgu aaccggcccc   2760aaguucgccc gggccuuccg gaaccugacc uuccagggcu ucgcaggccc cgugacccug   2820gacgacagcg gcgacaucga caacaucaug agccugcugu acgugagccu ggacacccgg   2880aaguacaagg ugcugaugaa guacgacacc cacaagaaca agaccauccc cguggccgag   2940aaccccaacu ucaucuggaa gaaccacaag cugcccaacg acgugcccgg ucugggaccg   3000cagauccuga ugaucgccgu guucacccug accggcaucc ugguggugcu gcugcugauc   3060gcccugcugg uccugcggaa guaccggcgg gaccac                             3096</s400><s200><s210>85</s210><s211>1032</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 85Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys Leu Gly Phe Thr1               5                   10                  15Gln Lys Ile Pro Gly Asn Asp Asn Ser Thr Ala Thr Leu Cys Leu Gly            20                  25                  30His His Ala Val Pro Asn Gly Thr Ile Val Lys Thr Ile Thr Asn Asp        35                  40                  45Arg Ile Glu Val Thr Asn Ala Thr Glu Leu Val Gln Asn Ser Ser Ile    50                  55                  60Gly Glu Ile Cys Asp Ser Pro His Gln Ile Leu Asp Gly Gly Asn Cys65                  70                  75                  80Thr Leu Ile Asp Ala Leu Leu Gly Asp Pro Gln Cys Asp Gly Phe Gln                85                  90                  95Asn Lys Lys Trp Asp Leu Phe Val Glu Arg Ser Arg Ala Tyr Ser Asn            100                 105                 110Cys Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Arg Ser Leu Val        115                 120                 125Ala Ser Ser Gly Thr Leu Glu Phe Lys Asn Glu Ser Phe Asn Trp Ala    130                 135                 140Gly Val Thr Gln Asn Gly Lys Ser Phe Ser Cys Ile Arg Gly Ser Ser145                 150                 155                 160Ser Ser Phe Phe Ser Arg Leu Asn Trp Leu Thr His Leu Asn Tyr Thr                165                 170                 175Tyr Pro Ala Leu Asn Val Thr Met Pro Asn Lys Glu Gln Phe Asp Lys            180                 185                 190Leu Tyr Ile Trp Gly Val His His Pro Gly Thr Asp Lys Asp Gln Ile        195                 200                 205Ser Leu Tyr Ala Gln Ser Ser Gly Arg Ile Thr Val Ser Thr Lys Arg    210                 215                 220Ser Gln Gln Ala Val Ile Pro Asn Ile Gly Ser Arg Pro Arg Ile Arg225                 230                 235                 240Asp Ile Pro Ser Arg Ile Ser Ile Tyr Trp Thr Ile Val Lys Pro Gly                245                 250                 255Asp Ile Leu Leu Ile Asn Ser Thr Gly Asn Leu Ile Ala Pro Arg Gly            260                 265                 270Tyr Phe Lys Ile Arg Ser Gly Lys Ser Ser Ile Met Arg Ser Asp Ala        275                 280                 285Pro Ile Gly Lys Cys Lys Ser Glu Cys Ile Thr Pro Asn Gly Ser Ile    290                 295                 300Pro Asn Asp Lys Pro Phe Gln Asn Val Asn Arg Ile Thr Tyr Gly Ala305                 310                 315                 320Cys Pro Arg Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr Gly Met                325                 330                 335Arg Asn Val Pro Glu Lys Gln Thr Arg Gly Ile Phe Gly Ala Ile Ala            340                 345                 350Gly Phe Ile Glu Asn Gly Trp Glu Gly Met Val Asp Gly Trp Tyr Gly        355                 360                 365Phe Arg His Gln Asn Ser Glu Gly Arg Gly Gln Ala Ala Asp Leu Lys    370                 375                 380Ser Thr Gln Ala Ala Ile Asp Gln Ile Asn Gly Lys Leu Asn Arg Leu385                 390                 395                 400Ile Gly Lys Thr Asn Glu Lys Phe His Gln Ile Glu Lys Glu Phe Ser                405                 410                 415Glu Val Glu Gly Arg Val Gln Asp Leu Glu Lys Tyr Val Glu Asp Thr            420                 425                 430Lys Ile Asp Leu Trp Ser Tyr Asn Ala Glu Leu Leu Val Ala Leu Glu        435                 440                 445Asn Gln His Thr Ile Asp Leu Thr Asp Ser Glu Met Asn Lys Leu Phe    450                 455                 460Glu Lys Thr Lys Lys Gln Leu Arg Glu Asn Ala Glu Asp Met Gly Asn465                 470                 475                 480Gly Cys Phe Lys Ile Tyr His Lys Cys Asp Asn Ala Cys Ile Gly Ser                485                 490                 495Ile Arg Asn Glu Thr Tyr Asp His Asn Val Tyr Arg Asp Glu Ala Leu            500                 505                 510Asn Asn Arg Phe Gln Ile Lys Gly Val Glu Leu Lys Ser Gly Tyr Lys        515                 520                 525Asp Trp Ile Leu Trp Ile Ser Phe Ala Ile Ser Cys Phe Leu Leu Cys    530                 535                 540Val Ala Leu Leu Gly Phe Ile Met Trp Ala Cys Gln Lys Gly Asn Ile545                 550                 555                 560Arg Cys Asn Ile Cys Ile Gly Ser Gly Ser Gly Ser Thr Ser Leu Leu                565                 570                 575Gly Leu Ala Val Arg Leu Leu Leu Phe Gln Pro Ala Leu Met Val Phe            580                 585                 590Trp Ala Ser Gln Val Arg Gln Asn Cys Arg Asn Gly Ser Tyr Glu Ile        595                 600                 605Ser Val Leu Met Met Asp Asn Ser Ala Tyr Lys Glu Pro Met Gln Asn    610                 615                 620Leu Arg Glu Ala Val Glu Glu Gly Leu Asp Ile Val Arg Lys Arg Leu625                 630                 635                 640Arg Glu Ala Asp Leu Asn Val Thr Val Asn Ala Thr Phe Ile Tyr Ser                645                 650                 655Asp Gly Leu Ile His Lys Ser Gly Asp Cys Arg Ser Ser Thr Cys Glu            660                 665                 670Gly Leu Asp Leu Leu Arg Glu Ile Thr Arg Asp His Lys Met Gly Cys        675                 680                 685Ala Leu Met Gly Pro Ser Cys Thr Tyr Ser Thr Phe Gln Met Tyr Leu    690                 695                 700Asp Thr Glu Leu Asn Tyr Pro Met Ile Ser Ala Gly Ser Tyr Gly Leu705                 710                 715                 720Ser Cys Asp Tyr Lys Glu Thr Leu Thr Arg Ile Leu Pro Pro Ala Arg                725                 730                 735Lys Leu Met Tyr Phe Leu Val Asp Phe Trp Lys Val Asn Asn Ala Ser            740                 745                 750Phe Lys Pro Phe Ser Trp Asn Ser Ser Tyr Val Tyr Lys Asn Gly Ser        755                 760                 765Glu Pro Glu Asp Cys Phe Trp Tyr Leu Asn Ala Leu Glu Ala Gly Val    770                 775                 780Ser Tyr Phe Ser Glu Val Leu Asn Phe Lys Asp Val Leu Arg Arg Ser785                 790                 795                 800Glu Gln Phe Gln Glu Ile Leu Thr Gly His Asn Arg Lys Ser Asn Val                805                 810                 815Ile Val Met Cys Gly Thr Pro Glu Ser Phe Tyr Asp Val Lys Gly Asp            820                 825                 830Leu Gln Val Ala Glu Asp Thr Val Val Ile Leu Val Asp Leu Phe Ser        835                 840                 845Asn His Tyr Phe Glu Glu Asn Thr Thr Ala Pro Glu Tyr Met Asp Asn    850                 855                 860Val Leu Val Leu Thr Leu Pro Ser Glu Gln Ser Thr Ser Asn Thr Ser865                 870                 875                 880Val Ala Glu Arg Phe Ser Ser Gly Arg Ser Asp Phe Ser Leu Ala Tyr                885                 890                 895Leu Glu Gly Thr Leu Leu Phe Gly His Met Leu Gln Thr Phe Leu Glu            900                 905                 910Asn Gly Glu Asn Val Thr Gly Pro Lys Phe Ala Arg Ala Phe Arg Asn        915                 920                 925Leu Thr Phe Gln Gly Phe Ala Gly Pro Val Thr Leu Asp Asp Ser Gly    930                 935                 940Asp Ile Asp Asn Ile Met Ser Leu Leu Tyr Val Ser Leu Asp Thr Arg945                 950                 955                 960Lys Tyr Lys Val Leu Met Lys Tyr Asp Thr His Lys Asn Lys Thr Ile                965                 970                 975Pro Val Ala Glu Asn Pro Asn Phe Ile Trp Lys Asn His Lys Leu Pro            980                 985                 990Asn Asp Val Pro Gly Leu Gly Pro  Gln Ile Leu Met Ile  Ala Val Phe        995                 1000                 1005Thr Leu  Thr Gly Ile Leu Val  Val Leu Leu Leu Ile  Ala Leu Leu    1010                 1015                 1020Val Leu  Arg Lys Tyr Arg Arg  Asp His    1025                 1030</s400><s200><s210>86</s210><s211>1874</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 86gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aagaccauca ucgcccugag cuacauccug ugccugggcu ucacccagaa gauccccggc    120aacgauaaca gcaccgccac ccugugucug ggacaccacg ccgugcccaa cggcaccauc    180gugaagacua ucaccaacga ccggaucgag gugaccaacg ccaccgagcu ggugcagaac    240agcagcaucg gcgagaucug cgacagcccu caccagaucc uggacggcgg caacugcacc    300cugaucgacg cacugcuggg cgacccucag ugcgacggcu uucagaacaa gaagugggac    360cuguucgugg agagaucgcg ggccuacagc aacugcuacc ccuacgacgu ccccgacuac    420gcaagccuga gaagccucgu ggccucaagc ggcacccugg aguucaagaa cgagagcuuc    480aacugggccg gcgugaccca gaacggcaag ucauucagcu gcauccgggg cuccagcagc    540agcuucuucu cacggcugaa cuggcugacc caccugaacu acaccuaccc cgcccugaac    600gugaccaugc ccaacaagga gcaguucgac aagcuguaca ucuggggagu gcaccauccc    660ggcaccgaca aggaccagau uagccuguac gcccagucua gcggccggau caccgugagc    720accaagcgga gccagcaggc cgugaucccc aacaucggcu cucggcccag aauccgggac    780auccccagcc ggaucagcau cuacuggacc auugugaagc ccggcgacau ccugcugauc    840aacuccaccg gcaaccugau cgccccucgg ggcuauuuca agauccggag cggcaagagc    900agcaucaugc ggagcgacgc cccuaucggc aagugcaaga gcgagugcau cacacccaac    960ggaagcaucc ccaacgacaa gcccuuccag aacgugaacc ggauaaccua cggcgccugc   1020ccuagauacg ugaagcagaa cacccugaag cuggccaccg gcaugcggaa cgugcccgag   1080aagcagacuc ggggcaucuu cggcgccauc gccggcuuca ucgagaacgg cugggagggc   1140augguggacg gcugguacgg cuuccggcac cagaacucug agggcagagg acaggccgca   1200gaccugaaga gcacccaggc cgccaucgac cagaucaacg gcaagcugaa ccggcugauc   1260ggcaagacca acgagaaguu ccaccagauc gagaaggagu ucagcgaggu ggagggcagg   1320guacaggacc uggagaagua cguggaggac accaagaucg accuguggag cuacaacgcc   1380gagcugcugg uagcccugga gaaccagcac accaucgacc ugaccgacag cgagaugaac   1440aagcuguucg agaagaccaa gaagcagcug cgggagaacg ccgaggacau gggcaacggc   1500ugcuucaaga ucuaccacaa gugcgacaac gccugcaucg gcagcauccg gaacgagacc   1560uacgaccaca acguguaccg ggacgaggcc cugaacaacc gguuccagau caagggcgug   1620gagcugaaga gcggcuacaa ggacuggauc cuguggauca gcuucgccau cuccugcuuc   1680cugcugugcg uggcccugcu ggguuucauc augugggccu gccagaaggg caacauccgg   1740ugcaacaucu gcaucugaua auaggcugga gccucggugg ccuagcuucu ugccccuugg   1800gccucccccc agccccuccu ccccuuccug cacccguacc cccguggucu uugaauaaag   1860ucugaguggg cggc                                                     1874</s400><s200><s210>87</s210><s211>1698</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 87augaagacca ucaucgcccu gagcuacauc cugugccugg gcuucaccca gaagaucccc     60ggcaacgaua acagcaccgc cacccugugu cugggacacc acgccgugcc caacggcacc    120aucgugaaga cuaucaccaa cgaccggauc gaggugacca acgccaccga gcuggugcag    180aacagcagca ucggcgagau cugcgacagc ccucaccaga uccuggacgg cggcaacugc    240acccugaucg acgcacugcu gggcgacccu cagugcgacg gcuuucagaa caagaagugg    300gaccuguucg uggagagauc gcgggccuac agcaacugcu accccuacga cguccccgac    360uacgcaagcc ugagaagccu cguggccuca agcggcaccc uggaguucaa gaacgagagc    420uucaacuggg ccggcgugac ccagaacggc aagucauuca gcugcauccg gggcuccagc    480agcagcuucu ucucacggcu gaacuggcug acccaccuga acuacaccua ccccgcccug    540aacgugacca ugcccaacaa ggagcaguuc gacaagcugu acaucugggg agugcaccau    600cccggcaccg acaaggacca gauuagccug uacgcccagu cuagcggccg gaucaccgug    660agcaccaagc ggagccagca ggccgugauc cccaacaucg gcucucggcc cagaauccgg    720gacaucccca gccggaucag caucuacugg accauuguga agcccggcga cauccugcug    780aucaacucca ccggcaaccu gaucgccccu cggggcuauu ucaagauccg gagcggcaag    840agcagcauca ugcggagcga cgccccuauc ggcaagugca agagcgagug caucacaccc    900aacggaagca uccccaacga caagcccuuc cagaacguga accggauaac cuacggcgcc    960ugcccuagau acgugaagca gaacacccug aagcuggcca ccggcaugcg gaacgugccc   1020gagaagcaga cucggggcau cuucggcgcc aucgccggcu ucaucgagaa cggcugggag   1080ggcauggugg acggcuggua cggcuuccgg caccagaacu cugagggcag aggacaggcc   1140gcagaccuga agagcaccca ggccgccauc gaccagauca acggcaagcu gaaccggcug   1200aucggcaaga ccaacgagaa guuccaccag aucgagaagg aguucagcga gguggagggc   1260aggguacagg accuggagaa guacguggag gacaccaaga ucgaccugug gagcuacaac   1320gccgagcugc ugguagcccu ggagaaccag cacaccaucg accugaccga cagcgagaug   1380aacaagcugu ucgagaagac caagaagcag cugcgggaga acgccgagga caugggcaac   1440ggcugcuuca agaucuacca caagugcgac aacgccugca ucggcagcau ccggaacgag   1500accuacgacc acaacgugua ccgggacgag gcccugaaca accgguucca gaucaagggc   1560guggagcuga agagcggcua caaggacugg auccugugga ucagcuucgc caucuccugc   1620uuccugcugu gcguggcccu gcuggguuuc aucauguggg ccugccagaa gggcaacauc   1680cggugcaaca ucugcauc                                                 1698</s400><s200><s210>88</s210><s211>566</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 88Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys Leu Gly Phe Thr1               5                   10                  15Gln Lys Ile Pro Gly Asn Asp Asn Ser Thr Ala Thr Leu Cys Leu Gly            20                  25                  30His His Ala Val Pro Asn Gly Thr Ile Val Lys Thr Ile Thr Asn Asp        35                  40                  45Arg Ile Glu Val Thr Asn Ala Thr Glu Leu Val Gln Asn Ser Ser Ile    50                  55                  60Gly Glu Ile Cys Asp Ser Pro His Gln Ile Leu Asp Gly Gly Asn Cys65                  70                  75                  80Thr Leu Ile Asp Ala Leu Leu Gly Asp Pro Gln Cys Asp Gly Phe Gln                85                  90                  95Asn Lys Lys Trp Asp Leu Phe Val Glu Arg Ser Arg Ala Tyr Ser Asn            100                 105                 110Cys Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Arg Ser Leu Val        115                 120                 125Ala Ser Ser Gly Thr Leu Glu Phe Lys Asn Glu Ser Phe Asn Trp Ala    130                 135                 140Gly Val Thr Gln Asn Gly Lys Ser Phe Ser Cys Ile Arg Gly Ser Ser145                 150                 155                 160Ser Ser Phe Phe Ser Arg Leu Asn Trp Leu Thr His Leu Asn Tyr Thr                165                 170                 175Tyr Pro Ala Leu Asn Val Thr Met Pro Asn Lys Glu Gln Phe Asp Lys            180                 185                 190Leu Tyr Ile Trp Gly Val His His Pro Gly Thr Asp Lys Asp Gln Ile        195                 200                 205Ser Leu Tyr Ala Gln Ser Ser Gly Arg Ile Thr Val Ser Thr Lys Arg    210                 215                 220Ser Gln Gln Ala Val Ile Pro Asn Ile Gly Ser Arg Pro Arg Ile Arg225                 230                 235                 240Asp Ile Pro Ser Arg Ile Ser Ile Tyr Trp Thr Ile Val Lys Pro Gly                245                 250                 255Asp Ile Leu Leu Ile Asn Ser Thr Gly Asn Leu Ile Ala Pro Arg Gly            260                 265                 270Tyr Phe Lys Ile Arg Ser Gly Lys Ser Ser Ile Met Arg Ser Asp Ala        275                 280                 285Pro Ile Gly Lys Cys Lys Ser Glu Cys Ile Thr Pro Asn Gly Ser Ile    290                 295                 300Pro Asn Asp Lys Pro Phe Gln Asn Val Asn Arg Ile Thr Tyr Gly Ala305                 310                 315                 320Cys Pro Arg Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr Gly Met                325                 330                 335Arg Asn Val Pro Glu Lys Gln Thr Arg Gly Ile Phe Gly Ala Ile Ala            340                 345                 350Gly Phe Ile Glu Asn Gly Trp Glu Gly Met Val Asp Gly Trp Tyr Gly        355                 360                 365Phe Arg His Gln Asn Ser Glu Gly Arg Gly Gln Ala Ala Asp Leu Lys    370                 375                 380Ser Thr Gln Ala Ala Ile Asp Gln Ile Asn Gly Lys Leu Asn Arg Leu385                 390                 395                 400Ile Gly Lys Thr Asn Glu Lys Phe His Gln Ile Glu Lys Glu Phe Ser                405                 410                 415Glu Val Glu Gly Arg Val Gln Asp Leu Glu Lys Tyr Val Glu Asp Thr            420                 425                 430Lys Ile Asp Leu Trp Ser Tyr Asn Ala Glu Leu Leu Val Ala Leu Glu        435                 440                 445Asn Gln His Thr Ile Asp Leu Thr Asp Ser Glu Met Asn Lys Leu Phe    450                 455                 460Glu Lys Thr Lys Lys Gln Leu Arg Glu Asn Ala Glu Asp Met Gly Asn465                 470                 475                 480Gly Cys Phe Lys Ile Tyr His Lys Cys Asp Asn Ala Cys Ile Gly Ser                485                 490                 495Ile Arg Asn Glu Thr Tyr Asp His Asn Val Tyr Arg Asp Glu Ala Leu            500                 505                 510Asn Asn Arg Phe Gln Ile Lys Gly Val Glu Leu Lys Ser Gly Tyr Lys        515                 520                 525Asp Trp Ile Leu Trp Ile Ser Phe Ala Ile Ser Cys Phe Leu Leu Cys    530                 535                 540Val Ala Leu Leu Gly Phe Ile Met Trp Ala Cys Gln Lys Gly Asn Ile545                 550                 555                 560Arg Cys Asn Ile Cys Ile                565</s400><s200><s210>89</s210><s211>1874</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 89gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aagaccauca ucgcccugag cuacauccug ugccuggugu ucgcccagaa gauccccggc    120aacgauaaca gcaccgccac ccugugucug ggacaccacg ccgugcccaa cggcaccauc    180gugaagacua ucaccaacga ccggaucgag gugaccaacg ccaccgagcu ggugcagaac    240agcagcaucg gcgagaucug cgacagcccu caccagaucc uggacggcgg caacugcacc    300cugaucgacg cacugcuggg cgacccucag ugcgacggcu uucagaacaa ggagugggac    360cuguucgugg agagaucgcg ggccaacagc aacugcuacc ccuacgacgu ccccgacuac    420gcaagccuga gaagccucgu ggccucaagc ggcacccugg aguucaagaa cgagagcuuc    480aacuggaccg gcgugaagca gaacggcacc ucaagcgccu gcauccgggg cuccagcagc    540agcuucuucu cacggcugaa cuggcugacc caccugaacu acaccuaccc cgcccugaac    600gugaccaugc ccaacaacga gcaguucgac aagcuguaca ucuggggagu gcaccauccc    660agcaccgaca aggaccagau uagccuguuc gcccagccca gcggccggau caccgugagc    720accaagcgga gccagcaggc cgugaucccc aacaucggcu cucggcccag aauccgggac    780auccccagcc ggaucagcau cuacuggacc auugugaagc ccggcgacau ccugcugauc    840aacuccaccg gcaaccugau cgccccucgg ggcuauuuca agauccggag cggcaagagc    900agcaucaugc ggagcgacgc cccuaucggc aagugcaaga gcgagugcau cacacccaac    960ggaagcaucc ccaacgacaa gcccuuccag aacgugaacc ggauaaccua cggcgccugc   1020ccuagauacg ugaagcagag cacccugaag cuggccaccg gcaugcggaa cgugcccgag   1080aagcagacuc ggggcaucuu cggcgccauc gccggcuuca ucgagaacgg cugggagggc   1140augguggacg gcugguacgg cuuccggcac cagaacucug agggcagagg acaggccgca   1200gaccugaaga gcacccaggc cgccaucgac cagaucaacg gcaagcugaa ccggcugauc   1260ggcaagacca acgagaaguu ccaccagauc gagaaggagu ucagcgaggu ggagggcagg   1320guacaggacc uggagaagua cguggaggac accaagaucg accuguggag cuacaacgcc   1380gagcugcugg uagcccugga gaaccagcac accaucgacc ugaccgacag cgagaugaac   1440aagcuguucg agaagaccaa gaagcagcug cgggagaacg ccgaggacau gggcaacggc   1500ugcuucaaga ucuaccacaa gugcgacaac gccugcaucg gcagcauccg gaacgagacc   1560uacgaccaca acguguaccg ggacgaggcc cugaacaacc gguuccagau caagggcgug   1620gagcugaaga gcggcuacaa ggacuggauc cuguggauca gcuucgccau guccugcuuc   1680cugcugugca ucgcccugcu ggguuucauc augugggccu gccagaaggg caacauccgg   1740ugcaacaucu gcaucugaua auaggcugga gccucggugg ccuagcuucu ugccccuugg   1800gccucccccc agccccuccu ccccuuccug cacccguacc cccguggucu uugaauaaag   1860ucugaguggg cggc                                                     1874</s400><s200><s210>90</s210><s211>1698</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 90augaagacca ucaucgcccu gagcuacauc cugugccugg uguucgccca gaagaucccc     60ggcaacgaua acagcaccgc cacccugugu cugggacacc acgccgugcc caacggcacc    120aucgugaaga cuaucaccaa cgaccggauc gaggugacca acgccaccga gcuggugcag    180aacagcagca ucggcgagau cugcgacagc ccucaccaga uccuggacgg cggcaacugc    240acccugaucg acgcacugcu gggcgacccu cagugcgacg gcuuucagaa caaggagugg    300gaccuguucg uggagagauc gcgggccaac agcaacugcu accccuacga cguccccgac    360uacgcaagcc ugagaagccu cguggccuca agcggcaccc uggaguucaa gaacgagagc    420uucaacugga ccggcgugaa gcagaacggc accucaagcg ccugcauccg gggcuccagc    480agcagcuucu ucucacggcu gaacuggcug acccaccuga acuacaccua ccccgcccug    540aacgugacca ugcccaacaa cgagcaguuc gacaagcugu acaucugggg agugcaccau    600cccagcaccg acaaggacca gauuagccug uucgcccagc ccagcggccg gaucaccgug    660agcaccaagc ggagccagca ggccgugauc cccaacaucg gcucucggcc cagaauccgg    720gacaucccca gccggaucag caucuacugg accauuguga agcccggcga cauccugcug    780aucaacucca ccggcaaccu gaucgccccu cggggcuauu ucaagauccg gagcggcaag    840agcagcauca ugcggagcga cgccccuauc ggcaagugca agagcgagug caucacaccc    900aacggaagca uccccaacga caagcccuuc cagaacguga accggauaac cuacggcgcc    960ugcccuagau acgugaagca gagcacccug aagcuggcca ccggcaugcg gaacgugccc   1020gagaagcaga cucggggcau cuucggcgcc aucgccggcu ucaucgagaa cggcugggag   1080ggcauggugg acggcuggua cggcuuccgg caccagaacu cugagggcag aggacaggcc   1140gcagaccuga agagcaccca ggccgccauc gaccagauca acggcaagcu gaaccggcug   1200aucggcaaga ccaacgagaa guuccaccag aucgagaagg aguucagcga gguggagggc   1260aggguacagg accuggagaa guacguggag gacaccaaga ucgaccugug gagcuacaac   1320gccgagcugc ugguagcccu ggagaaccag cacaccaucg accugaccga cagcgagaug   1380aacaagcugu ucgagaagac caagaagcag cugcgggaga acgccgagga caugggcaac   1440ggcugcuuca agaucuacca caagugcgac aacgccugca ucggcagcau ccggaacgag   1500accuacgacc acaacgugua ccgggacgag gcccugaaca accgguucca gaucaagggc   1560guggagcuga agagcggcua caaggacugg auccugugga ucagcuucgc cauguccugc   1620uuccugcugu gcaucgcccu gcuggguuuc aucauguggg ccugccagaa gggcaacauc   1680cggugcaaca ucugcauc                                                 1698</s400><s200><s210>91</s210><s211>566</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 91Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys Leu Val Phe Ala1               5                   10                  15Gln Lys Ile Pro Gly Asn Asp Asn Ser Thr Ala Thr Leu Cys Leu Gly            20                  25                  30His His Ala Val Pro Asn Gly Thr Ile Val Lys Thr Ile Thr Asn Asp        35                  40                  45Arg Ile Glu Val Thr Asn Ala Thr Glu Leu Val Gln Asn Ser Ser Ile    50                  55                  60Gly Glu Ile Cys Asp Ser Pro His Gln Ile Leu Asp Gly Gly Asn Cys65                  70                  75                  80Thr Leu Ile Asp Ala Leu Leu Gly Asp Pro Gln Cys Asp Gly Phe Gln                85                  90                  95Asn Lys Glu Trp Asp Leu Phe Val Glu Arg Ser Arg Ala Asn Ser Asn            100                 105                 110Cys Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Arg Ser Leu Val        115                 120                 125Ala Ser Ser Gly Thr Leu Glu Phe Lys Asn Glu Ser Phe Asn Trp Thr    130                 135                 140Gly Val Lys Gln Asn Gly Thr Ser Ser Ala Cys Ile Arg Gly Ser Ser145                 150                 155                 160Ser Ser Phe Phe Ser Arg Leu Asn Trp Leu Thr His Leu Asn Tyr Thr                165                 170                 175Tyr Pro Ala Leu Asn Val Thr Met Pro Asn Asn Glu Gln Phe Asp Lys            180                 185                 190Leu Tyr Ile Trp Gly Val His His Pro Ser Thr Asp Lys Asp Gln Ile        195                 200                 205Ser Leu Phe Ala Gln Pro Ser Gly Arg Ile Thr Val Ser Thr Lys Arg    210                 215                 220Ser Gln Gln Ala Val Ile Pro Asn Ile Gly Ser Arg Pro Arg Ile Arg225                 230                 235                 240Asp Ile Pro Ser Arg Ile Ser Ile Tyr Trp Thr Ile Val Lys Pro Gly                245                 250                 255Asp Ile Leu Leu Ile Asn Ser Thr Gly Asn Leu Ile Ala Pro Arg Gly            260                 265                 270Tyr Phe Lys Ile Arg Ser Gly Lys Ser Ser Ile Met Arg Ser Asp Ala        275                 280                 285Pro Ile Gly Lys Cys Lys Ser Glu Cys Ile Thr Pro Asn Gly Ser Ile    290                 295                 300Pro Asn Asp Lys Pro Phe Gln Asn Val Asn Arg Ile Thr Tyr Gly Ala305                 310                 315                 320Cys Pro Arg Tyr Val Lys Gln Ser Thr Leu Lys Leu Ala Thr Gly Met                325                 330                 335Arg Asn Val Pro Glu Lys Gln Thr Arg Gly Ile Phe Gly Ala Ile Ala            340                 345                 350Gly Phe Ile Glu Asn Gly Trp Glu Gly Met Val Asp Gly Trp Tyr Gly        355                 360                 365Phe Arg His Gln Asn Ser Glu Gly Arg Gly Gln Ala Ala Asp Leu Lys    370                 375                 380Ser Thr Gln Ala Ala Ile Asp Gln Ile Asn Gly Lys Leu Asn Arg Leu385                 390                 395                 400Ile Gly Lys Thr Asn Glu Lys Phe His Gln Ile Glu Lys Glu Phe Ser                405                 410                 415Glu Val Glu Gly Arg Val Gln Asp Leu Glu Lys Tyr Val Glu Asp Thr            420                 425                 430Lys Ile Asp Leu Trp Ser Tyr Asn Ala Glu Leu Leu Val Ala Leu Glu        435                 440                 445Asn Gln His Thr Ile Asp Leu Thr Asp Ser Glu Met Asn Lys Leu Phe    450                 455                 460Glu Lys Thr Lys Lys Gln Leu Arg Glu Asn Ala Glu Asp Met Gly Asn465                 470                 475                 480Gly Cys Phe Lys Ile Tyr His Lys Cys Asp Asn Ala Cys Ile Gly Ser                485                 490                 495Ile Arg Asn Glu Thr Tyr Asp His Asn Val Tyr Arg Asp Glu Ala Leu            500                 505                 510Asn Asn Arg Phe Gln Ile Lys Gly Val Glu Leu Lys Ser Gly Tyr Lys        515                 520                 525Asp Trp Ile Leu Trp Ile Ser Phe Ala Met Ser Cys Phe Leu Leu Cys    530                 535                 540Ile Ala Leu Leu Gly Phe Ile Met Trp Ala Cys Gln Lys Gly Asn Ile545                 550                 555                 560Arg Cys Asn Ile Cys Ile                565</s400><s200><s210>92</s210><s211>1874</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 92gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaggccaucc uggucgugau gcuguacacc uucaccaccg ccaacgccga cacccugugc    120aucggcuacc acgccaacaa cagcaccgac accguggaca ccgugcugga gaagaacgug    180accgugaccc acagcgugaa ccugcuggag gacaagcaca acggcaagcu gugcaagcug    240aggggagugg caccccugca ccugggcaag ugcaacaucg ccggcuggau ccugggcaac    300cccgagugcg agagccugag cacagcccgg agcuggagcu acaucgugga gaccagcaac    360agcgacaacg gcaccuguua ccccggcgac uucaucaacu acgaggagcu gcgggagcag    420cugagcagcg ugagcagcuu cgagcgguuc gagaucuucc ccaagaccag cagcuggccc    480aaccacgaca gcgacaacgg cgugacagca gccuguccac acgccggagc caagagcuuc    540uacaagaacc ugaucuggcu ggugaagaag ggcaagagcu accccaagau caaccagacc    600uacaucaacg acaagggcaa ggaggugcug gugcuguggg gcauccacca cccaccuacc    660aucgccgacc agcagagccu guaccagaac gccgacgccu acguguucgu gggcaccagc    720cgguacagca agaaguucaa gccagagauc gccacccggc ccaaggugag agaccaggag    780ggccggauga acuacuacug gacccuggug gagcccggag acaagauuac cuucgaggcc    840accggcaacc ugguggcccc ucgguacgcc uucaccaugg aacgggacgc uggcagcggc    900aucaucauca gcgacacucc cgugcacgac ugcaacacca ccugccagac ucccgagggc    960gcuaucaaca ccagccugcc cuuccagaac gugcacccca ucaccaucgg caagugcccc   1020aaguacguaa agagcaccaa auugcggcug gccaccggac ucaggaacgu gcccagcauc   1080caaagccggg gccuguuugg cgcaaucgcc ggcuucaucg agggcggcug gacuggcaug   1140guggacggcu gguacggcua ccaccaccag aacgaacagg ggagcggcua cgcagcugac   1200cugaagagca cccagaacgc caucgacaag aucaccaaca aggugaacag cgugaucgag   1260aagaugaaca cccaguucac cgccgugggc aaggaguuca accaccugga gaagcggauc   1320gagaaccuga acaagaaggu ggacgacggc uuccuggaca ucuggaccua caacgccgag   1380cugcugguuc ugcuggagaa cgagcggacc cuggacuauc acgacagcaa cgugaagaac   1440cuguacgaga aggugcggaa ccagcugaag aacaacgcca aggagaucgg caacggcugc   1500uucgaguucu accacaagug cgacaacacc ugcauggaga gcgugaagaa cggcaccuac   1560gacuacccca aguacagcga ggaggccaag cugaaccggg agaagaucga cggcgugaag   1620cuggacagca cccggaucua ccagauccug gccaucuaca gcaccguggc cagcagccug   1680gugcuggugg ugagccuggg cgccaucagc uucuggaugu gcagcaacgg cagccugcag   1740ugccggaucu gcaucugaua auaggcugga gccucggugg ccuagcuucu ugccccuugg   1800gccucccccc agccccuccu ccccuuccug cacccguacc cccguggucu uugaauaaag   1860ucugaguggg cggc                                                     1874</s400><s200><s210>93</s210><s211>1698</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 93augaaggcca uccuggucgu gaugcuguac accuucacca ccgccaacgc cgacacccug     60ugcaucggcu accacgccaa caacagcacc gacaccgugg acaccgugcu ggagaagaac    120gugaccguga cccacagcgu gaaccugcug gaggacaagc acaacggcaa gcugugcaag    180cugaggggag uggcaccccu gcaccugggc aagugcaaca ucgccggcug gauccugggc    240aaccccgagu gcgagagccu gagcacagcc cggagcugga gcuacaucgu ggagaccagc    300aacagcgaca acggcaccug uuaccccggc gacuucauca acuacgagga gcugcgggag    360cagcugagca gcgugagcag cuucgagcgg uucgagaucu uccccaagac cagcagcugg    420cccaaccacg acagcgacaa cggcgugaca gcagccuguc cacacgccgg agccaagagc    480uucuacaaga accugaucug gcuggugaag aagggcaaga gcuaccccaa gaucaaccag    540accuacauca acgacaaggg caaggaggug cuggugcugu ggggcaucca ccacccaccu    600accaucgccg accagcagag ccuguaccag aacgccgacg ccuacguguu cgugggcacc    660agccgguaca gcaagaaguu caagccagag aucgccaccc ggcccaaggu gagagaccag    720gagggccgga ugaacuacua cuggacccug guggagcccg gagacaagau uaccuucgag    780gccaccggca accugguggc cccucgguac gccuucacca uggaacggga cgcuggcagc    840ggcaucauca ucagcgacac ucccgugcac gacugcaaca ccaccugcca gacucccgag    900ggcgcuauca acaccagccu gcccuuccag aacgugcacc ccaucaccau cggcaagugc    960cccaaguacg uaaagagcac caaauugcgg cuggccaccg gacucaggaa cgugcccagc   1020auccaaagcc ggggccuguu uggcgcaauc gccggcuuca ucgagggcgg cuggacuggc   1080augguggacg gcugguacgg cuaccaccac cagaacgaac aggggagcgg cuacgcagcu   1140gaccugaaga gcacccagaa cgccaucgac aagaucacca acaaggugaa cagcgugauc   1200gagaagauga acacccaguu caccgccgug ggcaaggagu ucaaccaccu ggagaagcgg   1260aucgagaacc ugaacaagaa gguggacgac ggcuuccugg acaucuggac cuacaacgcc   1320gagcugcugg uucugcugga gaacgagcgg acccuggacu aucacgacag caacgugaag   1380aaccuguacg agaaggugcg gaaccagcug aagaacaacg ccaaggagau cggcaacggc   1440ugcuucgagu ucuaccacaa gugcgacaac accugcaugg agagcgugaa gaacggcacc   1500uacgacuacc ccaaguacag cgaggaggcc aagcugaacc gggagaagau cgacggcgug   1560aagcuggaca gcacccggau cuaccagauc cuggccaucu acagcaccgu ggccagcagc   1620cuggugcugg uggugagccu gggcgccauc agcuucugga ugugcagcaa cggcagccug   1680cagugccgga ucugcauc                                                 1698</s400><s200><s210>94</s210><s211>566</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 94Met Lys Ala Ile Leu Val Val Met Leu Tyr Thr Phe Thr Thr Ala Asn1               5                   10                  15Ala Asp Thr Leu Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr            20                  25                  30Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn        35                  40                  45Leu Leu Glu Asp Lys His Asn Gly Lys Leu Cys Lys Leu Arg Gly Val    50                  55                  60Ala Pro Leu His Leu Gly Lys Cys Asn Ile Ala Gly Trp Ile Leu Gly65                  70                  75                  80Asn Pro Glu Cys Glu Ser Leu Ser Thr Ala Arg Ser Trp Ser Tyr Ile                85                  90                  95Val Glu Thr Ser Asn Ser Asp Asn Gly Thr Cys Tyr Pro Gly Asp Phe            100                 105                 110Ile Asn Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe        115                 120                 125Glu Arg Phe Glu Ile Phe Pro Lys Thr Ser Ser Trp Pro Asn His Asp    130                 135                 140Ser Asp Asn Gly Val Thr Ala Ala Cys Pro His Ala Gly Ala Lys Ser145                 150                 155                 160Phe Tyr Lys Asn Leu Ile Trp Leu Val Lys Lys Gly Lys Ser Tyr Pro                165                 170                 175Lys Ile Asn Gln Thr Tyr Ile Asn Asp Lys Gly Lys Glu Val Leu Val            180                 185                 190Leu Trp Gly Ile His His Pro Pro Thr Ile Ala Asp Gln Gln Ser Leu        195                 200                 205Tyr Gln Asn Ala Asp Ala Tyr Val Phe Val Gly Thr Ser Arg Tyr Ser    210                 215                 220Lys Lys Phe Lys Pro Glu Ile Ala Thr Arg Pro Lys Val Arg Asp Gln225                 230                 235                 240Glu Gly Arg Met Asn Tyr Tyr Trp Thr Leu Val Glu Pro Gly Asp Lys                245                 250                 255Ile Thr Phe Glu Ala Thr Gly Asn Leu Val Ala Pro Arg Tyr Ala Phe            260                 265                 270Thr Met Glu Arg Asp Ala Gly Ser Gly Ile Ile Ile Ser Asp Thr Pro        275                 280                 285Val His Asp Cys Asn Thr Thr Cys Gln Thr Pro Glu Gly Ala Ile Asn    290                 295                 300Thr Ser Leu Pro Phe Gln Asn Val His Pro Ile Thr Ile Gly Lys Cys305                 310                 315                 320Pro Lys Tyr Val Lys Ser Thr Lys Leu Arg Leu Ala Thr Gly Leu Arg                325                 330                 335Asn Val Pro Ser Ile Gln Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly            340                 345                 350Phe Ile Glu Gly Gly Trp Thr Gly Met Val Asp Gly Trp Tyr Gly Tyr        355                 360                 365His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Leu Lys Ser    370                 375                 380Thr Gln Asn Ala Ile Asp Lys Ile Thr Asn Lys Val Asn Ser Val Ile385                 390                 395                 400Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu Phe Asn His                405                 410                 415Leu Glu Lys Arg Ile Glu Asn Leu Asn Lys Lys Val Asp Asp Gly Phe            420                 425                 430Leu Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu Glu Asn        435                 440                 445Glu Arg Thr Leu Asp Tyr His Asp Ser Asn Val Lys Asn Leu Tyr Glu    450                 455                 460Lys Val Arg Asn Gln Leu Lys Asn Asn Ala Lys Glu Ile Gly Asn Gly465                 470                 475                 480Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Thr Cys Met Glu Ser Val                485                 490                 495Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ala Lys Leu            500                 505                 510Asn Arg Glu Lys Ile Asp Gly Val Lys Leu Asp Ser Thr Arg Ile Tyr        515                 520                 525Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Val    530                 535                 540Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu545                 550                 555                 560Gln Cys Arg Ile Cys Ile                565</s400><s200><s210>95</s210><s211>1874</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 95gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaggccaucc uggucgugau gcuguacacc uucaccaccg ccaacgccga cacccugugc    120aucggcuacc acgccaacaa cagcaccgac accguggaca ccgugcugug caagaacgug    180accgugaccc acagcgugaa ccugcuggag gacaagcaca acggcaagcu gugcaagcug    240aggggagugg caccccugca ccugggcaag ugcaacaucg ccggcuggau ccugggcaac    300cccgagugcg agagccugag cacagcccgg agcuggagcu acaucgugga gaccagcaac    360agcgacaacg gcaccuguua ccccggcgac uucaucaacu acgaggagcu gcgggagcag    420cugagcagcg ugagcagcuu cgagcgguuc gagaucuucc ccaagaccag cagcuggccc    480aaccacgaca gcgacaacgg cgugacagca gccuguccac acgccggagc caagagcuuc    540uacaagaacc ugaucuggcu ggugaagaag ggcaagagcu accccaagau caaccagacc    600uacaucaacg acaagggcaa ggaggugcug gugcuguggg gcauccacca cccaccuacc    660aucgccgacc agcagagccu guaccagaac gccgacgccu acguguucgu gggcaccagc    720cgguacagca agaaguucaa gccagagauc gccacccggc ccaaggugag agaccaggag    780ggccggauga acuacuacug gacccuggug gagcccggag acaagauuac cuucgaggcc    840accggcaacc ugguggcccc ucgguacgcc uucaccaugg aacgggacgc uggcagcggc    900aucaucauca gcgacacucc cgugcacgac ugcaacacca ccugccagac ucccgagggc    960gcuaucaaca ccagccugcc cuuccagaac gugcacccca ucaccaucgg caagugcccc   1020aaguacguaa agagcaccaa auugcggcug gccaccggac ucaggaacgu gcccagcauc   1080caaagccggg gccuguuugg cgcaaucgcc ggcuucaucg agggcggcug gacuggcaug   1140guggacggcu gguacggcua ccaccaccag aacgaacagg ggagcggcua cgcagcugac   1200cugaagagca cccagaacgc caucgacugc aucaccaaca aggugaacag cgugaucgag   1260aagaugaaca cccaguucac cgccgugggc aaggaguuca accaccugga gaagcggauc   1320gagaaccuga acaagaaggu ggacgacggc uuccuggaca ucuggaccua caacgccgag   1380cugcugguuc ugcuggagaa cgagcggacc cuggacuauc acgacagcaa cgugaagaac   1440cuguacgaga aggugcggaa ccagcugaag aacaacgcca aggagaucgg caacggcugc   1500uucgaguucu accacaagug cgacaacacc ugcauggaga gcgugaagaa cggcaccuac   1560gacuacccca aguacagcga ggaggccaag cugaaccggg agaagaucga cggcgugaag   1620cuggacagca cccggaucua ccagauccug gccaucuaca gcaccguggc cagcagccug   1680gugcuggugg ugagccuggg cgccaucagc uucuggaugu gcagcaacgg cagccugcag   1740ugccggaucu gcaucugaua auaggcugga gccucggugg ccuagcuucu ugccccuugg   1800gccucccccc agccccuccu ccccuuccug cacccguacc cccguggucu uugaauaaag   1860ucugaguggg cggc                                                     1874</s400><s200><s210>96</s210><s211>1698</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 96augaaggcca uccuggucgu gaugcuguac accuucacca ccgccaacgc cgacacccug     60ugcaucggcu accacgccaa caacagcacc gacaccgugg acaccgugcu gugcaagaac    120gugaccguga cccacagcgu gaaccugcug gaggacaagc acaacggcaa gcugugcaag    180cugaggggag uggcaccccu gcaccugggc aagugcaaca ucgccggcug gauccugggc    240aaccccgagu gcgagagccu gagcacagcc cggagcugga gcuacaucgu ggagaccagc    300aacagcgaca acggcaccug uuaccccggc gacuucauca acuacgagga gcugcgggag    360cagcugagca gcgugagcag cuucgagcgg uucgagaucu uccccaagac cagcagcugg    420cccaaccacg acagcgacaa cggcgugaca gcagccuguc cacacgccgg agccaagagc    480uucuacaaga accugaucug gcuggugaag aagggcaaga gcuaccccaa gaucaaccag    540accuacauca acgacaaggg caaggaggug cuggugcugu ggggcaucca ccacccaccu    600accaucgccg accagcagag ccuguaccag aacgccgacg ccuacguguu cgugggcacc    660agccgguaca gcaagaaguu caagccagag aucgccaccc ggcccaaggu gagagaccag    720gagggccgga ugaacuacua cuggacccug guggagcccg gagacaagau uaccuucgag    780gccaccggca accugguggc cccucgguac gccuucacca uggaacggga cgcuggcagc    840ggcaucauca ucagcgacac ucccgugcac gacugcaaca ccaccugcca gacucccgag    900ggcgcuauca acaccagccu gcccuuccag aacgugcacc ccaucaccau cggcaagugc    960cccaaguacg uaaagagcac caaauugcgg cuggccaccg gacucaggaa cgugcccagc   1020auccaaagcc ggggccuguu uggcgcaauc gccggcuuca ucgagggcgg cuggacuggc   1080augguggacg gcugguacgg cuaccaccac cagaacgaac aggggagcgg cuacgcagcu   1140gaccugaaga gcacccagaa cgccaucgac ugcaucacca acaaggugaa cagcgugauc   1200gagaagauga acacccaguu caccgccgug ggcaaggagu ucaaccaccu ggagaagcgg   1260aucgagaacc ugaacaagaa gguggacgac ggcuuccugg acaucuggac cuacaacgcc   1320gagcugcugg uucugcugga gaacgagcgg acccuggacu aucacgacag caacgugaag   1380aaccuguacg agaaggugcg gaaccagcug aagaacaacg ccaaggagau cggcaacggc   1440ugcuucgagu ucuaccacaa gugcgacaac accugcaugg agagcgugaa gaacggcacc   1500uacgacuacc ccaaguacag cgaggaggcc aagcugaacc gggagaagau cgacggcgug   1560aagcuggaca gcacccggau cuaccagauc cuggccaucu acagcaccgu ggccagcagc   1620cuggugcugg uggugagccu gggcgccauc agcuucugga ugugcagcaa cggcagccug   1680cagugccgga ucugcauc                                                 1698</s400><s200><s210>97</s210><s211>566</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 97Met Lys Ala Ile Leu Val Val Met Leu Tyr Thr Phe Thr Thr Ala Asn1               5                   10                  15Ala Asp Thr Leu Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr            20                  25                  30Val Asp Thr Val Leu Cys Lys Asn Val Thr Val Thr His Ser Val Asn        35                  40                  45Leu Leu Glu Asp Lys His Asn Gly Lys Leu Cys Lys Leu Arg Gly Val    50                  55                  60Ala Pro Leu His Leu Gly Lys Cys Asn Ile Ala Gly Trp Ile Leu Gly65                  70                  75                  80Asn Pro Glu Cys Glu Ser Leu Ser Thr Ala Arg Ser Trp Ser Tyr Ile                85                  90                  95Val Glu Thr Ser Asn Ser Asp Asn Gly Thr Cys Tyr Pro Gly Asp Phe            100                 105                 110Ile Asn Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe        115                 120                 125Glu Arg Phe Glu Ile Phe Pro Lys Thr Ser Ser Trp Pro Asn His Asp    130                 135                 140Ser Asp Asn Gly Val Thr Ala Ala Cys Pro His Ala Gly Ala Lys Ser145                 150                 155                 160Phe Tyr Lys Asn Leu Ile Trp Leu Val Lys Lys Gly Lys Ser Tyr Pro                165                 170                 175Lys Ile Asn Gln Thr Tyr Ile Asn Asp Lys Gly Lys Glu Val Leu Val            180                 185                 190Leu Trp Gly Ile His His Pro Pro Thr Ile Ala Asp Gln Gln Ser Leu        195                 200                 205Tyr Gln Asn Ala Asp Ala Tyr Val Phe Val Gly Thr Ser Arg Tyr Ser    210                 215                 220Lys Lys Phe Lys Pro Glu Ile Ala Thr Arg Pro Lys Val Arg Asp Gln225                 230                 235                 240Glu Gly Arg Met Asn Tyr Tyr Trp Thr Leu Val Glu Pro Gly Asp Lys                245                 250                 255Ile Thr Phe Glu Ala Thr Gly Asn Leu Val Ala Pro Arg Tyr Ala Phe            260                 265                 270Thr Met Glu Arg Asp Ala Gly Ser Gly Ile Ile Ile Ser Asp Thr Pro        275                 280                 285Val His Asp Cys Asn Thr Thr Cys Gln Thr Pro Glu Gly Ala Ile Asn    290                 295                 300Thr Ser Leu Pro Phe Gln Asn Val His Pro Ile Thr Ile Gly Lys Cys305                 310                 315                 320Pro Lys Tyr Val Lys Ser Thr Lys Leu Arg Leu Ala Thr Gly Leu Arg                325                 330                 335Asn Val Pro Ser Ile Gln Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly            340                 345                 350Phe Ile Glu Gly Gly Trp Thr Gly Met Val Asp Gly Trp Tyr Gly Tyr        355                 360                 365His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Leu Lys Ser    370                 375                 380Thr Gln Asn Ala Ile Asp Cys Ile Thr Asn Lys Val Asn Ser Val Ile385                 390                 395                 400Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu Phe Asn His                405                 410                 415Leu Glu Lys Arg Ile Glu Asn Leu Asn Lys Lys Val Asp Asp Gly Phe            420                 425                 430Leu Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu Glu Asn        435                 440                 445Glu Arg Thr Leu Asp Tyr His Asp Ser Asn Val Lys Asn Leu Tyr Glu    450                 455                 460Lys Val Arg Asn Gln Leu Lys Asn Asn Ala Lys Glu Ile Gly Asn Gly465                 470                 475                 480Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Thr Cys Met Glu Ser Val                485                 490                 495Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ala Lys Leu            500                 505                 510Asn Arg Glu Lys Ile Asp Gly Val Lys Leu Asp Ser Thr Arg Ile Tyr        515                 520                 525Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Val    530                 535                 540Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu545                 550                 555                 560Gln Cys Arg Ile Cys Ile                565</s400><s200><s210>98</s210><s211>1874</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 98gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaggccaucc uggucgugau gcuguacacc uucaccaccg ccaacgccga cacccugugc    120aucggcuacc acgccaacaa cagcaccgac accguggaca ccgugcugug caagaacgug    180accgugaccc acagcgugaa ccugcuggag gacaagcaca acggcaagcu gugcaagcug    240aggggagugg caccccugca ccugggcaag ugcaacaucg ccggcuggau ccugggcaac    300cccgagugcg agagccugag cacagcccgg agcuggagcu acaucgugga gaccagcaac    360agcgacaacg gcaccuguua ccccggcgac uucaucaacu acgaggagcu gcgggagcag    420cugagcagcg ugagcagcuu cgagcgguuc gagaucuucc ccaagaccag cagcuggccc    480aaccacgaca gcgacaacgg cgugacagca gccuguccac acgccggagc caagagcuuc    540uacaagaacc ugaucuggcu ggugaagaag ggcaagagcu accccaagau caaccagacc    600uacaucaacg acaagggcaa ggaggugcug gugcuguggg gcauccacca cccaccuacc    660aucgccgacc agcagagccu guaccagaac gccgacgccu acguguucgu gggcaccagc    720cgguacagca agaaguucaa gccagagauc gccacccggc ccaaggugag agaccaggag    780ggccggauga acuacuacug gacccuggug gagcccggag acaagauuac cuucgaggcc    840accggcaacc ugguggcccc ucgguacgcc uucaccaugg aacgggacgc uggcagcggc    900aucaucauca gcgacacucc cgugcacgac ugcaacacca ccugccagac ucccgagggc    960gcuaucaaca ccagccugcc cuuccagaac gugcacccca ucaccaucgg caagugcccc   1020aaguacguaa agagcaccaa auugcggcug gccaccggac ucaggaacgu gcccagcauc   1080caagccgccg gccuguuugg cgcaaucgcc ggcuucaucg agggcggcug gacuggcaug   1140guggacggcu gguacggcua ccaccaccag aacgaacagg ggagcggcua cgcagcugac   1200cugaagagca cccagaacgc caucgacugc aucaccaaca aggugaacag cgugaucgag   1260aagaugaaca cccaguucac cgccgugggc aaggaguuca accaccugga gaagcggauc   1320gagaaccuga acaagaaggu ggacgacggc uuccuggaca ucuggaccua caacgccgag   1380cugcugguuc ugcuggagaa cgagcggacc cuggacuauc acgacagcaa cgugaagaac   1440cuguacgaga aggugcggaa ccagcugaag aacaacgcca aggagaucgg caacggcugc   1500uucgaguucu accacaagug cgacaacacc ugcauggaga gcgugaagaa cggcaccuac   1560gacuacccca aguacagcga ggaggccaag cugaaccggg agaagaucga cggcgugaag   1620cuggacagca cccggaucua ccagauccug gccaucuaca gcaccguggc cagcagccug   1680gugcuggugg ugagccuggg cgccaucagc uucuggaugu gcagcaacgg cagccugcag   1740ugccggaucu gcaucugaua auaggcugga gccucggugg ccuagcuucu ugccccuugg   1800gccucccccc agccccuccu ccccuuccug cacccguacc cccguggucu uugaauaaag   1860ucugaguggg cggc                                                     1874</s400><s200><s210>99</s210><s211>1698</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 99augaaggcca uccuggucgu gaugcuguac accuucacca ccgccaacgc cgacacccug     60ugcaucggcu accacgccaa caacagcacc gacaccgugg acaccgugcu gugcaagaac    120gugaccguga cccacagcgu gaaccugcug gaggacaagc acaacggcaa gcugugcaag    180cugaggggag uggcaccccu gcaccugggc aagugcaaca ucgccggcug gauccugggc    240aaccccgagu gcgagagccu gagcacagcc cggagcugga gcuacaucgu ggagaccagc    300aacagcgaca acggcaccug uuaccccggc gacuucauca acuacgagga gcugcgggag    360cagcugagca gcgugagcag cuucgagcgg uucgagaucu uccccaagac cagcagcugg    420cccaaccacg acagcgacaa cggcgugaca gcagccuguc cacacgccgg agccaagagc    480uucuacaaga accugaucug gcuggugaag aagggcaaga gcuaccccaa gaucaaccag    540accuacauca acgacaaggg caaggaggug cuggugcugu ggggcaucca ccacccaccu    600accaucgccg accagcagag ccuguaccag aacgccgacg ccuacguguu cgugggcacc    660agccgguaca gcaagaaguu caagccagag aucgccaccc ggcccaaggu gagagaccag    720gagggccgga ugaacuacua cuggacccug guggagcccg gagacaagau uaccuucgag    780gccaccggca accugguggc cccucgguac gccuucacca uggaacggga cgcuggcagc    840ggcaucauca ucagcgacac ucccgugcac gacugcaaca ccaccugcca gacucccgag    900ggcgcuauca acaccagccu gcccuuccag aacgugcacc ccaucaccau cggcaagugc    960cccaaguacg uaaagagcac caaauugcgg cuggccaccg gacucaggaa cgugcccagc   1020auccaagccg ccggccuguu uggcgcaauc gccggcuuca ucgagggcgg cuggacuggc   1080augguggacg gcugguacgg cuaccaccac cagaacgaac aggggagcgg cuacgcagcu   1140gaccugaaga gcacccagaa cgccaucgac ugcaucacca acaaggugaa cagcgugauc   1200gagaagauga acacccaguu caccgccgug ggcaaggagu ucaaccaccu ggagaagcgg   1260aucgagaacc ugaacaagaa gguggacgac ggcuuccugg acaucuggac cuacaacgcc   1320gagcugcugg uucugcugga gaacgagcgg acccuggacu aucacgacag caacgugaag   1380aaccuguacg agaaggugcg gaaccagcug aagaacaacg ccaaggagau cggcaacggc   1440ugcuucgagu ucuaccacaa gugcgacaac accugcaugg agagcgugaa gaacggcacc   1500uacgacuacc ccaaguacag cgaggaggcc aagcugaacc gggagaagau cgacggcgug   1560aagcuggaca gcacccggau cuaccagauc cuggccaucu acagcaccgu ggccagcagc   1620cuggugcugg uggugagccu gggcgccauc agcuucugga ugugcagcaa cggcagccug   1680cagugccgga ucugcauc                                                 1698</s400><s200><s210>100</s210><s211>566</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 100Met Lys Ala Ile Leu Val Val Met Leu Tyr Thr Phe Thr Thr Ala Asn1               5                   10                  15Ala Asp Thr Leu Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr            20                  25                  30Val Asp Thr Val Leu Cys Lys Asn Val Thr Val Thr His Ser Val Asn        35                  40                  45Leu Leu Glu Asp Lys His Asn Gly Lys Leu Cys Lys Leu Arg Gly Val    50                  55                  60Ala Pro Leu His Leu Gly Lys Cys Asn Ile Ala Gly Trp Ile Leu Gly65                  70                  75                  80Asn Pro Glu Cys Glu Ser Leu Ser Thr Ala Arg Ser Trp Ser Tyr Ile                85                  90                  95Val Glu Thr Ser Asn Ser Asp Asn Gly Thr Cys Tyr Pro Gly Asp Phe            100                 105                 110Ile Asn Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe        115                 120                 125Glu Arg Phe Glu Ile Phe Pro Lys Thr Ser Ser Trp Pro Asn His Asp    130                 135                 140Ser Asp Asn Gly Val Thr Ala Ala Cys Pro His Ala Gly Ala Lys Ser145                 150                 155                 160Phe Tyr Lys Asn Leu Ile Trp Leu Val Lys Lys Gly Lys Ser Tyr Pro                165                 170                 175Lys Ile Asn Gln Thr Tyr Ile Asn Asp Lys Gly Lys Glu Val Leu Val            180                 185                 190Leu Trp Gly Ile His His Pro Pro Thr Ile Ala Asp Gln Gln Ser Leu        195                 200                 205Tyr Gln Asn Ala Asp Ala Tyr Val Phe Val Gly Thr Ser Arg Tyr Ser    210                 215                 220Lys Lys Phe Lys Pro Glu Ile Ala Thr Arg Pro Lys Val Arg Asp Gln225                 230                 235                 240Glu Gly Arg Met Asn Tyr Tyr Trp Thr Leu Val Glu Pro Gly Asp Lys                245                 250                 255Ile Thr Phe Glu Ala Thr Gly Asn Leu Val Ala Pro Arg Tyr Ala Phe            260                 265                 270Thr Met Glu Arg Asp Ala Gly Ser Gly Ile Ile Ile Ser Asp Thr Pro        275                 280                 285Val His Asp Cys Asn Thr Thr Cys Gln Thr Pro Glu Gly Ala Ile Asn    290                 295                 300Thr Ser Leu Pro Phe Gln Asn Val His Pro Ile Thr Ile Gly Lys Cys305                 310                 315                 320Pro Lys Tyr Val Lys Ser Thr Lys Leu Arg Leu Ala Thr Gly Leu Arg                325                 330                 335Asn Val Pro Ser Ile Gln Ala Ala Gly Leu Phe Gly Ala Ile Ala Gly            340                 345                 350Phe Ile Glu Gly Gly Trp Thr Gly Met Val Asp Gly Trp Tyr Gly Tyr        355                 360                 365His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Leu Lys Ser    370                 375                 380Thr Gln Asn Ala Ile Asp Cys Ile Thr Asn Lys Val Asn Ser Val Ile385                 390                 395                 400Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu Phe Asn His                405                 410                 415Leu Glu Lys Arg Ile Glu Asn Leu Asn Lys Lys Val Asp Asp Gly Phe            420                 425                 430Leu Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu Glu Asn        435                 440                 445Glu Arg Thr Leu Asp Tyr His Asp Ser Asn Val Lys Asn Leu Tyr Glu    450                 455                 460Lys Val Arg Asn Gln Leu Lys Asn Asn Ala Lys Glu Ile Gly Asn Gly465                 470                 475                 480Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Thr Cys Met Glu Ser Val                485                 490                 495Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ala Lys Leu            500                 505                 510Asn Arg Glu Lys Ile Asp Gly Val Lys Leu Asp Ser Thr Arg Ile Tyr        515                 520                 525Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Val    530                 535                 540Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu545                 550                 555                 560Gln Cys Arg Ile Cys Ile                565</s400><s200><s210>101</s210><s211>1868</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 101gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60gagaacauug uguuacugcu ggccauugug ucacugguga aauccgacca gauuugcauu    120gguuaccacg ccaauaacuc aaccgagcag guggauacua ucauggagaa gaacguaacc    180gucacccacg cccaggacau uuuggagaag acacauaacg guaaacucug ugaccugaac    240ggggugaagc ccuugauacu gaaggauugc ucuguagcgg gcuggcuacu cggaaauccu    300augugcgacg aauuuauucg cguaccugag uggaguuaua ucguugagag agccaaucca    360gcuaacgauc ugugcuaucc uggcagucug aacgauuacg aagagcuuaa acaccuccug    420ucccggauua accauuucga gaagauauug auaaucccga agagcagcug gccaaaucac    480gaaaccuccc ugggagugag cgcugcuugc cccuaccagg gagccccuuc auucuucagg    540aacgugguuu ggcugaucaa gaagaacgac gcauacccaa cuauuaagau cuccuacaau    600aauaccaacc gggaggaccu gcuaaucuug ugggguaucc aucacagcaa caacgcagaa    660gagcaaacua accuguauaa gaacccgacc accuauaucu cggucggaac aagcacguua    720aaccagcggu uggucccgaa gaucgccaca aggucucagg ugaacggcca gagaggaaga    780auggacuucu ucuggaccau auugaagcca gacgacgcaa uacauuucga gucuaacgga    840aacuucauug cuccggaaua cgcguacaag auuguuaaga agggcgauuc gaccauuaug    900aaaucagggg uggaauacgg ucacuguaac accaagugcc aaacuccugu gggcgcuauu    960aacucaucaa ugcccuucca caauauucac ccacugacua uuggugagug cccgaaauac   1020guaaagucua auaaacucgu guuggcgacc ggccuaagaa acagcccaca gaucgagacc   1080aggggcuugu uuggggcgau ugcaggauuu aucgaaggcg gcuggcaggg uaugguggac   1140ggcugguacg gauaucauca cagcaacgaa caagggucag gauacgccgc agacaaagaa   1200ucgacucaga aagcuauaga cggagugacg aacaaaguga acucgaucau ugauaagaug   1260aauacacagu uugaagcggu cggcagagaa uuuaacaacu uggaacggag aauugagaau   1320cugaacaaga agauggagga cggcuuucug gacgugugga cuuauaacgc cgagcuccuc   1380gugcugaugg agaacgaaag gacucuugac uuucacgauu caaacgucaa gaaccuguac   1440gacaagguua gauugcagcu gcgggacaac gccaaagaac uggguaacgg cuguuucgag   1500uucuaccaua agugcgauaa cgagugcaug gaaucuguca gaaacgguac cuacgacuau   1560ccccaguauu cugaagaggc ccgccucaaa cgagaggaga ucucuggagu gaagcuggag   1620uccauuggca cguaccaaau ucugucaauc uacuccaccg cugcaucaag ccuagcucug   1680gcgaucauga uggcggggcu cagucugugg auguguucaa acgguucccu gcagugucgc   1740auuuguaucu gauaauaggc uggagccucg guggccuagc uucuugcccc uugggccucc   1800ccccagcccc uccuccccuu ccugcacccg uacccccgug gucuuugaau aaagucugag   1860ugggcggc                                                            1868</s400><s200><s210>102</s210><s211>1692</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 102auggagaaca uuguguuacu gcuggccauu gugucacugg ugaaauccga ccagauuugc     60auugguuacc acgccaauaa cucaaccgag cagguggaua cuaucaugga gaagaacgua    120accgucaccc acgcccagga cauuuuggag aagacacaua acgguaaacu cugugaccug    180aacgggguga agcccuugau acugaaggau ugcucuguag cgggcuggcu acucggaaau    240ccuaugugcg acgaauuuau ucgcguaccu gaguggaguu auaucguuga gagagccaau    300ccagcuaacg aucugugcua uccuggcagu cugaacgauu acgaagagcu uaaacaccuc    360cugucccgga uuaaccauuu cgagaagaua uugauaaucc cgaagagcag cuggccaaau    420cacgaaaccu cccugggagu gagcgcugcu ugccccuacc agggagcccc uucauucuuc    480aggaacgugg uuuggcugau caagaagaac gacgcauacc caacuauuaa gaucuccuac    540aauaauacca accgggagga ccugcuaauc uuguggggua uccaucacag caacaacgca    600gaagagcaaa cuaaccugua uaagaacccg accaccuaua ucucggucgg aacaagcacg    660uuaaaccagc gguugguccc gaagaucgcc acaaggucuc aggugaacgg ccagagagga    720agaauggacu ucuucuggac cauauugaag ccagacgacg caauacauuu cgagucuaac    780ggaaacuuca uugcuccgga auacgcguac aagauuguua agaagggcga uucgaccauu    840augaaaucag ggguggaaua cggucacugu aacaccaagu gccaaacucc ugugggcgcu    900auuaacucau caaugcccuu ccacaauauu cacccacuga cuauugguga gugcccgaaa    960uacguaaagu cuaauaaacu cguguuggcg accggccuaa gaaacagccc acagaucgag   1020accaggggcu uguuuggggc gauugcagga uuuaucgaag gcggcuggca ggguauggug   1080gacggcuggu acggauauca ucacagcaac gaacaagggu caggauacgc cgcagacaaa   1140gaaucgacuc agaaagcuau agacggagug acgaacaaag ugaacucgau cauugauaag   1200augaauacac aguuugaagc ggucggcaga gaauuuaaca acuuggaacg gagaauugag   1260aaucugaaca agaagaugga ggacggcuuu cuggacgugu ggacuuauaa cgccgagcuc   1320cucgugcuga uggagaacga aaggacucuu gacuuucacg auucaaacgu caagaaccug   1380uacgacaagg uuagauugca gcugcgggac aacgccaaag aacuggguaa cggcuguuuc   1440gaguucuacc auaagugcga uaacgagugc auggaaucug ucagaaacgg uaccuacgac   1500uauccccagu auucugaaga ggcccgccuc aaacgagagg agaucucugg agugaagcug   1560gaguccauug gcacguacca aauucuguca aucuacucca ccgcugcauc aagccuagcu   1620cuggcgauca ugauggcggg gcucagucug uggauguguu caaacgguuc ccugcagugu   1680cgcauuugua uc                                                       1692</s400><s200><s210>103</s210><s211>564</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 103Met Glu Asn Ile Val Leu Leu Leu Ala Ile Val Ser Leu Val Lys Ser1               5                   10                  15Asp Gln Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Gln Val            20                  25                  30Asp Thr Ile Met Glu Lys Asn Val Thr Val Thr His Ala Gln Asp Ile        35                  40                  45Leu Glu Lys Thr His Asn Gly Lys Leu Cys Asp Leu Asn Gly Val Lys    50                  55                  60Pro Leu Ile Leu Lys Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn65                  70                  75                  80Pro Met Cys Asp Glu Phe Ile Arg Val Pro Glu Trp Ser Tyr Ile Val                85                  90                  95Glu Arg Ala Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Ser Leu Asn            100                 105                 110Asp Tyr Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu        115                 120                 125Lys Ile Leu Ile Ile Pro Lys Ser Ser Trp Pro Asn His Glu Thr Ser    130                 135                 140Leu Gly Val Ser Ala Ala Cys Pro Tyr Gln Gly Ala Pro Ser Phe Phe145                 150                 155                 160Arg Asn Val Val Trp Leu Ile Lys Lys Asn Asp Ala Tyr Pro Thr Ile                165                 170                 175Lys Ile Ser Tyr Asn Asn Thr Asn Arg Glu Asp Leu Leu Ile Leu Trp            180                 185                 190Gly Ile His His Ser Asn Asn Ala Glu Glu Gln Thr Asn Leu Tyr Lys        195                 200                 205Asn Pro Thr Thr Tyr Ile Ser Val Gly Thr Ser Thr Leu Asn Gln Arg    210                 215                 220Leu Val Pro Lys Ile Ala Thr Arg Ser Gln Val Asn Gly Gln Arg Gly225                 230                 235                 240Arg Met Asp Phe Phe Trp Thr Ile Leu Lys Pro Asp Asp Ala Ile His                245                 250                 255Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile            260                 265                 270Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Gly Val Glu Tyr Gly        275                 280                 285His Cys Asn Thr Lys Cys Gln Thr Pro Val Gly Ala Ile Asn Ser Ser    290                 295                 300Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys305                 310                 315                 320Tyr Val Lys Ser Asn Lys Leu Val Leu Ala Thr Gly Leu Arg Asn Ser                325                 330                 335Pro Gln Ile Glu Thr Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile            340                 345                 350Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly Tyr His His        355                 360                 365Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Lys Glu Ser Thr Gln    370                 375                 380Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser Ile Ile Asp Lys385                 390                 395                 400Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe Asn Asn Leu Glu                405                 410                 415Arg Arg Ile Glu Asn Leu Asn Lys Lys Met Glu Asp Gly Phe Leu Asp            420                 425                 430Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu Asn Glu Arg        435                 440                 445Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr Asp Lys Val    450                 455                 460Arg Leu Gln Leu Arg Asp Asn Ala Lys Glu Leu Gly Asn Gly Cys Phe465                 470                 475                 480Glu Phe Tyr His Lys Cys Asp Asn Glu Cys Met Glu Ser Val Arg Asn                485                 490                 495Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala Arg Leu Lys Arg            500                 505                 510Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Ile Gly Thr Tyr Gln Ile        515                 520                 525Leu Ser Ile Tyr Ser Thr Ala Ala Ser Ser Leu Ala Leu Ala Ile Met    530                 535                 540Met Ala Gly Leu Ser Leu Trp Met Cys Ser Asn Gly Ser Leu Gln Cys545                 550                 555                 560Arg Ile Cys Ile</s400><s200><s210>104</s210><s211>1877</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 104gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60gagaacauug uguuacugcu ggccauugug ucacugguga aauccgacca gauuugcauu    120gguuaccacg ccaauaacuc aaccgagcag guggauacua ucauggagaa gaacguaacc    180gucacccacg cccaggacau uuuggagaag acacauaacg guaaacucug ugaccugaac    240ggggugaagc ccuugauacu gaaggauugc ucuguagcgg gcuggcuacu cggaaauccu    300augugcgacg aauuuauucg cguaccugag uggaguuaua ucguugagag agccaaucca    360gcuaacgauc ugugcuaucc uggcagucug aacgauuacg aagagcuuaa acaccuccug    420ucccggauua accauuucga gaagauauug auaaucccga agagcagcug gccaaaucac    480gaaaccuccc ugggagugag cgcugcuugc cccuaccagg gagccccuuc auucuucagg    540aacgugguuu ggcugaucaa gaagaacgac gcauacccaa cuauuaagau cuccuacaau    600aauaccaacc gggaggaccu gcuaaucuug ugggguaucc aucacagcaa caacgcagaa    660gagcaaacua accuguauaa gaacccgacc accuauaucu cggucggaac aagcacguua    720aaccagcggu uggucccgaa gaucgccaca aggucucagg ugaacggcca gagaggaaga    780auggacuucu ucuggaccau auugaagcca gacgacgcaa uacauuucga gucuaacgga    840aacuucauug cuccggaaua cgcguacaag auuguuaaga agggcgauuc gaccauuaug    900aaaucagggg uggaauacgg ucacuguaac accaagugcc aaacuccugu gggcgcuauu    960aacucaucaa ugcccuucca caauauucac ccacugacua uuggugagug cccgaaauac   1020guaaagucua auaaacucgu guuggcgacc ggccuaagaa acagcccacu ucgcgagaag   1080aggcggaaga ggggcuuguu uggggcgauu gcaggauuua ucgaaggcgg cuggcagggu   1140augguggacg gcugguacgg auaucaucac agcaacgaac aagggucagg auacgccgca   1200gacaaagaau cgacucagaa agcuauagac ggagugacga acaaagugaa cucgaucauu   1260gauaagauga auacacaguu ugaagcgguc ggcagagaau uuaacaacuu ggaacggaga   1320auugagaauc ugaacaagaa gauggaggac ggcuuucugg acguguggac uuauaacgcc   1380gagcuccucg ugcugaugga gaacgaaagg acucuugacu uucacgauuc aaacgucaag   1440aaccuguacg acaagguuag auugcagcug cgggacaacg ccaaagaacu ggguaacggc   1500uguuucgagu ucuaccauaa gugcgauaac gagugcaugg aaucugucag aaacgguacc   1560uacgacuauc cccaguauuc ugaagaggcc cgccucaaac gagaggagau cucuggagug   1620aagcuggagu ccauuggcac guaccaaauu cugucaaucu acuccaccgc ugcaucaagc   1680cuagcucugg cgaucaugau ggcggggcuc agucugugga uguguucaaa cgguucccug   1740cagugucgca uuuguaucug auaauaggcu ggagccucgg uggccuagcu ucuugccccu   1800ugggccuccc cccagccccu ccuccccuuc cugcacccgu acccccgugg ucuuugaaua   1860aagucugagu gggcggc                                                  1877</s400><s200><s210>105</s210><s211>1701</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 105auggagaaca uuguguuacu gcuggccauu gugucacugg ugaaauccga ccagauuugc     60auugguuacc acgccaauaa cucaaccgag cagguggaua cuaucaugga gaagaacgua    120accgucaccc acgcccagga cauuuuggag aagacacaua acgguaaacu cugugaccug    180aacgggguga agcccuugau acugaaggau ugcucuguag cgggcuggcu acucggaaau    240ccuaugugcg acgaauuuau ucgcguaccu gaguggaguu auaucguuga gagagccaau    300ccagcuaacg aucugugcua uccuggcagu cugaacgauu acgaagagcu uaaacaccuc    360cugucccgga uuaaccauuu cgagaagaua uugauaaucc cgaagagcag cuggccaaau    420cacgaaaccu cccugggagu gagcgcugcu ugccccuacc agggagcccc uucauucuuc    480aggaacgugg uuuggcugau caagaagaac gacgcauacc caacuauuaa gaucuccuac    540aauaauacca accgggagga ccugcuaauc uuguggggua uccaucacag caacaacgca    600gaagagcaaa cuaaccugua uaagaacccg accaccuaua ucucggucgg aacaagcacg    660uuaaaccagc gguugguccc gaagaucgcc acaaggucuc aggugaacgg ccagagagga    720agaauggacu ucuucuggac cauauugaag ccagacgacg caauacauuu cgagucuaac    780ggaaacuuca uugcuccgga auacgcguac aagauuguua agaagggcga uucgaccauu    840augaaaucag ggguggaaua cggucacugu aacaccaagu gccaaacucc ugugggcgcu    900auuaacucau caaugcccuu ccacaauauu cacccacuga cuauugguga gugcccgaaa    960uacguaaagu cuaauaaacu cguguuggcg accggccuaa gaaacagccc acuucgcgag   1020aagaggcgga agaggggcuu guuuggggcg auugcaggau uuaucgaagg cggcuggcag   1080gguauggugg acggcuggua cggauaucau cacagcaacg aacaaggguc aggauacgcc   1140gcagacaaag aaucgacuca gaaagcuaua gacggaguga cgaacaaagu gaacucgauc   1200auugauaaga ugaauacaca guuugaagcg gucggcagag aauuuaacaa cuuggaacgg   1260agaauugaga aucugaacaa gaagauggag gacggcuuuc uggacgugug gacuuauaac   1320gccgagcucc ucgugcugau ggagaacgaa aggacucuug acuuucacga uucaaacguc   1380aagaaccugu acgacaaggu uagauugcag cugcgggaca acgccaaaga acuggguaac   1440ggcuguuucg aguucuacca uaagugcgau aacgagugca uggaaucugu cagaaacggu   1500accuacgacu auccccagua uucugaagag gcccgccuca aacgagagga gaucucugga   1560gugaagcugg aguccauugg cacguaccaa auucugucaa ucuacuccac cgcugcauca   1620agccuagcuc uggcgaucau gauggcgggg cucagucugu ggauguguuc aaacgguucc   1680cugcaguguc gcauuuguau c                                             1701</s400><s200><s210>106</s210><s211>567</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 106Met Glu Asn Ile Val Leu Leu Leu Ala Ile Val Ser Leu Val Lys Ser1               5                   10                  15Asp Gln Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Gln Val            20                  25                  30Asp Thr Ile Met Glu Lys Asn Val Thr Val Thr His Ala Gln Asp Ile        35                  40                  45Leu Glu Lys Thr His Asn Gly Lys Leu Cys Asp Leu Asn Gly Val Lys    50                  55                  60Pro Leu Ile Leu Lys Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn65                  70                  75                  80Pro Met Cys Asp Glu Phe Ile Arg Val Pro Glu Trp Ser Tyr Ile Val                85                  90                  95Glu Arg Ala Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Ser Leu Asn            100                 105                 110Asp Tyr Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu        115                 120                 125Lys Ile Leu Ile Ile Pro Lys Ser Ser Trp Pro Asn His Glu Thr Ser    130                 135                 140Leu Gly Val Ser Ala Ala Cys Pro Tyr Gln Gly Ala Pro Ser Phe Phe145                 150                 155                 160Arg Asn Val Val Trp Leu Ile Lys Lys Asn Asp Ala Tyr Pro Thr Ile                165                 170                 175Lys Ile Ser Tyr Asn Asn Thr Asn Arg Glu Asp Leu Leu Ile Leu Trp            180                 185                 190Gly Ile His His Ser Asn Asn Ala Glu Glu Gln Thr Asn Leu Tyr Lys        195                 200                 205Asn Pro Thr Thr Tyr Ile Ser Val Gly Thr Ser Thr Leu Asn Gln Arg    210                 215                 220Leu Val Pro Lys Ile Ala Thr Arg Ser Gln Val Asn Gly Gln Arg Gly225                 230                 235                 240Arg Met Asp Phe Phe Trp Thr Ile Leu Lys Pro Asp Asp Ala Ile His                245                 250                 255Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile            260                 265                 270Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Gly Val Glu Tyr Gly        275                 280                 285His Cys Asn Thr Lys Cys Gln Thr Pro Val Gly Ala Ile Asn Ser Ser    290                 295                 300Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys305                 310                 315                 320Tyr Val Lys Ser Asn Lys Leu Val Leu Ala Thr Gly Leu Arg Asn Ser                325                 330                 335Pro Leu Arg Glu Lys Arg Arg Lys Arg Gly Leu Phe Gly Ala Ile Ala            340                 345                 350Gly Phe Ile Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly        355                 360                 365Tyr His His Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Lys Glu    370                 375                 380Ser Thr Gln Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser Ile385                 390                 395                 400Ile Asp Lys Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe Asn                405                 410                 415Asn Leu Glu Arg Arg Ile Glu Asn Leu Asn Lys Lys Met Glu Asp Gly            420                 425                 430Phe Leu Asp Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu        435                 440                 445Asn Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr    450                 455                 460Asp Lys Val Arg Leu Gln Leu Arg Asp Asn Ala Lys Glu Leu Gly Asn465                 470                 475                 480Gly Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Glu Cys Met Glu Ser                485                 490                 495Val Arg Asn Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala Arg            500                 505                 510Leu Lys Arg Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Ile Gly Thr        515                 520                 525Tyr Gln Ile Leu Ser Ile Tyr Ser Thr Ala Ala Ser Ser Leu Ala Leu    530                 535                 540Ala Ile Met Met Ala Gly Leu Ser Leu Trp Met Cys Ser Asn Gly Ser545                 550                 555                 560Leu Gln Cys Arg Ile Cys Ile                565</s400><s200><s210>107</s210><s211>1583</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 107gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aacccgaacc agaagaucau caccaucggc agcgugagcc ugaccaucag caccaucugc    120uucuucaugc agaucgccau ccugaucacc accgugaccc ugcacuucaa gcaguacgag    180uucaacagcc ugcccaacaa ccaggugaug cugugcgagc ccaccaucau cgagcggaac    240aucaccgaga ucguguaccu gaccaacacc accaucgaga aggagaucug ccccaagccc    300gccgaguacc ggaacuggag caagccccag ugcggcauca ccggcuucgc cccauucagc    360aaggacaaca gcaucagacu gagugccggc ggcgacaucu gggugacccg ggagcccuac    420gugagcugcg accuggacaa gugcuaccag uucgcccugg gacagggcac cacccugaac    480aacgugcaca gcaacaacac ugugcgggac cggaccccau accggacccu gcugaugaac    540gagcugggcg ugcccuucca ccugggcacc aagcaggugu gcaucgccug gagcagcagc    600agcugccacg acggcaaggc cuggcugcac gugugcauua ccggcgacga caagaacgcc    660accgccagcu ucaucuacaa cggcaggcug guggacagcg uggugagcug gagcaacgac    720auccugcgga cccaggagag cgagugcgug ugcaucaacg gcaccugcac cguggugaug    780acugacggca acgccaccgg caaggccgac accaagaucc uguucaucga ggaggggaag    840aucgugcaca ccagcaagcu gucuggcagc gcccagcacg uggaggagug cagcugcuac    900ccucgguacc ccggcgugag gugcgugugc cgggacaacu ggaagggcag caaccggccc    960aucaucgaca ucaacaucaa ggaccacagc auagugagca gcuacgugug cagcggucug   1020gugggcgaca cuccccggaa gagcgacagc agcuccagca gccacugccu gaaccccaac   1080aacgaggagg guggucacgg cgugaagggc ugggccuucg acgacggcaa cgacgugugg   1140augggccgga ccaucaacga gaccagcaga cugggcuacg agaccuucaa ggugguggag   1200ggcuggagca aucccaagag caagcugcag aucaaccggc aggugaucgu cgaucggggc   1260gaucggagcg gcuacagcgg caucuucagc guggagggca agagcugcau caaccggugc   1320uucuacgugg agcugauccg gggccggaag gaggagaccg aggugcugug gaccagcaac   1380agcaucgugg uguucugcgg caccagcggc accuacggca ccggauccug gccagacggc   1440gccgaucuga accugaugca caucugauaa uaggcuggag ccucgguggc cuagcuucuu   1500gccccuuggg ccucccccca gccccuccuc cccuuccugc acccguaccc ccguggucuu   1560ugaauaaagu cugagugggc ggc                                           1583</s400><s200><s210>108</s210><s211>1407</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 108augaacccga accagaagau caucaccauc ggcagcguga gccugaccau cagcaccauc     60ugcuucuuca ugcagaucgc cauccugauc accaccguga cccugcacuu caagcaguac    120gaguucaaca gccugcccaa caaccaggug augcugugcg agcccaccau caucgagcgg    180aacaucaccg agaucgugua ccugaccaac accaccaucg agaaggagau cugccccaag    240cccgccgagu accggaacug gagcaagccc cagugcggca ucaccggcuu cgccccauuc    300agcaaggaca acagcaucag acugagugcc ggcggcgaca ucugggugac ccgggagccc    360uacgugagcu gcgaccugga caagugcuac caguucgccc ugggacaggg caccacccug    420aacaacgugc acagcaacaa cacugugcgg gaccggaccc cauaccggac ccugcugaug    480aacgagcugg gcgugcccuu ccaccugggc accaagcagg ugugcaucgc cuggagcagc    540agcagcugcc acgacggcaa ggccuggcug cacgugugca uuaccggcga cgacaagaac    600gccaccgcca gcuucaucua caacggcagg cugguggaca gcguggugag cuggagcaac    660gacauccugc ggacccagga gagcgagugc gugugcauca acggcaccug caccguggug    720augacugacg gcaacgccac cggcaaggcc gacaccaaga uccuguucau cgaggagggg    780aagaucgugc acaccagcaa gcugucuggc agcgcccagc acguggagga gugcagcugc    840uacccucggu accccggcgu gaggugcgug ugccgggaca acuggaaggg cagcaaccgg    900cccaucaucg acaucaacau caaggaccac agcauaguga gcagcuacgu gugcagcggu    960cuggugggcg acacuccccg gaagagcgac agcagcucca gcagccacug ccugaacccc   1020aacaacgagg agggugguca cggcgugaag ggcugggccu ucgacgacgg caacgacgug   1080uggaugggcc ggaccaucaa cgagaccagc agacugggcu acgagaccuu caagguggug   1140gagggcugga gcaaucccaa gagcaagcug cagaucaacc ggcaggugau cgucgaucgg   1200ggcgaucgga gcggcuacag cggcaucuuc agcguggagg gcaagagcug caucaaccgg   1260ugcuucuacg uggagcugau ccggggccgg aaggaggaga ccgaggugcu guggaccagc   1320aacagcaucg ugguguucug cggcaccagc ggcaccuacg gcaccggauc cuggccagac   1380ggcgccgauc ugaaccugau gcacauc                                       1407</s400><s200><s210>109</s210><s211>469</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 109Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Val Ser Leu Thr1               5                   10                  15Ile Ser Thr Ile Cys Phe Phe Met Gln Ile Ala Ile Leu Ile Thr Thr            20                  25                  30Val Thr Leu His Phe Lys Gln Tyr Glu Phe Asn Ser Leu Pro Asn Asn        35                  40                  45Gln Val Met Leu Cys Glu Pro Thr Ile Ile Glu Arg Asn Ile Thr Glu    50                  55                  60Ile Val Tyr Leu Thr Asn Thr Thr Ile Glu Lys Glu Ile Cys Pro Lys65                  70                  75                  80Pro Ala Glu Tyr Arg Asn Trp Ser Lys Pro Gln Cys Gly Ile Thr Gly                85                  90                  95Phe Ala Pro Phe Ser Lys Asp Asn Ser Ile Arg Leu Ser Ala Gly Gly            100                 105                 110Asp Ile Trp Val Thr Arg Glu Pro Tyr Val Ser Cys Asp Leu Asp Lys        115                 120                 125Cys Tyr Gln Phe Ala Leu Gly Gln Gly Thr Thr Leu Asn Asn Val His    130                 135                 140Ser Asn Asn Thr Val Arg Asp Arg Thr Pro Tyr Arg Thr Leu Leu Met145                 150                 155                 160Asn Glu Leu Gly Val Pro Phe His Leu Gly Thr Lys Gln Val Cys Ile                165                 170                 175Ala Trp Ser Ser Ser Ser Cys His Asp Gly Lys Ala Trp Leu His Val            180                 185                 190Cys Ile Thr Gly Asp Asp Lys Asn Ala Thr Ala Ser Phe Ile Tyr Asn        195                 200                 205Gly Arg Leu Val Asp Ser Val Val Ser Trp Ser Asn Asp Ile Leu Arg    210                 215                 220Thr Gln Glu Ser Glu Cys Val Cys Ile Asn Gly Thr Cys Thr Val Val225                 230                 235                 240Met Thr Asp Gly Asn Ala Thr Gly Lys Ala Asp Thr Lys Ile Leu Phe                245                 250                 255Ile Glu Glu Gly Lys Ile Val His Thr Ser Lys Leu Ser Gly Ser Ala            260                 265                 270Gln His Val Glu Glu Cys Ser Cys Tyr Pro Arg Tyr Pro Gly Val Arg        275                 280                 285Cys Val Cys Arg Asp Asn Trp Lys Gly Ser Asn Arg Pro Ile Ile Asp    290                 295                 300Ile Asn Ile Lys Asp His Ser Ile Val Ser Ser Tyr Val Cys Ser Gly305                 310                 315                 320Leu Val Gly Asp Thr Pro Arg Lys Ser Asp Ser Ser Ser Ser Ser His                325                 330                 335Cys Leu Asn Pro Asn Asn Glu Glu Gly Gly His Gly Val Lys Gly Trp            340                 345                 350Ala Phe Asp Asp Gly Asn Asp Val Trp Met Gly Arg Thr Ile Asn Glu        355                 360                 365Thr Ser Arg Leu Gly Tyr Glu Thr Phe Lys Val Val Glu Gly Trp Ser    370                 375                 380Asn Pro Lys Ser Lys Leu Gln Ile Asn Arg Gln Val Ile Val Asp Arg385                 390                 395                 400Gly Asp Arg Ser Gly Tyr Ser Gly Ile Phe Ser Val Glu Gly Lys Ser                405                 410                 415Cys Ile Asn Arg Cys Phe Tyr Val Glu Leu Ile Arg Gly Arg Lys Glu            420                 425                 430Glu Thr Glu Val Leu Trp Thr Ser Asn Ser Ile Val Val Phe Cys Gly        435                 440                 445Thr Ser Gly Thr Tyr Gly Thr Gly Ser Trp Pro Asp Gly Ala Asp Leu    450                 455                 460Asn Leu Met His Ile465</s400><s200><s210>110</s210><s211>1583</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 110gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aacccgaacc agaagaucau caccaucggc agcgugagcc ugaccaucag caccaucugc    120uucuucaugc agaucgccau ccugaucacc accgugaccc ugcacuucaa gcaguacgag    180uucaacagcc cucccaacaa ccaggugaug cugugcgagc ccaccaucau cgagcggaac    240augaccgaga ucguguaccu gaccaacacc accaucgaga aggagaucug ccccaagccc    300gccgaguacc ggaacuggag caagccccag ugcggcauca ccggcuucgc cccauucagc    360aaggacaaca gcaucagacu gagugccggc ggcgacaucu gggugacccg ggagcccuac    420gugagcugcg accuggacaa gugcuaccag uucgcccugg gacagggcac cacccugaac    480aacgugcaca gcaacaacac ugugcgggac cggaccccau accggacccu gcugaugaac    540gagcugggcg ugcccuucca ccugggcacc aagcaggugu gcaucgccug gagcagcagc    600agcugccacg acggcaaggc cuggcugcac gugugcauua ccggcgacga caagaacgcc    660accgccagcu ucaucuacaa cggcaggcug guggacagcg uggugagcug gagcaacgac    720auccugcgga cccaggagag cgagugcgug ugcaucaacg gcaccugcac cguggugaug    780acugacggca acgccaccgg caaggccgac accaagaucc uguucaucga ggaggggaag    840aucgugcaca ccagcaagcu gucuggcagc gcccagcacg uggaggagug cagcugcuac    900ccucgguacc ccggcgugag gugcgugugc cgggacaacu ggaagggcag caaccggccc    960aucaucgaca ucaacaucaa ggaccacagc auagugagca gauacgugug cagcggucug   1020gugggcgaca cuccccggaa gagcgacagc agcuccagca gccacugccu gaaccccaac   1080aacgagaagg gugaccacgg cgugaagggc ugggccuucg acgacggcaa cgacgugugg   1140augggccgga ccaucaacga gaccagcaga cugggcuacg agaccuucaa ggugguggag   1200ggcuggagca aucccaagag caagcugcag aucaaccggc aggugaucgu cgaucggggc   1260gaucggagcg gcuacagcgg caucuucagc guggagggca agagcugcau caaccggugc   1320uucuacgugg agcugauccg gggccggaag gaggagaccg aggugcugug gaccagcaac   1380agcaucgugg uguucugcgg caccagcggc accuacggca ccggauccug gccagacggc   1440gccaaccuga gccugaugca caucugauaa uaggcuggag ccucgguggc cuagcuucuu   1500gccccuuggg ccucccccca gccccuccuc cccuuccugc acccguaccc ccguggucuu   1560ugaauaaagu cugagugggc ggc                                           1583</s400><s200><s210>111</s210><s211>1407</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 111augaacccga accagaagau caucaccauc ggcagcguga gccugaccau cagcaccauc     60ugcuucuuca ugcagaucgc cauccugauc accaccguga cccugcacuu caagcaguac    120gaguucaaca gcccucccaa caaccaggug augcugugcg agcccaccau caucgagcgg    180aacaugaccg agaucgugua ccugaccaac accaccaucg agaaggagau cugccccaag    240cccgccgagu accggaacug gagcaagccc cagugcggca ucaccggcuu cgccccauuc    300agcaaggaca acagcaucag acugagugcc ggcggcgaca ucugggugac ccgggagccc    360uacgugagcu gcgaccugga caagugcuac caguucgccc ugggacaggg caccacccug    420aacaacgugc acagcaacaa cacugugcgg gaccggaccc cauaccggac ccugcugaug    480aacgagcugg gcgugcccuu ccaccugggc accaagcagg ugugcaucgc cuggagcagc    540agcagcugcc acgacggcaa ggccuggcug cacgugugca uuaccggcga cgacaagaac    600gccaccgcca gcuucaucua caacggcagg cugguggaca gcguggugag cuggagcaac    660gacauccugc ggacccagga gagcgagugc gugugcauca acggcaccug caccguggug    720augacugacg gcaacgccac cggcaaggcc gacaccaaga uccuguucau cgaggagggg    780aagaucgugc acaccagcaa gcugucuggc agcgcccagc acguggagga gugcagcugc    840uacccucggu accccggcgu gaggugcgug ugccgggaca acuggaaggg cagcaaccgg    900cccaucaucg acaucaacau caaggaccac agcauaguga gcagauacgu gugcagcggu    960cuggugggcg acacuccccg gaagagcgac agcagcucca gcagccacug ccugaacccc   1020aacaacgaga agggugacca cggcgugaag ggcugggccu ucgacgacgg caacgacgug   1080uggaugggcc ggaccaucaa cgagaccagc agacugggcu acgagaccuu caagguggug   1140gagggcugga gcaaucccaa gagcaagcug cagaucaacc ggcaggugau cgucgaucgg   1200ggcgaucgga gcggcuacag cggcaucuuc agcguggagg gcaagagcug caucaaccgg   1260ugcuucuacg uggagcugau ccggggccgg aaggaggaga ccgaggugcu guggaccagc   1320aacagcaucg ugguguucug cggcaccagc ggcaccuacg gcaccggauc cuggccagac   1380ggcgccaacc ugagccugau gcacauc                                       1407</s400><s200><s210>112</s210><s211>469</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 112Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Val Ser Leu Thr1               5                   10                  15Ile Ser Thr Ile Cys Phe Phe Met Gln Ile Ala Ile Leu Ile Thr Thr            20                  25                  30Val Thr Leu His Phe Lys Gln Tyr Glu Phe Asn Ser Pro Pro Asn Asn        35                  40                  45Gln Val Met Leu Cys Glu Pro Thr Ile Ile Glu Arg Asn Met Thr Glu    50                  55                  60Ile Val Tyr Leu Thr Asn Thr Thr Ile Glu Lys Glu Ile Cys Pro Lys65                  70                  75                  80Pro Ala Glu Tyr Arg Asn Trp Ser Lys Pro Gln Cys Gly Ile Thr Gly                85                  90                  95Phe Ala Pro Phe Ser Lys Asp Asn Ser Ile Arg Leu Ser Ala Gly Gly            100                 105                 110Asp Ile Trp Val Thr Arg Glu Pro Tyr Val Ser Cys Asp Leu Asp Lys        115                 120                 125Cys Tyr Gln Phe Ala Leu Gly Gln Gly Thr Thr Leu Asn Asn Val His    130                 135                 140Ser Asn Asn Thr Val Arg Asp Arg Thr Pro Tyr Arg Thr Leu Leu Met145                 150                 155                 160Asn Glu Leu Gly Val Pro Phe His Leu Gly Thr Lys Gln Val Cys Ile                165                 170                 175Ala Trp Ser Ser Ser Ser Cys His Asp Gly Lys Ala Trp Leu His Val            180                 185                 190Cys Ile Thr Gly Asp Asp Lys Asn Ala Thr Ala Ser Phe Ile Tyr Asn        195                 200                 205Gly Arg Leu Val Asp Ser Val Val Ser Trp Ser Asn Asp Ile Leu Arg    210                 215                 220Thr Gln Glu Ser Glu Cys Val Cys Ile Asn Gly Thr Cys Thr Val Val225                 230                 235                 240Met Thr Asp Gly Asn Ala Thr Gly Lys Ala Asp Thr Lys Ile Leu Phe                245                 250                 255Ile Glu Glu Gly Lys Ile Val His Thr Ser Lys Leu Ser Gly Ser Ala            260                 265                 270Gln His Val Glu Glu Cys Ser Cys Tyr Pro Arg Tyr Pro Gly Val Arg        275                 280                 285Cys Val Cys Arg Asp Asn Trp Lys Gly Ser Asn Arg Pro Ile Ile Asp    290                 295                 300Ile Asn Ile Lys Asp His Ser Ile Val Ser Arg Tyr Val Cys Ser Gly305                 310                 315                 320Leu Val Gly Asp Thr Pro Arg Lys Ser Asp Ser Ser Ser Ser Ser His                325                 330                 335Cys Leu Asn Pro Asn Asn Glu Lys Gly Asp His Gly Val Lys Gly Trp            340                 345                 350Ala Phe Asp Asp Gly Asn Asp Val Trp Met Gly Arg Thr Ile Asn Glu        355                 360                 365Thr Ser Arg Leu Gly Tyr Glu Thr Phe Lys Val Val Glu Gly Trp Ser    370                 375                 380Asn Pro Lys Ser Lys Leu Gln Ile Asn Arg Gln Val Ile Val Asp Arg385                 390                 395                 400Gly Asp Arg Ser Gly Tyr Ser Gly Ile Phe Ser Val Glu Gly Lys Ser                405                 410                 415Cys Ile Asn Arg Cys Phe Tyr Val Glu Leu Ile Arg Gly Arg Lys Glu            420                 425                 430Glu Thr Glu Val Leu Trp Thr Ser Asn Ser Ile Val Val Phe Cys Gly        435                 440                 445Thr Ser Gly Thr Tyr Gly Thr Gly Ser Trp Pro Asp Gly Ala Asn Leu    450                 455                 460Ser Leu Met His Ile465</s400><s200><s210>113</s210><s211>1583</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 113gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aacccgaacc agaagaucau caccaucggc agcgugagcc ugaccaucag caccaucugc    120uucuucaugc agaucgccau ccugaucacc accgugaccc ugcacuucaa gcaguacgag    180uucaacagcc cucccaacaa ccaggugaug cugugcgagc ccaccaucau cgagcggaac    240augaccgaga ucguguaccu gaccaacacc accaucgaga aggagaucug ccccaagccc    300gccgaguacc ggaacuggag caagccccag ugcggcauca ccggcuucgc cccauucagc    360aaggacaaca gcaucagacu gagugccggc ggcgacaucu gggugacccg ggagcccuac    420gugagcugcg accuggacaa gugcuaccag uucgcccugg gacagggcac cacccugaac    480aacgugcaca gcaacaacac ugugcggggc cggaccccau accggacccu gcugaugaac    540gagcugggcg ugcccuucca ccugggcacc aagcaggugu gcaucgccug gagcagcagc    600agcugccacg acggcaaggc cuggcugcac gugugcauua ccggcgacga caagaacgcc    660accgccagcu ucaucuacaa cggcaggcug guggacagcg uggugagcug gagcaacgac    720auccugcgga cccaggagag cgagugcgug ugcaucaacg gcaccugcac cguggugaug    780acugacggca acgccaccgg caaggccgac accaagaucc uguucaucga ggaggggaag    840aucgugcaca ccagcaagcu gucuggcagc gcccagcacg uggaggagug cagcugcuac    900ccucgguacc ccggcgugag gugcgugugc cgggacaacu ggaagggcag caaccggccc    960aucaucgaca ucaacaucaa ggaccacagc auagugagca gauacgugug cagcggucug   1020gugggcgaca cuccccggaa gagcgacagc agcuccagca gccacugccu gaaccccaac   1080aacgagaagg gugaccacgg cgugaagggc ugggccuucg acgacggcaa cgacgugugg   1140augggccgga ccaucaacga gaccagcaga cugggcuacg agaccuucaa ggugguggag   1200ggcuggagca aucccaagag caagcugcag aucaaccggc aggugaucgu cgaucggggc   1260gaucggagcg gcuacagcgg caucuucagc guggagggca agagcugcau caaccggugc   1320uucuacgugg agcugauccg gggccggaag gaggagaccg aggugcugug gaccagcaac   1380agcaucgugg uguucugcgg caccagcggc accuacggca ccggauccug gccagacggc   1440gccaaccuga gccugaugca caucugauaa uaggcuggag ccucgguggc cuagcuucuu   1500gccccuuggg ccucccccca gccccuccuc cccuuccugc acccguaccc ccguggucuu   1560ugaauaaagu cugagugggc ggc                                           1583</s400><s200><s210>114</s210><s211>1407</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 114augaacccga accagaagau caucaccauc ggcagcguga gccugaccau cagcaccauc     60ugcuucuuca ugcagaucgc cauccugauc accaccguga cccugcacuu caagcaguac    120gaguucaaca gcccucccaa caaccaggug augcugugcg agcccaccau caucgagcgg    180aacaugaccg agaucgugua ccugaccaac accaccaucg agaaggagau cugccccaag    240cccgccgagu accggaacug gagcaagccc cagugcggca ucaccggcuu cgccccauuc    300agcaaggaca acagcaucag acugagugcc ggcggcgaca ucugggugac ccgggagccc    360uacgugagcu gcgaccugga caagugcuac caguucgccc ugggacaggg caccacccug    420aacaacgugc acagcaacaa cacugugcgg ggccggaccc cauaccggac ccugcugaug    480aacgagcugg gcgugcccuu ccaccugggc accaagcagg ugugcaucgc cuggagcagc    540agcagcugcc acgacggcaa ggccuggcug cacgugugca uuaccggcga cgacaagaac    600gccaccgcca gcuucaucua caacggcagg cugguggaca gcguggugag cuggagcaac    660gacauccugc ggacccagga gagcgagugc gugugcauca acggcaccug caccguggug    720augacugacg gcaacgccac cggcaaggcc gacaccaaga uccuguucau cgaggagggg    780aagaucgugc acaccagcaa gcugucuggc agcgcccagc acguggagga gugcagcugc    840uacccucggu accccggcgu gaggugcgug ugccgggaca acuggaaggg cagcaaccgg    900cccaucaucg acaucaacau caaggaccac agcauaguga gcagauacgu gugcagcggu    960cuggugggcg acacuccccg gaagagcgac agcagcucca gcagccacug ccugaacccc   1020aacaacgaga agggugacca cggcgugaag ggcugggccu ucgacgacgg caacgacgug   1080uggaugggcc ggaccaucaa cgagaccagc agacugggcu acgagaccuu caagguggug   1140gagggcugga gcaaucccaa gagcaagcug cagaucaacc ggcaggugau cgucgaucgg   1200ggcgaucgga gcggcuacag cggcaucuuc agcguggagg gcaagagcug caucaaccgg   1260ugcuucuacg uggagcugau ccggggccgg aaggaggaga ccgaggugcu guggaccagc   1320aacagcaucg ugguguucug cggcaccagc ggcaccuacg gcaccggauc cuggccagac   1380ggcgccaacc ugagccugau gcacauc                                       1407</s400><s200><s210>115</s210><s211>469</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 115Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Val Ser Leu Thr1               5                   10                  15Ile Ser Thr Ile Cys Phe Phe Met Gln Ile Ala Ile Leu Ile Thr Thr            20                  25                  30Val Thr Leu His Phe Lys Gln Tyr Glu Phe Asn Ser Pro Pro Asn Asn        35                  40                  45Gln Val Met Leu Cys Glu Pro Thr Ile Ile Glu Arg Asn Met Thr Glu    50                  55                  60Ile Val Tyr Leu Thr Asn Thr Thr Ile Glu Lys Glu Ile Cys Pro Lys65                  70                  75                  80Pro Ala Glu Tyr Arg Asn Trp Ser Lys Pro Gln Cys Gly Ile Thr Gly                85                  90                  95Phe Ala Pro Phe Ser Lys Asp Asn Ser Ile Arg Leu Ser Ala Gly Gly            100                 105                 110Asp Ile Trp Val Thr Arg Glu Pro Tyr Val Ser Cys Asp Leu Asp Lys        115                 120                 125Cys Tyr Gln Phe Ala Leu Gly Gln Gly Thr Thr Leu Asn Asn Val His    130                 135                 140Ser Asn Asn Thr Val Arg Gly Arg Thr Pro Tyr Arg Thr Leu Leu Met145                 150                 155                 160Asn Glu Leu Gly Val Pro Phe His Leu Gly Thr Lys Gln Val Cys Ile                165                 170                 175Ala Trp Ser Ser Ser Ser Cys His Asp Gly Lys Ala Trp Leu His Val            180                 185                 190Cys Ile Thr Gly Asp Asp Lys Asn Ala Thr Ala Ser Phe Ile Tyr Asn        195                 200                 205Gly Arg Leu Val Asp Ser Val Val Ser Trp Ser Asn Asp Ile Leu Arg    210                 215                 220Thr Gln Glu Ser Glu Cys Val Cys Ile Asn Gly Thr Cys Thr Val Val225                 230                 235                 240Met Thr Asp Gly Asn Ala Thr Gly Lys Ala Asp Thr Lys Ile Leu Phe                245                 250                 255Ile Glu Glu Gly Lys Ile Val His Thr Ser Lys Leu Ser Gly Ser Ala            260                 265                 270Gln His Val Glu Glu Cys Ser Cys Tyr Pro Arg Tyr Pro Gly Val Arg        275                 280                 285Cys Val Cys Arg Asp Asn Trp Lys Gly Ser Asn Arg Pro Ile Ile Asp    290                 295                 300Ile Asn Ile Lys Asp His Ser Ile Val Ser Arg Tyr Val Cys Ser Gly305                 310                 315                 320Leu Val Gly Asp Thr Pro Arg Lys Ser Asp Ser Ser Ser Ser Ser His                325                 330                 335Cys Leu Asn Pro Asn Asn Glu Lys Gly Asp His Gly Val Lys Gly Trp            340                 345                 350Ala Phe Asp Asp Gly Asn Asp Val Trp Met Gly Arg Thr Ile Asn Glu        355                 360                 365Thr Ser Arg Leu Gly Tyr Glu Thr Phe Lys Val Val Glu Gly Trp Ser    370                 375                 380Asn Pro Lys Ser Lys Leu Gln Ile Asn Arg Gln Val Ile Val Asp Arg385                 390                 395                 400Gly Asp Arg Ser Gly Tyr Ser Gly Ile Phe Ser Val Glu Gly Lys Ser                405                 410                 415Cys Ile Asn Arg Cys Phe Tyr Val Glu Leu Ile Arg Gly Arg Lys Glu            420                 425                 430Glu Thr Glu Val Leu Trp Thr Ser Asn Ser Ile Val Val Phe Cys Gly        435                 440                 445Thr Ser Gly Thr Tyr Gly Thr Gly Ser Trp Pro Asp Gly Ala Asn Leu    450                 455                 460Ser Leu Met His Ile465</s400><s200><s210>116</s210><s211>1583</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 116gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aacccgaacc agaagaucau caccaucggc agcgugagcc ugaccaucag caccaucugc    120uucuucaugc agaucgccau ccugaucacc accgugaccc ugcacuucaa gcaguacgag    180uucaacagcc cucccaacaa ccaggugaug cugugcgagc ccaccaucau cgagcggaac    240augaccgaga ucguguaccu gaccaacacc accaucgaga aggagaucug ccccaagccc    300gccgaguacc ggaacuggag caagccccag ugcggcauca ccggcuucgc cccauucagc    360aaggacaaca gcaucagacu gagugccggc ggcgacaucu gggugacccg ggagcccuac    420gugagcugcg accuggacaa gugcuaccag uucgcccugg gacagggcac cacccugaac    480aacgugcaca gcaacaacac ugugcgggac cggaccccau accggacccu gcugaugaac    540gagcugggcg ugcccuucca ccugggcacc aagcaggugu gcaucgccug gagcagcagc    600agcugccacg acggcaaggc cuggcugcac gugugcauua ccggcgacga caagaacgcc    660accgccagcu ucaucuacaa cggcaggcug guggacagcg uggugagcug gagcaacgac    720auccugcgga cccaggacag cgagugcgug ugcaucaacg gcaccugcac cguggugaug    780acugacggca acgccaccgg caaggccgac accaagaucc uguucaucga ggaggggaag    840aucgugcaca ccagcaagcu gucuggcagc gcccagcacg uggaggagug cagcugcuac    900ccucgguacc ccggcgugag gugcgugugc cgggacaacu ggaagggcag caaccggccc    960aucaucgaca ucaacaucaa ggaccacagc auagugagca gauacgugug cagcggucug   1020gugggcgaca cuccccggaa gagcgacagc agcuccagca gccacugccu gaaccccaac   1080aacgagaagg gugaccacgg cgugaagggc ugggccuucg acgacggcaa cgacgugugg   1140augggccgga ccaucaacga gaccagcaga cugggcuacg agaccuucaa ggugguggag   1200ggcuggagca aucccaagag caagcugcag aucaaccggc aggugaucgu cgaucggggc   1260gaucggagcg gcuacagcgg caucuucagc guggagggca agagcugcau caaccggugc   1320uucuacgugg agcugauccg gggccggaag gaggagaccg aggugcugug gaccagcaac   1380agcaucgugg uguucugcgg caccagcggc accuacggca ccggauccug gccagacggc   1440gccaaccuga gccugaugca caucugauaa uaggcuggag ccucgguggc cuagcuucuu   1500gccccuuggg ccucccccca gccccuccuc cccuuccugc acccguaccc ccguggucuu   1560ugaauaaagu cugagugggc ggc                                           1583</s400><s200><s210>117</s210><s211>1407</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 117augaacccga accagaagau caucaccauc ggcagcguga gccugaccau cagcaccauc     60ugcuucuuca ugcagaucgc cauccugauc accaccguga cccugcacuu caagcaguac    120gaguucaaca gcccucccaa caaccaggug augcugugcg agcccaccau caucgagcgg    180aacaugaccg agaucgugua ccugaccaac accaccaucg agaaggagau cugccccaag    240cccgccgagu accggaacug gagcaagccc cagugcggca ucaccggcuu cgccccauuc    300agcaaggaca acagcaucag acugagugcc ggcggcgaca ucugggugac ccgggagccc    360uacgugagcu gcgaccugga caagugcuac caguucgccc ugggacaggg caccacccug    420aacaacgugc acagcaacaa cacugugcgg gaccggaccc cauaccggac ccugcugaug    480aacgagcugg gcgugcccuu ccaccugggc accaagcagg ugugcaucgc cuggagcagc    540agcagcugcc acgacggcaa ggccuggcug cacgugugca uuaccggcga cgacaagaac    600gccaccgcca gcuucaucua caacggcagg cugguggaca gcguggugag cuggagcaac    660gacauccugc ggacccagga cagcgagugc gugugcauca acggcaccug caccguggug    720augacugacg gcaacgccac cggcaaggcc gacaccaaga uccuguucau cgaggagggg    780aagaucgugc acaccagcaa gcugucuggc agcgcccagc acguggagga gugcagcugc    840uacccucggu accccggcgu gaggugcgug ugccgggaca acuggaaggg cagcaaccgg    900cccaucaucg acaucaacau caaggaccac agcauaguga gcagauacgu gugcagcggu    960cuggugggcg acacuccccg gaagagcgac agcagcucca gcagccacug ccugaacccc   1020aacaacgaga agggugacca cggcgugaag ggcugggccu ucgacgacgg caacgacgug   1080uggaugggcc ggaccaucaa cgagaccagc agacugggcu acgagaccuu caagguggug   1140gagggcugga gcaaucccaa gagcaagcug cagaucaacc ggcaggugau cgucgaucgg   1200ggcgaucgga gcggcuacag cggcaucuuc agcguggagg gcaagagcug caucaaccgg   1260ugcuucuacg uggagcugau ccggggccgg aaggaggaga ccgaggugcu guggaccagc   1320aacagcaucg ugguguucug cggcaccagc ggcaccuacg gcaccggauc cuggccagac   1380ggcgccaacc ugagccugau gcacauc                                       1407</s400><s200><s210>118</s210><s211>469</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 118Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Val Ser Leu Thr1               5                   10                  15Ile Ser Thr Ile Cys Phe Phe Met Gln Ile Ala Ile Leu Ile Thr Thr            20                  25                  30Val Thr Leu His Phe Lys Gln Tyr Glu Phe Asn Ser Pro Pro Asn Asn        35                  40                  45Gln Val Met Leu Cys Glu Pro Thr Ile Ile Glu Arg Asn Met Thr Glu    50                  55                  60Ile Val Tyr Leu Thr Asn Thr Thr Ile Glu Lys Glu Ile Cys Pro Lys65                  70                  75                  80Pro Ala Glu Tyr Arg Asn Trp Ser Lys Pro Gln Cys Gly Ile Thr Gly                85                  90                  95Phe Ala Pro Phe Ser Lys Asp Asn Ser Ile Arg Leu Ser Ala Gly Gly            100                 105                 110Asp Ile Trp Val Thr Arg Glu Pro Tyr Val Ser Cys Asp Leu Asp Lys        115                 120                 125Cys Tyr Gln Phe Ala Leu Gly Gln Gly Thr Thr Leu Asn Asn Val His    130                 135                 140Ser Asn Asn Thr Val Arg Asp Arg Thr Pro Tyr Arg Thr Leu Leu Met145                 150                 155                 160Asn Glu Leu Gly Val Pro Phe His Leu Gly Thr Lys Gln Val Cys Ile                165                 170                 175Ala Trp Ser Ser Ser Ser Cys His Asp Gly Lys Ala Trp Leu His Val            180                 185                 190Cys Ile Thr Gly Asp Asp Lys Asn Ala Thr Ala Ser Phe Ile Tyr Asn        195                 200                 205Gly Arg Leu Val Asp Ser Val Val Ser Trp Ser Asn Asp Ile Leu Arg    210                 215                 220Thr Gln Asp Ser Glu Cys Val Cys Ile Asn Gly Thr Cys Thr Val Val225                 230                 235                 240Met Thr Asp Gly Asn Ala Thr Gly Lys Ala Asp Thr Lys Ile Leu Phe                245                 250                 255Ile Glu Glu Gly Lys Ile Val His Thr Ser Lys Leu Ser Gly Ser Ala            260                 265                 270Gln His Val Glu Glu Cys Ser Cys Tyr Pro Arg Tyr Pro Gly Val Arg        275                 280                 285Cys Val Cys Arg Asp Asn Trp Lys Gly Ser Asn Arg Pro Ile Ile Asp    290                 295                 300Ile Asn Ile Lys Asp His Ser Ile Val Ser Arg Tyr Val Cys Ser Gly305                 310                 315                 320Leu Val Gly Asp Thr Pro Arg Lys Ser Asp Ser Ser Ser Ser Ser His                325                 330                 335Cys Leu Asn Pro Asn Asn Glu Lys Gly Asp His Gly Val Lys Gly Trp            340                 345                 350Ala Phe Asp Asp Gly Asn Asp Val Trp Met Gly Arg Thr Ile Asn Glu        355                 360                 365Thr Ser Arg Leu Gly Tyr Glu Thr Phe Lys Val Val Glu Gly Trp Ser    370                 375                 380Asn Pro Lys Ser Lys Leu Gln Ile Asn Arg Gln Val Ile Val Asp Arg385                 390                 395                 400Gly Asp Arg Ser Gly Tyr Ser Gly Ile Phe Ser Val Glu Gly Lys Ser                405                 410                 415Cys Ile Asn Arg Cys Phe Tyr Val Glu Leu Ile Arg Gly Arg Lys Glu            420                 425                 430Glu Thr Glu Val Leu Trp Thr Ser Asn Ser Ile Val Val Phe Cys Gly        435                 440                 445Thr Ser Gly Thr Tyr Gly Thr Gly Ser Trp Pro Asp Gly Ala Asn Leu    450                 455                 460Ser Leu Met His Ile465</s400><s200><s210>119</s210><s211>1586</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 119gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aacccuaauc agaagauugc gaccauuggc agcauuucuc uuggccucgu gguguucaac    120gucuugcugc acgcccuauc caucauccuc augguccugg cccuugguaa gagcgagaac    180aacgguauuu guaagggaac aaucaucaga gaguacaacg agaccguucg gaucgagaag    240guaacacagu gguacaauac gucaguugug gaguacgugc cgcacuggaa cgagggcgcu    300uauauuaaca acaccgagcc aaucugcgac gugaagggcu uugcgccuuu uagcaaagac    360aacggaaucc gaaucggaag cagagggcau aucuuuguua uuagggaacc auuugugucu    420uguagucccg ucgagugccg aaccuucuuc cuuacacagg gcgcauugcu gaacgauaag    480cauuccaacg gcaccguuaa ggacaggagc ccauucagga cacugauguc aguggaaguu    540ggucaaucgc cuaacguuua ucaggcacgc uuugaggccg uggccuggag ugcaaccgcc    600ugucacgacg gcaagaagug gaugacaauu ggggugacug guccugacag caaggcaauc    660gcaguuguuc acuacggcgg uguccccacg gacaucguga auucgugggc cggagacauc    720cugcggacuc aggaaucuuc guguaccugc auccagggca acuguuacug gguaaugacu    780gacgguccua guaaccguca ggcccaauau agaauauaca aggccaacca gggcaagauu    840auugaccaag ccgacguauc cuucuccggc ggccauaucg aggagugcuc uuguuauccu    900aacgacggaa aggucgagug ugugugccgc gacaacugga ucgggaccaa ccgcccugug    960cuggucauau cuccugaucu gucauaucgu gugggauauc uuugugcagg auugccaucc   1020gauacacccc gaggugagga cgcccaguuc guagggagcu guacuagccc uaugggaaau   1080cagggauacg gcguuaaggg uuuuggauuc cgccaaggua ccgacgucug gaugggcagg   1140accauaagca ggaccagcag auccggauuu gaaaucauca ggaucaagaa cggguggacc   1200cagacgucua aagagcaaau ucgucggcaa gugguuguag acaaucuaaa uuggucuggc   1260uauagcggaa guuucacucu uccaguugaa cucagcggcc gugagugucu ggugccgugc   1320uuuugggugg aaaugaucag aggcaggccc gaggagcgua caaucuggac aucuucuucc   1380uccaucguga uguguggggu ugaucacgag aucgcagacu ggagcuggca cgacggugcg   1440auacugccau ucgacauuga cggaauguga uaauaggcug gagccucggu ggccuagcuu   1500cuugccccuu gggccucccc ccagccccuc cuccccuucc ugcacccgua cccccguggu   1560cuuugaauaa agucugagug ggcggc                                        1586</s400><s200><s210>120</s210><s211>1410</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 120augaacccua aucagaagau ugcgaccauu ggcagcauuu cucuuggccu cgugguguuc     60aacgucuugc ugcacgcccu auccaucauc cucauggucc uggcccuugg uaagagcgag    120aacaacggua uuuguaaggg aacaaucauc agagaguaca acgagaccgu ucggaucgag    180aagguaacac agugguacaa uacgucaguu guggaguacg ugccgcacug gaacgagggc    240gcuuauauua acaacaccga gccaaucugc gacgugaagg gcuuugcgcc uuuuagcaaa    300gacaacggaa uccgaaucgg aagcagaggg cauaucuuug uuauuaggga accauuugug    360ucuuguaguc ccgucgagug ccgaaccuuc uuccuuacac agggcgcauu gcugaacgau    420aagcauucca acggcaccgu uaaggacagg agcccauuca ggacacugau gucaguggaa    480guuggucaau cgccuaacgu uuaucaggca cgcuuugagg ccguggccug gagugcaacc    540gccugucacg acggcaagaa guggaugaca auugggguga cugguccuga cagcaaggca    600aucgcaguug uucacuacgg cggugucccc acggacaucg ugaauucgug ggccggagac    660auccugcgga cucaggaauc uucguguacc ugcauccagg gcaacuguua cuggguaaug    720acugacgguc cuaguaaccg ucaggcccaa uauagaauau acaaggccaa ccagggcaag    780auuauugacc aagccgacgu auccuucucc ggcggccaua ucgaggagug cucuuguuau    840ccuaacgacg gaaaggucga gugugugugc cgcgacaacu ggaucgggac caaccgcccu    900gugcugguca uaucuccuga ucugucauau cgugugggau aucuuugugc aggauugcca    960uccgauacac cccgagguga ggacgcccag uucguaggga gcuguacuag cccuauggga   1020aaucagggau acggcguuaa ggguuuugga uuccgccaag guaccgacgu cuggaugggc   1080aggaccauaa gcaggaccag cagauccgga uuugaaauca ucaggaucaa gaacgggugg   1140acccagacgu cuaaagagca aauucgucgg caagugguug uagacaaucu aaauuggucu   1200ggcuauagcg gaaguuucac ucuuccaguu gaacucagcg gccgugagug ucuggugccg   1260ugcuuuuggg uggaaaugau cagaggcagg cccgaggagc guacaaucug gacaucuucu   1320uccuccaucg ugaugugugg gguugaucac gagaucgcag acuggagcug gcacgacggu   1380gcgauacugc cauucgacau ugacggaaug                                    1410</s400><s200><s210>121</s210><s211>470</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 121Met Asn Pro Asn Gln Lys Ile Ala Thr Ile Gly Ser Ile Ser Leu Gly1               5                   10                  15Leu Val Val Phe Asn Val Leu Leu His Ala Leu Ser Ile Ile Leu Met            20                  25                  30Val Leu Ala Leu Gly Lys Ser Glu Asn Asn Gly Ile Cys Lys Gly Thr        35                  40                  45Ile Ile Arg Glu Tyr Asn Glu Thr Val Arg Ile Glu Lys Val Thr Gln    50                  55                  60Trp Tyr Asn Thr Ser Val Val Glu Tyr Val Pro His Trp Asn Glu Gly65                  70                  75                  80Ala Tyr Ile Asn Asn Thr Glu Pro Ile Cys Asp Val Lys Gly Phe Ala                85                  90                  95Pro Phe Ser Lys Asp Asn Gly Ile Arg Ile Gly Ser Arg Gly His Ile            100                 105                 110Phe Val Ile Arg Glu Pro Phe Val Ser Cys Ser Pro Val Glu Cys Arg        115                 120                 125Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His Ser Asn    130                 135                 140Gly Thr Val Lys Asp Arg Ser Pro Phe Arg Thr Leu Met Ser Val Glu145                 150                 155                 160Val Gly Gln Ser Pro Asn Val Tyr Gln Ala Arg Phe Glu Ala Val Ala                165                 170                 175Trp Ser Ala Thr Ala Cys His Asp Gly Lys Lys Trp Met Thr Ile Gly            180                 185                 190Val Thr Gly Pro Asp Ser Lys Ala Ile Ala Val Val His Tyr Gly Gly        195                 200                 205Val Pro Thr Asp Ile Val Asn Ser Trp Ala Gly Asp Ile Leu Arg Thr    210                 215                 220Gln Glu Ser Ser Cys Thr Cys Ile Gln Gly Asn Cys Tyr Trp Val Met225                 230                 235                 240Thr Asp Gly Pro Ser Asn Arg Gln Ala Gln Tyr Arg Ile Tyr Lys Ala                245                 250                 255Asn Gln Gly Lys Ile Ile Asp Gln Ala Asp Val Ser Phe Ser Gly Gly            260                 265                 270His Ile Glu Glu Cys Ser Cys Tyr Pro Asn Asp Gly Lys Val Glu Cys        275                 280                 285Val Cys Arg Asp Asn Trp Ile Gly Thr Asn Arg Pro Val Leu Val Ile    290                 295                 300Ser Pro Asp Leu Ser Tyr Arg Val Gly Tyr Leu Cys Ala Gly Leu Pro305                 310                 315                 320Ser Asp Thr Pro Arg Gly Glu Asp Ala Gln Phe Val Gly Ser Cys Thr                325                 330                 335Ser Pro Met Gly Asn Gln Gly Tyr Gly Val Lys Gly Phe Gly Phe Arg            340                 345                 350Gln Gly Thr Asp Val Trp Met Gly Arg Thr Ile Ser Arg Thr Ser Arg        355                 360                 365Ser Gly Phe Glu Ile Ile Arg Ile Lys Asn Gly Trp Thr Gln Thr Ser    370                 375                 380Lys Glu Gln Ile Arg Arg Gln Val Val Val Asp Asn Leu Asn Trp Ser385                 390                 395                 400Gly Tyr Ser Gly Ser Phe Thr Leu Pro Val Glu Leu Ser Gly Arg Glu                405                 410                 415Cys Leu Val Pro Cys Phe Trp Val Glu Met Ile Arg Gly Arg Pro Glu            420                 425                 430Glu Arg Thr Ile Trp Thr Ser Ser Ser Ser Ile Val Met Cys Gly Val        435                 440                 445Asp His Glu Ile Ala Asp Trp Ser Trp His Asp Gly Ala Ile Leu Pro    450                 455                 460Phe Asp Ile Asp Gly Met465                 470</s400><s200><s210>122</s210><s211>1586</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 122gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aacccuaauc agaagauugc gaccauuggc agcauuucuc uuggccucgu gguguucaac    120gucuugcugc acgcccuauc caucauccuc augguccugg cccuugguaa gagcgagaac    180aacgguauuu guaagggaac aaucaucaga gaguacaacg agaccguucg gaucgagaag    240guaacacagu gguacaauac gucaguugug gaguacgugc cgcacuggaa cgagggcgcu    300uauauuaaca acaccgagcc aaucugcgac gugaagggcu uugcgccuuu uagcaaagac    360aacggaaucc gaaucggaag cagagggcau aucuuuguua uuagggaacc auuugugucu    420uguagucccg ucgagugccg aaccuucuuc cuuacacagg gcgcauugcu gaacgauaag    480cauuccaacg gcaccguuaa gggcaggagc ccauucagga cacugauguc aguggaaguu    540ggucaaucgc cuaacguuua ucaggcacgc uuugaggccg uggccuggag ugcaaccgcc    600ugucacgacg gcaagaagug gaugacaauu ggggugacug guccugacag caaggcaauc    660gcaguuguuc acuacggcgg uguccccacg gacaucguga auucgugggc cggagacauc    720cugcggacuc aggaaucuuc guguaccugc auccagggca acuguuacug gguaaugacu    780gacgguccua guaaccguca ggcccaauau agaauauaca aggccaacca gggcaagauu    840auugaccaag ccgacguauc cuucuccggc ggccauaucg aggagugcuc uuguuauccu    900aacgacggaa aggucgagug ugugugccgc gacaacugga ucgggaccaa ccgcccugug    960cuggucauau cuccugaucu gucauaucgu gugggauauc uuugugcagg auugccaucc   1020gauacacccc gaggugagga cgcccaguuc guagggagcu guacuagccc uaugggaaau   1080cagggauacg gcguuaaggg uuuuggauuc cgccaaggua ccgacgucug gaugggcagg   1140accauaagca ggaccagcag auccggauuu gaaaucauca ggaucaagaa cggguggacc   1200cagacgucua aagagcaaau ucgucggcaa gugguuguag acaaucuaaa uuggucuggc   1260uauagcggaa guuucacucu uccaguugaa cucagcggcc gugagugucu ggugccgugc   1320uuuugggugg aaaugaucag aggcaggccc gaggagcgua caaucuggac aucuucuucc   1380uccaucguga uguguggggu ugaucacgag aucgcagacu ggagcuggca cgacggugcg   1440auacugccau ucgacauuga cggaauguga uaauaggcug gagccucggu ggccuagcuu   1500cuugccccuu gggccucccc ccagccccuc cuccccuucc ugcacccgua cccccguggu   1560cuuugaauaa agucugagug ggcggc                                        1586</s400><s200><s210>123</s210><s211>1410</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 123augaacccua aucagaagau ugcgaccauu ggcagcauuu cucuuggccu cgugguguuc     60aacgucuugc ugcacgcccu auccaucauc cucauggucc uggcccuugg uaagagcgag    120aacaacggua uuuguaaggg aacaaucauc agagaguaca acgagaccgu ucggaucgag    180aagguaacac agugguacaa uacgucaguu guggaguacg ugccgcacug gaacgagggc    240gcuuauauua acaacaccga gccaaucugc gacgugaagg gcuuugcgcc uuuuagcaaa    300gacaacggaa uccgaaucgg aagcagaggg cauaucuuug uuauuaggga accauuugug    360ucuuguaguc ccgucgagug ccgaaccuuc uuccuuacac agggcgcauu gcugaacgau    420aagcauucca acggcaccgu uaagggcagg agcccauuca ggacacugau gucaguggaa    480guuggucaau cgccuaacgu uuaucaggca cgcuuugagg ccguggccug gagugcaacc    540gccugucacg acggcaagaa guggaugaca auugggguga cugguccuga cagcaaggca    600aucgcaguug uucacuacgg cggugucccc acggacaucg ugaauucgug ggccggagac    660auccugcgga cucaggaauc uucguguacc ugcauccagg gcaacuguua cuggguaaug    720acugacgguc cuaguaaccg ucaggcccaa uauagaauau acaaggccaa ccagggcaag    780auuauugacc aagccgacgu auccuucucc ggcggccaua ucgaggagug cucuuguuau    840ccuaacgacg gaaaggucga gugugugugc cgcgacaacu ggaucgggac caaccgcccu    900gugcugguca uaucuccuga ucugucauau cgugugggau aucuuugugc aggauugcca    960uccgauacac cccgagguga ggacgcccag uucguaggga gcuguacuag cccuauggga   1020aaucagggau acggcguuaa ggguuuugga uuccgccaag guaccgacgu cuggaugggc   1080aggaccauaa gcaggaccag cagauccgga uuugaaauca ucaggaucaa gaacgggugg   1140acccagacgu cuaaagagca aauucgucgg caagugguug uagacaaucu aaauuggucu   1200ggcuauagcg gaaguuucac ucuuccaguu gaacucagcg gccgugagug ucuggugccg   1260ugcuuuuggg uggaaaugau cagaggcagg cccgaggagc guacaaucug gacaucuucu   1320uccuccaucg ugaugugugg gguugaucac gagaucgcag acuggagcug gcacgacggu   1380gcgauacugc cauucgacau ugacggaaug                                    1410</s400><s200><s210>124</s210><s211>470</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 124Met Asn Pro Asn Gln Lys Ile Ala Thr Ile Gly Ser Ile Ser Leu Gly1               5                   10                  15Leu Val Val Phe Asn Val Leu Leu His Ala Leu Ser Ile Ile Leu Met            20                  25                  30Val Leu Ala Leu Gly Lys Ser Glu Asn Asn Gly Ile Cys Lys Gly Thr        35                  40                  45Ile Ile Arg Glu Tyr Asn Glu Thr Val Arg Ile Glu Lys Val Thr Gln    50                  55                  60Trp Tyr Asn Thr Ser Val Val Glu Tyr Val Pro His Trp Asn Glu Gly65                  70                  75                  80Ala Tyr Ile Asn Asn Thr Glu Pro Ile Cys Asp Val Lys Gly Phe Ala                85                  90                  95Pro Phe Ser Lys Asp Asn Gly Ile Arg Ile Gly Ser Arg Gly His Ile            100                 105                 110Phe Val Ile Arg Glu Pro Phe Val Ser Cys Ser Pro Val Glu Cys Arg        115                 120                 125Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His Ser Asn    130                 135                 140Gly Thr Val Lys Gly Arg Ser Pro Phe Arg Thr Leu Met Ser Val Glu145                 150                 155                 160Val Gly Gln Ser Pro Asn Val Tyr Gln Ala Arg Phe Glu Ala Val Ala                165                 170                 175Trp Ser Ala Thr Ala Cys His Asp Gly Lys Lys Trp Met Thr Ile Gly            180                 185                 190Val Thr Gly Pro Asp Ser Lys Ala Ile Ala Val Val His Tyr Gly Gly        195                 200                 205Val Pro Thr Asp Ile Val Asn Ser Trp Ala Gly Asp Ile Leu Arg Thr    210                 215                 220Gln Glu Ser Ser Cys Thr Cys Ile Gln Gly Asn Cys Tyr Trp Val Met225                 230                 235                 240Thr Asp Gly Pro Ser Asn Arg Gln Ala Gln Tyr Arg Ile Tyr Lys Ala                245                 250                 255Asn Gln Gly Lys Ile Ile Asp Gln Ala Asp Val Ser Phe Ser Gly Gly            260                 265                 270His Ile Glu Glu Cys Ser Cys Tyr Pro Asn Asp Gly Lys Val Glu Cys        275                 280                 285Val Cys Arg Asp Asn Trp Ile Gly Thr Asn Arg Pro Val Leu Val Ile    290                 295                 300Ser Pro Asp Leu Ser Tyr Arg Val Gly Tyr Leu Cys Ala Gly Leu Pro305                 310                 315                 320Ser Asp Thr Pro Arg Gly Glu Asp Ala Gln Phe Val Gly Ser Cys Thr                325                 330                 335Ser Pro Met Gly Asn Gln Gly Tyr Gly Val Lys Gly Phe Gly Phe Arg            340                 345                 350Gln Gly Thr Asp Val Trp Met Gly Arg Thr Ile Ser Arg Thr Ser Arg        355                 360                 365Ser Gly Phe Glu Ile Ile Arg Ile Lys Asn Gly Trp Thr Gln Thr Ser    370                 375                 380Lys Glu Gln Ile Arg Arg Gln Val Val Val Asp Asn Leu Asn Trp Ser385                 390                 395                 400Gly Tyr Ser Gly Ser Phe Thr Leu Pro Val Glu Leu Ser Gly Arg Glu                405                 410                 415Cys Leu Val Pro Cys Phe Trp Val Glu Met Ile Arg Gly Arg Pro Glu            420                 425                 430Glu Arg Thr Ile Trp Thr Ser Ser Ser Ser Ile Val Met Cys Gly Val        435                 440                 445Asp His Glu Ile Ala Asp Trp Ser Trp His Asp Gly Ala Ile Leu Pro    450                 455                 460Phe Asp Ile Asp Gly Met465                 470</s400><s200><s210>125</s210><s211>1586</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 125gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aacccuaauc agaagauugc gaccauuggc agcauuucuc uuggccucgu gguguucaac    120gucuugcugc acgcccuauc caucauccuc augguccugg cccuugguaa gagcgagaac    180aacgguauuu guaagggaac aaucaucaga gaguacaacg agaccguucg gaucgagaag    240guaacacagu gguacaauac gucaguugug gaguacgugc cgcacuggaa cgagggcgcu    300uauauuaaca acaccgagcc aaucugcgac gugaagggcu uugcgccuuu uagcaaagac    360aacggaaucc gaaucggaag cagagggcau aucuuuguua uuagggaacc auuugugucu    420uguagucccg ucgagugccg aaccuucuuc cuuacacagg gcgcauugcu gaacgauaag    480cauuccaacg gcaccguuaa ggacaggagc ccauucagga cacugauguc aguggaaguu    540ggucaaucgc cuaacguuua ucaggcacgc uuugaggccg uggccuggag ugcaaccgcc    600ugucacgacg gcaagaagug gaugacaauu ggggugacug guccugacag caaggcaauc    660gcaguuguuc acuacggcgg uguccccacg gacaucguga auucgugggc cggagacauc    720cugcggacuc aggacucuuc guguaccugc auccagggca acuguuacug gguaaugacu    780gacgguccua guaaccguca ggcccaauau agaauauaca aggccaacca gggcaagauu    840auugaccaag ccgacguauc cuucuccggc ggccauaucg aggagugcuc uuguuauccu    900aacgacggaa aggucgagug ugugugccgc gacaacugga ucgggaccaa ccgcccugug    960cuggucauau cuccugaucu gucauaucgu gugggauauc uuugugcagg auugccaucc   1020gauacacccc gaggugagga cgcccaguuc guagggagcu guacuagccc uaugggaaau   1080cagggauacg gcguuaaggg uuuuggauuc cgccaaggua ccgacgucug gaugggcagg   1140accauaagca ggaccagcag auccggauuu gaaaucauca ggaucaagaa cggguggacc   1200cagacgucua aagagcaaau ucgucggcaa gugguuguag acaaucuaaa uuggucuggc   1260uauagcggaa guuucacucu uccaguugaa cucagcggcc gugagugucu ggugccgugc   1320uuuugggugg aaaugaucag aggcaggccc gaggagcgua caaucuggac aucuucuucc   1380uccaucguga uguguggggu ugaucacgag aucgcagacu ggagcuggca cgacggugcg   1440auacugccau ucgacauuga cggaauguga uaauaggcug gagccucggu ggccuagcuu   1500cuugccccuu gggccucccc ccagccccuc cuccccuucc ugcacccgua cccccguggu   1560cuuugaauaa agucugagug ggcggc                                        1586</s400><s200><s210>126</s210><s211>1410</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 126augaacccua aucagaagau ugcgaccauu ggcagcauuu cucuuggccu cgugguguuc     60aacgucuugc ugcacgcccu auccaucauc cucauggucc uggcccuugg uaagagcgag    120aacaacggua uuuguaaggg aacaaucauc agagaguaca acgagaccgu ucggaucgag    180aagguaacac agugguacaa uacgucaguu guggaguacg ugccgcacug gaacgagggc    240gcuuauauua acaacaccga gccaaucugc gacgugaagg gcuuugcgcc uuuuagcaaa    300gacaacggaa uccgaaucgg aagcagaggg cauaucuuug uuauuaggga accauuugug    360ucuuguaguc ccgucgagug ccgaaccuuc uuccuuacac agggcgcauu gcugaacgau    420aagcauucca acggcaccgu uaaggacagg agcccauuca ggacacugau gucaguggaa    480guuggucaau cgccuaacgu uuaucaggca cgcuuugagg ccguggccug gagugcaacc    540gccugucacg acggcaagaa guggaugaca auugggguga cugguccuga cagcaaggca    600aucgcaguug uucacuacgg cggugucccc acggacaucg ugaauucgug ggccggagac    660auccugcgga cucaggacuc uucguguacc ugcauccagg gcaacuguua cuggguaaug    720acugacgguc cuaguaaccg ucaggcccaa uauagaauau acaaggccaa ccagggcaag    780auuauugacc aagccgacgu auccuucucc ggcggccaua ucgaggagug cucuuguuau    840ccuaacgacg gaaaggucga gugugugugc cgcgacaacu ggaucgggac caaccgcccu    900gugcugguca uaucuccuga ucugucauau cgugugggau aucuuugugc aggauugcca    960uccgauacac cccgagguga ggacgcccag uucguaggga gcuguacuag cccuauggga   1020aaucagggau acggcguuaa ggguuuugga uuccgccaag guaccgacgu cuggaugggc   1080aggaccauaa gcaggaccag cagauccgga uuugaaauca ucaggaucaa gaacgggugg   1140acccagacgu cuaaagagca aauucgucgg caagugguug uagacaaucu aaauuggucu   1200ggcuauagcg gaaguuucac ucuuccaguu gaacucagcg gccgugagug ucuggugccg   1260ugcuuuuggg uggaaaugau cagaggcagg cccgaggagc guacaaucug gacaucuucu   1320uccuccaucg ugaugugugg gguugaucac gagaucgcag acuggagcug gcacgacggu   1380gcgauacugc cauucgacau ugacggaaug                                    1410</s400><s200><s210>127</s210><s211>470</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 127Met Asn Pro Asn Gln Lys Ile Ala Thr Ile Gly Ser Ile Ser Leu Gly1               5                   10                  15Leu Val Val Phe Asn Val Leu Leu His Ala Leu Ser Ile Ile Leu Met            20                  25                  30Val Leu Ala Leu Gly Lys Ser Glu Asn Asn Gly Ile Cys Lys Gly Thr        35                  40                  45Ile Ile Arg Glu Tyr Asn Glu Thr Val Arg Ile Glu Lys Val Thr Gln    50                  55                  60Trp Tyr Asn Thr Ser Val Val Glu Tyr Val Pro His Trp Asn Glu Gly65                  70                  75                  80Ala Tyr Ile Asn Asn Thr Glu Pro Ile Cys Asp Val Lys Gly Phe Ala                85                  90                  95Pro Phe Ser Lys Asp Asn Gly Ile Arg Ile Gly Ser Arg Gly His Ile            100                 105                 110Phe Val Ile Arg Glu Pro Phe Val Ser Cys Ser Pro Val Glu Cys Arg        115                 120                 125Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His Ser Asn    130                 135                 140Gly Thr Val Lys Asp Arg Ser Pro Phe Arg Thr Leu Met Ser Val Glu145                 150                 155                 160Val Gly Gln Ser Pro Asn Val Tyr Gln Ala Arg Phe Glu Ala Val Ala                165                 170                 175Trp Ser Ala Thr Ala Cys His Asp Gly Lys Lys Trp Met Thr Ile Gly            180                 185                 190Val Thr Gly Pro Asp Ser Lys Ala Ile Ala Val Val His Tyr Gly Gly        195                 200                 205Val Pro Thr Asp Ile Val Asn Ser Trp Ala Gly Asp Ile Leu Arg Thr    210                 215                 220Gln Asp Ser Ser Cys Thr Cys Ile Gln Gly Asn Cys Tyr Trp Val Met225                 230                 235                 240Thr Asp Gly Pro Ser Asn Arg Gln Ala Gln Tyr Arg Ile Tyr Lys Ala                245                 250                 255Asn Gln Gly Lys Ile Ile Asp Gln Ala Asp Val Ser Phe Ser Gly Gly            260                 265                 270His Ile Glu Glu Cys Ser Cys Tyr Pro Asn Asp Gly Lys Val Glu Cys        275                 280                 285Val Cys Arg Asp Asn Trp Ile Gly Thr Asn Arg Pro Val Leu Val Ile    290                 295                 300Ser Pro Asp Leu Ser Tyr Arg Val Gly Tyr Leu Cys Ala Gly Leu Pro305                 310                 315                 320Ser Asp Thr Pro Arg Gly Glu Asp Ala Gln Phe Val Gly Ser Cys Thr                325                 330                 335Ser Pro Met Gly Asn Gln Gly Tyr Gly Val Lys Gly Phe Gly Phe Arg            340                 345                 350Gln Gly Thr Asp Val Trp Met Gly Arg Thr Ile Ser Arg Thr Ser Arg        355                 360                 365Ser Gly Phe Glu Ile Ile Arg Ile Lys Asn Gly Trp Thr Gln Thr Ser    370                 375                 380Lys Glu Gln Ile Arg Arg Gln Val Val Val Asp Asn Leu Asn Trp Ser385                 390                 395                 400Gly Tyr Ser Gly Ser Phe Thr Leu Pro Val Glu Leu Ser Gly Arg Glu                405                 410                 415Cys Leu Val Pro Cys Phe Trp Val Glu Met Ile Arg Gly Arg Pro Glu            420                 425                 430Glu Arg Thr Ile Trp Thr Ser Ser Ser Ser Ile Val Met Cys Gly Val        435                 440                 445Asp His Glu Ile Ala Asp Trp Ser Trp His Asp Gly Ala Ile Leu Pro    450                 455                 460Phe Asp Ile Asp Gly Met465                 470</s400><s200><s210>128</s210><s211>9</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 128ccrccaugg                                                              9</s400><s200><s210>129</s210><s211>1867</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 129gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aagaccauca ucgcccugag cuacauccug ugccuggugu ucgcccagaa gauccccggc    120aacgauaaca gcaccgccac ccugugucug ggacaccacg ccgugcccaa cggcaccauc    180gugaagacua ucaccaacga ccggaucgag gugaccaacg ccaccgagcu ggugcagaac    240agcagcaucg gcgagaucug cgacagcccu caccagaucc uggacggcgg caacugcacc    300cugaucgacg cacugcuggg cgacccucag ugcgacggcu uucagaacaa ggagugggac    360cuguucgugg agagaucgcg ggccaacagc aacugcuacc ccuacgacgu ccccgacuac    420gcaagccuga gaagccucgu ggccucaagc ggcacccugg aguucaagaa cgagagcuuc    480aacuggaccg gcgugaagca gaacggcacc ucaagcgccu gcauccgggg cuccagcagc    540agcuucuucu cacggcugaa cuggcugacc caccugaacu acaccuaccc cgcccugaac    600gugaccaugc ccaacaacga gcaguucgac aagcuguaca ucuggggagu gcaccauccc    660agcaccgaca aggaccagau uagccuguuc gcccagccca gcggccggau caccgugagc    720accaagcgga gccagcaggc cgugaucccc aacaucggcu cucggcccag aauccgggac    780auccccagcc ggaucagcau cuacuggacc auugugaagc ccggcgacau ccugcugauc    840aacuccaccg gcaaccugau cgccccucgg ggcuauuuca agauccggag cggcaagagc    900agcaucaugc ggagcgacgc cccuaucggc aagugcaaga gcgagugcau cacacccaac    960ggaagcaucc ccaacgacaa gcccuuccag aacgugaacc ggauaaccua cggcgccugc   1020ccuagauacg ugaagcagag cacccugaag cuggccaccg gcaugcggaa cgugcccgag   1080aagcagacuc ggggcaucuu cggcgccauc gccggcuuca ucgagaacgg cugggagggc   1140augguggacg gcugguacgg cuuccggcac cagaacucug agggcagagg acaggccgca   1200gaccugaaga gcacccaggc cgccaucgac cagaucaacg gcaagcugaa ccggcugauc   1260ggcaagacca acgagaaguu ccaccagauc gagaaggagu ucagcgaggu ggagggcagg   1320guacaggacc uggagaagua cguggaggac accaagaucg accuguggag cuacaacgcc   1380gagcugcugg uagcccugga gaaccagcac accaucgacc ugaccgacag cgagaugaac   1440aagcuguucg agaagaccaa gaagcagcug cgggagaacg ccgaggacau gggcaacggc   1500ugcuucaaga ucuaccacaa gugcgacaac gccugcaucg gcagcauccg gaacgagacc   1560uacgaccaca acguguaccg ggacgaggcc cugaacaacc gguuccagau caagggcgug   1620gagcugaaga gcggcuacaa ggacuggauc cuguggauca gcuucgccau guccugcuuc   1680cugcugugca ucgcccugcu ggguuucauc augugggccu gccagaaggg caacauccgg   1740ugcaacaucu gcaucugaua auaggcugga gccucggugg cacgagaacg gcaccaucac   1800cccucccccc agccccuccu ccccuuccug caggaagugg ucuuugaaua aagucugagu   1860gggcggc                                                             1867</s400><s200><s210>130</s210><s211>112</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 130ugauaauagg cuggagccuc gguggcacga gaacggcacc aucaccccuc cccccagccc     60cuccuccccu uccugcagga aguggucuuu gaauaaaguc ugagugggcg gc            112</s400><s200><s210>131</s210><s211>1915</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 131gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaggccauca ucgugcuguu aaugguggug accagcaacg ccgaccggau cugcaccggc    120aucaccucua gcaacagccc ucacguggug aagaccgcca cacagggcga ggugaacgug    180accggcguga uuccccugac caccaccccu accaagagcc acuucgccaa ccugaaggga    240accgagaccc ggggcaagcu gugucccaag ugccugaacu gcaccgaccu ggacguggcc    300cugggcagac ccaagugcac cggcaagauc cccagcgccc gggugucuau ccugcacgaa    360gugcggcccg ugacuagcgg cugcuucccc aucaugcacg accggaccaa gauccggcag    420cugcccaacc ugcugcgggg cuacgagcac gugcggcuga gcacccacaa cgugaucaac    480gccgaagacg cacccgggag accauacgag aucggcacca gcggcucuug ccccaacauc    540accaacggca acggcuucuu cgcuaccaug gccugggccg ugccaaagaa caagacugcc    600accaacccuc ugaccaucga ggugcccuac aucugcaccg agggcgagga ccagaucacc    660guguggggcu uccacagcga cagcgagacc cagauggcca agcuguacgg cgacagcaag    720ccccagaagu ucaccagcag cgccaacggc gugaccaccc acuacgugag ccagaucggc    780ggcuucccca accagaccga ggacggcggc uuaccccaga gcggccggau cgugguggac    840uacauggugc agaagagcgg caagaccggc accaucaccu accagcgggg cauccugcug    900ccacagaagg uguggugcgc cucagggcgg ucaaagguga ucaagggcag ccugccacug    960auuggcgagg ccgacugccu gcacgagaag uacggcggcc ugaacaagag caagcccuac   1020uacaccggcg agcacgccaa ggcaaucggc aacugcccca ucugggugaa gacaccccug   1080aagcuggcca acggcaccaa guaccggcca cccgccaaac ugcugaagga gcggggcuuc   1140uucggcgcca uugccggcuu ccucgaaggc gguugggagg gcaugaucgc cggcuggcac   1200ggcuacacua gccacggcgc acacggagua gcaguggccg ccgaccugaa gagcacccag   1260gaggccauca acaagaucac caagaaccug aacagccuga gcgagcugga ggugaagaau   1320cugcagcggc ugucuggcgc uauggacgag cugcacaacg agauccugga gcuggacgag   1380aagguggacg acuuacgggc cgacaccauc agcagccaga ucgagcuggc cgugcugcug   1440agcaacgagg gcaucaucaa cagcgaggac gagcaccugc uggcccugga gggaagcuga   1500agaagaugcu gggcccuucu gccguggaga ucgguaacgg cugcuucgag accaagcaca   1560agugcaacca gaccugccug gaucggaucg cagccggcac cuuugacgcc ggggaguuca   1620gccugcccac cuucgacagc cugaacauca ccgccgccag ccugaacgac gacggccugg   1680acaaccacac cauccugcug uacuacucua cagccgcuag cagccuggcc gugacccuga   1740ugaucgccau cuucguggug uacaugguga gccgggacaa cgugagcugc agcaucugcc   1800ugugauaaua ggcuggagcc ucgguggcaa ccuacgccga agaccacgcc uccccccagc   1860cccuccuccc cuuccugcag guuagugguc uuugaauaaa gucugagugg gcggc        1915</s400><s200><s210>132</s210><s211>113</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 132ugauaauagg cuggagccuc gguggcaacc uacgccgaag accacgccuc cccccagccc     60cuccuccccu uccugcaggu uaguggucuu ugaauaaagu cugagugggc ggc           113</s400><s200><s210>133</s210><s211>1923</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 133gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaggccauca ucgugcuacu gaugguggug accagcaacg ccgaccggau cugcaccggc    120aucaccagca gcaacagccc gcacguggug aagaccgcca cccaaggcga ggugaacgug    180accggcguga ucccacugac caccacuccc accaagagcu acuucgccaa ccugaagggc    240acacggacuc ggggcaagcu gugccccgac ugccugaacu gcaccgaccu ggacguggcc    300cugggcagac ccaugugcgu gggcaccacc ccuucugcca aggccagcau ccugcacgag    360gugagacccg ugaccagcgg gugcuucccc aucaugcacg accggaccaa gauccggcag    420cugcccaacc ugcugcgggg cuacgagaag auccggcuga gcacccagaa cgugaucgac    480gccgagaagg ccccuggagg ucccuaccgg cugggcacca gcggaagcug ccccaacgcc    540accagcaaga ucggcuucuu cgccaccaug gccugggcug ugcccaagga caacuacaag    600aacgccacca auccccugac cguggaggug cccuacaucu gcaccgaggg cgaggaccag    660aucaccgugu ggggcuucca cagcgacaac aagacccaga ugaagagccu guacggcgac    720agcaaucccc agaaguucac aagcagcgcc aacggcguga ccacccacua cgugagccag    780aucggcgacu uccccgacca gaccgaggac ggagggcugc cucagagugg ccggaucgug    840guggacuaca ugaugcagaa gcccggcaag accggcacca ucguguacca gcggggcgug    900cuguugccuc agaaaguuug gugugccagc ggcaggagca aggugaucaa gggcagccug    960ccccugaucg gcgaggcaga cugccuccac gaggaguacg gcggccugaa caagagcaag   1020cccuacuaca ccggcaagca cgccaaggcc aucggcaacu gccccaucug ggugaagacc   1080ccucugaagc uggccaacgg caccaaguac cggccaccag ccaagcugcu gaaggagcgg   1140ggcuucuuug gcgccauugc cggcuuccuc gagggaggcu gggagggcau gaucgccggc   1200uggcacggcu acacaagcca cggcgcacac ggaguggcug uggcugccga ccugaagagc   1260acccaggagg ccaucaacaa gaucaccaag aaccugaaca gccugagcga gcuggaggug   1320aagaaccugc agcggcuguc aggcgccaug gacgagcugc acaacgagau ccuggagcug   1380gacgagaagg uggacgaccu gcgugccgac accaucagca gccagaucga gcuggccgug   1440cugcugagca acgagggcau caucaacagc gaggacgagc accugcuggc ccuggagcgg   1500aaacugaaga agaugcuggg acccucugcc guggacaucg gcaacggcug cuucgagacc   1560aagcacaagu gcaaccagac cugccuggau cggaucgccg ccggaaccuu caacgccggc   1620gaguucagcc ugcccaccuu cgacagccug aacaucaccg ccgccagccu gaacgacgac   1680ggccuggaca accacaccau ccugcuguac uacagcacug ccgccucaag ccuggccgug   1740acccugaugc uggccaucuu caucguguac auggugagcc gggacaacgu gagcugcagc   1800aucugccugu gauaauaggc uggagccucg guggcaacga cccugccgca gcaaaccucc   1860ccccagcccc uccuccccuu ccugcaggac caguggucuu ugaauaaagu cugagugggc   1920ggc                                                                 1923</s400><s200><s210>134</s210><s211>114</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 134ugauaauagg cuggagccuc gguggcaacg acccugccgc agcaaaccuc cccccagccc     60cuccuccccu uccugcagga ccaguggucu uugaauaaag ucugaguggg cggc          114</s400><s200><s210>135</s210><s211>1870</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 135gggaaauaag agagaaaaga agaguaagaa gaaauauaag accccggcgc cgccaccaug     60aaggccaucc uggucgugau gcuguacacc uucaccaccg ccaacgccga cacccugugc    120aucggcuacc acgccaacaa cagcaccgac accguggaca ccgugcugga gaagaacgug    180accgugaccc acagcgugaa ccugcuggag gacaagcaca acggcaagcu gugcaagcug    240aggggagugg caccccugca ccugggcaag ugcaacaucg ccggcuggau ccugggcaac    300cccgagugcg agagccugag cacagcccgg agcuggagcu acaucgugga gaccagcaac    360agcgacaacg gcaccuguua ccccggcgac uucaucaacu acgaggagcu gcgggagcag    420cugagcagcg ugagcagcuu cgagcgguuc gagaucuucc ccaagaccag cagcuggccc    480aaccacgaca gcgacaacgg cgugacagca gccuguccac acgccggagc caagagcuuc    540uacaagaacc ugaucuggcu ggugaagaag ggcaagagcu accccaagau caaccagacc    600uacaucaacg acaagggcaa ggaggugcug gugcuguggg gcauccacca cccaccuacc    660aucgccgacc agcagagccu guaccagaac gccgacgccu acguguucgu gggcaccagc    720cgguacagca agaaguucaa gccagagauc gccacccggc ccaaggugag agaccaggag    780ggccggauga acuacuacug gacccuggug gagcccggag acaagauuac cuucgaggcc    840accggcaacc ugguggcccc ucgguacgcc uucaccaugg aacgggacgc uggcagcggc    900aucaucauca gcgacacucc cgugcacgac ugcaacacca ccugccagac ucccgagggc    960gcuaucaaca ccagccugcc cuuccagaac gugcacccca ucaccaucgg caagugcccc   1020aaguacguaa agagcaccaa auugcggcug gccaccggac ucaggaacgu gcccagcauc   1080caaagccggg gccuguuugg cgcaaucgcc ggcuucaucg agggcggcug gacuggcaug   1140guggacggcu gguacggcua ccaccaccag aacgaacagg ggagcggcua cgcagcugac   1200cugaagagca cccagaacgc caucgacaag aucaccaaca aggugaacag cgugaucgag   1260aagaugaaca cccaguucac cgccgugggc aaggaguuca accaccugga gaagcggauc   1320gagaaccuga acaagaaggu ggacgacggc uuccuggaca ucuggaccua caacgccgag   1380cugcugguuc ugcuggagaa cgagcggacc cuggacuauc acgacagcaa cgugaagaac   1440cuguacgaga aggugcggaa ccagcugaag aacaacgcca aggagaucgg caacggcugc   1500uucgaguucu accacaagug cgacaacacc ugcauggaga gcgugaagaa cggcaccuac   1560gacuacccca aguacagcga ggaggccaag cugaaccggg agaagaucga cggcgugaag   1620cuggacagca cccggaucua ccagauccug gccaucuaca gcaccguggc cagcagccug   1680gugcuggugg ugagccuggg cgccaucagc uucuggaugu gcagcaacgg cagccugcag   1740ugccggaucu gcaucugaua auaggcugga gccucggugg ccaccgaagc agccaucagc   1800accucccccc agccccuccu ccccuuccug caggccaaag uggucuuuga auaaagucug   1860agugggcggc                                                          1870</s400><s200><s210>136</s210><s211>115</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 136ugauaauagg cuggagccuc gguggccacc gaagcagcca ucagcaccuc cccccagccc     60cuccuccccu uccugcaggc caaagugguc uuugaauaaa gucugagugg gcggc         115</s400><s200><s210>137</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 137Ile Tyr Ser Thr Val Ala Ser Ser Leu1               5</s400><s200><s210>138</s210><s211>11</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 138gggauccuac c                                                          11</s400><s200><s210>139</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 139Arg Ile Ile Val1</s400><s200><s210>140</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 140Gly Arg Phe Tyr Gln1               5</s400><s200><s210>141</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 141Thr Tyr Asp Pro1</s400><s200><s210>142</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 142Glu Gly Leu Val1</s400><s200><s210>143</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 143Gly Phe Arg Tyr Gln1               5</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000971A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000971</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17775475</doc-number><date>20201118</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><priority-claims><priority-claim sequence="01" kind="regional"><country>EP</country><doc-number>19209839.0</doc-number><date>20191118</date></priority-claim></priority-claims><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>145</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>7</main-group><subgroup>02</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>145</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>7</main-group><subgroup>025</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2760</main-group><subgroup>16121</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2760</main-group><subgroup>16134</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2760</main-group><subgroup>16152</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e61">METHOD FOR PRODUCING REASSORTANT INFLUENZA VIRUSES</invention-title><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Seqirus Pty Ltd.</orgname><address><city>Victoria</city><country>AU</country></address></addressbook><residence><country>AU</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>ROCKMAN</last-name><first-name>Steven</first-name><address><city>Victoria</city><country>AU</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>ONG</last-name><first-name>Chi</first-name><address><city>Victoria</city><country>AU</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>VERITY</last-name><first-name>Erin</first-name><address><city>Victoria</city><country>AU</country></address></addressbook></inventor></inventors></us-parties><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/EP2020/082587</doc-number><date>20201118</date></document-id><us-371c12-date><date>20220509</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">A method for producing reassortant influenza viruses is provided. Also provided are reassortant influenza viruses produced according to the method, as well as vaccines based on said reassortant influenza viruses.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="76.12mm" wi="158.75mm" file="US20230000971A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="185.84mm" wi="167.56mm" file="US20230000971A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="181.02mm" wi="167.47mm" file="US20230000971A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="164.51mm" wi="95.50mm" orientation="landscape" file="US20230000971A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">TECHNICAL FIELD</heading><p id="p-0002" num="0001">The present invention is in the field of reassortant influenza viruses. It is concerned with methods of preparing reassortant influenza viruses, in particular reassortant viruses that can be used as seed viruses in the context of manufacturing influenza vaccines. Reassortant influenza viruses and vaccines produced by the methods of the invention are also aspects of the invention.</p><heading id="h-0002" level="1">BACKGROUND ART</heading><p id="p-0003" num="0002">Reassortant influenza viruses have a genome that contains segments which are derived from two or more parent influenza strains. Such reassortant viruses are useful for manufacturing influenza vaccines because the properties of a high growth influenza strain can be harnessed to increase production of the hemagglutinin (HA) and/or neuraminidase (NA) antigens of a circulating strain, with the HA and/or NA antigens of the circulating strain being typical components of influenza vaccines. In vaccine manufacture, a reassortant virus (which may be referred to as a seed virus) typically contains the HA and NA segments of a circulating strain, and the backbone segments (i.e. PB1, PB2, PA, M, NS and NP) of a high growth influenza strain. This seed virus can be used to grow virus containing HA and NA more rapidly than simply propagating the circulating strain, which may have poor growth characteristics in the culture host platforms (e.g. eggs or cells) that are used in the influenza vaccine manufacturing process. For example, it has recently been shown that reassortant influenza A virus containing the HA and NA of the circulating strain and six backbone genes from the high growth parent A/Puerto Rico/8/34 (PR8) is a preferred seed virus for vaccine manufacture due to the high yield of circulating strain HA in the context of the PR8 backbone [1]. Two methods have been used to generate reassortant influenza viruses; classical reassortment and reverse genetics.</p><p id="p-0004" num="0003">In classical reassortment, a culture host (typically an avian egg) is inoculated with both parent strains (i.e. the circulating strain and the high growth strain). Reassortant viruses that comprise the HA and/or NA of the circulating strain are then selected by growing the culture host in the presence of antibodies against the HA and/or NA of the high growth strain. Reassortant viruses containing the desired HA and NA surface genes can be isolated and used as seed viruses for vaccine manufacture.</p><p id="p-0005" num="0004">However, one drawback associated with classical reassortment is that it does not allow for the controlled manipulation of gene sequences, which can be a problem when seeking to generate candidate seed viruses from highly pathogenic influenza viruses. For example, the HA of some H5 or H7 influenza strains contains a pathogenic determinant in the form of a polybasic cleavage site which cannot be deleted using the classical reassortment method. Classical reassortment can also produce of a mixture of reassortant viruses having 7:1, 6:2, 5:3 or 4:4 gene constellation ratios from each of the parent strains because the culture host is inoculated with two influenza strains, meaning that sixteen genes are present (i.e. eight from each parent strain). As a result, it can be time consuming to isolate the desired reassortant influenza virus for use as a seed virus in vaccine manufacture. For instance, it currently takes approximately 35 days from the arrival of a new influenza strain to obtain the final high-growth reassortant that is to be used as a seed virus in vaccine manufacture.</p><p id="p-0006" num="0005">In reverse genetics, the genetic information required to produce the desired influenza virus is delivered to a cell, which is then able to generate influenza virus. Reverse genetics initially required the in vitro assembly and transfection of viral ribonucleoprotein (RNP) into cells infected with a helper virus [2,3]. Subsequent techniques involved the transfection of RNA polymerase I plasmids encoding all of the viral RNAs (vRNAs) together with protein expression constructs for the polymerase and NP genes [4]. More recently, reverse genetics methods involve the use of modified RNA polymerase I systems that allow the expression of both negative sense vRNA and positive mRNA from the same template [5]. In this method, each of the desired genes is cloned into the pHW2000 plasmid, which consists of the viral cDNA inserted between the RNA polymerase I promoter and termination sequences, and flanked by the CMV promoter and polyadenylation signal. After transfection of the eight plasmids into cells, synthesis of both vRNA and mRNA occurs, resulting in the production of virus. Further refinement has led to the development of systems in which linear DNA expression constructs are used instead of plasmids [6], and the use of a single expression construct [7].</p><p id="p-0007" num="0006">In contrast to classical reassortment, reverse genetics allows manipulation of the gene sequences used to produce the virus. Thus, reverse genetics can be used to generate seed viruses for the production of live attenuated influenza vaccines because the viral gene sequences can be manipulated prior to transfection of the expression construct in the cell to produce a virus with an attenuated phenotype. Synthetic DNA sequences may also be used to produce seed viruses in reverse genetics, thereby negating the requirement to handle wild-type pandemic viruses [8]. Reverse genetics also allows for seed viruses to be produced in 4-7 days, which is substantially quicker than is provided by classical reassortment.</p><p id="p-0008" num="0007">However, there are a number of drawbacks associated with reverse genetics. For instance, in reverse genetics the sequence of each influenza gene is pre-determined when the expression construct is prepared, meaning that the technique produces a more homogenous population of reassortant viruses compared to classical reassortment. This can be a problem if a circulating HA and NA are less compatible with the backbone genes that are used as standards in reverse genetics and so do not grow effectively. In this situation the HA and NA may grow more effectively with a different constellation of backbone genes, but it is time-consuming to identify and test for more appropriate backbone genes for use in reverse genetics. This can result in several passages of a reverse genetics derived reassortant influenza virus to enable the development of viruses having sequence variation in the backbone segments and selection of a seed virus with suitable growth characteristics. Another problem with some reverse genetics systems is that it can be difficult to introduce the required expression constructs into a culture host (due to low transfection efficiency, for example) which can make the reverse genetics system inefficient.</p><p id="p-0009" num="0008">Methods of producing reassortant influenza viruses that combine elements of classical reassortment and reverse genetics have been discussed previously. For instance, a method in which a host cell is infected with a first influenza strain and transfected with one or more expression construct(s) encoding at least one segment from a second influenza strain are discussed in reference 11. This method is described only in the context of using an agent that inhibits translation and/or transcription of an influenza virus segment, such as siRNA, to produce a reassortant virus in which the segment targeted by the siRNA is absent.</p><p id="p-0010" num="0009">It is therefore an object of the invention to provide improved methods of generating reassortant influenza viruses, which overcome the drawbacks associated with both classical reassortment and reverse genetics methods.</p><heading id="h-0003" level="1">SUMMARY OF INVENTION</heading><p id="p-0011" num="0010">In a first aspect, the invention provides a method for generating reassortant influenza viruses comprising the steps of (i) contacting a culture host with a parent influenza virus strain comprising a first hemagglutinin (HA) gene and a first neuraminidase (NA) gene; (ii) introducing into the culture host one or more expression construct(s) comprising one or more influenza genes, wherein said influenza genes comprise a second HA gene or a second NA gene; (iii) culturing the culture host in order to produce reassortant viruses; (iv) selecting for reassortant viruses that comprise the second HA gene or the second NA gene; and optionally (v) isolating a reassortant influenza virus comprising the second HA gene or the second NA gene.</p><p id="p-0012" num="0011">The invention also provides a population of reassortant influenza viruses produced by the methods of the invention.</p><p id="p-0013" num="0012">The invention also provides an isolated reassortant influenza virus produced by the methods of the invention.</p><p id="p-0014" num="0013">The methods of the invention are advantageous because the parent influenza virus strain that provides the first HA gene and the first NA gene, comprises a non-homogenous population of virions (i.e. sequence variants/quasi-species are present). This introduces sequence variability in backbone segments that are delivered to the culture host thereby enabling the methods of the invention to produce a wider diversity of reassortant viruses than reverse genetics techniques where clonal expression construct(s) (e.g. plasmids) are utilised. In contrast to reverse genetics systems, where the initially rescued virus may need to be passaged multiple times to introduce sequence variation and select for a virus with improved properties, the methods of the invention enable sequence variants to be present immediately in a reassorted virus produced by the methods of the invention (owing to the accumulated sequence variations that have accumulated naturally during propagation of a parent influenza strain). The greater diversity of reassortant viruses produced by the method also increases the likelihood of identifying a reassortant virus having one or more particularly desired properties (e.g. high HA yield and/or high growth).</p><p id="p-0015" num="0014">Another advantage of the methods of the invention is that the methods inherently select against any sequences in the viral genome that have poor compatibility with the desired HA and/or NA that would otherwise result in a non-functional reassortant virus. These non-functional viruses will not propagate effectively in the culture host and be out-competed by variants that have the desired high growth characteristics. This contrasts with reverse genetics techniques, in which sequence incompatibility would be identified only after the expression constructs had been produced and delivered to a culture host and there have been problems with the generation of a desired reassortant virus. In a related advantage, the methods of the invention also allow easier and more frequent identification of reassortant viruses containing combinations of mutations that synergize to provide improved growth properties. In fact, multiple mutations may not be identified at all using reverse genetics. For instance, in situations where a single mutation had a negative effect, this variant may be discarded, and thus not tested in the context of further sequence variants, which could rescue the negative effect and elicit further advantages in combination.</p><p id="p-0016" num="0015">The invention is distinguished from classical reassortment because the second HA gene or the second NA gene is introduced into a culture host as part of an expression construct, instead of infection with a second influenza virus strain. Provision of the second HA gene or the second NA gene using an expression construct means that the HA gene or NA gene can be manipulated before it is provided to the culture host in a way that is not possible in classical reassortment. This ability to manipulate the HA sequence is particularly advantageous in the context of pandemic or potentially pandemic strains (such as H5 and H7 strains) because it allows deletion of pathogenic determinants, such as the polybasic cleavage site. Another advantage of delivering an HA gene or NA gene on an expression construct is that this allows for expression of a single HA or NA clone with a pre-determined sequence. This contrasts with methods in which the HA and NA genes are delivered in the context of a replicating virus (such as classical reassortment), where there is a risk that mutations are introduced into an HA or NA gene during replication, that may result in, for example, reduced antigenicity.</p><p id="p-0017" num="0016">The method therefore allows the HA segment or NA segment that is to be present in the reassortant influenza virus to be controlled, as it may be in reverse genetics, but at the same time provides a pool of backbone segments with some intrinsic variability by introducing a population of backbone genes to the culture host through infection with a parent influenza virus strain. This is advantageous because the method allows an optimised seed virus for use in vaccine manufacture to be generated more quickly, particularly in situations where backbone genes that are typically used in reverse genetics (e.g. PR8) provide suboptimal properties when reassorted with the HA and/or NA of a circulating strain. In such situations, the virus that is initially rescued in a reverse genetics experiment requires multiple passages in a culture host in order to improve the growth of the virus. The same multiple passages are not necessarily required in the methods of the invention because a reassortant virus with strong growth properties can be selected from the diverse pool of reassortant viruses that are produced by the method. In other words, diversity of backbone genes in the parent strain, generated in the context of a replicating virus, combined with low-level selection against, and elimination of, non-viable or poorly growing reassortant viruses, allows for more efficient generation of high growth reassortant viruses.</p><p id="p-0018" num="0017">A reassortant influenza virus produced by the methods of the invention may be particularly useful for the manufacture of an influenza vaccine. Accordingly, in a further aspect the invention provides a method of preparing a vaccine, comprising the steps of (a) preparing a reassortant influenza virus by the method of the invention, and (b) preparing a vaccine from the reassortant influenza virus. Also provided is a vaccine produced by the methods of the invention.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0004" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0019" num="0018"><figref idref="DRAWINGS">FIG. <b>1</b></figref> is a graphical representation of the sequence variation present in M1 proteins of H1N1 viruses produced by classical reassortment and viruses produced by reverse genetics, as described in Table 1. A value of 0% cf consensus backbone indicates that there are no sequence variants present at that position relative to the consensus backbone sequence. There are no sequence variants in the M1 protein of the viruses produced by reverse genetics.</p><p id="p-0020" num="0019"><figref idref="DRAWINGS">FIG. <b>2</b></figref> is a graphical representation of the sequence variation present in NP proteins of H1N1 and H3N2 viruses produced by classical reassortment and viruses produced by reverse genetics, as described in Table 2. A 0% cf consensus backbone value indicates that there are no sequence variants present at that position. In the viruses prepared by classical reassortment, the NP proteins show variation throughout the sequence, whereas the NP proteins of viruses obtained by reverse genetics show variation at only four sequence positions.</p><p id="p-0021" num="0020"><figref idref="DRAWINGS">FIG. <b>3</b></figref> is a graphical representation of the sequence variation present in NS1 proteins of H1N1 and H3N2 viruses produced by classical reassortment and viruses produced by reverse genetics, as described in Table 3. A 0% cf consensus backbone value indicates that there are no sequence variants present at that position. In the viruses prepared by classical reassortment, the NS1 proteins show variation throughout the sequence, whereas the NS1 proteins of viruses obtained by reverse genetics show variation at only three sequence positions.</p><p id="p-0022" num="0021"><figref idref="DRAWINGS">FIG. <b>4</b></figref> is a graphical representation of the sequence variation present in PA proteins of H1N1 and H3N2 viruses produced by classical reassortment and viruses produced by reverse genetics, as described in Table 4. A 0% cf consensus backbone value indicates that there are no sequence variants present at that position. In the viruses prepared by classical reassortment, the PA proteins show variation throughout the sequence, whereas the PA proteins of viruses obtained by reverse genetics show variation at only two sequence positions.</p><p id="p-0023" num="0022"><figref idref="DRAWINGS">FIG. <b>5</b></figref> is a graphical representation of the sequence variation present in PB2 segments of H1N1 and H3N2 viruses produced by classical reassortment and viruses produced by reverse genetics, as described in Table 5. A 0% cf consensus backbone value indicates that there are no sequence variants present at that position. In the viruses prepared by classical reassortment, the PB2 proteins show variation throughout the sequence, whereas the PB2 proteins of viruses obtained by reverse genetics show variation at only eight sequence positions.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0005" level="1">DETAILED DESCRIPTION</heading><heading id="h-0006" level="2">Reassortant Influenza Viruses</heading><p id="p-0024" num="0023">Influenza viruses are segmented negative strand RNA viruses. The influenza A and B virus genomes contain eight single-stranded viral RNA (vRNA) segments. The eight genomic segments of influenza A and B viruses are, in order of size, PB2, PB1, PA, HA, NP, NA, M, NS. The PB2, PB1, PA, NP, M and NS encode the internal and non-structural proteins, and may be referred to as the backbone segments. The HA and NA segments encode the surface glycoproteins. The methods of the invention may be used to produce reassortant influenza A viruses. Alternatively, the methods of the invention may be used to produce reassortant influenza B viruses.</p><p id="p-0025" num="0024">For influenza A viruses the eight genome segments encode eleven proteins, as follows: haemagglutinin (HA), neuraminidase (NA), two matrix proteins (M1 and M2), a heterotrimeric RNA-dependent RNA polymerase (made up of one polymerase acidic subunit (PA), and two polymerase basic subunits (PB1 and PB2)), nucleoprotein (NP), and two non-structural proteins (NS1 and NS2; NS2 is also known as nuclear export protein (NEP)). Some influenza A viruses also express a pro-apoptotic peptide, PB1-F2. The PB2, PA, HA, NP and NA segments each encode a single expressed protein. The PB1, M and NS segments encode more than one protein. The PB1 segment encodes the PB1 protein, as well as the PB1-F2 protein (which is encoded in a +1 reading frame on the PB1 segment). The M segment encodes the M1 and M2 proteins. The NS segment encodes the NS1 and NS2/NEP proteins. The M2 and NS2/NEP protein are expressed from spliced mRNAs from the M and NS segments.</p><p id="p-0026" num="0025">For influenza B viruses, the eight genome segments also encode eleven proteins, although there are a few differences from influenza A viruses. As for influenza A viruses, the PB2, PA, HA and NP segments each encode a single expressed protein, and the NS segment encodes the NS1 and NS2/NEP protein. The PB1-F2 protein is not present in influenza B viruses, meaning that the PB1 segment encodes the PB1 protein alone. In addition to the NA protein, the NA segment in influenza B viruses also encodes the NB matrix protein in an alternate &#x2212;1 reading frame. The NB matrix protein corresponds to the M2 protein in influenza A. The M segment encodes the M1 protein, and in an alternate +2 reading frame, the BM2 protein.</p><p id="p-0027" num="0026">A reassortant influenza virus comprises genome segments that are derived from two or more parent influenza virus strains. Reassortant influenza viruses produced by the methods of the invention comprise one or more gene segments from a first parent influenza virus strain (the donor strain), and one or more gene segments from a second parent influenza virus strain (the vaccine strain). Influenza donor strains are strains which typically provide the backbone segment in a reassortant influenza virus, even though they may sometimes also provide the NA segment of the virus. The vaccine strain is the influenza strain that provides the HA or NA segment. Typically, both the HA and the NA segment in a reassortant influenza virus will be from the vaccine strain. In the methods of the invention, the second HA gene or the second NA gene which is introduced into a culture host as part of an expression construct is derived from the vaccine strain. The vaccine strain is typically a circulating strain. The vaccine strain is different from the donor strain.</p><p id="p-0028" num="0027">The genome segments that are present in a reassortant virus can be described using a gene constellation ratio, which indicates the number of segments that are provided by each parent influenza virus strain. For instance, when a reassortant virus contains genome segments from two parent influenza virus strains (such as a donor strain and a vaccine strain), it may have a gene constellation ratio of 1:7, 2:6, 3:5, 4:4, 5:3, 6:2, or 7:1. A reassortant virus may comprise genome segments from three parent influenza virus strains, where present. In these embodiments, the reassortant virus may have a gene constellation ratio of 1:1:6, 1:2:5, 1:3:4, 1:4:3, 1:5:2, 1:6:1, 2:1:5, 2:2:4, 2:3:3, 2:4:2, 2:5:1, 3:1:2, 3:2:1, 4:1:3, 4:2:2, 4:3:1, 5:1:2, 5:2:1, or 6:1:1.</p><p id="p-0029" num="0028">The majority of genome segments of the reassortant viruses produced by the invention are typically from the donor strain because it is desirable to harness the properties of the donor strain through reassortment of the donor strains segments with segments from the vaccine strain. In certain such embodiments, the reassortant influenza virus produced by the methods of the invention has a gene constellation ratio of 5:3, 6:2, or 7:1, wherein the first number of the ratio indicates the number of segments from the donor strain and the second number of the ratio indicates the number of segments from the vaccine strain.</p><p id="p-0030" num="0029">In preferred embodiments, the reassortant influenza virus has a gene constellation ratio of 6:2. In these embodiments the reassortant influenza virus comprises six backbone segments (i.e. PB1, PB2, PA, NP, M, and NS) from the donor strain and two segments (i.e. HA and NA) from the vaccine strain. In particularly preferred embodiments the reassortant influenza virus is a reassortant influenza A virus having a gene constellation ratio of 6:2.</p><p id="p-0031" num="0030">In other embodiments, the reassortant influenza virus has a gene constellation ratio of 7:1. In some of these embodiments, the reassortant influenza virus comprises the six backbone segments from the donor strain, the HA segment from the vaccine strain, and the NA segment from the donor strain. In other words, the reassortant influenza virus comprises the HA segment from the vaccine strain and the remaining seven segments from the donor strain. In other embodiments, the reassortant influenza virus comprises the six backbone segments and the HA segment from the donor strain, and the NA segment from the vaccine strain. In other words, the reassortant influenza virus comprises the NA segment from the vaccine strain and the remaining seven segments from the donor strain. A 7:1 gene constellation ratio is preferred for reassortant influenza B viruses.</p><p id="p-0032" num="0031">In other embodiments, the reassortant influenza virus has a gene constellation ratio of 5:3. In these embodiments, the reassortant virus comprises five backbone segments (i.e. five segments selected from the group consisting of: PB1, PB2, PA, NP, M, and NS) and three segments from the vaccine strain. In these embodiments the three segments from the vaccine strain are HA, NA and one backbone segment (i.e. one segment selected from the group consisting of: PB1, PB2, PA, NP, M and NS). In a preferred embodiment, the three segments from the vaccine strain are HA, NA and PB1 and the remaining five backbone segments (i.e. PB2, PA, NP, M and NS) are from the donor strain.</p><heading id="h-0007" level="2">Influenza Virus Strains</heading><p id="p-0033" num="0032">In the methods of the invention, the parent influenza virus strain that the culture host is contacted with is the donor strain. The donor strain is replication-competent (i.e. it can propagate itself in the culture host following infection). Contacting the culture host with the donor strain causes the genome segments of the donor strain to be delivered to the culture host when the virus infects the culture host.</p><p id="p-0034" num="0033">Any influenza virus strain that possesses a set of desired characteristics may be used as a donor strain. In certain embodiments, the donor strain is a strain which has good growth characteristics in cells and/or eggs. Typically, good growth characteristics are measured according to the yield of HA when the virus is propagated in a culture host. A donor strain that has good growth characteristics may be referred to as a high growth parent strain (HGP strain). Thus, in certain embodiments, the parent influenza virus strain that the culture host is contacted with is a high growth parent strain. Examples of high growth parent strains that may be used in the methods of the invention are A/Puerto Rico/8/1934 (PR8), A/Texas/1/1977, A/New York/55/2004, A/Ann Arbor/6/60, A/Leningrad/134/17/57, B/Ann Arbor/1/66, B/Florida/4/2006, B/Panama/45/1990 and B/Lee/1940. In a preferred embodiment, A/Puerto Rico/8/1934 is the donor strain for influenza A viruses. A strain which grows to similar or higher viral titres compared to a high growth parent strain may be used as the donor strain.</p><p id="p-0035" num="0034">An influenza strain that may be used as the donor strain in the methods of the invention typically provides the culture host with a population of backbone segments that is not homogenous. This is because the donor strain comprises a population of virions that are not homogenous (i.e. sequence variants are present). These variant backbone segments may arise from spontaneous mutation in the influenza virus genome. The mutation rate may be expressed as substitutions per nucleotide per cell infection (s/n/c) and may range from 10<sup>&#x2212;5 </sup>to 10<sup>&#x2212;7 </sup>for influenza viruses. This means approximately 1 in 1000 influenza virions in a population of virions comprise a mutation in a genome segment. Thus, the donor strain that may be used in the methods of the invention comprises a population of closely-related quasi-species influenza viruses. The term &#x201c;quasi-species&#x201d; is used to denote influenza viruses that are derived from a single source but contain sequence variants. This differs from sequence variations between influenza viruses derived from different sources (which are considered separate species). The methods of the invention therefore involve contacting a culture host with a donor strain comprising a population of quasi-species of influenza viruses (i.e. influenza viruses having sequence variations that are derived from a single source). In this way, a population of variant backbone segments is delivered to the culture host.</p><p id="p-0036" num="0035">The variation within a population of backbone segments (e.g. NP segments) may be expressed as a percentage according to the number of sequence positions that differ between the two most divergent sequences within the population of backbone segments when the sequences of backbone segments are aligned. A sequence difference may be a substitution, deletion or insertion. To identify the two most divergent sequences within a population, a multiple sequence alignment may be performed. Suitable tools for aligning multiple protein sequences are available (for example, the Clustal Omega tool using its default parameters, as mentioned in Maderia et al. <i>Nucleic Acids Research </i>2019 (47) doi: 10. 1093/nar/gkz268). For instance, as discussed in Example 5, the NP protein has a sequence of 498 amino acids and 44 mutations were identified in the NP protein amino acid sequences of H1N1 viruses produced by classical reassortment. This corresponds to about 9% variation across the NP protein when comparing the two most divergent NP protein sequences within the H1N1 reassortant group. A percentage sequence variation across the backbone protein may be calculated using the formula:</p><p id="p-0037" num="0000"><maths id="MATH-US-00001" num="00001"><math overflow="scroll"> <mrow>  <mfrac>   <mrow>    <mi>Number</mi>    <mo>&#x2062;</mo>    <mtext>   </mtext>    <mi>of</mi>    <mo>&#x2062;</mo>    <mtext>   </mtext>    <mi>variant</mi>    <mo>&#x2062;</mo>    <mtext>   </mtext>    <mi>positions</mi>   </mrow>   <mrow>    <mi>Total</mi>    <mo>&#x2062;</mo>    <mtext>   </mtext>    <mi>number</mi>    <mo>&#x2062;</mo>    <mtext>   </mtext>    <mi>of</mi>    <mo>&#x2062;</mo>    <mtext>   </mtext>    <mi>amino</mi>    <mo>&#x2062;</mo>    <mtext>   </mtext>    <mi>acids</mi>    <mo>&#x2062;</mo>    <mtext>   </mtext>    <mi>in</mi>    <mo>&#x2062;</mo>    <mtext>   </mtext>    <mi>protein</mi>   </mrow>  </mfrac>  <mo>&#xd7;</mo>  <mn>100</mn> </mrow></math></maths></p><p id="p-0038" num="0036">In some embodiments, the donor strain comprises a population of quasi-species of influenza viruses comprising at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15% or at least 20% amino acid sequence variation in one or more of the backbone segments. The donor strain population of quasi-species may comprise no more than 30% amino acid sequence variation in any backbone segment.</p><p id="p-0039" num="0037">In some embodiments, the donor strain comprises a population of quasi-species of influenza viruses comprising at least 5% amino acid sequence variation in the M1 protein.</p><p id="p-0040" num="0038">In some embodiments, the donor strain comprises a population of quasi-species of influenza viruses comprising at least 5% amino acid sequence variation in the NP protein. In some embodiments, the donor strain comprises a population of quasi-species of influenza viruses comprising at least 8% amino acid sequence variation in the NP protein.</p><p id="p-0041" num="0039">In some embodiments, the donor strain comprises a population of quasi-species of influenza viruses comprising at least 5% amino acid sequence variation in the NS1 protein. In some embodiments, the donor strain comprises a population of quasi-species of influenza viruses comprising at least 15% amino acid sequence variation in the NS1 protein.</p><p id="p-0042" num="0040">In some embodiments, the donor strain comprises a population of quasi-species of influenza viruses comprising at least 5% amino acid sequence variation in the PA protein.</p><p id="p-0043" num="0041">In some embodiments, the donor strain comprises a population of quasi-species of influenza viruses comprising at least 5% amino acid sequence variation in the PB2 protein.</p><p id="p-0044" num="0042">In some embodiments, the donor strain comprises a population of quasi-species of influenza viruses comprising at least 5% amino acid sequence variation in the M1 protein, at least 5% amino acid sequence variation in the NP protein, at least 5% amino acid sequence variation in the NS1 protein, at least 5% amino acid sequence variation in the PA protein and least 5% amino acid sequence variation in the PB2 protein.</p><p id="p-0045" num="0043">In some embodiments, the donor strain comprises a population of quasi-species of influenza viruses comprising at least 5% amino acid sequence variation in the M1 protein, at least 8% amino acid sequence variation in the NP protein, at least 15% amino acid sequence variation in the NS1 protein, at least 5% amino acid sequence variation in the PA protein and least 5% amino acid sequence variation in the PB2 protein.</p><p id="p-0046" num="0044">Other donor strains may be produced for use in the methods of the invention. To produce a donor strain for use in the methods of the invention, an influenza virus strain may be propagated in the culture host that is used in the methods of the invention. Passaging an influenza virus strain in the culture host that is used in the methods of the invention leads to the generation of variant influenza strains which contain sequence variations that allow the variant strain to grow to higher viral titres (in the same time and under the same growth conditions) compared to the influenza virus strain from which they are derived. The variant influenza strain therefore has improved growth characteristics in the culture host that is used in the method of the invention and is a preferred donor strain. For example, passaging the A/Puerto Rico/8/1934 influenza strain several times in cell culture produced a variant influenza strain (the PR8-X strain) which grows to higher viral titres in those cells compared to the original A/Puerto Rico/8/1934 strain. Thus, in certain embodiments, the PR8-X strain is the donor strain. Similarly, passaging the A/New Caledonia/20/1999 strain several times in cell culture produced a variant strain (the 105p30 strain) which grows to higher viral titres compared to the wild-type A/New Caledonia/20/1999 strain in the same time and under the same growth conditions.</p><p id="p-0047" num="0045">The gene segments of PR8-X have the nucleotide sequences of SEQ ID NO: 1 (PA), SEQ ID NO: 2 (PB1), SEQ ID NO: 3 (PB2), SEQ ID NO: 4 (NP), SEQ ID NO: 5 (M), SEQ ID NO: 6 (NS), SEQ ID NO: 7 (HA) or SEQ ID NO: 8 (NA). In some embodiments, an influenza strain comprising gene segments that encode the same amino acid sequence as the gene segments of PR8-X may be used as the donor strain.</p><p id="p-0048" num="0046">The gene segments of 105p30 have the nucleotide sequences of SEQ ID NO: 9 (PA), SEQ ID NO: 10 (PB1), SEQ ID NO: 11 (PB2), SEQ ID NO: 12 (NP), SEQ ID NO: 13 (M), SEQ ID NO: 14 (NS), SEQ ID NO: 15 (HA) or SEQ ID NO: 16 (NA). In some embodiments, an influenza strain comprising gene segments that encode the same amino acid sequence as the gene segments of 105p30 may be used as a donor strain.</p><p id="p-0049" num="0047">Donor strains suitable for use in the methods of the present invention will typically achieve improved viral titres and/or growth kinetics when compared to the viral titres obtained with the influenza strain from which the donor strain was derived. In certain embodiments, the improved viral titre of the donor strain is at least 10%, at least 20%, at least 50%, at least 100%, at least 200%, at least 500%, or at least 1000% higher when grown under the same growth conditions and for the same time (for example 12 hours, 24 hours, 48 hours or 72 hours) as the influenza strain from which the donor strain was derived.</p><p id="p-0050" num="0048">In certain embodiments, the donor strain is a strain that has regulatory approval for use in vaccine manufacture. It is advantageous to use a donor strain that has regulatory approval because reassortant viruses generated by the method of the invention may be used to prepare vaccines, which may be able to be marketed more easily than if the donor strain does not have pre-existing regulatory approval.</p><p id="p-0051" num="0049">The inventors have found that production of reassortant influenza is enhanced when the culture host is contacted with a purified donor strain. Purification of the donor strain may be advantageous when the donor strain is delivered to the culture host concurrently with transfection of the second HA gene and/or second NA gene. This is because contaminating egg proteins or cell culture proteins (which may be present following propagation of the donor strain) may interfere with transfection of an expression construct to the culture host. Accordingly, in some embodiments, the culture host is contacted with a purified donor strain. In certain such embodiments, the culture host is contacted with a purified donor strain and the one or more expression construct(s) comprising the second HA gene or the second NA gene are introduced into the culture host by transfection.</p><p id="p-0052" num="0050">A donor strain may have been propagated in cell culture and/or eggs prior to use in the method. In some embodiments, the method comprises a step of passaging an influenza virus strain in cell culture or eggs to produce the donor strain (e.g. the donor strain population) for infecting the culture host. A pre-passaging step (or more than one pre-passaging step) may be advantageous as this may increase the number sequence variants that are present in the population of virions that are delivered to the culture host.</p><p id="p-0053" num="0051">The donor strain may be concentrated and purified from cell culture medium or allantoic fluid using standard methods. In some embodiments, the methods comprise a step of purifying the donor strain before the culture host is contacted with the donor strain. For example, a purification process may involve centrifugation using a sucrose gradient solution or affinity chromatography methods. In one embodiment, the donor strain is purified by filtration and/or centrifugation. In one embodiment, a step of purifying the donor strain comprises a filtration step followed by a centrifugation step. For example, culture medium or allantoic fluid comprising the donor strain may be filtered through a 0.45 &#x3bc;m filter, and subsequently purified by centrifugation, for example at approximately 1400&#xd7;g for 1 hr using a centrifugal filter device. After purification, the donor strain may be suspended in buffer, for example PBS, which allows the purified donor strain to be stored and transported, prior to use in the methods of the invention.</p><p id="p-0054" num="0052">Helper viruses were used in early reverse genetics techniques to facilitate the expression of the influenza gene segments from the expression constructs (e.g. by providing components such as an RNA-dependent RNA polymerase (RdRp) or other proteins involved in replication of the viral genome). Typically, these early reverse genetics systems used expression constructs in the form of ribonucleoprotein complexes comprising a viral segment-encoding RNA, purified RNA-dependent RNA polymerase proteins and viral nucleoprotein components. These protein components delivered the machinery required to replicate the viral segments encoded by the RNA to the culture host. The protein components of the ribonucleoprotein complexes (RdRp and NP) needed to be purified from influenza viruses prior to in vitro assembly with a viral segment-encoding RNA. In addition to transfecting a culture host with the RNP component, a helper virus was required for efficient production of viruses. However, the components of the helper virus were generally not intended for incorporation into the reassortant viruses that were produced in these reverse genetics techniques. Subsequent developments in the expression constructs used in reverse genetics systems has meant that neither the RNP nor helper virus components are necessary because the later expression constructs can provide all of the components required to produce viral particles.</p><p id="p-0055" num="0053">The parent influenza virus strain that is contacted with a culture host in the methods of the invention is not a helper virus because the components of parent influenza virus strain that are involved in the replication of the viral genome are intended for incorporation into the reassortant influenza viruses produced by the methods of the invention. Accordingly, in some embodiments, the methods of the invention are helper virus-free.</p><heading id="h-0008" level="2">Expression Constructs</heading><p id="p-0056" num="0054">In the methods of the invention, one or more expression construct(s) comprising one or more influenza genes are introduced into the culture host. The one or more expression construct(s) may be introduced into a cell culture using any method for introducing expression construct(s) from known reverse genetics techniques.</p><p id="p-0057" num="0055">The methods of the present invention do not require the use of exogenously added RNPs, and so do not require additional viral RNA-directed RNA polymerase proteins and viral nucleoprotein to be provided with the one or more expression construct(s). Accordingly, in the context of the invention a ribonucleoprotein complex (e.g. a viral segment-encoding RNA complexed with purified RNA-dependent RNA polymerase proteins and viral nucleoproteins) is not an expression construct. An expression construct according to the invention is free of RNPs. The step of introducing one or more expression construct(s) into a culture host comprises the delivery of one or more expression construct(s) into the culture host without contacting or transfecting the culture host with a ribonucleoprotein complex (e.g. without simultaneously, or separately contacting or transfecting the culture host with a RNP complex).</p><p id="p-0058" num="0056">In the context of the invention, an influenza virion is not an expression construct. This means that contacting a culture host with an influenza strain does not amount to introducing one or more expression construct(s) into the culture host. In other words, the step of introducing one or more expression construct(s) into a culture host comprises the delivery of one or more expression construct(s) into the culture host via means that is not contacting or infecting the culture host with an influenza virion. This differs from classical reassortment, in which all of the influenza genes are delivered to the culture host through infection by parent influenza virus strains.</p><p id="p-0059" num="0057">Expression constructs for use in the invention are typically recombinant or synthetic nucleic acid constructs, which may have been assembled in vitro (e.g. using recombinant techniques known to those skilled in the art). Use of one or more expression construct(s) means that the sequence of the influenza genes can be precisely manipulated, in a way that is not possible were the requisite influenza genes to be provided by infection with an influenza virus (as is the case with classical reassortment methodologies).</p><p id="p-0060" num="0058">Expression constructs suitable for use in the methods of the invention may be uni-directional or bi-directional expression constructs. As influenza viruses require a protein for infectivity, it is generally preferred to use bi-directional expression constructs as this reduces the total number of expression constructs required by the host cell. Thus, the methods of the invention may utilise at least one bi-directional expression construct wherein at least one gene or cDNA is located between an upstream pol II promoter and a downstream non-endogenous pol I promoter. Transcription of the gene or cDNA from the pol II promoter produces capped positive-sense viral mRNA which can be translated into a protein, while transcription from the non-endogenous pol I promoter produces negative-sense vRNA. The bi-directional expression construct may be a bi-directional expression vector.</p><p id="p-0061" num="0059">Bi-directional expression constructs contain at least two promoters which drive expression in different directions (i.e. both 5&#x2032; to 3&#x2032; and 3&#x2032; to 5&#x2032;) from the same construct. The two promoters can be operably linked to different strands of the same double stranded DNA. Preferably, one of the promoters is a pol I promoter and at least one of the other promoters is a pol II promoter. This is useful as the pol I promoter can be used to express uncapped vRNAs while the pol II promoter can be used to transcribe mRNAs which can subsequently be translated into proteins, thus allowing simultaneous expression of RNA and protein from the same construct. Where more than one expression construct is used within an expression system, the promoters may be a mixture of endogenous and non-endogenous promoters.</p><p id="p-0062" num="0060">The pol I and pol II promoters used in the expression constructs may be endogenous to an organism from the same taxonomic order from which the host cell is derived. Alternatively, the promoters can be derived from an organism in a different taxonomic order than the host cell. The term &#x201c;order&#x201d; refers to conventional taxonomic ranking, and examples of orders are primates, rodentia, carnivora, marsupialia, cetacean, etc. Humans and chimpanzees are in the same taxonomic order (primates), but humans and dogs are in different orders (primates vs. carnivora). For example, the human pol I promoter can be used to express viral segments in canine cells (e.g. MDCK cells) [9].</p><p id="p-0063" num="0061">The expression construct will typically include an RNA transcription termination sequence. The termination sequence may be an endogenous termination sequence or a termination sequence which is not endogenous to the host cell. Suitable termination sequences will be evident to those of skill in the art and include, but are not limited to, RNA polymerase I transcription termination sequence, RNA polymerase II transcription termination sequence, and ribozymes. Furthermore, the expression constructs may contain one or more polyadenylation signals for mRNAs, particularly at the end of a gene whose expression is controlled by a pol II promoter.</p><p id="p-0064" num="0062">An expression construct may be a vector, such as a plasmid or other episomal construct. Such vectors will typically comprise at least one bacterial and/or eukaryotic origin of replication. Furthermore, the vector may comprise a selectable marker which allows for selection in prokaryotic and/or eukaryotic cells. Examples of such selectable markers are genes conferring resistance to antibiotics, such as ampicillin or kanamycin. The vector may further comprise one or more multiple cloning sites to facilitate cloning of a DNA sequence.</p><p id="p-0065" num="0063">An expression construct may be a linear expression construct. Such linear expression constructs will typically not contain any amplification and/or selection sequences. However, linear constructs comprising such amplification and/or selection sequences are also within the scope of the present invention. Reference 6 describes a linear expression construct which describes individual linear expression constructs for each viral segment. It is also possible to include more than one, for example two, three four, five or six viral segments on the same linear expression construct. Such a system has been described, for example, in reference 6.</p><p id="p-0066" num="0064">Expression constructs can be generated using methods known in the art. Such methods were described, for example, in reference 10. Where the expression construct is a linear expression construct, it is possible to linearise it before introduction into the host cell utilising a single restriction enzyme site. Alternatively, it is possible to excise the expression construct from a vector using at least two restriction enzyme sites. Furthermore, it is also possible to obtain a linear expression construct by amplifying it using a nucleic acid amplification technique (e.g. by PCR).</p><p id="p-0067" num="0065">The expression constructs used in the methods of the invention may be non-bacterial expression constructs. This means that the construct can drive expression in a eukaryotic cell of viral RNA segments encoded therein, but it does not include components which would be required for propagation of the construct in bacteria. Thus the construct will not include a bacterial origin of replication (ori), and usually will not include a bacterial selection marker (e.g. an antibiotic resistance marker). Such expression constructs are described in reference 7.</p><p id="p-0068" num="0066">The expression constructs may be prepared by chemical synthesis. The expression constructs may either be prepared entirely or in part by chemical synthesis. Suitable methods for preparing expression constructs by chemical synthesis are described, for example, in reference 7. Thus, in certain embodiments the expression construct may comprise a synthetic nucleic acid sequence. In some embodiments the expression construct may comprise a synthetic DNA sequence. In some embodiments, the expression construct may comprise a synthetic RNA sequence.</p><p id="p-0069" num="0067">The expression constructs used in the methods of the invention can be introduced into host cells using any technique known to those of skill in the art. For example, expression constructs of the invention can be introduced into host cells by employing electroporation, DEAE-dextran, calcium phosphate precipitation, liposomes, microinjection, or microparticle-bombardment.</p><p id="p-0070" num="0068">In some embodiments, an expression construct may be in the form of naked nucleic acid. The naked nucleic acid may have been purified from an influenza virus. In another embodiment, an expression construct may be in the form of transcribed RNA. In other embodiments, expression construct may be in the form of one or more shuttle vectors. Examples of shuttle vectors include non-influenza viruses and replicons, for instance alphavirus based replicons.</p><p id="p-0071" num="0069">The nucleotide sequence of the expression construct may be manipulated, which allows the sequence of the influenza segments present in the reassortant viruses produced in the methods of the invention to be controlled. Accordingly, influenza HA encoded by an expression construct may have a natural HA as found in a wild-type virus, or a modified HA. For instance, it is known to modify HA to remove determinants (e.g. hyper-basic regions around the HA1/HA2 cleavage site) that cause a virus to be highly pathogenic. In some embodiments, the HA is modified to remove the polybasic cleavage site. In certain such embodiments, the HA is from an H5 or H7 influenza strain and does not comprise a polybasic cleavage site. Similarly, influenza NA encoded by an expression construct may have an NA as found in a wild-type virus, or a modified NA. For instance, an NA may be modified to confer susceptibility to antiviral neuraminidase inhibitors if the vaccine strain NA comprises pre-existing neuraminidase inhibitor resistance mutations. Introducing an influenza gene (for example, an HA or NA gene) into the culture host on an expression construct allows the sequence to modified prior to introduction into the culture host.</p><p id="p-0072" num="0070">HA and/or NA sequences may also be manipulated to produce chimeric HA or chimeric NA sequences containing sequences from more than one influenza strain. For instance, a chimeric HA or chimeric NA may contain the cytoplasmic, or cytoplasmic and transmembrane portions of the HA or NA from one strain and at least the extracellular antigenic portion of the HA or NA from a different strain. This approach has been described previously as a technique for producing influenza viruses containing the antigenic portion of the HA or NA in circumstances where the unmodified HA and/or NA segment may be produced at low yields. However, the methods of the present invention may avoid the need for the use of chimeric HA and/or chimeric NA segment because the sequence variants that are present in the population of virions that are delivered to the culture host by infection with an influenza virus strain may provide sufficient variation for the efficient production of reassortant viruses comprising an non-chimeric HA and and/or an non-chimeric NA.</p><p id="p-0073" num="0071">Accordingly, in some embodiments, the HA sequence is a non-chimeric HA sequence. In other words, the HA sequence comprises the cytoplasmic, transmembrane and extracellular domain from the same influenza strain. In some embodiments, the NA sequence is a non-chimeric NA sequence. In other words, the NA sequence comprises the cytoplasmic, transmembrane and extracellular domain from the same influenza strain. In certain such embodiments, although the HA sequence and/or NA sequence is a non-chimeric sequence, it may comprise other modifications as described herein. For instance, a non-chimeric HA sequence may be modified to remove determinants (e.g. hyper-basic regions around the HA1/HA2 cleavage site) that cause a virus to be highly pathogenic. Similarly, a non-chimeric NA sequence may be modified to confer susceptibility to antiviral neuraminidase inhibitors if the vaccine strain NA comprises pre-existing neuraminidase inhibitor resistance mutations.</p><p id="p-0074" num="0072">The number of influenza genes that are delivered to the culture host may be controlled in the methods of the invention. In certain embodiments, the one or more expression construct(s) comprise no more than seven influenza genes. Providing no more than seven influenza genes is advantageous because it means that fewer influenza genes are provided to the culture host than in classical reassortment (where eight segments are provided by a second influenza virus strain), and so reduces the number of gene constellation ratios that may be present in the reassortant viruses generated by the methods. By further limiting the number of influenza genes, the gene constellation ratios that may be present in the reassortant viruses generated by the method are also limited. Thus, in certain embodiments the one or more expression construct(s) comprise no more than six influenza genes. In other embodiments, the one or more expression construct(s) comprise no more than five influenza gene. In further embodiments, the one or more expression construct(s) comprise no more than four influenza genes.</p><p id="p-0075" num="0073">The provision of fewer influenza genes can be particularly advantageous when seeking to maximise the production of a reassortant virus having a particular gene constellation ratio. For example, when the one or more expression construct(s) comprise no more than a single HA gene and a single NA gene the likelihood of producing 7:1 and 6:2 viruses is increased. This is because the only backbone segments that are present in the culture host for the production of reassortant viruses are from the donor strain. Thus, in a preferred embodiment, the one or more expression construct(s) comprise no more than two influenza genes. In certain such embodiments, the one or more expression construct(s) comprise one HA gene and one NA gene.</p><p id="p-0076" num="0074">In some embodiments, the one or more expression construct(s) comprise no more than three influenza gene. In these embodiments, the one or more expression construct(s) comprise one HA gene, one NA gene and one backbone gene. The backbone gene is selected from the group consisting of: PB2, PB1, PA, NP, M, and NS. Preferably, the backbone gene is PB1. Introducing a single backbone segment with the HA and NA gene to the culture host allows for the production of 5:3 reassortant viruses. In these embodiments, negative selection against the corresponding backbone segment from the donor strain can be preferably performed using an agent that inhibits the transcription and/or translation of the backbone segment. In certain embodiments, an RNAi agent is used. Use of an agent that inhibits transcription and/or translation is advantageous because the backbone segment is less exposed on the surface of an influenza virion than HA and NA, and thus less amenable to selection using one or more antibodies for or against a backbone segment.</p><p id="p-0077" num="0075">In some embodiments, the one or more expression construct(s) comprises no more than a single influenza gene. In certain such embodiments, the single influenza gene is a second HA gene. This aspect of the invention is useful in situations where it is desirable to produce reassortant viruses having the NA gene from the donor strain. Use of one more expression construct(s) comprising no more than a single HA gene increases the production of 7:1 reassortant viruses because only a single second HA gene is present in the culture host. In other embodiments, the single influenza gene is a second NA gene. This aspect of the invention is useful in situations where it is desirable to produce reassortant viruses having the HA gene from the donor strain. Use of one more expression construct(s) comprising no more than a single NA gene increases the production of 7:1 reassortant viruses because only a single second NA gene is present in the culture host. These embodiments of the invention may be particularly useful when seeking to produce reassortant influenza B virus because reassortant influenza B viruses having desirable characteristics may contain the NA segment of the parent influenza B strain.</p><p id="p-0078" num="0076">In certain embodiments, the one or more expression construct(s) are introduced into the culture host at the same time as the culture host is contacted with the donor strain. Introduction of the one or more expression construct(s) into the culture host at the same time as the culture host is contacted with the donor strain can also be described as co-delivery. The inventors have found that delivery of the expression construct(s) and infection with the donor strain at the same time enhances the production of reassortant influenza viruses. In the context of the present invention, the same time means within 5 minutes. As a result, contacting the culture host with the donor strain followed by the introduction of the one or more expression construct(s) to the culture host up to 5 minutes later is considered to be delivery at the same time.</p><p id="p-0079" num="0077">In one embodiment, co-delivery of the one or more expression construct(s) and contacting the culture host with the donor strain comprises co-transfection of the expression construct(s) and purified donor strain. In certain such embodiments, the one or more expression construct(s) are mixed with the purified parent influenza strain and delivered to the host cell using any transfection method known to those skilled in the art. Suitable transfection methods include electroporation, DEAE-dextran, calcium phosphate precipitation, liposomes, microinjection, microparticle-bombardment, or other transfection reagents.</p><p id="p-0080" num="0078">In other embodiments, the one or more expression construct(s) are introduced into the culture host before the culture host is contacted with the donor strain. In other embodiments, the one or more expression construct(s) are introduced into the culture host after the culture host is contacted with the donor strain. In certain embodiments the time difference between contacting the culture host and introduction of the one or more expression constructs is no more than 10, 20, 30, 40, 50, 60, 90, 120 or 180 minutes. In other embodiments the time difference between contacting the culture host and introduction of the one or more expression constructs is no more than 3, 4, 5, 6, 8, 10, 12, 18 or 24 hours. In certain embodiments the time difference between contacting the culture host and introduction of the one or more expression constructs is 1-3 hours. Such staggered delivery may be advantageous in circumstances were co-delivery is not practical.</p><p id="p-0081" num="0079">The one or more expression construct(s) introduced into the culture host may contain influenza A virus HA subtypes H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15 or H16. They may contain the influenza A virus NA subtypes N1, N2, N3, N4, N5, N6, N7, N8 or N9. The one or more expression construct(s) introduced into the culture host may comprise one or more influenza genes from a seasonal influenza strain. In these embodiments, the one or more expression construct(s) may, for example, contain an HA having an H1 or H3 subtype. In one embodiment of the invention the one or more expression construct(s) comprise influenza genes from a vaccine strain which is a H1N1 or H3N2 strain.</p><heading id="h-0009" level="2">Production, Selection and Isolation of Reassortant Viruses</heading><p id="p-0082" num="0080">The reassortant viruses produced by culturing a culture host that has been contacted with the donor strain, and to which one or more expression constructs comprising a second HA gene or second NA gene have been introduced, comprise influenza genes from the donor strain and the second HA gene or the second NA gene that are encoded by the one or more expression construct(s). In a preferred embodiment, the reassortant viruses produced by culturing a culture host that has been contacted with the donor strain, and to which one or more expression constructs comprising a second HA gene and second NA gene have been introduced, comprise influenza genes from the donor strain and the second HA gene and second NA gene that are encoded by the one or more expression construct(s). In further embodiments, the reassortant viruses produced by culturing a culture host that has been contacted with the donor strain, and to which one or more expression constructs comprising a second HA gene, a second NA gene, and a second backbone gene (i.e. a PB1, PB2, PA, M, NS or NP gene) have been introduced, comprise influenza genes from the donor strain, the second HA gene, second NA gene and second backbone gene that are encoded by the one or more expression construct(s).</p><p id="p-0083" num="0081">The methods of the invention also further comprise a selection step to enhance the production of reassortant viruses comprising the second HA gene (i.e. the vaccine strain's HA gene). The selection step may comprise any method that enhances the selection of reassortant viruses comprising an HA derived from the vaccine strain (the second HA gene). In some embodiments, the selection step is carried out after the culture host has been cultured in order to produce reassortant influenza viruses. Accordingly, in some embodiments, the methods of the invention comprise the steps of: (i) contacting a culture host with a parent influenza virus strain comprising a first hemagglutinin (HA) gene and a first neuraminidase (NA) gene; (ii) introducing into the culture host one or more expression construct(s) comprising one or more influenza genes, wherein said influenza genes comprise a second HA gene or a second NA gene; (iii) culturing the culture host in order to produce reassortant viruses; and subsequently, after reassortant viruses have been produced, (iv) selecting for reassortant viruses that comprise the second HA gene or the second NA gene.</p><p id="p-0084" num="0082">In some embodiments, the methods comprise a step of separating reassortant viruses from the culture host prior to the selection step. For instance, in certain embodiments, cell culture supernatant comprising the reassortant viruses is separated from the culture host and the selection step is performed on the supernatant that comprises the reassortant viruses.</p><p id="p-0085" num="0083">In some embodiments, the selection step may comprise negative selection against reassortant viruses comprising the HA from the donor strain. In some embodiments, the selection step may comprises positive selection for reassortant viruses comprising the HA from the vaccine strain. In some embodiments, the selection step comprises one or more negative selection steps and one or more positive selections steps. In other embodiments, the selection step comprises one or more negative selection steps but no positive selection steps. In other embodiments, the selection step comprises one or more positive selection steps but no negative selection steps. One or more negative selection step(s) may be used to enhance the production of reassortant viruses comprising an HA derived from the vaccine strain. Similarly, one or more positive selection step(s) may be used to enhance production of reassortant viruses comprising an HA derived from the vaccine strain.</p><p id="p-0086" num="0084">Negative and/or positive selection steps may also be used to enhance production of reassortant viruses comprising other segments from the vaccine strain. In certain embodiments, the selection step enhances the selection of reassortant viruses comprising an NA derived from the vaccine strain (the second NA gene). In preferred embodiments, the selection step enhances the selection of reassortant comprising the HA and NA from the vaccine strain. In further embodiments, the selection step enhances the selection of reassortant viruses comprising the PB1, PB2, PA, M, NS or NP segment from the vaccine strain. In preferred embodiments the selection step enhances the selection of reassortant viruses comprising the vaccine strain's HA, NA and a backbone segment selected from the group consisting of PB1, PB2, PA, M, NS or NP segments.</p><p id="p-0087" num="0085">In some embodiments, negative selection comprises contacting the culture host with one or more antibodies against the first HA protein. In some embodiments, negative selection comprises contacting reassortant viruses that have been separated from the culture host with one or more antibodies against the first HA protein. In certain embodiments, negative selection comprises contacting cell culture supernatant comprising the reassortant viruses produced by the method with one or more antibodies against the first HA protein. In certain embodiments, the antibodies are present in antisera against the first HA protein. In other embodiments, one or more monoclonal antibodies against the first HA protein are used in a negative selection step.</p><p id="p-0088" num="0086">Negative selection may also comprise exposure of the culture host to inhibitory agents that preferentially reduce the transcription and/or translation of the donor strain's HA gene or protein relative to the vaccine strain's HA gene or protein. The preferential reduction of the donor strain's HA gene or protein levels either at the transcriptional or translational level favours the formation of reassortant influenza viruses comprising the vaccine strain's HA because the likelihood that the HA gene of the vaccine strain will be incorporated and propagated increases with their relative abundance increases. Suitable inhibitory agents will be known to the skilled person and are described elsewhere [11]. In certain embodiments, the inhibitory agent that preferentially reduces the transcription and/or translation of the donor strain's HA gene or protein is selected from the group consisting of short interfering RNAs (siRNA), double-stranded RNAs (dsRNA), micro-RNAs (miRNAs), short hairpin RNAs (shRNA), or small interfering DNAs (siDNAs) like e.g., phosphorothioate oligomers (PSOs) or phosphorodiamidate morpholino oligomer (PMOs). In certain embodiments, more than one inhibitory agent that preferentially reduces the transcription and/or translation of the donor strain's HA gene or protein is used.</p><p id="p-0089" num="0087">In some embodiments, the method does not comprise exposure of the culture host to inhibitory agents that preferentially reduce the transcription and/or translation of the donor strain's HA gene or protein relative to the vaccine strain's HA gene or protein.</p><p id="p-0090" num="0088">In preferred embodiments, the one or more expression construct(s) comprise a second HA gene and a second NA gene. In these embodiments, the selection step may comprise contacting the culture host with one or more antibodies against the first HA protein and/or one or more antibodies against the NA protein. In particularly preferred embodiments, the antibodies are present in antisera against the first HA and/or NA proteins. In other embodiments, one or more monoclonal antibodies against the first HA protein and/or one or more monoclonal antibodies against the first NA protein are used in a negative selection step.</p><p id="p-0091" num="0089">In certain embodiments, the one or more expression construct(s) comprise a second PB1, PB2, PA, M, NS or NP gene. In these embodiments an additional backbone segment (i.e. a PB1, PB2, PA, M, NS or NP segment) is provided to the culture host by the vaccine strain. Such embodiments may comprise a negative selection step against the first PB1, PB2, PA, M, NS or NP gene of the donor strain in order to enhance the production of reassortant viruses containing the second PB1, PB2, PA, M, NS or NP gene segment. Negative selection using an inhibitory agents that preferentially reduce the transcription and/or translation of the donor strain's PB1, PB2, PA, M, NS or NP gene segment relative to the vaccine strain's PB1, PB2, PA, M, NS or NP gene segment are preferred. This is because the protein encoded by the backbone segment is not as readily accessible to antibodies at the surface of an influenza virion as the HA and NA protein, and so inhibiting translation or transcription of the backbone segment is more effective as a negative selection step than exposure to one or more antibodies. Nevertheless, exposure of the culture host to one or more antibodies against the second PB1, PB2, PA, M, NS or NP gene segment may alternatively, or in addition, be used as a negative selection step. In some embodiments, the method does not comprise exposure of the culture host to inhibitory agents that preferentially reduce the transcription and/or translation of the donor strain's PB1, PB2, PA, M, NS or NP gene segment relative to the vaccine strain's PB1, PB2, PA, M, NS or NP gene segment.</p><p id="p-0092" num="0090">In some embodiments, a positive selection step comprises contacting the culture host with one or more antibodies that are specific for the second HA protein. In some embodiments, a positive selection step comprises contacting the reassortant viruses that have been separated from the culture host with one or more antibodies that are specific for the second HA protein. In certain embodiments, a positive selection step comprises contacting cell culture supernatant comprising the reassortant viruses produced by the method with one or more antibodies that are specific for the second HA protein. In this way, reassortant viruses that comprise the second HA gene can be positively selected from the culture host. In preferred embodiments, one or more antibodies used for positive selection are labelled (for example, with a magnetic bead). Labelling aids subsequent isolation of reassortant viruses comprising the second HA gene.</p><p id="p-0093" num="0091">The methods of the invention may comprise one or more selection steps. For example, reassortant virus may be passaged multiple times in the presence of antisera. Multiple selection steps are performed to enhance the selection of reassortant influenza viruses comprising the second HA gene. In preferred embodiments, multiple selection steps are preformed to enhance selection of reassortant influenza viruses comprising the second HA gene. In certain embodiments, the methods comprise two, three, four, five or six negative selection steps. In preferred embodiments, the methods comprise two negative selection steps. In other preferred embodiments, the methods comprise three negative selection steps.</p><p id="p-0094" num="0092">The use of one or more expression construct(s) in the methods of the invention means that the culture host comprises fewer undesirable sequence variants or quasi-species than are present in classical reassortment, when all influenza gene segments are provided by parent influenza virus strains. As a result, the method typically requires fewer selection steps to produce a desired reassortant virus. Fewer selection steps means that the reassortant virus can be produced more rapidly than in classical reassortment. Thus, in one embodiment, the methods comprise no more than a single selection step. In another embodiment, the methods comprise no more than two selection steps. In a further embodiments, the methods comprise no more than three selection steps. Selection steps may be performed concurrently (i.e. at the same time), or sequentially (i.e. one after another).</p><p id="p-0095" num="0093">A selection step may be used to select for viruses having a particular gene constellation ratio. For instance, a selection step for or against a single gene only can be used to increase production of 7:1 viruses. In certain embodiments, negative selection is against a single influenza segment. In certain embodiments, negative selection is against an HA gene alone. In other embodiments, negative selection is against an NA gene alone. Similarly, when seeking to increase production of 6:2 reassortant viruses, negative selection is against two influenza segments. In these embodiments, selection is typically negative selection against the HA and NA segments from the donor strain.</p><p id="p-0096" num="0094">In some embodiments, the selection step is carried out in the same culture host that is used in the first step of the method. In other embodiments, the selection step is carried out in a different culture host. In these embodiments, the virus that is produced in step (iii) of the method is transferred from the first culture host to a second culture host in which one or more negative selection steps are performed. The first culture host and second culture host may be the same or different. In one embodiment, the first culture host is a cell and the second culture host is an embryonated hen egg.</p><p id="p-0097" num="0095">The methods of the invention produce a pool of reassortant viruses from which a particular class of reassortant virus can be isolated. This provides a greater capacity to select for a virus certain properties than is provided by reverse genetics because fewer variants and less virus diversity is produced in reverse genetics techniques. Isolation of a particular reassortant influenza virus means that a reassortant virus having advantageous properties can be selected for further processing. For instance, a reassortant virus having high growth properties and comprising the HA and NA of the circulating influenza strain can be isolated for use a seed virus in vaccine manufacture. Accordingly, the methods of the invention may further comprise the step of isolating a reassortant influenza virus comprising the second HA gene and the second NA gene.</p><p id="p-0098" num="0096">In certain embodiments, the method produces reassortant influenza A viruses or reassortant viruses having influenza A HA. In some embodiments, the method produces reassortant influenza A viruses or reassortant viruses having influenza A HA and NA. Analysis of vaccine seed viruses has demonstrated that 95% of influenza A seed viruses have either 6:2 or 5:3 gene constellation ratios. The methods of the present invention are therefore particularly effective at generating influenza A seed viruses because the methods provide a limited number of backbone segments, thereby increasing the likelihood of generating 6:2 or 5:3 reassortant viruses.</p><p id="p-0099" num="0097">The reassortant influenza viruses produced by the methods of the invention may contain the influenza A virus HA subtypes H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15 or H16. They may contain the influenza A virus NA subtypes N1, N2, N3, N4, N5, N6, N7, N8 or N9. Where the vaccine strain used in the reassortant influenza viruses of the invention is a seasonal influenza strain, the vaccine strain may have a H1 or H3 subtype. In one aspect of the invention the vaccine strain is a H1N1 or H3N2 strain.</p><p id="p-0100" num="0098">In other embodiments, the method generates reassortant influenza B viruses or reassortant viruses having influenza B HA. In some embodiments, the method produces reassortant influenza B viruses or reassortant viruses having influenza B HA and NA. Gene constellation ratios in influenza B viruses have greater variety and are less predictable. The methods of the invention are advantageous because they provide improved control in the gene constellation ratios of the reassortant influenza B viruses. The reassortant influenza viruses produced by the methods of the invention may contain the HA segment of an influenza B strain.</p><p id="p-0101" num="0099">In certain embodiments, the methods of the invention are used to produce reassortant influenza virus based on a pandemic strains or potentially pandemic strains. In certain embodiments, the reassortant virus comprises an HA from a pandemic strain or potentially pandemic strain. The characteristics of an influenza strain that give it the potential to cause a pandemic outbreak are: (a) it contains a new hemagglutinin compared to the hemagglutinins in currently-circulating human strains, i.e. one that has not been evident in the human population for over a decade (e.g. H2), or has not previously been seen at all in the human population (e.g. H5, H6 or H9, that have generally been found only in bird populations), such that the human population will be immunologically na&#xef;ve to the strain's hemagglutinin; (b) it is capable of being transmitted horizontally in the human population; and (c) it is pathogenic to humans. In certain embodiments, the methods of the invention produce a reassortant influenza virus comprising an H5 hemagglutinin type. An H5 hemagglutinin type is preferred where the reassortant virus is used in vaccines for immunizing against pandemic influenza, such as a H5N1 strain. Other possible strains include H5N3, H9N2, H2N2, H7N1 and H7N7, and any other emerging potentially pandemic strains. The invention is suitable for producing reassortant viruses for use in a vaccine for protecting against potential pandemic virus strains that can or have spread from a non-human animal population to humans, for example a swine-origin H1N1 influenza strain.</p><heading id="h-0010" level="2">Culture Host</heading><p id="p-0102" num="0100">A culture host for use in the methods of the present invention can be embryonated hen eggs or cells. In a preferred embodiment, the culture host is a cell culture.</p><p id="p-0103" num="0101">One method for influenza virus growth uses specific pathogen-free (SPF) embryonated hen eggs, with virus being inoculated into, grown and purified from the egg contents (allantoic fluid). Influenza viruses may also be grown in animal cell culture and, for reasons of replication accuracy, speed and patient allergies, this growth method is preferred. If egg-based viral growth is used then one or more amino acids may be introduced into the allantoic fluid of the egg together with the virus [42].</p><p id="p-0104" num="0102">When cells are used, the invention will typically use a cell line although, for example, primary cells may be used as an alternative. The cells will typically be mammalian. Suitable mammalian cells of origin include, but are not limited to, hamster, cattle, primate (including humans and monkeys) and dog cells. Various cell types may be used, such as kidney cells, fibroblasts, retinal cells, lung cells, etc. Examples of suitable hamster cells are the cell lines having the names BHK21 or HKCC. Suitable monkey cells are e.g. African green monkey cells, such as kidney cells as in the Vero cell line [12-14]. Suitable dog cells are e.g. kidney cells, as in the CLDK and MDCK cell line. Thus suitable cell lines include, but are not limited to: MDCK; CHO; 293T; BHK; Vero; MRC-5; PER.C6; WI-38; etc. Preferred mammalian cell lines for growing influenza viruses include: MDCK cells [15-18], derived from Madin Darby canine kidney; Vero cells [12-14], derived from African green monkey (<i>Cercopithecus aethiops</i>) kidney; or PER.C6 cells [19], derived from human embryonic retinoblasts. These cell lines are widely available e.g. from the American Type Cell Culture (ATCC) collection [20], from the Coriell Cell Repositories [21], or from the European Collection of Cell Cultures (ECACC). For example, the ATCC supplies various different Vero cells under catalog numbers CCL-81, CCL-81.2, CRL-1586 and CRL-1587, and it supplies MDCK cells under catalog number CCL-34. PER.C6 is available from the ECACC under deposit number 96022940. As a less-preferred alternative to mammalian cell lines, virus can be grown on avian cell lines [e.g. refs. 22-24], including cell lines derived from ducks (e.g. duck retina) or hens e.g. chicken embryo fibroblasts (CEF), etc. Examples include avian embryonic stem cells [22,25], including the EBx cell line derived from chicken embryonic stem cells, EB45, EB14, and EB14-074 [26]. EB66 is a preferred cell line.</p><p id="p-0105" num="0103">Particularly preferred cells for use in the invention are MDCK cells [15-1618], derived from Madin Darby canine kidney. The original MDCK cells are available from the ATCC as CCL-34. Derivatives of MDCK cells may also be used. For instance, reference 15 discloses a MDCK cell line that was adapted for growth in suspension culture (&#x2018;MDCK 33016&#x2019;, deposited as DSM ACC 2219). Similarly, reference 27 discloses a MDCK-derived cell line that grows in suspension in serum-free culture (B-702&#x2032;, deposited as FERM BP-7449). Reference 28 discloses non-tumorigenic MDCK cells, including &#x2018;MDCK-S&#x2019; (ATCC PTA-6500), &#x2018;MDCK-SF101&#x2019; (ATCC PTA-6501), &#x2018;MDCK-SF102&#x2019; (ATCC PTA-6502) and &#x2018;MDCK-SF103&#x2019; (PTA-6503). Reference 29 discloses MDCK cell lines with high susceptibility to infection, including &#x2018;MDCK.5F1&#x2019; cells (ATCC CRL-12042). Any of these MDCK cell lines can be used.</p><p id="p-0106" num="0104">For growth on a cell line, such as on MDCK cells, virus may be grown on cells in suspension [15,30,31] or in adherent culture. One preferred MDCK cell line for suspension culture is MDCK 33016 (deposited as DSM ACC 2219). As an alternative, microcarrier culture can be used.</p><p id="p-0107" num="0105">Cell lines supporting influenza virus replication are preferably grown in serum-free culture media and/or protein free media. A medium is referred to as a serum-free medium in the context of the present invention if it contains no additives from serum of human or animal origin. Protein-free is understood to mean cultures in which multiplication of the cells occurs with exclusion of proteins, growth factors, other protein additives and non-serum proteins, but can optionally include proteins such as trypsin or other proteases that may be necessary for viral growth. The cells growing in such cultures naturally contain proteins themselves.</p><p id="p-0108" num="0106">Cell lines supporting influenza virus replication are preferably grown below 37&#xb0; C. [33] (e.g. 30-36&#xb0; C., or at about 30&#xb0; C., 31&#xb0; C., 32&#xb0; C., 33&#xb0; C., 34&#xb0; C., 35&#xb0; C., 36&#xb0; C.), for example during viral replication.</p><p id="p-0109" num="0107">Where virus is grown on a cell line then the growth culture, and also the viral inoculum used to start the culture, is preferably free from (i.e. will have been tested for and given a negative result for contamination by) herpes simplex virus, respiratory syncytial virus, parainfluenza virus 3, SARS coronavirus, adenovirus, rhinovirus, reoviruses, polyomaviruses, birnaviruses, circoviruses, and/or parvoviruses [32].</p><p id="p-0110" num="0108">Where virus has been grown on a mammalian cell line then the composition will advantageously be free from egg proteins (e.g. ovalbumin and ovomucoid) and from chicken DNA, thereby reducing allergenicity. The avoidance of allergens is useful for minimizing Th2 responses. Where cells are used as a culture host in the methods of the invention, it is known that cell culture conditions (e.g. temperature, cell density, pH value, etc.) are variable over a wide range subject to the cell line and the influenza virus strain employed and can be adapted to the requirements of the application. The following information therefore merely represents guidelines.</p><p id="p-0111" num="0109">Multiplication of the cells can be conducted in accordance with methods known to those of skill in the art. For example, the cells can be cultivated in a perfusion system using ordinary support methods like centrifugation or filtration. Moreover, the cells can be multiplied according to the invention in a fed-batch system before infection. In the context of the present invention, a culture system is referred to as a fed-batch system in which the cells are initially cultured in a batch system and depletion of nutrients (or part of the nutrients) in the medium is compensated by controlled feeding of concentrated nutrients. It can be advantageous to adjust the pH value of the medium during multiplication of cells before infection to a value between pH 6.6 and pH 7.8 and especially between a value between pH 7.2 and pH 7.3. Culturing of cells preferably occurs at a temperature between 30 and 40&#xb0; C. After infection with the influenza viruses, the cells are preferably cultured at a temperature of between 30&#xb0; C. and 36&#xb0; C. or between 32&#xb0; C. and 34&#xb0; C. or at about 33&#xb0; C. This is particularly preferred as it has been shown that incubation of infected cells in this temperature range results in production of a virus that results in improved efficacy when formulated into a vaccine [33]. The oxygen partial pressure can be adjusted during culturing before infection preferably at a value between 25% and 95% and especially at a value between 35% and 60%. The values for the oxygen partial pressure stated in the context of the invention are based on saturation of air. Infection of cells occurs at a cell density of preferably about 8-25&#xd7;10<sup>5 </sup>cells/mL in the batch system or preferably about 5-20&#xd7;10<sup>6 </sup>cells/mL in the perfusion system. The cells can be infected with a viral dose (MOI value, &#x201c;multiplicity of infection&#x201d;; corresponds to the number of virus units per cell at the time of infection) between 10&#x2032; and 10, preferably between 0.0001 and 0.5.</p><p id="p-0112" num="0110">The methods according to the invention can include harvesting and isolation of viruses or the proteins generated by them. During isolation of viruses or proteins, the cells are separated from the culture medium by standard methods like separation, filtration or ultrafiltration. The viruses or the proteins are then concentrated according to methods known to those skilled in the art, like gradient centrifugation, filtration, precipitation, chromatography, etc., and then purified. It is preferred that the viruses are inactivated during or after purification. Virus inactivation can occur, for example, by &#x3b2;-propiolactone or formaldehyde at any point within the purification process.</p><heading id="h-0011" level="2">Host Cell DNA</heading><p id="p-0113" num="0111">Where virus has been isolated and/or grown on a cell line, it is standard practice to minimize the amount of residual cell line DNA in the final vaccine, in order to minimize any potential oncogenic activity of the DNA.</p><p id="p-0114" num="0112">Thus a vaccine composition prepared according to the invention preferably contains less than 10 ng (preferably less than 1 ng, and more preferably less than 100 pg) of residual host cell DNA per dose, although trace amounts of host cell DNA may be present.</p><p id="p-0115" num="0113">It is preferred that the average length of any residual host cell DNA is less than 500 bp e.g. less than 400 bp, less than 300 bp, less than 200 bp, less than 100 bp, etc.</p><p id="p-0116" num="0114">Contaminating DNA can be removed during vaccine preparation using standard purification procedures e.g. chromatography, etc. Removal of residual host cell DNA can be enhanced by nuclease treatment e.g. by using a DNase. A convenient method for reducing host cell DNA contamination is disclosed in references 34 &#x26; 35, involving a two-step treatment, first using a DNase (e.g. Benzonase), which may be used during viral growth, and then a cationic detergent (e.g. CTAB), which may be used during virion disruption. Treatment with an alkylating agent, such as &#x3b2;-propiolactone, can also be used to remove host cell DNA, and advantageously may also be used to inactivate virions [36].</p><heading id="h-0012" level="2">Vaccines</heading><p id="p-0117" num="0115">The invention utilises virus produced according to the method to produce vaccines.</p><p id="p-0118" num="0000">Influenza vaccines are generally based either on live virus or on inactivated virus. Inactivated vaccines may be based on whole virions, &#x2018;split&#x2019; virions, or on purified surface antigens. Antigens can also be presented in the form of virosomes. The invention can be used for manufacturing any of these types of vaccine.</p><p id="p-0119" num="0116">Where an inactivated influenza virus is used, the vaccine may comprise whole virion, split virion, or purified surface antigens (including hemagglutinin and, usually, also including neuraminidase). Chemical means for inactivating a virus include treatment with an effective amount of one or more of the following agents: detergents, formaldehyde, &#x3b2;-propiolactone, methylene blue, psoralen, carboxyfullerene (C60), binary ethylamine, acetyl ethyleneimine, or combinations thereof. Non-chemical methods of viral inactivation are known in the art, such as for example UV light or gamma irradiation.</p><p id="p-0120" num="0117">Virions can be harvested from virus-containing fluids, e.g. allantoic fluid or cell culture supernatant, by various methods. For example, a purification process may involve zonal centrifugation using a linear sucrose gradient solution (that optionally includes detergent to disrupt the virions) or affinity chromatography methods. Antigens may then be purified, after optional dilution, by diafiltration.</p><p id="p-0121" num="0118">Split virions are obtained by treating purified virions with detergents (e.g. ethyl ether, polysorbate 80, deoxycholate, tri-N-butyl phosphate, Triton X-100, Triton N101, cetyltrimethylammonium bromide, Tergitol NP9, etc.) to produce subvirion preparations, including the &#x2018;Tween-ether&#x2019; splitting process. Methods of splitting influenza viruses, for example are well known in the art e.g. see refs. 37-42, etc. Splitting of the virus is typically carried out by disrupting or fragmenting whole virus, whether infectious or non-infectious with a disrupting concentration of a splitting agent. The disruption results in a full or partial solubilisation of the virus proteins, altering the integrity of the virus. Preferred splitting agents are non-ionic and ionic (e.g. cationic) surfactants e.g. alkylglycosides, alkylthioglycosides, acyl sugars, sulphobetaines, betains, polyoxyethylenealkylethers, N,N-dialkyl-Glucamides, Hecameg, alkylphenoxy-polyethoxyethanols, NP9, quaternary ammonium compounds, sarcosyl, CTABs (cetyl trimethyl ammonium bromides), tri-N-butyl phosphate, Cetavlon, myristyltrimethylammonium salts, lipofectin, lipofectamine, and DOT-MA, the octyl- or nonylphenoxy polyoxyethanols (e.g. the Triton surfactants, such as Triton X-100 or Triton N101), polyoxyethylene sorbitan esters (the Tween surfactants), polyoxyethylene ethers, polyoxyethlene esters, etc. One useful splitting procedure uses the consecutive effects of sodium deoxycholate and formaldehyde, and splitting can take place during initial virion purification (e.g. in a sucrose density gradient solution). Thus a splitting process can involve clarification of the virion-containing material (to remove non-virion material), concentration of the harvested virions (e.g. using an adsorption method, such as CaHPO4 adsorption), separation of whole virions from non-virion material, splitting of virions using a splitting agent in a density gradient centrifugation step (e.g. using a sucrose gradient that contains a splitting agent such as sodium deoxycholate), and then filtration (e.g. ultrafiltration) to remove undesired materials. Split virions can usefully be resuspended in sodium phosphate-buffered isotonic sodium chloride solution. Examples of split influenza vaccines are the BEGRIVAC&#x2122;, FLUARIX&#x2122;, FLUZONE&#x2122; and FLUSHIELD&#x2122; products.</p><p id="p-0122" num="0119">Purified influenza virus surface antigen vaccines comprise the surface antigens hemagglutinin and, typically, also neuraminidase. Processes for preparing these proteins in purified form are well known in the art. The FLUVIRIN&#x2122;, AGRIPPAL&#x2122; and INFLUVAC&#x2122; products are influenza subunit vaccines.</p><p id="p-0123" num="0120">Another form of inactivated antigen is the virosome [43] (nucleic acid free viral-like liposomal particles). Virosomes can be prepared by solubilization of virus with a detergent followed by removal of the nucleocapsid and reconstitution of the membrane containing the viral glycoproteins. An alternative method for preparing virosomes involves adding viral membrane glycoproteins to excess amounts of phospholipids, to give liposomes with viral proteins in their membrane.</p><p id="p-0124" num="0121">The method of the invention may also be used to produce live vaccines. Such vaccines are usually prepared by purifying virions from virion-containing fluids. For example, the fluids may be clarified by centrifugation, and stabilized with buffer (e.g. containing sucrose, potassium phosphate, and monosodium glutamate). Various forms of influenza virus vaccine are currently available (e.g. see chapters 17 &#x26; 18 of reference 44). Live virus vaccines include MedImmune's FLUMIST&#x2122; product (trivalent live virus vaccine).</p><p id="p-0125" num="0122">The virus may be attenuated. The virus may be temperature-sensitive. The virus may be cold-adapted. These three features are particularly useful when using live virus as an antigen.</p><p id="p-0126" num="0123">HA is the main immunogen in current inactivated influenza vaccines, and vaccine doses are standardised by reference to HA levels, typically measured by SRID. Existing vaccines typically contain about 15 &#x3bc;g of HA per strain, although lower doses can be used e.g. for children, or in pandemic situations, or when using an adjuvant. Fractional doses such as &#xbd; (i.e. 7.5 &#x3bc;g HA per strain), &#xbc; and &#x215b; have been used, as have higher doses (e.g. 3&#xd7; or 9&#xd7; doses [45,46]). Thus vaccines may include between 0.1 and 150 &#x3bc;g of HA per influenza strain, preferably between 0.1 and 50 &#x3bc;g e.g. 0.1-20 &#x3bc;g, 0.1-15 &#x3bc;g, 0.1-10 &#x3bc;g, 0.1-7.5 &#x3bc;g, 0.5-5 &#x3bc;g, etc. Particular doses include e.g. about 45, about 30, about 15, about 10, about 7.5, about 5, about 3.8, about 3.75, about 1.9, about 1.5, etc. per strain.</p><p id="p-0127" num="0124">For live vaccines, dosing is measured by median tissue culture infectious dose (TCID50) rather than HA content, and a TCID50 of between 10<sup>6 </sup>and 10<sup>8 </sup>(preferably between 10<sup>6.5</sup>-10<sup>7.5</sup>) per strain is typical.</p><p id="p-0128" num="0125">As well as being suitable for immunizing against inter-pandemic strains, the compositions of the invention may be useful for immunizing against pandemic or potentially-pandemic strains. The invention is suitable for vaccinating humans as well as non-human animals.</p><p id="p-0129" num="0126">Other strains whose antigens can usefully be included in the compositions are strains which are resistant to antiviral therapy (e.g. resistant to oseltamivir [47] and/or zanamivir), including resistant pandemic strains [48].</p><p id="p-0130" num="0127">Compositions of the invention (e.g. vaccines produced according to the invention) may include antigen(s) from one or more (e.g. 1, 2, 3, 4 or more) influenza virus strains, including influenza A virus and/or influenza B virus. Where a vaccine includes more than one strain of influenza, the different strains may be grown separately and are mixed after the viruses have been harvested and antigens have been prepared. Thus a process of the invention may include the step of mixing antigens from more than one influenza strain. A trivalent vaccine is typical, including antigens from two influenza A virus strains and one influenza B virus strain. A tetravalent vaccine is also useful [49], including antigens from two influenza A virus strains and two influenza B virus strains, or three influenza A virus strains and one influenza B virus strain.</p><heading id="h-0013" level="2">Pharmaceutical Compositions</heading><p id="p-0131" num="0128">Vaccine compositions manufactured according to the invention are pharmaceutically acceptable. They usually include components in addition to the antigens e.g. they typically include one or more pharmaceutical carrier(s) and/or excipient(s). A &#x201c;pharmaceutically acceptable carrier&#x201d; includes any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, sucrose, trehalose, lactose, and lipid aggregates (such as oil droplets or liposomes). Such carriers are well known to those of ordinary skill in the art. The compositions may also contain a pharmaceutically acceptable diluent, such as water, saline, glycerol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present. Sterile pyrogen-free, phosphate-buffered physiologic saline is a typical carrier (a thorough discussion of such components is available in reference 50). As described below, adjuvants may also be included.</p><p id="p-0132" num="0129">Vaccine compositions will generally be in aqueous form. However, some vaccines may be in dry form, e.g. in the form of injectable solids or dried or polymerized preparations on a patch.</p><p id="p-0133" num="0000">Vaccine compositions may include preservatives such as thiomersal or 2-phenoxyethanol. It is preferred, however, that the vaccine should be substantially free from (i.e. less than 5 &#x3bc;g/ml) mercurial material e.g. thiomersal-free [41,51]. Vaccines containing no mercury are more preferred. An &#x3b1;-tocopherol succinate can be included as an alternative to mercurial compounds [41]. Preservative-free vaccines are particularly preferred.</p><p id="p-0134" num="0130">To control tonicity, it is preferred to include a physiological salt, such as a sodium salt. Sodium chloride (NaCl) is preferred, which may be present at between 1 and 20 mg/ml. Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, disodium phosphate dehydrate, magnesium chloride, calcium chloride, etc.</p><p id="p-0135" num="0131">Vaccine compositions will generally have an osmolality of between 200 mOsm/kg and 400 mOsm/kg, preferably between 240-360 mOsm/kg, and will more preferably fall within the range of 290-310 mOsm/kg. Osmolality has previously been reported not to have an impact on pain caused by vaccination [52], but keeping osmolality in this range is nevertheless preferred.</p><p id="p-0136" num="0132">Vaccine compositions may include one or more buffers. Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer (particularly with an aluminium hydroxide adjuvant); or a citrate buffer. Buffers will typically be included in the 5-20 mM range.</p><p id="p-0137" num="0133">The pH of a vaccine composition will generally be between 5.0 and 8.1, and more typically between 6.0 and 8.0 e.g. 6.5 and 7.5, or between 7.0 and 7.8. A process of the invention may therefore include a step of adjusting the pH of the bulk vaccine prior to packaging.</p><p id="p-0138" num="0000">The vaccine composition is preferably sterile. The vaccine composition is preferably non-pyrogenic e.g. containing &#x3c;1 EU (endotoxin unit, a standard measure) per dose, and preferably &#x3c;0.1 EU per dose. The vaccine composition is preferably gluten-free.</p><p id="p-0139" num="0134">Vaccine compositions of the invention may include detergent e.g. a polyoxyethylene sorbitan ester surfactant (known as &#x2018;Tweens&#x2019;), an octoxynol (such as octoxynol-9 (Triton X-100) or t-octylphenoxypolyethoxyethanol), a cetyl trimethyl ammonium bromide (&#x2032;CTAW), or sodium deoxycholate, particularly for a split or surface antigen vaccine. The detergent may be present only at trace amounts. Thus the vaccine may include less than 1 mg/ml of each of octoxynol-10 and polysorbate 80. Other residual components in trace amounts could be antibiotics (e.g. neomycin, kanamycin, polymyxin B).</p><p id="p-0140" num="0135">A vaccine composition may include material for a single immunisation, or may include material for multiple immunisations (i.e. a &#x2018;multidose&#x2019; kit). The inclusion of a preservative is preferred in multidose arrangements. As an alternative (or in addition) to including a preservative in multidose compositions, the compositions may be contained in a container having an aseptic adaptor for removal of material.</p><p id="p-0141" num="0136">Influenza vaccines are typically administered in a dosage volume of about 0.5 ml, although a half dose (i.e. about 0.25 ml) may be administered to children.</p><p id="p-0142" num="0137">Compositions and kits are preferably stored at between 2&#xb0; C. and 8&#xb0; C. They should not be frozen. They should ideally be kept out of direct light.</p><heading id="h-0014" level="2">Adjuvants</heading><p id="p-0143" num="0138">Compositions of the invention (e.g. vaccines produced according to the invention) may advantageously include an adjuvant, which can function to enhance the immune responses (humoral and/or cellular) elicited in a subject who receives the composition.</p><p id="p-0144" num="0139">The adjuvant is preferably an oil-in-water emulsion adjuvant as they have been shown to work well with influenza antigens.</p><heading id="h-0015" level="2">Oil-In-Water Emulsion Adjuvants</heading><p id="p-0145" num="0140">Oil-in-water emulsions have been found to be particularly suitable for use in adjuvanting influenza virus vaccines. Various such emulsions are known, and they typically include at least one oil and at least one surfactant, with the oil(s) and surfactant(s) being biodegradable (metabolisable) and biocompatible. The oil droplets in the emulsion are generally less than 5 &#x3bc;m in diameter, and may even have a sub-micron diameter, with these small sizes being achieved with a microfluidiser to provide stable emulsions. Droplets with an average size less than 220 nm are preferred as they can be subjected to filter sterilization.</p><p id="p-0146" num="0141">In preferred embodiments, the oil-in-water emulsion is uniform. A uniform emulsion is characterized in that a majority of droplets (particles) dispersed therein is within a specified size range (e.g., in diameter). Suitable specified size range can be, for example, between 50-220 nm, between 50-180 nm, between 80-180 nm, between 100-175 nm, between 120-185 nm, between 130-190 nm, between 135-175 nm, between 150-175 nm. In some embodiments, the uniform emulsion contains &#x2264;10% of the number of droplets (particles) that are outside of the specified range of diameters. In some embodiments, mean particle size of oil droplets in the oil-in-water emulsion preparation is between 135-175 nm, e.g., 155 nm 20 nm as measured by dynamic light scattering, and such a preparation contains not more than 1&#xd7;10<sup>7 </sup>large particles per mL of the preparation, as measured by optical particle sensing. &#x201c;Large particles&#x201d; as used herein mean those having diameters &#x3e;1.2 &#x3bc;m, typically between 1.2-400 &#x3bc;m. In preferred embodiments, the uniform emulsion contains less than 10%, less than 5%, or less than 3% of the droplets that fall outside of the preferred size range. In some embodiments, the mean droplet size of particles in an oil-in-water emulsion preparation is between 125-185 nm, e.g., about 130 nm, about 140 nm, about 150 nm, about 155 nm, about 160 nm, about 170 nm, or about 180 nm, and the oil-in-water emulsion is uniform in that less than 5% of the number of droplets in the preparation fall outside the 125-185 nm range.</p><p id="p-0147" num="0142">The invention can be used with oils such as those from an animal (such as fish) or vegetable source. Sources for vegetable oils include nuts, seeds and grains. Peanut oil, soybean oil, coconut oil, and olive oil, the most commonly available, exemplify the nut oils. Jojoba oil can be used e.g. obtained from the jojoba bean. Seed oils include safflower oil, cottonseed oil, sunflower seed oil, sesame seed oil and the like. In the grain group, corn oil is the most readily available, but the oil of other cereal grains such as wheat, oats, rye, rice, teff, triticale and the like may also be used. 6-10 carbon fatty acid esters of glycerol and 1,2-propanediol, while not occurring naturally in seed oils, may be prepared by hydrolysis, separation and esterification of the appropriate materials starting from the nut and seed oils. Fats and oils from mammalian milk are metabolizable and may therefore be used in the practice of this invention. The procedures for separation, purification, saponification and other means necessary for obtaining pure oils from animal sources are well known in the art. Most fish contain metabolizable oils which may be readily recovered. For example, cod liver oil, shark liver oils, and whale oil such as spermaceti exemplify several of the fish oils which may be used herein. A number of branched chain oils are synthesized biochemically in 5-carbon isoprene units and are generally referred to as terpenoids. Shark liver oil contains a branched, unsaturated terpenoids known as squalene, 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene, which is particularly preferred herein. Squalane, the saturated analog to squalene, is also a preferred oil. Fish oils, including squalene and squalane, are readily available from commercial sources or may be obtained by methods known in the art. Other preferred oils are the tocopherols (see below). Mixtures of oils can be used.</p><p id="p-0148" num="0143">Surfactants can be classified by their &#x2018;HLB&#x2019; (hydrophile/lipophile balance). Preferred surfactants of the invention have a HLB of at least 10, preferably at least 15, and more preferably at least 16. The invention can be used with surfactants including, but not limited to: the polyoxyethylene sorbitan esters surfactants (commonly referred to as the Tweens), especially polysorbate 20 and polysorbate 80; copolymers of ethylene oxide (EO), propylene oxide (PO), and/or butylene oxide (BO), sold under the DOWFAX&#x2122; tradename, such as linear EO/PO block copolymers; octoxynols, which can vary in the number of repeating ethoxy (oxy-1,2-ethanediyl) groups, with octoxynol-9 (Triton X-100, or t-octylphenoxypolyethoxyethanol) being of particular interest; (octylphenoxy)polyethoxyethanol (IGEPAL CA-630/NP-40); phospholipids such as phosphatidylcholine (lecithin); polyoxyethylene fatty ethers derived from lauryl, cetyl, stearyl and oleyl alcohols (known as Brij surfactants), such as triethyleneglycol monolauryl ether (Brij 30); and sorbitan esters (commonly known as the SPANs), such as sorbitan trioleate (Span 85) and sorbitan monolaurate. Non-ionic surfactants are preferred. Preferred surfactants for including in the emulsion are Tween 80 (polyoxyethylene sorbitan monooleate), Span 85 (sorbitan trioleate), lecithin and Triton X-100.</p><p id="p-0149" num="0144">Mixtures of surfactants can be used, e.g., Tween 80/Span 85 mixtures. A combination of a polyoxyethylene sorbitan ester such as polyoxyethylene sorbitan monooleate (Tween 80) and an octoxynol such as t-octylphenoxypolyethoxyethanol (Triton X-100) is also suitable. Another useful combination comprises laureth 9 plus a polyoxyethylene sorbitan ester and/or an octoxynol.</p><p id="p-0150" num="0000">Preferred amounts of surfactants (% by weight) are: polyoxyethylene sorbitan esters (such as Tween 80) 0.01 to 1%, in particular about 0.1%; octyl- or nonylphenoxy polyoxyethanols (such as Triton X-100, or other detergents in the Triton series) 0.001 to 0.1%, in particular 0.005 to 0.02%; polyoxyethylene ethers (such as laureth 9) 0.1 to 20%, preferably 0.1 to 10% and in particular 0.1 to 1% or about 0.5%.</p><p id="p-0151" num="0145">The most preferred oil-in-water emulsions are squalene-in-water emulsions, preferably submicron squalene-in-water emulsions.</p><p id="p-0152" num="0146">Specific oil-in-water emulsions useful with the invention include, but are not limited to, the following, from which squalene-containing emulsions are preferred:</p><p id="p-0153" num="0147">A submicron emulsion of squalene, polysorbate 80, and sorbitan trioleate. The emulsion may include citrate ions in the aqueous phase, e.g., 10 mM sodium citrate buffer. The emulsion may comprise 3.2-4.6 mg/ml squalene, 4.1-5.3 mg/ml polysorbate 80, and 4.1-5.3 mg/ml sorbitan trioleate. The composition of the emulsion by volume can be about 4.6% squalene, about 0.45% polysorbate 80 and about 0.5% sorbitan trioleate. The adjuvant known as &#x201c;MF59&#x201d; [53, 54, 55] is described in more detail in chapter 10 of reference 56 and chapter 12 of reference 57. Squalene, polysorbate 80 and sorbitan trioleate may be present at a weight ratio of 9750:1175:1175. Concentrations of about 39 mg/mL squalene, about 4.7 mg/mL polysorbate 80, and about 4.7 mg/mL sorbitan trioleate are typical. A Z-average droplet size of between 155-185 nm is preferred, with a polydispersity of &#x3c;0.2.</p><p id="p-0154" num="0148">An emulsion comprising squalene, a tocopherol (in particular, DL-&#x3b1;-tocopherol), and polysorbate 80. The emulsion may include phosphate buffered saline. These emulsions may have by volume from 2 to 10% squalene, from 2 to 10% tocopherol and from 0.3 to 3% polysorbate 80, and the weight ratio of squalene:tocopherol is preferably &#x3c;1 (e.g., 0.90) as this can provide a more stable emulsion. Squalene and polysorbate 80 may be present volume ratio of about 5:2 or at a weight ratio of about 11:5. Thus the three components (squalene, tocopherol, polysorbate 80) may be present at a weight ratio of 1068:1186:485 or around 55:61:25. One such emulsion (&#x201c;AS03&#x201d;) includes 4.3% by weight squalene, 4.8% by weight tocopherol, and 2% by weight polysorbate 80. Concentrations of about 42.7 mg/mL squalene, about 47.4 mg/mL DL-&#x3b1;-tocopherol, and about 19.4 mg/mL polysorbate 80 are typical. A Z-average droplet size of between 140-170 nm is preferred. The emulsion may also include a 3-de-O-acylated monophosphoryl lipid A (3d MPL). Another useful emulsion of this type may comprise, per human dose, 0.5-10 mg squalene, 0.5-11 mg tocopherol, and 0.1-4 mg polysorbate 80 [58], e.g., in the ratios discussed above.</p><p id="p-0155" num="0149">An emulsion comprising squalene, an aqueous solvent, a polyoxyethylene alkyl ether hydrophilic nonionic surfactant (e.g., polyoxyethylene (12) cetostearyl ether) and a hydrophobic nonionic surfactant (e.g., a sorbitan ester or mannide ester, such as sorbitan monoleate or &#x2018;Span 80&#x2019;). The emulsion is preferably thermoreversible and/or has at least 90% of the oil droplets (by volume) with a size less than 200 nm [59]. The emulsion may also include one or more of: alditol; a cryoprotective agent (e.g. a sugar, such as dodecylmaltoside and/or sucrose); and/or an alkylpolyglycoside. The emulsion may include a TLR4 agonist [60]. Such emulsions may be lyophilized. A preferred emulsion includes squalene, sorbitan oleate, polyoxyethylene cetostearyl ether and mannitol (e.g., 32.5% squalene, 4.82% sorbitan oleate, 6.18% polyoxyethylene cetostearyl ether and 6% mannitol; % s by weight), with an average droplet size below 150 nm. Concentrations of about 49.6 mg/mL squalene, about 7.6 mg/mL sorbitan oleate, and about 9.6 mg/mL polyoxyethylene cetostearyl ether, and 9.2 mg/mL mannitol are typical.</p><p id="p-0156" num="0150">An emulsion comprising squalene, phosphatidylcholine, poloxamer 188, glycerol and an ammonium phosphate buffer [61], optionally also including an &#x3b1;-tocopherol (&#x2018;SE&#x2019;).</p><p id="p-0157" num="0000">An emulsion of squalene, a tocopherol, and a Triton detergent (e.g. Triton X-100). The emulsion may also include a 3d-MPL (see below). The emulsion may contain a phosphate buffer.</p><p id="p-0158" num="0151">An emulsion comprising a polysorbate (e.g., polysorbate 80), a Triton detergent (e.g., Triton X-100) and a tocopherol (e.g., an &#x3b1;-tocopherol succinate). The emulsion may include these three components at a mass ratio of about 75:11:10 (e.g., 750 &#x3bc;g/ml polysorbate 80, 110 &#x3bc;g/ml Triton X-100 and 100 &#x3bc;g/ml &#x3b1;-tocopherol succinate), and these concentrations should include any contribution of these components from antigens. The emulsion may also include squalene. The aqueous phase may contain a phosphate buffer.</p><p id="p-0159" num="0152">An emulsion of squalane, polysorbate 80 and poloxamer 401 (&#x201c;Pluronic&#x2122; L121&#x201d;). The emulsion can be formulated in phosphate buffered saline, pH 7.4. This emulsion is a useful delivery vehicle for muramyl dipeptides, and has been used with threonyl-MDP in the &#x201c;SAF-1&#x201d; adjuvant [62] (0.05-1% Thr-MDP, 5% squalane, 2.5% Pluronic L121 and 0.2% polysorbate 80). It can also be used without the Thr-MDP, as in the &#x201c;AF&#x201d; adjuvant [63] (5% squalane, 1.25% Pluronic L121 and 0.2% polysorbate 80). Microfluidisation is preferred.</p><p id="p-0160" num="0153">An emulsion of squalene, poloxamer 105 and Abil-Care [64]. The final concentration (weight) of these components in adjuvanted vaccines are 5% squalene, 4% poloxamer 105 (pluronic polyol) and 2% Abil-Care 85 (Bis-PEG/PPG-16/16 PEG/PPG-16/16 dimethicone; caprylic/capric triglyceride).</p><p id="p-0161" num="0154">An emulsion having from 0.5-50% oil, 0.1-10% phospholipid, and 0.05-5% non-ionic surfactant. As described in reference 65, preferred phospholipid components are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, sphingomyelin and cardiolipin. Submicron droplet sizes are advantageous.</p><p id="p-0162" num="0155">A submicron oil-in-water emulsion of a non-metabolizable oil (such as light mineral oil) and at least one surfactant (such as lecithin, Tween 80 or Span 80). Additives may be included, such as QuilA saponin, cholesterol, a saponin-lipophile conjugate (such as GPI-0100, described in reference 66, produced by addition of aliphatic amine to desacylsaponin via the carboxyl group of glucuronic acid), dimethyldioctadecylammonium bromide and/or N,N-dioctadecyl-N,N-bis (2-hydroxyethyl)propanediamine.</p><p id="p-0163" num="0156">An emulsion in which a saponin (e.g., QuilA or QS21) and a sterol (e.g., a cholesterol) are associated as helical micelles [67].</p><p id="p-0164" num="0157">An emulsion comprising a mineral oil, a non-ionic lipophilic ethoxylated fatty alcohol, and a non-ionic hydrophilic surfactant (e.g., an ethoxylated fatty alcohol and/or polyoxyethylene-polyoxypropylene block copolymer) [68].</p><p id="p-0165" num="0158">To make a vaccine for injection these emulsions will generally be mixed with an aqueous immunogen preparation. This mixing typically involves the emulsion in aqueous form with the immunogen in aqueous form at a 1:1 volume ratio, in which case the proportion of the emulsion's components will be halved in a final vaccine. For instance, an emulsion with 5% by volume squalene can be mixed at a 1:1 ratio with an antigen solution to give a vaccine with a final concentration of 2.5% by volume. Other mixing ratios are, of course, possible e.g. using a volume ratio of the two liquids for mixing between 5:1 and 1:5. Thus in a vaccine composition the concentrations of components of the emulsions noted above may be modified by dilution (e.g., by an integer, such as 2 or 3) in which their ratios stay the same. For example, pediatric vaccines may contain lower concentrations of an adjuvant, e.g., 4%, 3.5%, 3%, 2.5%, 2%, 1.5%, or 1% by volume squalene.</p><p id="p-0166" num="0159">After the antigen and adjuvant have been mixed, hemagglutinin antigen will generally remain in aqueous solution but may distribute itself around the oil/water interface. In general, little if any hemagglutinin will enter the oil phase of the emulsion.</p><p id="p-0167" num="0160">Where a composition includes a tocopherol, any of the &#x3b1;, &#x3b2;, &#x3b3;, &#x3b4;, &#x3be; or tocopherols can be used, but &#x3b1;-tocopherols are preferred. The tocopherol can take several forms, e.g., different salts and/or isomers. Salts include organic salts, such as succinate, acetate, nicotinate, etc. D-&#x3b1;-tocopherol and DL-&#x3b1;-tocopherol can both be used. Tocopherols are advantageously included in vaccines for use in elderly patients (e.g., aged 60 years or older) because vitamin E has been reported to have a positive effect on the immune response in this patient group [69]. They also have antioxidant properties that may help to stabilize the emulsions [70]. A preferred &#x3b1;-tocopherol is DL-&#x3b1;-tocopherol, and the preferred salt of this tocopherol is the succinate. The succinate salt has been found to cooperate with TNF-related ligands in vivo. Moreover, &#x3b1;-tocopherol succinate is known to be compatible with influenza vaccines and to be a useful preservative as an alternative to mercurial compounds [41]. Preservative-free vaccines are particularly preferred.</p><heading id="h-0016" level="2">Packaging of Vaccine Compositions</heading><p id="p-0168" num="0161">Suitable containers for compositions of the invention (or kit components) include vials, syringes (e.g. disposable syringes), nasal sprays, etc. These containers should be sterile.</p><p id="p-0169" num="0162">Where a composition/component is located in a vial, the vial is preferably made of a glass or plastic material. The vial is preferably sterilized before the composition is added to it. To avoid problems with latex-sensitive patients, vials are preferably sealed with a latex-free stopper, and the absence of latex in all packaging material is preferred. The vial may include a single dose of vaccine, or it may include more than one dose (a &#x2018;multidose&#x2019; vial) e.g. 10 doses. Preferred vials are made of colourless glass.</p><p id="p-0170" num="0163">A vial can have a cap (e.g. a Luer lock) adapted such that a pre-filled syringe can be inserted into the cap, the contents of the syringe can be expelled into the vial (e.g. to reconstitute lyophilised material therein), and the contents of the vial can be removed back into the syringe. After removal of the syringe from the vial, a needle can then be attached and the composition can be administered to a patient. The cap is preferably located inside a seal or cover, such that the seal or cover has to be removed before the cap can be accessed. A vial may have a cap that permits aseptic removal of its contents, particularly for multidose vials.</p><p id="p-0171" num="0164">Where a component is packaged into a syringe, the syringe may have a needle attached to it. If a needle is not attached, a separate needle may be supplied with the syringe for assembly and use. Such a needle may be sheathed. Safety needles are preferred. 1-inch 23-gauge, 1-inch 25-gauge and &#x215d;-inch 25-gauge needles are typical. Syringes may be provided with peel-off labels on which the lot number, influenza season and expiration date of the contents may be printed, to facilitate record keeping. The plunger in the syringe preferably has a stopper to prevent the plunger from being accidentally removed during aspiration. The syringes may have a latex rubber cap and/or plunger. Disposable syringes contain a single dose of vaccine. The syringe will generally have a tip cap to seal the tip prior to attachment of a needle, and the tip cap is preferably made of a butyl rubber. If the syringe and needle are packaged separately then the needle is preferably fitted with a butyl rubber shield. Preferred syringes are those marketed under the trade name &#x201c;Tip-Lok&#x201d;&#x2122;.</p><p id="p-0172" num="0165">Containers may be marked to show a half-dose volume e.g. to facilitate delivery to children. For instance, a syringe containing a 0.5 ml dose may have a mark showing a 0.25 ml volume.</p><p id="p-0173" num="0166">Where a glass container (e.g. a syringe or a vial) is used, then it is preferred to use a container made from a borosilicate glass rather than from a soda lime glass.</p><p id="p-0174" num="0167">A kit or composition may be packaged (e.g. in the same box) with a leaflet including details of the vaccine e.g. instructions for administration, details of the antigens within the vaccine, etc. The instructions may also contain warnings e.g. to keep a solution of adrenaline readily available in case of anaphylactic reaction following vaccination, etc.</p><heading id="h-0017" level="2">Methods of Treatment, and Administration of the Vaccine</heading><p id="p-0175" num="0168">The invention provides a vaccine manufactured according to the invention. These vaccine compositions are suitable for administration to human or non-human animal subjects, such as pigs, and the invention provides a method of raising an immune response in a subject, comprising the step of administering a vaccine composition of the invention to the subject. The invention also provides a composition of the invention for use as a medicament, and provides the use of a composition of the invention for the manufacture of a medicament for raising an immune response in a subject.</p><p id="p-0176" num="0169">The immune response raised by these methods and uses will generally include an antibody response, preferably a protective antibody response. Methods for assessing antibody responses, neutralising capability and protection after influenza virus vaccination are well known in the art. Human studies have shown that antibody titers against hemagglutinin of human influenza virus are correlated with protection (a serum sample hemagglutination-inhibition titer of about 30-40 gives around 50% protection from infection by a homologous virus) [71]. Antibody responses are typically measured by hemagglutination inhibition, by microneutralisation, by single radial immunodiffusion (SRID), and/or by single radial hemolysis (SRH). These assay techniques are well known in the art. Compositions of the invention can be administered in various ways. The most preferred immunisation route is by intramuscular injection (e.g. into the arm or leg), but other available routes include subcutaneous injection, intranasal [72-74], oral [75], intradermal [76,77], transcutaneous, transdermal [78], etc.</p><p id="p-0177" num="0170">Vaccines prepared according to the invention may be used to treat both children and adults. Influenza vaccines are currently recommended for use in pediatric and adult immunisation, from the age of 6 months. Thus a human subject may be less than 1 year old, 1-5 years old, 5-15 years old, 15-55 years old, or at least 55 years old. Preferred subjects for receiving the vaccines are the elderly (e.g. &#x2265;50 years old, &#x2265;60 years old, and preferably &#x2265;65 years), the young (e.g. &#x2264;5 years old), hospitalised subjects, healthcare workers, armed service and military personnel, pregnant women, the chronically ill, immunodeficient subjects, subjects who have taken an antiviral compound (e.g. an oseltamivir or zanamivir compound; see below) in the 7 days prior to receiving the vaccine, people with egg allergies and people travelling abroad. The vaccines are not suitable solely for these groups, however, and may be used more generally in a population. For pandemic strains, administration to all age groups is preferred.</p><p id="p-0178" num="0000">Preferred compositions of the invention satisfy 1, 2 or 3 of the CPMP criteria for efficacy. In adults (18-60 years), these criteria are: (1)&#x2265;70% seroprotection; (2)&#x2265;40% seroconversion; and/or (3) a GMT increase of &#x2265;2.5-fold. In elderly (&#x2265;60 years), these criteria are: (1)&#x2265;60% seroprotection; (2)&#x2265;30% seroconversion; and/or (3) a GMT increase of &#x2265;2-fold. These criteria are based on open label studies with at least 50 patients.</p><p id="p-0179" num="0171">Treatment can be by a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunisation schedule and/or in a booster immunisation schedule. In a multiple dose schedule the various doses may be given by the same or different routes e.g. a parenteral prime and mucosal boost, a mucosal prime and parenteral boost, etc. Administration of more than one dose (typically two doses) is particularly useful in immunologically na&#xef;ve patients e.g. for people who have never received an influenza vaccine before, or for vaccinating against a new HA subtype (as in a pandemic outbreak). Multiple doses will typically be administered at least 1 week apart (e.g. about 2 weeks, about 3 weeks, about 4 weeks, about 6 weeks, about 8 weeks, about 10 weeks, about 12 weeks, about 16 weeks, etc.).</p><p id="p-0180" num="0172">Vaccines produced by the invention may be administered to patients at substantially the same time as (e.g. during the same medical consultation or visit to a healthcare professional or vaccination centre) other vaccines e.g. at substantially the same time as a measles vaccine, a mumps vaccine, a rubella vaccine, a MMR vaccine, a varicella vaccine, a MMRV vaccine, a diphtheria vaccine, a tetanus vaccine, a pertussis vaccine, a DTP vaccine, a conjugated <i>H. influenzae </i>type b vaccine, an inactivated poliovirus vaccine, a hepatitis B virus vaccine, a meningococcal conjugate vaccine (such as a tetravalent A-C-W135-Y vaccine), a respiratory syncytial virus vaccine, a pneumococcal conjugate vaccine, etc. Administration at substantially the same time as a pneumococcal vaccine and/or a meningococcal vaccine is particularly useful in elderly patients.</p><p id="p-0181" num="0173">Similarly, vaccines of the invention may be administered to patients at substantially the same time as (e.g. during the same medical consultation or visit to a healthcare professional) an antiviral compound, and in particular an antiviral compound active against influenza virus (e.g. oseltamivir and/or zanamivir). These antivirals include neuraminidase inhibitors, such as a (3R,4R,5S)-4-acetylamino-5-amino-3(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid or 5-(acetylamino)-4-[(aminoiminomethyl)-amino]-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galactonon-2-enonic acid, including esters thereof (e.g. the ethyl esters) and salts thereof (e.g. the phosphate salts). A preferred antiviral is (3R,4R,5S)-4-acetylamino-5-amino-3(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid, ethyl ester, phosphate (1:1), also known as oseltamivir phosphate (TAMIFLU&#x2122;).</p><heading id="h-0018" level="1">Definitions</heading><p id="p-0182" num="0174">The term &#x201c;comprising&#x201d; encompasses &#x201c;including&#x201d; as well as &#x201c;consisting&#x201d; e.g. a composition &#x201c;comprising&#x201d; X may consist exclusively of X or may include something additional e.g. X+Y.</p><p id="p-0183" num="0175">The word &#x201c;substantially&#x201d; does not exclude &#x201c;completely&#x201d; e.g. a composition which is &#x201c;substantially free&#x201d; from Y may be completely free from Y. Where necessary, the word &#x201c;substantially&#x201d; may be omitted from the definition of the invention.</p><p id="p-0184" num="0176">The term &#x201c;about&#x201d; in relation to a numerical value x is optional and means, for example, x&#xb1;10%.</p><heading id="h-0019" level="1">EXAMPLES</heading><heading id="h-0020" level="2">Materials and Methods</heading><p id="p-0185" num="0177">Unless otherwise indicated, the following materials and methods were used in the following examples.</p><heading id="h-0021" level="2">Cells, Viruses and Antiserum</heading><p id="p-0186" num="0178">293T cells were obtained from Melbourne University and were maintained in DMEM containing 10% FBS, 1&#xd7;GlutaMAX (Gibco) and 1&#xd7;antibiotic/antimycotic (Gibco). MDCK (WHO) cells were obtained from the WHO and were maintained in DMEM containing 10% FBS, 1&#xd7;GlutaMAX (Gibco) and 1&#xd7;antibiotic/antimycotic (Gibco). MDCK 33016PF cells [79] were maintained in chemically defined medium (Lonza).</p><p id="p-0187" num="0179">The A/Texas/1/1977 high growth parent (HGP) virus (a 5:3 reassortant with PR8) was obtained from D274 (Seqirus). The PR8 HGP virus was generated using reverse genetics. Viruses were propagated in embryonated chicken eggs.</p><p id="p-0188" num="0180">Trypsin periodate-treated sheep antisera to A/PR/8/1934 and A/Texas/1/1977 were generated at Seqirus.</p><heading id="h-0022" level="2">Plasmids</heading><p id="p-0189" num="0181">Plasmids containing the HA and NA of PR8 (H1N1), A/Wyoming/3/2003 (H3N2), and A/Indonesia/NIHRD11771/2011 (H5N1) in the pHW2000 vector [80] were generated using standard molecular biology techniques. For H6N1, plasmids encoding H6 (A/turkey/Massachusetts/3740/1965) and N1 (A/Brisbane/59/2007 and A/California/07/2009) were generated using standard molecular biology techniques.</p><heading id="h-0023" level="2">Purification of HGP Viruses</heading><p id="p-0190" num="0182">High growth parent viruses (PR8 and A/Texas/1/1977) were purified prior to infection of the culture host. For each parent influenza virus strain, 2 ml of infected allantoic fluid was filtered through a 0.45 &#x3bc;m filter, and purified by centrifugation using a Microsep 300K Omega centrifugal device (PALL), at approximately 1400&#xd7; g for 1 hr. Retained virus was diluted in phosphate buffered saline (PBS)<sup>&#x2212; </sup>and centrifuged again using a fresh Microsep device. Retained virus was diluted to 1 ml using PBS<sup>&#x2212;</sup>, and frozen at &#x2212;80&#xb0; C. in 100 &#x3bc;l aliquots.</p><heading id="h-0024" level="2">Staggered Delivery of Influenza Virus Genes to Culture Host</heading><p id="p-0191" num="0183">Staggered delivery of influenza genes for the production of reassortant influenza viruses was performed by transfection of 293T/MDCK cocultures with plasmid DNA, followed by infection with the HGP at 1-24 hr post transfection. Transfection of 293T/MDCK cells with 1-2 &#x3bc;g of plasmids expressing viral HA and NA was performed using TransIT-293 (Minis), Lipofectamine 2000 (Invitrogen), or Lipofectamine 3000 (Invitrogen) transfection reagents according to the manufacturers' instructions.</p><p id="p-0192" num="0184">At approximately 3 hr post-transfection, the cells were washed with PBS<sup>&#x2212;</sup>, and the supernatant was replaced with 1 ml/well of fresh OptiMEM. The cells were then infected with HGP. TPCK-trypsin was added on day 1 post-transfection (1 &#x3bc;g/ml). Supernatant was collected on day 3 post-transfection.</p><heading id="h-0025" level="2">Co-Delivery of Influenza Virus Genes to Culture Host</heading><p id="p-0193" num="0185">Co-cultures of 293T and MDCK cells (WHO or MDCK 33016PF, suspension or adherent) were co-transfected with a purified HGP virus (10-20 &#x3bc;l/transfection (6 well plate) of neat purified HGP virus) along with 1-2 &#x3bc;g each of plasmid DNA encoding viral HA and NA. Transfection reagents TransIT-293 (Minis), Lipofectamine 2000 (Invitrogen), or Lipofectamine 3000 (Invitrogen) were used according to the manufacturers' instructions. Cells transfected using TransIT-293 were washed at approximately 3 hr post transfection. TPCK-trypsin (1 &#x3bc;g/ml) was added at day 1 post-transfection as described previously, or 4-8 h post-transfection. Supernatant was collected on days 3-6 post-transfection.</p><heading id="h-0026" level="2">Selection of Reassortant Influenza Viruses</heading><p id="p-0194" num="0186">Transfection supernatant subsequently underwent passaging in eggs in the presence of antiserum raised against the HGP virus. Briefly, for the first antiserum passage embryonated eggs were inoculated with 200 &#x3bc;l/egg of neat transfection supernatant, and an hour later were inoculated with 200 &#x3bc;l/egg of trypsin periodate-treated antiserum (raised against PR8 or A/Texas/1/1977, as appropriate). For the second antiserum passage, infected allantoic fluid harvested from the first antiserum passage were diluted according to HA titre and incubated for 1 hr at RT with an equal volume of antiserum, before inoculation of eggs at 200 &#x3bc;l/egg. For some transfections, viruses were cloned by limiting dilution.</p><p id="p-0195" num="0187">The HA and NA genotype of the reassortants was determined by real time PCR using gene-specific primers (Geneworks) and probes (Applied Biosystems or Sigma). Reactions were prepared using Taqman RT-PCR mastermix (Applied Biosystems) and PCR was performed using a 7500 Fast Real-Time PCR system (Applied Biosystems), according to the manufacturers' instructions.</p><heading id="h-0027" level="1">Example 1&#x2014;Generation of an H5N1 (A/Indonesia/NIHRD11771/2011) Reassortant Virus</heading><p id="p-0196" num="0188">An H5N1 reassortant virus was generated using a high growth parent strain (A/Texas/1/1977) and plasmids encoding the HA and NA genes of A/Indonesia/NIHRD11771/2011.</p><p id="p-0197" num="0189">Co-cultures of 293T/MDCK (WHO) were either transfected with a plasmid encoding the HA and NA genes of A/Indonesia/NIHRD11771/2011 and subsequently infected with the high growth parent strain, or co-transfected with HA- and NA-encoding plasmids and the high growth parent strain simultaneously (Table 1).</p><p id="p-0198" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="294pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Rescue of A/Indonesia/NIHRD11771/2011 reassortant virus</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="70pt" align="center"/><colspec colname="5" colwidth="77pt" align="center"/><tbody valign="top"><row><entry/><entry>Staggered</entry><entry>Co-delivered</entry><entry>1<sup>st </sup>antiserum passage</entry><entry>2<sup>nd </sup>antiserum passage</entry></row><row><entry>Virus</entry><entry>HGP delivery</entry><entry>HGP</entry><entry>maximum HA titre</entry><entry>maximum HA titre</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="70pt" align="char" char="."/><colspec colname="5" colwidth="77pt" align="char" char="."/><tbody valign="top"><row><entry>A/Indonesia</entry><entry>+</entry><entry>&#x2212;</entry><entry>65</entry><entry>&#x2265;905</entry></row><row><entry>(staggered)</entry><entry/><entry/><entry/><entry/></row><row><entry>A/Indonesia</entry><entry>&#x2212;</entry><entry>+</entry><entry>&#x2265;686</entry><entry>&#x2265;905</entry></row><row><entry>(co-delivered)</entry><entry/><entry/><entry/><entry/></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0199" num="0190">After transfection, the cell cultures were treated with antiserum. Following the first antiserum passage, HA titres were detected for both experiments, although higher HA titres were observed where the high growth parent had been delivered to cell culture simultaneously with the plasmid. A second antiserum passage demonstrated similar levels of virus replication for both the simultaneous transfection, as well as the experiment in which the cell culture was transfected with a plasmid prior to transfection with the high growth parent strain.</p><p id="p-0200" num="0191">Genotyping by RT-PCR indicated both viruses to be reassortants.</p><heading id="h-0028" level="1">Example 2&#x2014;Generation of an H1N1 (A/PR/8/1934) Reassortant Virus</heading><p id="p-0201" num="0192">A reassortant H1N1 virus (A/PR/8/1934) was generated using a high growth parent strain (A/Texas/1/77) and plasmids encoding the HA and NA genes of A/PR/8/1934.</p><p id="p-0202" num="0193">Co-cultures of 293T/MDCK (WHO) were co-transfected with the HA- and NA-encoding plasmids and the HGP simultaneously (Table 2).</p><p id="p-0203" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="364pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 2</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Rescue of A/PR/8/1934 reassortant virus.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="56pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="70pt" align="center"/><colspec colname="5" colwidth="70pt" align="center"/><colspec colname="6" colwidth="70pt" align="center"/><tbody valign="top"><row><entry/><entry>Staggered </entry><entry>Co-delivered</entry><entry>1<sup>st </sup>antiserum passage </entry><entry>2<sup>nd </sup>antiserum passage </entry><entry>3<sup>rd </sup>antiserum passage </entry></row><row><entry>Virus</entry><entry>HGP delivery</entry><entry>HGP</entry><entry>maximum HA titre</entry><entry>maximum HA titre</entry><entry>maximum HA titre</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="56pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="70pt" align="char" char="."/><colspec colname="5" colwidth="70pt" align="char" char="."/><colspec colname="6" colwidth="70pt" align="char" char="."/><tbody valign="top"><row><entry>PR8</entry><entry>&#x2212;</entry><entry>+</entry><entry>422</entry><entry>86</entry><entry>1040</entry></row><row><entry>(co-delivered)</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0204" num="0194">To confirm virus isolation, a third antiserum passage was performed, involving pre-incubation of virus with antisera as for the second antiserum method. Following this third antiserum passage, the HA titre of the progeny virus increased to levels typical of wild type A/PR/8/1934. Genotyping of the virus after the third antiserum passage showed the HA and NA genes of A/PR/8/1934, demonstrating successful generation of a 6:2 reassortant.</p><heading id="h-0029" level="1">Example 3&#x2014;Generation of an H3N1 (A/Wyoming/3/2003) Reassortant Virus</heading><p id="p-0205" num="0195">A reassortant H3N1 virus was generated through the use of a H1N1 HGP virus (A/PR/8/1934) and plasmids encoding the HA and NA genes of A/Wyoming/3/2003.</p><p id="p-0206" num="0196">Co-cultures of 293T/MDCK (WHO) were either transfected with plasmids encoding the HA and NA genes of A/Wyoming/3/2003 and subsequently infected with the HGP at approximately 3.5 h post-transfection, or co-transfected with HA- and NA-encoding plasmids and the HGP simultaneously (Table 3).</p><p id="p-0207" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="259pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 3</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Rescue of A/Wyoming/3/2003 reassortant virus.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="63pt" align="center"/><colspec colname="5" colwidth="63pt" align="center"/><tbody valign="top"><row><entry/><entry>Staggered HGP</entry><entry>Co-delivered</entry><entry>1<sup>st </sup>antiserum passage</entry><entry>2<sup>nd </sup>antiserum passage</entry></row><row><entry>Virus</entry><entry>delivery</entry><entry>HGP</entry><entry>maximum HA titre</entry><entry>maximum HA titre</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>A/Wyoming</entry><entry>+</entry><entry>&#x2212;</entry><entry>640</entry><entry>1372</entry></row><row><entry>(staggered)</entry><entry/><entry/><entry/><entry/></row><row><entry>A/Wyoming</entry><entry>&#x2212;</entry><entry>+</entry><entry>343</entry><entry>1280</entry></row><row><entry>(co-</entry><entry/><entry/><entry/><entry/></row><row><entry>delivered)</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0208" num="0197">Following the first antiserum passage, HA titres were detected for both the staggered HGP reassortant and the co-delivered HGP reassortant. A second antiserum passage demonstrated similar levels of virus replication for the two hybrid reassortment methods. Genotyping by real time PCR showed both viruses were reassortants.</p><heading id="h-0030" level="1">Example 4&#x2014;Generation of H6N1 Reassortant Viruses</heading><p id="p-0209" num="0198">Reassortant H6N1 viruses were generated through the use of a H3N2 HGP virus (A/Texas/1/1977) and plasmids encoding H6 (A/turkey/Massachusetts/3740/1965) and N1 (A/Brisbane/59/2007 and A/California/07/2009) genes.</p><p id="p-0210" num="0199">Co-cultures of 293T/adherent MDCK 33016PF cells were co-transfected with HA- and NA-encoding plasmids and the HGP simultaneously (Table 4).</p><p id="p-0211" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="266pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 4</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Rescue of H6N1 reassortant virus.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="49pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><colspec colname="7" colwidth="42pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry>1<sup>st </sup>antiserum</entry><entry>2<sup>nd </sup>antiserum</entry><entry>1<sup>st </sup>cloning</entry><entry>2<sup>nd </sup>cloning</entry></row><row><entry/><entry>Staggered</entry><entry>Co-</entry><entry>passage</entry><entry>passage</entry><entry>passage</entry><entry>passage</entry></row><row><entry/><entry>HGP</entry><entry>delivered</entry><entry>maximum</entry><entry>maximum</entry><entry>Maximum</entry><entry>maximum</entry></row><row><entry>Virus</entry><entry>delivery</entry><entry>HGP</entry><entry>HA titre</entry><entry>HA titre</entry><entry>HA titre</entry><entry>HA titre</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="49pt" align="char" char="."/><colspec colname="6" colwidth="35pt" align="center"/><colspec colname="7" colwidth="42pt" align="center"/><tbody valign="top"><row><entry>H6N1</entry><entry>&#x2212;</entry><entry>+</entry><entry>+ve</entry><entry>40</entry><entry>844</entry><entry>1280</entry></row><row><entry>(A/Bris</entry></row><row><entry>NA)</entry></row><row><entry>H6N1</entry><entry>&#x2212;</entry><entry>+</entry><entry>197</entry><entry>905</entry><entry>394</entry><entry>ND</entry></row><row><entry>(A/Cal</entry></row><row><entry>NA)</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row><row><entry namest="1" nameend="7" align="left" id="FOO-00001">ND&#x2014;not done</entry></row></tbody></tgroup></table></tables></p><p id="p-0212" num="0200">Genotyping by real time PCR showed both H6N1 progeny viruses were reassortants.</p><heading id="h-0031" level="1">Example 5&#x2014;Assessment of Genetic Diversity</heading><p id="p-0213" num="0201">Genetic diversity that can arise in the context of a replicating influenza virus to produce quasi-species was assessed by comparing the sequences of non-surface influenza proteins that are present in influenza A viruses obtained by classical reassortment or reverse genetics (RG). The nucleic acid sequence of backbone genes from a pool of 10 RG viruses (originally rescued by Seqirus, CDC and NIBSC) were sequenced and then translated to determine protein sequence. These sequences compared to corresponding sequences for 16 H1N1 and 32 H3N2 viruses obtained by classical reassortment (reassortants generated by Seqirus, NYMC and NIBSC).</p><p id="p-0214" num="0202">The analysis of M1, NP, NS1, PA and PB2 protein sequences demonstrated greater levels of sequence variation present in the reassorted viruses than the RG rescued viruses. The sequence divergence within each dataset was consistently greater for the reassortant virus datasets than for RG rescued viruses.</p><p id="p-0215" num="0203">Amino acid sequence variation in each backbone segment is illustrated in Tables 1-5 below. The frequency of an amino acid at specified positions is expressed as percentage of the number of sequences analysed for each source. The same data are presented in <figref idref="DRAWINGS">FIGS. <b>1</b>-<b>5</b></figref>.</p><p id="p-0216" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Ml protein sequence variation</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="84pt" align="center"/><colspec colname="2" colwidth="56pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>Sequence source</entry><entry>H1N1 reassortant</entry><entry>H3N2 reassortant</entry><entry>RG</entry></row><row><entry># M1 sequences analysed</entry><entry>16</entry><entry>32</entry><entry>10</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="133pt" align="center"/><tbody valign="top"><row><entry>Position</entry><entry>Amino acid</entry><entry>Frequency</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="char" char="."/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><colspec colname="5" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>30</entry><entry>D</entry><entry>88%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>13%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>41</entry><entry>V</entry><entry>88%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>13%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>95</entry><entry>K</entry><entry>88%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>13%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>101</entry><entry>R</entry><entry>88%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>13%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>115</entry><entry>I</entry><entry>88%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>13%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>121</entry><entry>A</entry><entry>88%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>13%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>137</entry><entry>A</entry><entry>88%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>13%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>142</entry><entry>V</entry><entry>88%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>13%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>166</entry><entry>V</entry><entry>88%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>13%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>207</entry><entry>S</entry><entry>88%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>13%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>209</entry><entry>A</entry><entry>88%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>13%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>214</entry><entry>Q</entry><entry>88%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>H</entry><entry>13%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>231</entry><entry>N</entry><entry>88%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>D</entry><entry>13%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0217" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 2</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>NP amino acid sequence variation</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="84pt" align="center"/><colspec colname="2" colwidth="56pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>Sequence source</entry><entry>H1N1 reassortant</entry><entry>H3N2 reassortant</entry><entry>RG</entry></row><row><entry># NP sequences analysed</entry><entry>16</entry><entry>32</entry><entry>11</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="133pt" align="center"/><tbody valign="top"><row><entry>Position</entry><entry>Amino acid</entry><entry>Frequency</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="char" char="."/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><colspec colname="5" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>16</entry><entry>D</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>G</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>18</entry><entry>E</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>D</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>21</entry><entry>N</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>D</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>31</entry><entry>K</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>34</entry><entry>G</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>D</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>52</entry><entry>Y</entry><entry>100%</entry><entry>&#x2002;88%</entry><entry>100%</entry></row><row><entry/><entry>H</entry><entry>&#x2003;0%</entry><entry>&#x2003;9%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>L</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>53</entry><entry>E</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>D</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>60</entry><entry>S</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>61</entry><entry>L</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>65</entry><entry>R</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>85</entry><entry>A</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>100</entry><entry>V</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>101</entry><entry>N</entry><entry>&#x2002;81%</entry><entry>&#x2002;84%</entry><entry>100%</entry></row><row><entry/><entry>D</entry><entry>&#x2002;19%</entry><entry>&#x2002;16%</entry><entry>&#x2003;0%</entry></row><row><entry>102</entry><entry>G</entry><entry>&#x2002;81%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2002;19%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>109</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>116</entry><entry>I</entry><entry>&#x2002;56%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>M</entry><entry>&#x2002;44%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>X</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>127</entry><entry>D</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>E</entry><entry>&#x2002;19%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>130</entry><entry>T</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>131</entry><entry>A</entry><entry>100%</entry><entry>&#x2002;88%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>136</entry><entry>M</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2002;19%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>186</entry><entry>V</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>189</entry><entry>M</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>190</entry><entry>V</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>194</entry><entry>V</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2002;19%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>197</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;84%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;16%</entry><entry>&#x2003;0%</entry></row><row><entry>214</entry><entry>K</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>217</entry><entry>I</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;38%</entry><entry>&#x2003;0%</entry></row><row><entry>236</entry><entry>K</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2002;19%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>239</entry><entry>M</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>253</entry><entry>F</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2002;19%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>257</entry><entry>T</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>1</entry><entry>&#x2002;19%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>280</entry><entry>V</entry><entry>100%</entry><entry>&#x2002;88%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>283</entry><entry>P</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>L</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>286</entry><entry>A</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>289</entry><entry>Y</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>H</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>290</entry><entry>D</entry><entry>100%</entry><entry>&#x2002;91%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2003;0%</entry><entry>&#x2003;9%</entry><entry>&#x2003;0%</entry></row><row><entry>293</entry><entry>R</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>305</entry><entry>R</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2002;19%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>312</entry><entry>V</entry><entry>100%</entry><entry>&#x2002;88%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>313</entry><entry>Y</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>316</entry><entry>I</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>M</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>343</entry><entry>V</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>L</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>344</entry><entry>L</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>348</entry><entry>K</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2002;19%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>350</entry><entry>T</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>353</entry><entry>L</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>&#x2002;67%</entry></row><row><entry/><entry>I</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry><entry>&#x2002;33%</entry></row><row><entry>371</entry><entry>M</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>372</entry><entry>E</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>D</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>373</entry><entry>T</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>375</entry><entry>E</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>D</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>G</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>377</entry><entry>S</entry><entry>&#x2002;81%</entry><entry>&#x2002;97%</entry><entry>&#x2002;83%</entry></row><row><entry/><entry>N</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2002;17%</entry></row><row><entry/><entry>G</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>384</entry><entry>R</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>G</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>400</entry><entry>R</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>406</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>408</entry><entry>I</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2002;19%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>421</entry><entry>D</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>E</entry><entry>&#x2002;19%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>422</entry><entry>R</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>423</entry><entry>T</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>425</entry><entry>I</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>&#x2002;67%</entry></row><row><entry/><entry>V</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2002;33%</entry></row><row><entry>430</entry><entry>N</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>&#x2002;67%</entry></row><row><entry/><entry>S</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>T</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2002;33%</entry></row><row><entry>433</entry><entry>T</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>442</entry><entry>T</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>444</entry><entry>I</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>450</entry><entry>S</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>G</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>452</entry><entry>R</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2002;19%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>455</entry><entry>D</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>E</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>456</entry><entry>V</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>L</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>459</entry><entry>Q</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>472</entry><entry>A</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2002;19%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>473</entry><entry>S</entry><entry>&#x2002;81%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2002;19%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>495</entry><entry>E</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>G</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>498</entry><entry>N</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0218" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 3</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>NSI amino acid sequence variation</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="84pt" align="center"/><colspec colname="2" colwidth="56pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>Sequence source</entry><entry>H1N1 reassortant</entry><entry>H3N2 reassortant</entry><entry>RG</entry></row><row><entry># NSI sequences analysed</entry><entry>16</entry><entry>31</entry><entry>11</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="133pt" align="center"/><tbody valign="top"><row><entry>Position</entry><entry>Amino acid</entry><entry>Frequency</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="35pt" align="char" char="."/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><colspec colname="5" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>3</entry><entry>P</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;6%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>6</entry><entry>V</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>M</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>18</entry><entry>V</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;6%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>21</entry><entry>R</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>Q</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>22</entry><entry>V</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>F</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>23</entry><entry>A</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>&#x2002;64%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2002;36%</entry></row><row><entry>25</entry><entry>Q</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>26</entry><entry>E</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>G</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>28</entry><entry>G</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>41</entry><entry>K</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>44</entry><entry>R</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>48</entry><entry>S</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2003;6%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>55</entry><entry>K</entry><entry>&#x2002;31%</entry><entry>&#x2002;58%</entry><entry>&#x2002;45%</entry></row><row><entry/><entry>E</entry><entry>&#x2002;69%</entry><entry>&#x2002;42%</entry><entry>&#x2002;45%</entry></row><row><entry>56</entry><entry>T</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>59</entry><entry>R</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>H</entry><entry>&#x2003;6%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>60</entry><entry>A</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;6%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>67</entry><entry>R</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>W</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>74</entry><entry>D</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>76</entry><entry>A</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>77</entry><entry>L</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>F</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>78</entry><entry>K</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>81</entry><entry>M</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>82</entry><entry>A</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>84</entry><entry>V</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>86</entry><entry>A</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>87</entry><entry>S</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>L</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>90</entry><entry>L</entry><entry>&#x2002;81%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2002;19%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>91</entry><entry>T</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>95</entry><entry>L</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>98</entry><entry>M</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>L</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>101</entry><entry>D</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>&#x2002;55%</entry></row><row><entry/><entry>N</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2002;45%</entry></row><row><entry>103</entry><entry>S</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>F</entry><entry>&#x2003;6%</entry><entry>&#x2002;10%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>L</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>104</entry><entry>M</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>106</entry><entry>I</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>M</entry><entry>&#x2003;6%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>108</entry><entry>K</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>111</entry><entry>V</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>112</entry><entry>A</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>E</entry><entry>&#x2003;6%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>113</entry><entry>G</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>120</entry><entry>D</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>G</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>123</entry><entry>I</entry><entry>&#x2002;94%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;6%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>125</entry><entry>D</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>E</entry><entry>&#x2003;6%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>129</entry><entry>I</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>M</entry><entry>0</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>132</entry><entry>A</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>139</entry><entry>D</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>142</entry><entry>E</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>G</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>144</entry><entry>L</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>145</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>166</entry><entry>L</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>F</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>171</entry><entry>A</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>0</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>Y</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>178</entry><entry>V</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>189</entry><entry>D</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>G</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>196</entry><entry>E</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>197</entry><entry>T</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2003;6%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>198</entry><entry>L</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>205</entry><entry>S</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>206</entry><entry>S</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>C</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>207</entry><entry>N</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>D</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>211</entry><entry>R</entry><entry>100%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>G</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>213</entry><entry>P</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>215</entry><entry>T</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>P</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>217</entry><entry>K</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>E</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>221</entry><entry>E</entry><entry>&#x2002;94%</entry><entry>&#x2002;94%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;0%</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>&#x2014;</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>224</entry><entry>G</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>&#x2014;</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>226</entry><entry>I</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>&#x2014;</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>229</entry><entry>E</entry><entry>&#x2002;94%</entry><entry>&#x2002;87%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>&#x2014;</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0219" num="0000"><tables id="TABLE-US-00008" num="00008"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 4</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>PA amino acid sequence variation</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="84pt" align="center"/><colspec colname="2" colwidth="56pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>Sequence source</entry><entry>H1N1 reassortant</entry><entry>H3N2 reassortant</entry><entry>RG</entry></row><row><entry># PA sequences analysed</entry><entry>16</entry><entry>32</entry><entry>10</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="133pt" align="center"/><tbody valign="top"><row><entry>Position</entry><entry>Amino acid</entry><entry>Frequency</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="char" char="."/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><colspec colname="5" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>20</entry><entry>T</entry><entry>&#x2002;75%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>&#x2002;25%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>28</entry><entry>L</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>P</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>55</entry><entry>N</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>D</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>57</entry><entry>Q</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>62</entry><entry>1</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>65</entry><entry>L</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>66</entry><entry>G</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>D</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>85</entry><entry>T</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>100</entry><entry>A</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>101</entry><entry>E</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>G</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>142</entry><entry>K</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>158</entry><entry>K</entry><entry>100%</entry><entry>100%</entry><entry>&#x2002;50%</entry></row><row><entry/><entry>R</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry><entry>&#x2002;50%</entry></row><row><entry>184</entry><entry>S</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>186</entry><entry>G</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>204</entry><entry>R</entry><entry>&#x2002;75%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2002;25%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>208</entry><entry>T</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>213</entry><entry>K</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>225</entry><entry>S</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>C</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>228</entry><entry>N</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>241</entry><entry>Y</entry><entry>&#x2002;75%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>C</entry><entry>&#x2002;25%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>249</entry><entry>M</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>256</entry><entry>R</entry><entry>&#x2002;75%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2002;25%</entry><entry>0</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>Q</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>262</entry><entry>K</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>268</entry><entry>L</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>269</entry><entry>R</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>272</entry><entry>N</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>D</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>275</entry><entry>P</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>L</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>277</entry><entry>S</entry><entry>&#x2002;75%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>H</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>Y</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>311</entry><entry>M</entry><entry>100%</entry><entry>&#x2002;81%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry>312</entry><entry>R</entry><entry>&#x2002;75%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2002;25%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>321</entry><entry>N</entry><entry>&#x2002;81%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>Y</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>322</entry><entry>V</entry><entry>&#x2002;75%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>1</entry><entry>&#x2002;25%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>323</entry><entry>V</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>1</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>332</entry><entry>p</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>336</entry><entry>L</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>M</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>337</entry><entry>S</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>343</entry><entry>A</entry><entry>&#x2002;81%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>354</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>356</entry><entry>K</entry><entry>&#x2002;75%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2002;25%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>362</entry><entry>K</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>382</entry><entry>D</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>E</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>383</entry><entry>D</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>385</entry><entry>K</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>387</entry><entry>V</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>388</entry><entry>G</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>394</entry><entry>D</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>395</entry><entry>S</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>397</entry><entry>E</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>400</entry><entry>L</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>P</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>404</entry><entry>A</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>407</entry><entry>I</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>421</entry><entry>S</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>437</entry><entry>H</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>Y</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>448</entry><entry>S</entry><entry>&#x2002;75%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>&#x2002;25%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>472</entry><entry>A</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>538</entry><entry>E</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>G</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>550</entry><entry>I</entry><entry>&#x2002;75%</entry><entry>&#x2002;78%</entry><entry>&#x2002;50%</entry></row><row><entry/><entry>L</entry><entry>&#x2002;25%</entry><entry>&#x2002;22%</entry><entry>&#x2002;50%</entry></row><row><entry>552</entry><entry>S</entry><entry>&#x2002;75%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>556</entry><entry>Q</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>L</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>557</entry><entry>V</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>558</entry><entry>S</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>L</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>573</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>613</entry><entry>E</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>614</entry><entry>N</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>618</entry><entry>T</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>626</entry><entry>K</entry><entry>&#x2002;75%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2002;25%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>631</entry><entry>S</entry><entry>&#x2002;75%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>G</entry><entry>&#x2002;25%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>668</entry><entry>1</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>683</entry><entry>L</entry><entry>&#x2002;81%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2002;19%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>716</entry><entry>S</entry><entry>&#x2002;75%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2002;25%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0220" num="0000"><tables id="TABLE-US-00009" num="00009"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 5</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>PB2 amino acid sequence variation</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="84pt" align="center"/><colspec colname="2" colwidth="56pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>Sequence source</entry><entry>H1N1 reassortant</entry><entry>H3N2 reassortant</entry><entry>RG</entry></row><row><entry># PB2 sequences analysed</entry><entry>16</entry><entry>32</entry><entry>10</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="133pt" align="center"/><tbody valign="top"><row><entry>Position</entry><entry>Amino acid</entry><entry>Frequency</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="35pt" align="char" char="."/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><colspec colname="5" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>8</entry><entry>R</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>ND</entry></row><row><entry/><entry>Q</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>ND</entry></row><row><entry>44</entry><entry>A</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>63</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>67</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;78%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;22%</entry><entry>&#x2003;0%</entry></row><row><entry>82</entry><entry>N</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>105</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>&#x2002;50%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry/><entry>M</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry><entry>&#x2002;50%</entry></row><row><entry>107</entry><entry>N</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>112</entry><entry>P</entry><entry>100%</entry><entry>&#x2002;94%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry></row><row><entry>114</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>120</entry><entry>E</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>D</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>121</entry><entry>R</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>136</entry><entry>R</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>G</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>194</entry><entry>Q</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>221</entry><entry>A</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>227</entry><entry>V</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>249</entry><entry>E</entry><entry>100%</entry><entry>&#x2002;84%</entry><entry>100%</entry></row><row><entry/><entry>G</entry><entry>&#x2003;0%</entry><entry>&#x2002;16%</entry><entry>&#x2003;0%</entry></row><row><entry>251</entry><entry>R</entry><entry>100%</entry><entry>100%</entry><entry>&#x2002;50%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry><entry>&#x2002;50%</entry></row><row><entry>292</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>293</entry><entry>R</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>299</entry><entry>R</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>&#x2002;50%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2002;50%</entry></row><row><entry>340</entry><entry>R</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>353</entry><entry>K</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>360</entry><entry>Y</entry><entry>100%</entry><entry>100%</entry><entry>&#x2002;50%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry><entry>&#x2002;50%</entry></row><row><entry>368</entry><entry>R</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>K</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>382</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>451</entry><entry>V</entry><entry>100%</entry><entry>&#x2002;91%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2003;9%</entry><entry>&#x2003;0%</entry></row><row><entry>453</entry><entry>P</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>H</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>456</entry><entry>N</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>461</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;88%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;13%</entry><entry>&#x2003;0%</entry></row><row><entry>463</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>471</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>478</entry><entry>V</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>480</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>490</entry><entry>S</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>N</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>504</entry><entry>I</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>&#x2002;50%</entry></row><row><entry/><entry>V</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2002;50%</entry></row><row><entry>526</entry><entry>K</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>R</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>559</entry><entry>T</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>560</entry><entry>V</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>569</entry><entry>T</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>590</entry><entry>G</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>596</entry><entry>V</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>A</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry>613</entry><entry>A</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>636</entry><entry>F</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>L</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>661</entry><entry>A</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>667</entry><entry>V</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>676</entry><entry>T</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>682</entry><entry>G</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>684</entry><entry>A</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>S</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>697</entry><entry>L</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>100%</entry></row><row><entry/><entry>I</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2003;0%</entry></row><row><entry>702</entry><entry>K</entry><entry>100%</entry><entry>&#x2002;75%</entry><entry>&#x2002;50%</entry></row><row><entry/><entry>R</entry><entry>&#x2003;0%</entry><entry>&#x2002;25%</entry><entry>&#x2002;50%</entry></row><row><entry>706</entry><entry>P</entry><entry>&#x2002;94%</entry><entry>100%</entry><entry>100%</entry></row><row><entry/><entry>L</entry><entry>&#x2003;6%</entry><entry>&#x2003;0%</entry><entry>&#x2003;0%</entry></row><row><entry>722</entry><entry>A</entry><entry>100%</entry><entry>&#x2002;97%</entry><entry>100%</entry></row><row><entry/><entry>T</entry><entry>&#x2003;0%</entry><entry>&#x2003;3%</entry><entry>&#x2003;0%</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0221" num="0204">These data illustrate the sequence variability in backbone gene segments that are delivered to a culture host when the culture host is contacted with a parent influenza virus strain where quasi-species are present. These data also illustrate the lack of sequence variability in viruses where the backbone segments were originally delivered on expression constructs such as plasmid that are used in reverse genetics techniques.</p><p id="p-0222" num="0205">The sequence diversity that is present in viruses that are produced by classical reassortment and reverse genetics was also analysed by assessing the number of mutations present in the sequenced backbone genes. These analyses are presented in Tables 6-10 and illustrate the increased backbone gene sequence diversity in in viruses that are produced by delivering influenza gene segments to a culture host through infection with a population of influenza virions (e.g. in classical reassortment). A similarly enhanced degree of sequence variation, relative to that in RG reassortants, can be expected to occur in the backbone gene segments of a parent influenza virus strain when used in a hybrid reassortant method of the invention</p><p id="p-0223" num="0000"><tables id="TABLE-US-00010" num="00010"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 6</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Ml Sequence analysis</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="112pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Sequence diversity</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="63pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry>Variation across </entry></row><row><entry>Source</entry><entry># Sequences</entry><entry># mutations</entry><entry>M1 protein (252 AA)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="char" char="."/><colspec colname="3" colwidth="49pt" align="char" char="."/><colspec colname="4" colwidth="63pt" align="center"/><tbody valign="top"><row><entry>H1N1 reassortants</entry><entry>16</entry><entry>13</entry><entry>5.2%</entry></row><row><entry>H3N2 reassortants</entry><entry>32</entry><entry>0</entry><entry>0.0%</entry></row><row><entry>Sequenced RG</entry><entry>10</entry><entry>1</entry><entry>0.4%</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0224" num="0000"><tables id="TABLE-US-00011" num="00011"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 7</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>NP Sequence analysis</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="112pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Sequence diversity</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="63pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry>Variation across </entry></row><row><entry>Source</entry><entry># Sequences</entry><entry># mutations</entry><entry>NP protein (498 AA)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="char" char="."/><colspec colname="3" colwidth="49pt" align="char" char="."/><colspec colname="4" colwidth="63pt" align="center"/><tbody valign="top"><row><entry>H1N1 reassortants</entry><entry>16</entry><entry>44</entry><entry>8.8%</entry></row><row><entry>H3N2 reassortants</entry><entry>32</entry><entry>43</entry><entry>8.6%</entry></row><row><entry>Sequenced RG</entry><entry>11</entry><entry>3</entry><entry>0.6%</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0225" num="0000"><tables id="TABLE-US-00012" num="00012"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 8</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>NSI Sequence analysis</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="112pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Sequence diversity</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="70pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry>Variation across</entry></row><row><entry>Source</entry><entry># Sequences</entry><entry># mutations</entry><entry>NSI protein (230 AA)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="char" char="."/><colspec colname="3" colwidth="42pt" align="char" char="."/><colspec colname="4" colwidth="70pt" align="center"/><tbody valign="top"><row><entry>H1N1 reassortants</entry><entry>16</entry><entry>54</entry><entry>23.5%</entry></row><row><entry>H3N2 reassortants</entry><entry>31</entry><entry>36</entry><entry>15.7%</entry></row><row><entry>Sequenced RG</entry><entry>11</entry><entry>4</entry><entry>&#x2002;1.7%</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0226" num="0000"><tables id="TABLE-US-00013" num="00013"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 9</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>PA Sequence analysis</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="112pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Sequence diversity</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="63pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry>Variation across </entry></row><row><entry>Source</entry><entry># Sequences</entry><entry># mutations</entry><entry>PA protein (716 AA)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="char" char="."/><colspec colname="3" colwidth="49pt" align="char" char="."/><colspec colname="4" colwidth="63pt" align="center"/><tbody valign="top"><row><entry>H1N1 reassortants</entry><entry>16</entry><entry>34</entry><entry>4.7%</entry></row><row><entry>H3N2 reassortants</entry><entry>32</entry><entry>37</entry><entry>5.2%</entry></row><row><entry>Sequenced RG</entry><entry>10</entry><entry>1</entry><entry>0.1%</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0227" num="0000"><tables id="TABLE-US-00014" num="00014"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 10</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>PB2 Sequence analysis</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="112pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Sequence diversity</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="70pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry>Variation across </entry></row><row><entry>Source</entry><entry># Sequences</entry><entry># mutations</entry><entry>PB2 protein (759 AA)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="char" char="."/><colspec colname="3" colwidth="42pt" align="char" char="."/><colspec colname="4" colwidth="70pt" align="center"/><tbody valign="top"><row><entry>H1N1 reassortants</entry><entry>16</entry><entry>1</entry><entry>0.1%</entry></row><row><entry>H3N2 reassortants</entry><entry>32</entry><entry>40</entry><entry>5.3%</entry></row><row><entry>Sequenced RG</entry><entry>10</entry><entry>6</entry><entry>0.8%</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0228" num="0000"><tables id="TABLE-US-00015" num="00015"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="350pt" align="center"/><thead><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>SEQUENCES</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="350pt" align="left"/><tbody valign="top"><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;1&#x2003;(PA,&#x2003;PR8-X)</entry></row><row><entry>AGCGAAAGCAGGTACTGATCCAAAATGGAAGATTTTGTGCGACAATGCTTCAATCCGATGATTGTCGAGCTTGCGGAAAA</entry></row><row><entry>AACAATGAAAGAGTATGGGGAGGACCTGAAAATCGAAACAAACAAATTTGCAGCAATATGCACTCACTTGGAAGTATGCT</entry></row><row><entry>TCATGTATTCAGATTTTCACTTCATCAATGAGCAAGGCGAGTCAATAATCGTAGAACTTGGTGATCCAAATGCACTTTTG</entry></row><row><entry>AAGCACAGATTTGAAATAATCGAGGGAAGAGATCGCACAATGGCCTGGACAGTAGTAAACAGTATTTGCAACACTACAGG</entry></row><row><entry>GGCTGAGAAACCAAAGTTTCTACCAGATTTGTATGATTACAAGGAGAATAGATTTATCGAAATTGGAGTAACAAGGAGAG</entry></row><row><entry>AAGTTCACATATACTATCTGGAAAAGGCCAATAAAATTAAATCTGAGAAAACACACATCCACATTTTCTCGTTCACTGGG</entry></row><row><entry>GAAGAAATGGCCACAAAGGCAGACTACACTCTCGATGAAGAAAGCAGGGCTAGGATCAAAACCAGACTATTCACCATAAG</entry></row><row><entry>ACAAGAAATGGCCAGCAGAGGCCTCTGGGATTCCTTTCGTCAGTCCGAGAGAGGAGAAGAGACAATTGAAGAAAGGTTTG</entry></row><row><entry>AAATCACAGGAACAATGCGCAAGCTTGCCGACCAAAGTCTCCCGCCGAACTTCTCCAGCCTTGAAAATTTTAGAGCCTAT</entry></row><row><entry>GTGGATGGATTCGAACCGAACGGCTACATTGAGGGCAAGCTGTCTCAAATGTCCAAAGAAGTAAATGCTAGAATTGAACC</entry></row><row><entry>TTTTTTGAAAACAACACCACGACCACTTAGACTTCCGAATGGGCCTCCCTGTTCTCAGCGGTCCAAATTCCTGCTGATGG</entry></row><row><entry>ATGCCTTAAAATTAAGCATTGAGGACCCAAGTCATGAAGGAGAGGGAATACCGCTATATGATGCAATCAAATGCATGAGA</entry></row><row><entry>ACATTCTTTGGATGGAAGGAACCCAATGTTGTTAAACCACACGAAAAGGGAATAAATCCAAATTATCTTCTGTCATGGAA</entry></row><row><entry>GCAAGTACTGGCAGAACTGCAGGACATTGAGAATGAGGAGAAAATTCCAAAGACTAAAAATATGAAGAAAACAAGTCAGC</entry></row><row><entry>TAAAGTGGGCACTTGGTGAGAACATGGCACCAGAAAAGGTAGACTTTGACGACTGTAAAGATGTAGGTGATTTGAAGCAA</entry></row><row><entry>TATGATAGTGATGAACCAGAATTGAGGTCGCTTGCAAGTTGGATTCAGAATGAGTTTAACAAGGCATGCGAACTGACAGA</entry></row><row><entry>TTCAAGCTGGATAGAGCTCGATGAGATTGGAGAAGATGTGGCTCCAATTGAACACATTGCAAGCATGAGAAGGAATTATT</entry></row><row><entry>TCACATCAGAGGTGTCTCACTGCAGAGCCACAGAATACATAATGAAGGGGGTGTACATCAATACTGCCTTGCTTAATGCA</entry></row><row><entry>TCTTGTGCAGCAATGGATGATTTCCAATTAATTCCAATGATAAGCAAGTGTAGAACTAAGGAGGGAAGGCGAAAGACCAA</entry></row><row><entry>CTTGTATGGTTTCATCATAAAAGGAAGATCCCACTTAAGGAATGACACCGACGTGGTAAACTTTGTGAGCATGGAGTTTT</entry></row><row><entry>CTCTCACTGACCCAAGACTTGAACCACATAAATGGGAGAAGTACTGTGTTCTTGAGATAGGAGATATGCTTATAAGAAGT</entry></row><row><entry>GCCATAGGCCAGGTTTCAAGGCCCATGTTCTTGTATGTGAGAACAAATGGAACCTCAAAAATTAAAATGAAATGGGGAAT</entry></row><row><entry>GGAGATGAGGCGTTGCCTCCTCCAGTCACTTCAACAAATTGAGAGTATGATTGAAGCTGAGTCCTCTGTCAAAGAGAAAG</entry></row><row><entry>ACATGACCAAAGAGTTCTTTGAGAACAAATCAGAAACATGGCCCATTGGAGAGTCCCCCAAAGGAGTGGAGGAAAGTTCC</entry></row><row><entry>ATTGGGAAGGTCTGCAGGACTTTATTAGCAAAGTCGGTATTCAACAGCTTGTATGCATCTCCACAACTAGAAGGATTTTC</entry></row><row><entry>AGCTGAATCAAGAAAACTGCTTCTTATCGTTCAGGCTCTTAGGGACAACCTTGAACCTGGGACCTTTGATCTTGGGGGGC</entry></row><row><entry>TATATGAAGCAATTGAGGAGTGCCTGATTAATGATCCCTGGGTTTTGCTTAATGCTTCTTGGTTCAACTCCTTCCTTACA</entry></row><row><entry>CATGCATTGAGTTAGTTGTGGCAGTGCTACTATTTGCTATCCATACTGTCCAAAAAAGTACCTTGTTTCTACT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;2&#x2003;(PB1,&#x2003;PR8-X)</entry></row><row><entry>AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACCTTACTTTTCTTAAAAGTGCCAACACAAAATGCTATAAG</entry></row><row><entry>CACAACTTTCCCTTATACTGGAGACCCTCCTTACAGCCATGGGACAGGAACAGGATACACCATGGATACTGTCAACAGGA</entry></row><row><entry>CACATCAGTACTCAGAAAAGGGAAGATGGACAACAAACACCGAAACTGGAGCACCGCAACTCAACCCGATTGATGGGCCA</entry></row><row><entry>CTGCCAGAAGACAATGAACCAAGTGGTTATGCCCAAACAGATTGTGTATTGGAGGCGATGGCTTTCCTTGAGGAATCCCA</entry></row><row><entry>TCCTGGTATTTTTGAAAACTCGTGTATTGAAACGATGGAGGTTGTTCAGCAAACACGAGTAGACAAGCTGACACAAGGCC</entry></row><row><entry>GACAGACCTATGACTGGACTCTAAATAGAAACCAACCTGCTGCAACAGCATTGGCCAACACAATAGAAGTGTTCAGATCA</entry></row><row><entry>AATGGCCTCACGGCCAATGAGTCTGGAAGGCTCATAGACTTCCTTAAGGATGTAATGGAGTCAATGAACAAAGAAGAAAT</entry></row><row><entry>GGGGATCACAACTCATTTTCAGAGAAAGAGACGGGTGAGAGACAATATGACTAAGAAAATGATAACACAGAGAACAATGG</entry></row><row><entry>GTAAAAAGAAGCAGAGATTGAACAAAAGGAGTTATCTAATTAGAGCATTGACCCTGAACACAATGACCAAAGATGCTGAG</entry></row><row><entry>AGAGGGAAGCTAAAACGGAGAGCAATTGCAACCCCAGGGATGCAAATAAGGGGGTTTGTATACTTTGTTGAGACACTGGC</entry></row><row><entry>AAGGAGTATATGTGAGAAACTTGAACAATCAGGGTTGCCAGTTGGAGGCAATGAGAAGAAAGCAAAGTTGGCAAATGTTG</entry></row><row><entry>TAAGGAAGATGATGACCAATTCTCAGGACACCGAACTTTCTTTCACCATCACTGGAGATAACACCAAATGGAACGAAAAT</entry></row><row><entry>CAGAATCCTCGGATGTTTTTGGCCATGATCACATATATGACCAGAAATCAGCCCGAATGGTTCAGAAATGTTCTAAGTAT</entry></row><row><entry>TGCTCCAATAATGTTCTCAAACAAAATGGCGAGACTGGGAAAAGGGTATATGTTTGAGAGCAAGAGTATGAAACTTAGAA</entry></row><row><entry>CTCAAATACCTGCAGAAATGCTAGCAAGCATCGATTTGAAATATTTCAATGATTCAACAAGAAAGAAGATTGAAAAAATC</entry></row><row><entry>CGACCGCTCTTAATAGAGGGGACTGCATCATTGAGCCCTGGAATGATGATGGGCATGTTCAATATGTTAAGCACTGTATT</entry></row><row><entry>AGGCGTCTCCATCCTGAATCTTGGACAAAAGAGATACACCAAGACTACTTACTGGTGGGATGGTCTTCAATCCTCTGACG</entry></row><row><entry>ATTTTGCTCTGATTGTGAATGCACCCAATCATGAAGGGATTCAAGCCGGAGTCGACAGGTTTTATCGAACCTGTAAGCTA</entry></row><row><entry>CTTGGAATCAATATGAGCAAGAAAAAGTCTTACATAAACAGAACAGGTACATTTGAATTCACAAGTTTTTTCTATCGTTA</entry></row><row><entry>TGGGTTTGTTGCCAATTTCAGCATGGAGCTTCCCAGTTTTGGGGTGTCTGGGATCAACGAGTCAGCGGACATGAGTATTG</entry></row><row><entry>GAGTTACTGTCATCAAAAACAATATGATAAACAATGATCTTGGTCCAGCAACAGCTCAAATGGCCCTTCAGTTGTTCATC</entry></row><row><entry>AAAGATTACAGGTACACGTACCGATGCCATAGAGGTGACACACAAATACAAACCCGAAGATCATTTGAAATAAAGAAACT</entry></row><row><entry>GTGGGAGCAAACCCGTTCCAAAGCTGGACTGCTGGTCTCCGACGGAGGCCCAAATTTATACAACATTAGAAATCTCCACA</entry></row><row><entry>TTCCTGAAGTCTGCCTAAAATGGGAATTGATGGATGAGGATTACCAGGGGCGTTTATGCAACCCACTGAACCCATTTGTC</entry></row><row><entry>AGCCATAAAGAAATTGAATCAATGAACAATGCAGTGATGATGCCAGCACATGGTCCAGCCAAAAACATGGAGTATGATGC</entry></row><row><entry>TGTTGCAACAACACACTCCTGGATCCCCAAAAGAAATCGATCCATCTTGAATACAAGTCAAAGAGGAGTACTTGAGGATG</entry></row><row><entry>AACAAATGTACCAAAGGTGCTGCAATTTATTTGAAAAATTCTTCCCCAGCAGTTCATACAGAAGACCAGTCGGGATATCC</entry></row><row><entry>AGTATGGTGGAGGCTATGGTTTCCAGAGCCCGAATTGATGCACGGATTGATTTCGAATCTGGAAGGATAAAGAAAGAAGA</entry></row><row><entry>GTTCACTGAGATCATGAAGATCTGTTCCACCATTGAAGAGCTCAGACGGCAAAAATAGTGAATTTAGCTTGTCCTTCATG</entry></row><row><entry>AAAAAATGCCTTGTTTCTACT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;3&#x2003;(PB2,&#x2003;PR8-X)</entry></row><row><entry>AGCGAAAGCAGGTCAATTATATTCAATATGGAAAGAATAAAAGAACTAAGAAATCTAATGTCGCAGTCTCGCACCCGCGA</entry></row><row><entry>GATACTCACAAAAACCACCGTGGACCATATGGCCATAATCAAGAAGTACACATCAGGAAGACAGGAGAAGAACCCAGCAC</entry></row><row><entry>TTAGGATGAAATGGATGATGGCAATGAAATATCCAATTACAGCAGACAAGAGGATAACGGAAATGATTCCTGAGAGAAAT</entry></row><row><entry>GAGCAAGGACAAACTTTATGGAGTAAAATGAATGATGCCGGATCAGACCGAGTGATGGTATCACCTCTGGCTGTGACATG</entry></row><row><entry>GTGGAATAGGAATGGACCAATAACAAATACAGTTCATTATCCAAAAATCTACAAAACTTATTTTGAAAGAGTAGAAAGGC</entry></row><row><entry>TAAAGCATGGAACCTTTGGCCCTGTCCATTTTAGAAACCAAGTCAAAATACGTCGGAGAGTTGACATAAATCCTGGTCAT</entry></row><row><entry>GCAGATCTCAGTGCCAAGGAGGCACAGGATGTAATCATGGAAGTTGTTTTCCCTAACGAAGTGGGAGCCAGGATACTAAC</entry></row><row><entry>ATCGGAATCGCAACTAACGATAACCAAAGAGAAGAAAGAAGAACTCCAGGATTGCAAAATTTCTCCTTTGATGGTTGCAT</entry></row><row><entry>ACATGTTGGAGAGAGAACTGGTCCGCAAAACGAGATTCCTCCCAGTGGCTGGTGGAACAAGCAGTGTGTACATTGAAGTG</entry></row><row><entry>TTGCATTTGACTCAAGGAACATGCTGGGAACAGATGTATACTCCAGGAGGGGAAGTGAGGAATGATGATGTTGATCAAAG</entry></row><row><entry>CTTGATTATTGCTGCTAGGAACATAGTGAGAAGAGCTGCAGTATCAGCAGATCCACTAGCATCTTTATTGGAGATGTGCC</entry></row><row><entry>ACAGCACACAGATTGGTGGAATTAGGATGGTAGACATCCTTAGGCAGAACCCAACAGAAGAGCAAGCCGTGGATATATGC</entry></row><row><entry>AAGGCTGCAATGGGACTGAGAATTAGCTCATCCTTCAGTTTTGGTGGATTCACATTTAAGAGAACAAGCGGATCATCAGT</entry></row><row><entry>CAAGAGAGAGGAAGAGGTGCTTACGGGAAATCTTCAAACATTGAAGATAAGAGTGCATGAGGGATATGAAGAGTTCACAA</entry></row><row><entry>TGGTTGGGAGAAGAGCAACAGCCATACTCAGAAAAGCAACCAGGAGATTGATTCAGCTGATAGTGAGTGGGAGAGACGAA</entry></row><row><entry>CAGTCGATTGCCGAAGCAATAATTGTGGCCATGGTATTTTCACAAGAGGATTGTATGATAAAAGCAGTCAGAGGTGATCT</entry></row><row><entry>GAATTTCGTCAATAGGGCGAATCAGCGATTGAATCCTATGCATCAACTTTTAAGACATTTTCAGAAGGATGCGAGAGTGC</entry></row><row><entry>TTTTTCAAAATTGGGGAGTTGAACCTATCGACAATGTGATGGGAATGATTGGGATATTGCCCGACATGACTCCAAGCATC</entry></row><row><entry>GAGATGTCAATGAGAGGAGTGAGAATCAGCAAAATGGGTGTAGATGAGTACTCCAGCACGGAGAGGGTAGTGGTGAGCAT</entry></row><row><entry>TGACCGTTTTTTGAGAATCCGGGACCAACGAGGAAATGTACTACTGTCTCCCGAGGAGGTCAGTGAAACACAGGGAACAG</entry></row><row><entry>AGAAACTGACAATAACTTACTCATCGTCAATGATGTGGGAGATTAATGGTCCTGAATCAGTATTGGTCAATACCTATCAA</entry></row><row><entry>TGGATCATCAGAAACTGGGAAACTGTTAAAATTCAGTGGTCCCAGAACCCTACAATGCTATACAATAAAATGGAATTTGA</entry></row><row><entry>ACCATTTCAGTCTTTAGTACCTAAGGCCATTAGAGGCCAATACAGTGGGTTTGTAAGAACTCTGTTCCAACAAATGAGGG</entry></row><row><entry>ATGTGCTTGGGACATTTGATACCGCACAGATAATAAAACTTCTTCCCTTCGCAGCCGCTCCACCAAAGCAAAGTAGAATG</entry></row><row><entry>CAGTTCTCCTCATTTACTGTGAATGTGAGGGGATCAGGAATGAGAATACTTGTAAGGGGCAATTCTCCTGTATTCAACTA</entry></row><row><entry>TAACAAGGCCACGAAGAGACTCACAGTTCTCGGAAAGGATGCTGGCACTTTAACTGAAGACCCAGATGAAGGCACAGCTG</entry></row><row><entry>GAGTGGAGTCCGCTGTTCTGAGGGGATTCCTCATTCTGGGCAAAGAAGACAAGAGATATGGGCCAGCACTAAGCATCAAT</entry></row><row><entry>GAACTGAGCAACCTTGCGAAAGGAGAGAAGGCTAATGTGCTAATTGGGCAAGGAGACGTGGTGTTGGTAATGAAACGGAA</entry></row><row><entry>ACGGGACTCTAGCATACTTACTGACAGCCAGACAGCGACCAAAAGAATTCGGATGGCCATCAATTAGTGTCGAATAGTTT</entry></row><row><entry>AAAAACGACCTTGTTTCTACT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;4&#x2003;(NP,&#x2003;PR8-X)</entry></row><row><entry>AGCAAAAGCAGGGTAGATAATCACTCACTGAGTGACATCAAAATCATGGCGTCTCAAGGCACCAAACGATCTTACGAACA</entry></row><row><entry>GATGGAGACTGATGGAGAACGCCAGAATGCCACTGAAATCAGAGCATCCGTCGGAAAAATGATTGGTGGAATTGGACGAT</entry></row><row><entry>TCTACATCCAAATGTGCACCGAACTCAAACTCAGTGATTATGAGGGACGGTTGATCCAAAACAGCTTAACAATAGAGAGA</entry></row><row><entry>ATGGTGCTCTCTGCTTTTGACGAAAGGAGAAATAAATACCTTGAAGAACATCCCAGTGCGGGAAAAGATCCTAAGAAAAC</entry></row><row><entry>TGGAGGACCTATATACAGGAGAGTAAACGGAAAGTGGATGAGAGAACTCATCCTTTATGACAAAGAAGAAATAAGGCGAA</entry></row><row><entry>TCTGGCGCCAAGCTAATAATGGTGACGATGCAACGGCTGGTCTGACTCACATGATGATCTGGCATTCCAATTTGAATGAT</entry></row><row><entry>GCAACTTATCAGAGGACAAGAGCTCTTGTTCGCACCGGAATGGATCCCAGGATGTGCTCTCTGATGCAAGGTTCAACTCT</entry></row><row><entry>CCCTAGGAGGTCTGGAGCCGCAGGTGCTGCAGTCAAAGGAGTTGGAACAATGGTGATGGAATTGGTCAGAATGATCAAAC</entry></row><row><entry>GTGGGATCAATGATCGGAACTTCTGGAGGGGTGAGAATGGACGAAAAACAAGAATTGCTTATGAAAGAATGTGCAACATT</entry></row><row><entry>CTCAAAGGGAAATTTCAAACTGCTGCACAAAAAGCAATGATGGATCAAGTGAGAGAGAGCCGGAACCCAGGGAATGCTGA</entry></row><row><entry>GTTCGAAGATCTCACTTTTCTAGCACGGTCTGCACTCATATTGAGAGGGTCGGTTGCTCACAAGTCCTGCCTGCCTGCCT</entry></row><row><entry>GTGTGTATGGACCTGCCGTAGCCAGTGGGTACGACTTTGAAAGGGAGGGATACTCTCTAGTCGGAATAGACCCTTTCAGA</entry></row><row><entry>CTGCTTCAAAACAGCCAAGTGTACAGCCTAATCAGACCAAATGAGAATCCAGCACACAAGAGTCAACTGGTGTGGATGGC</entry></row><row><entry>ATGCCATTCTGCCGCATTTGAAGATCTAAGAGTATTAAGCTTCATCAAAGGGACGAAGGTGCTCCCAAGAGGGAAGCTTT</entry></row><row><entry>CCACTAGAGGAGTTCAAATTGCTTCCAATGAAAATATGGAGACTATGGAATCAAGTACACTTGAACTGAGAAGCAGGTAC</entry></row><row><entry>TGGGCCATAAGGACCAGAAGTGGAGGAAACACCAATCAACAGAGGGCATCTGCGGGCCAAATCAGCATACAACCTACGTT</entry></row><row><entry>CTCAGTACAGAGAAATCTCCCTTTTGACAGAACAACCATTATGGCAGCATTCAATGGGAATACAGAGGGGAGAACATCTG</entry></row><row><entry>ACATGAGGACCGAAATCATAAGGATGATGGAAAGTGCAAGACCAGAAGATGTGTCTTTCCAGGGGCGGGGAGTCTTCGAG</entry></row><row><entry>CTCTCGGACGAAAAGGCAGCGAGCCCGATCGTGCCTTCCTTTGACATGAGTAATGAAGGATCTTATTTCTTCGGAGACAA</entry></row><row><entry>TGCAGAGGAGTACGACAATTAAAGAAAAATACCCTTGTTTCTACT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;5&#x2003;(M,&#x2003;PR8-X)</entry></row><row><entry>AGCAAAAGCAGGTAGATATTGAAAGATGAGTCTTCTAACCGAGGTCGAAACGTACGTACTCTCTATCATCCCGTCAGGCC</entry></row><row><entry>CCCTCAAAGCCGAGATCGCACAGAGACTTGAAGATGTCTTTGCAGGGAAGAACACCGATCTTGAGGTTCTCATGGAATGG</entry></row><row><entry>CTAAAGACAAGACCAATCCTGTCACCTCTGACTAAGGGGATTTTAGGATTTGTGTTCACGCTCACCGTGCCCAGTGAGCG</entry></row><row><entry>AGGACTGCAGCGTAGACGCTTTGTCCAAAATGCCCTTAATGGGAACGGGGATCCAAATAACATGGACAAAGCAGTTAAAC</entry></row><row><entry>TGTATAGGAAGCTCAAGAGGGAGATAACATTCCATGGGGCCAAAGAAATCTCACTCAGTTATTCTGCTGGTGCACTTGCC</entry></row><row><entry>AGTTGTATGGGCCTCATATACAACAGGATGGGGGCTGTGACCACTGAAGTGGCATTTGGCCTGGTATGTGCAACCTGTGA</entry></row><row><entry>ACAGATTGCTGACTCCCAGCATCGGTCTCATAGGCAAATGGTGACAACAACCAATCCACTAATCAGACATGAGAACAGAA</entry></row><row><entry>TGGTTTTAGCCAGCACTACAGCTAAGGCTATGGAGCAAATGGCTGGATCGAGTGAGCAAGCAGCAGAGGCCATGGAGGTT</entry></row><row><entry>GCTAGTCAGGCTAGACAAATGGTGCAAGCGATGAGAACCATTGGGACTCATCCTAGCTCCAGTGCTGGTCTGAAAAATGA</entry></row><row><entry>TCTTCTTGAAAATTTGCAGGCCTATCAGAAACGAATGGGGGTGCAGATGCAACGGTTCAAGTGATCCTCTCACTATTGCC</entry></row><row><entry>GCAAATATCATTGGGATCTTGCACTTGACATTGTGGATTCTTGATCGTCTTTTTTTCAAATGCATTTACCGTCGCTTTAA</entry></row><row><entry>ATACGGACTGAAAGGAGGGCCTTCTACGGAAGGAGTGCCAAAGTCTATGAGGGAAGAATATCGAAAGGAACAGCAGAGTG</entry></row><row><entry>CTGTGGATGCTGACGATGGTCATTTTGTCAGCATAGAGCTGGAGTAAAAAACTACCTTGTTTCTACT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;6&#x2003;(NS,&#x2003;PR8-X)</entry></row><row><entry>AGCAAAAGCAGGGTGACAAAAACATAATGGATCCAAACACTGTGTCAAGCTTTCAGGTAGATTGCTTTCTTTGGCATGTC</entry></row><row><entry>CGCAAACGAGTTGCAGACCAAGAACTAGGTGATGCCCCATTCCTTGATCGGCTTCGCCGAGATCAGAAATCCCTAAGAGG</entry></row><row><entry>AAGGGGCAGTACTCTCGGTCTGGACATCAAGACAGCCACACGTGCTGGAAAGCAGATAGTGGAGCGGATTCTGAAAGAAG</entry></row><row><entry>AATCCGATGAGGCACTTAAAATGACCATGGCCTCTGTACCTGCGTCGCGTTACCTAACTGACATGACTCTTGAGGAAATG</entry></row><row><entry>TCAAGGGACTGGTCCATGCTCATACCCAAGCAGAAAGTGGCAGGCCCTCTTTGTATCAGAATGGACCAGGCGATCATGGA</entry></row><row><entry>TAAGAACATCATACTGAAAGCGAACTTCAGTGTGATTTTTGACCGGCTGGAGACTCTAATATTGCTAAGGGCTTTCACCG</entry></row><row><entry>AAGAGGGAGCAATTGTTGGCGAAATTTCACCATTGCCTTCTCTTCCAGGACATACTGCTGAGGATGTCAAAAATGCAGTT</entry></row><row><entry>GGAGTCCTCATCGGAGGACTTGAATGGAATGATAACACAGTTCGAGTCTCTGAAACTCTACAGAGATTCGCTTGGAGAAG</entry></row><row><entry>CAGTAATGAGAATGGGAGACCTCCACTCACTCCAAAACAGAAACGAGAAATGGCGGGAACAATTAGGTCAGAAGTTTGAA</entry></row><row><entry>GAAATAAGATGGTTGATTGAAGAAGTGAGACACAAACTGAAGATAACAGAGAATAGTTTTGAGCAAATAACATTTATGCA</entry></row><row><entry>AGCCTTACATCTATTGCTTGAAGTGGAGCAAGAGATAAGAACTTTCTCGTTTCAGCTTATTTAGTACTAAAAAACACCCT</entry></row><row><entry>TGTTTCTACT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;7&#x2003;(HA,&#x2003;PR8-X)</entry></row><row><entry>AGCAAAAGCAGGGGAAAATAAAAACAACCAAAATGAAGGCAAACCTACTGGTCCTGTTATGTGCACTTGCAGCTGCAGAT</entry></row><row><entry>GCAGACACAATATGTATAGGCTACCATACGAACAATTCAACCGACACTGTTGACACAGTACTCGAGAAGAATGTGACAGT</entry></row><row><entry>GACACACTCTGTTAACCTGCTCGAAGACAGCCACAACGGAAAACTATGTAGATTAAAAGGAATAGCCCCACTACAATTGG</entry></row><row><entry>GGAAATGTAACATCGCCGGATGGCTCTTGGGAAACCCAGAATGCGACCCACTGCTTCCAGTGAGATCATGGTCCTACATT</entry></row><row><entry>GTAGAAACACCAAACTCTGAGAATGGAATATGTTATCCAGGAGATTTCATCGACTATGAGGAGCTGAGGGAGCAATTGAG</entry></row><row><entry>CTCAGTGTCATCATTCGAAAGATTCGAAATATTTCCCAAAGAAAGCTCATGGCCCAACCACAACACAAACGGAGTAACGG</entry></row><row><entry>CAGCATGCTCCCATGAGGGGAAAAGCAGTTTTTACAGAAATTTGCTATGGCTGACGGAGAAGGAGGGCTCATACCCAAAG</entry></row><row><entry>CTGAAAAATTCTTATGTGAACAAAAAAGGGAAAGAAGTCCTTGTACTGTGGGGTATTCATCACCCGCCTAACAGTAAGGA</entry></row><row><entry>ACAACAGAATCTCTATCAGAATGAAAATGCTTATGTCTCTGTAGTGACTTCAAATTATAACAGGAGATTTACCCCGGAAA</entry></row><row><entry>TAGCAGAAAGACCCAAAGTAAGAGATCAAGCTGGGAGGATGAACTATTACTGGACCTTGCTAAAACCCGGAGACACAATA</entry></row><row><entry>ATATTTGAGGCAAATGGAAATCTAATAGCACCAATGTATGCTTTCGCACTGAGTAGAGGCTTTGGGTCCGGCATCATCAC</entry></row><row><entry>CTCAAACGCATCAATGCATGAGTGTAACACGAAGTGTCAAACACCCCTGGGAGCTATAAACAGCAGTCTCCCTTACCAGA</entry></row><row><entry>ATATACACCCAGTCACAATAGGAGAGTGCCCAAAATACGTCAGGAGTGCCAAATTGAGGATGGTTACAGGACTAAGGAAC</entry></row><row><entry>ATTCCGTCCATTCAATCCAGAGGTCTATTTGGAGCCATTGCCGGTTTTATTGAAGGGGGATGGACTGGAATGATAGATGG</entry></row><row><entry>ATGGTATGGTTATCATCATCAGAATGAACAGGGATCAGGCTATGCAGCGGATCAAAAAAGCACACAAAATGCCATTAACG</entry></row><row><entry>GGATTACAAACAAGGTGAACACTGTTATCGAGAAAATGAACATTCAATTCACAGCTGTGGGTAAAGAATTCAACAAATTA</entry></row><row><entry>GAAAAAAGGATGGAAAATTTAAATAAAAAAGTTGATGATGGATTTCTGGACATTTGGACATATAATGCAGAATTGTTAGT</entry></row><row><entry>TCTACTGGAAAATGAAAGGACTCTGGAATTCCATGACTCAAATGTGAAGAATCTGTATGAGAAAGTAAAAAGCCAATTAA</entry></row><row><entry>AGAATAATGCCAAAGAAATCGGAAATGGATGTTTTGAGTTCTACCACAAGTGTGACAATGAATGCATGGAAAGTGTAAGA</entry></row><row><entry>AATGGGACTTATGATTATCCCAAATATTCAGAAGAGTCAAAGTTGAACAGGGAAAAGGTAGATGGAGTGAAATTGGAATC</entry></row><row><entry>AATGGGGATCTATCAGATTCTGGCGATCTACTCAACTGTCGCCAGTTCACTGGTGCTTTTGGTCTCCCTGGGGGCAATCA</entry></row><row><entry>GTTTCTGGATGTGTTCTAATGGATCTTTGCAGTGCAGAATATGCATCTGAGATTAGAATTTCAGAGATATGAGGAAAAAC</entry></row><row><entry>ACCCTTGTTTCTACT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;8&#x2003;(NA,&#x2003;PR8-X)</entry></row><row><entry>AGCAAAAGCAGGGGTTTAAAATGAATCCAAATCAGAAAATAATAACCATTGGATCAATCTGTCTGGTAGTCGGACTAATT</entry></row><row><entry>AGCCTAATATTGCAAATAGGGAATATAATCTCAATATGGATTAGCCATTCAATTCAAACTGGAAGTCAAAACCATACTGG</entry></row><row><entry>AATATGCAACCAAAACATCATTACCTATAAAAATAGCACCTGGGTAAAGGACACAACTTCAGTGATATTAACCGGCAATT</entry></row><row><entry>CATCTCTTTGTCCCATCCGTGGGTGGGCTATATACAGCAAAGACAATAGCATAAGAATTGGTTCCAAAGGAGACGTTTTT</entry></row><row><entry>GTCATAAGAGAGCCCTTTATTTCATGTTCTCACTTGGAATGCAGGACCTTTTTTCTGACCCAAGGTGCCTTACTGAATGA</entry></row><row><entry>CAAGCATTCAAGTGGGACTGTTAAGGACAGAAGCCCTTATAGGGCCTTAATGAGCTGCCCTGTCGGTGAAGCTCCGTCCC</entry></row><row><entry>CGTACAATTCAAGATTTGAATCGGTTGCTTGGTCAGCAAGTGCATGTCATGATGGCATGGGCTGGCTAACAATCGGAATT</entry></row><row><entry>TCAGGTCCAGATAATGGAGCAGTGGCTGTATTAAAATACAACGGCATAATAACTGAAACCATAAAAAGTTGGAGGAAGAA</entry></row><row><entry>AATATTGAGGACACAAGAGTCTGAATGTGCCTGTGTAAATGGTTCATGTTTTACTATAATGACTGATGGCCCGAGTGATG</entry></row><row><entry>GGCTGGCCTCGTACAAAATTTTCAAGATCGAAAAGGGGAAGGTTACTAAATCAATAGAGTTGAATGCACCTAATTCTCAC</entry></row><row><entry>TATGAGGAATGTTCCTGTTACCCTGATACCGACAAAGTGATGTGTGTGTGCAGAGACAATTGGCATGGTTCGAACCGGCC</entry></row><row><entry>ATGGGTGTCTTTCGATCAAAACCTGGATTATCAAATAGGATACATCTGCAGTGGGGTTTTCGGTGACAACCCGCGTCCCG</entry></row><row><entry>AAGATGGAACAGGCAGCTGTGGTCCAGTGTATGTTGATGGAGCAAACGGAGTAAAGGGATTTTCATATAGGTATGGTAAT</entry></row><row><entry>GGTGTTTGGATAGGAAGGACCAAAAGTCACAGTTCCAGACATGGGTTTGAGATGATTTGGGATCCTAATGGATGGACAGA</entry></row><row><entry>GACTGATAGTAAGTTCTCTGTGAGGCAAGATGTTGTGGCAATGACTGATTGGTCAGGGTATAGCGGAAGTTTCGTTCAAC</entry></row><row><entry>ATCCTGAGCTGACAGGGCTAGACTGTATGAGGCCGTGCTTCTGGGTTGAATTAATCAGGGGACGACCTAAAGAAAAAACA</entry></row><row><entry>ATCTGGACTAGTGCGAGCAGCATTTCTTTTTGTGGCGTGAATAGTGATACTGTAGATTGGTCTTGGCCAGACGGTGCTGA</entry></row><row><entry>GTTGCCATTCAGCATTGACAAGTAGTCTGTTCAAAAAACTCCTTGTTTCTACT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;9&#x2003;(PA,&#x2003;105p30)</entry></row><row><entry>AGCGAAAGCAGGTACTGATTCGAAATGGAAGATTTTGTGCGACAATGCTTCAATCCGATGATTGTCGAGCTTGCGGAAAA</entry></row><row><entry>GGCAATGAAAGAGTATGGAGAGGACCTGAAAATCGAAACAAACAAATTTGCAGCAATATGCACCCACTTGGAAGTATGCT</entry></row><row><entry>TCATGTATTCAGATTTTCATTTCATCAATGAGCAAGGCGAATCAATAATAGTAGAGCCTGAGGACCCAAATGCACTTTTA</entry></row><row><entry>AAACACAGATTTGAGATAATAGAGGGGCGAGATCGTACAATGGCATGGACAGTTGTAAACAGTATTTGCAACACCACAGG</entry></row><row><entry>AGCTGAGAAACCAAAGTTTCTGCCAGATCTGTATGATTACAAAGAGAATAGGTTCATCGAAATTGGAGTGACAAGGAGAG</entry></row><row><entry>AAGTTCACATATACTATCTGGAAAAGGCCAACAAAATTAAATCTGAGAAGACACATATTCACATTTTCTCATTTACTGGC</entry></row><row><entry>GAAGAAATGGCCACAAAGGCCGATTACACTCTCGATGAAGAAAGCAGGGCTAGAATTAAAACCAGACTATTCACCATAAG</entry></row><row><entry>GCAAGAAATGGCAAGCAGAGGTCTTTGGGACTCCTTTCGTCAGTCCGAAAGAGGCGAAGAGACAATTGAAGAAAGGTTTG</entry></row><row><entry>AAATCACAGGGACAATGCGCAGGCTCGCTGATCAAAGCCTTCCGCCGAACTTCTCCTGCATTGAGAATTTTAGAGCCTAT</entry></row><row><entry>GTGGATGGATTTGAACCGAACGGCTACATTGAGGGCAAGCTTTCTCAAATGTCCAAAGAAGTAAATGCTAAAATTGAGCC</entry></row><row><entry>TTTTTTGAAAACAACACCTCGACCAATTAGACTTCCGAATGGGCCTCCTTGTTTTCAGCGGTCAAAATTCCTGCTGATGG</entry></row><row><entry>ATTCTTTAAAATTAAGCATTGAGGATCCAAATCATGAAGGGGAGGGAATACCACTATATGATGCAATCAAGTGTATGAGA</entry></row><row><entry>ACATTCTTTGGATGGAAAGAACCCACTGTTGTCAAGCCACACGAGAAGGGAATAAATCCGAATTATCTGCTGTCGTGGAA</entry></row><row><entry>GCAGGTGTTGGAAGAGCTGCAGGACATTGAGAGTGAGGAGAAGATTCCAAGAACAAAAAACATGAAAAAAACGAGTCAGT</entry></row><row><entry>TAAAGTGGGCACTTGGTGAGAACATGGCACCAGAGAAGGTGGATTTTGATGACTGTAAAGATATAAGCGATTTGAAGCAA</entry></row><row><entry>TATGATAGTGACGAACCTGAATTAAGGTCATTTTCAAGTTGGATCCAGAATGAGTTCAACAAGGCATGCGAGCTGACCGA</entry></row><row><entry>TTCAATCTGGATAGAGCTCGATGAGATTGGAGAAGATGTGGCCCCGATTGAACACATTGCAAGCATGAGAAGAAATTACT</entry></row><row><entry>TCACAGCTGAGGTGTCCCATTGCAGAGCCACTGAATATATAATGAAAGGGGTATACATTAATACTGCTTTGCTTAATGCA</entry></row><row><entry>TCCTGTGCAGCAATGGATGATTTCCAACTAATTCCTATGATAAGCAAATGTAGAACTAAAGAGGGAAGGAGAAAGACCAA</entry></row><row><entry>TTTGTACGGCTTCATCATAAAAGGAAGATCTCACTTAAGGAATGATACCGATGTGGTAAACTTTGTGAGCATGGAGTTTT</entry></row><row><entry>CCCTCACTGACCCAAGACTTGAGCCACACAAATGGGAGAAGTACTGTGTTCTTGAGATAGGAGATATGCTTCTAAGGAGT</entry></row><row><entry>GCAATAGGCCAAGTGTCAAGGCCCATGTTCTTGTATGTAAGAACAAATGGAACCTCAAAAATTAAAATGAAATGGGGAAT</entry></row><row><entry>GGAGATGAGGCGTTGCCTCCTCCAATCCCTCCAACAAATAGAGAGCATGATTGAAGCTGAGTCCTCTGTCAAGGAGAAAG</entry></row><row><entry>ACATGACAAAAGAGTTTTTTGAGAATAGATCAGAAACATGGCCCATTGGAGAGTCACCAAAAGGAGTGGAAGAAGGTTCC</entry></row><row><entry>ATTGGGAAAGTATGCAGGACACTATTGGCTAAATCAGTATTCAATAGTCTGTATGCATCTCCACAATTAGAAGGATTTTC</entry></row><row><entry>AGCTGAGTCAAGAAAGTTGCTCCTTATTGTTCAGGCTCTTAGGGACAATCTGGAACCTGGGACCTTTGATCTTGGGGGAC</entry></row><row><entry>TATATGAAGCAATTGAGGAGTGCCTGATTAATGATCCCTGGGTTTTGCTTAATGCTTCTTGGTTCAACTCCTTCCTAAAA</entry></row><row><entry>CATGCATTGAGATAGCTGAGGCAATGCTACTATTTGTTATCCATACTGTCCAAAAAAGTA</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;10&#x2003;(PB1,&#x2003;105p30)</entry></row><row><entry>AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACATTACTTTTCTTAAAAGTGCCAGCACAAAATGCTATAAG</entry></row><row><entry>CACAACTTTTCCTTATACTGGTGACCCTCCTTACAGCCATGGAACAGGAACAGGATACACCATGGATACAGTCAACAGGA</entry></row><row><entry>CACATCAGTACTCAGAAAGAGGAAGATGGACGAAAAATACCGAAACTGGAGCACCGCAACTCAACCCAATTGATGGGCCA</entry></row><row><entry>CTACCAGAAGACAATGAACCAAGTGGCTATGCCCAAACAGATTGTGTATTAGAGGCAATGGCTTTCCTTGAAGAATCCCA</entry></row><row><entry>TCCTGGTATTTTTGAAAACTCTTGTATTGAAACAATGGAGGTTGTTCAGCAAACAAGGGTGGACAAACTGACACAAGGCA</entry></row><row><entry>GACAAACCTATGACTGGACTCTAAATAGGAACCAGCCTGCTGCCACAGCATTGGCAAACACCATAGAAGTATTCAGATCA</entry></row><row><entry>AATGGCCTCATAGCAAATGAATCTGGAAGGCTAATAGACTTCCTTAAAGATGTAATGGAGTCGATGGACAGAGACGAAGT</entry></row><row><entry>AGAGGTCACAACTCATTTTCAAAGAAAGAGGAGAGTGAGAGACAATGTAACTAAAAAAATGGTGACCCAAAGAACAATAG</entry></row><row><entry>GAAAAAAGAAACATAAATTAGACAAAAGAAGTTACCTAATTAGGGCATTAACCCTGAACACAATGACCAAAGATGCTGAG</entry></row><row><entry>AGGGGGAAACTAAAACGCAGAGCAATTGCAACCCCAGGAATGCAAATAAGGGGGTTTGTATACTTTGTTGAGACACTGGC</entry></row><row><entry>AAGAAGCATATGTGAAAAGCTTGAACAATCAGGGTTGCCAGTTGGAGGAAATGAGAAGAAAGCAAAGTTAGCAAATGTTG</entry></row><row><entry>TAAGGAAGATGATGACCAACTCCCAGGACACTGAAATTTCTTTTACCATCACTGGAGATAACACAAAATGGAACGAAAAT</entry></row><row><entry>CAAAACCCTAGAATGTTCTTGGCCATGATCACATATATAACCAAAGATCAGCCTGAATGGTTCAGAAATATTCTAAGTAT</entry></row><row><entry>TGCTCCAATAATGTTTTCAAACAAAATGGCGAGACTAGGTAGGGGGTATATGTTTGAAAGCAAGAGTATGAAACTGAGAA</entry></row><row><entry>CCCAAATACCTGCAGAGATGCTAGCCAACATAGATTTGAAATATTTCAATGATTCAACTAAAAAGAAAATTGAAAAAATT</entry></row><row><entry>CGACCATTATTAATAGATGGAACTGCATCATTGAGTCCTGGAATGATGATGGGCATGTTCAATATGTTAAGCACCGTCTT</entry></row><row><entry>GGGCGTTTCCATTCTGAATCTTGGGCAAAAAAGATACACCAAGACTACTTACTGGTGGGATGGTCTTCAATCGTCTGATG</entry></row><row><entry>ATTTTGCTTTGATTGTGAATGCACCCAATTATGCAGGAATTCAAGCTGGAGTTGACAGGTTTTATCGAACCTGTAAGCTG</entry></row><row><entry>CTCGGAATTAATATGAGCAAAAAGAAGTCTTACATAAACAGAACAGGTACCTTTGAATTCACGAGCTTTTTCTATCGTTA</entry></row><row><entry>TGGGTTTGTTGCCAATTTCAGCATGGAGCTTCCTAGTTTTGGGGTGTCTGGGGTCAATGAATCTGCAGACATGAGTATTG</entry></row><row><entry>GAGTCACTGTCATCAAAAACAATATGATAAACAATGACCTTGGCCCAGCAACTGCTCAAATGGCCCTTCAGTTATTTATA</entry></row><row><entry>AAAGATTACAGGTACACTTATCGATGCCACAGAGGTGACACACAAATACAAACCCGGAGATCATTTGAAATAAAGAAACT</entry></row><row><entry>ATGGGACCAAACCCGCTCCAAAGCTGGGCTGTTGGTCTCTGATGGAGGCCCCAATTTATATAACATTAGGAATCTACATA</entry></row><row><entry>TTCCTGAAGTCTGCTTGAAATGGGAGTTGATGGATGAGGATTACCAGGGGCGTTTATGCAACCCATTGAACCCGTTTGTC</entry></row><row><entry>AGCCATAAAGAGATTGAATCAGTGAACAATGCAGTGATAATGCCGGCACATGGTCCAGCCAAAAATATGGAGTATGACGC</entry></row><row><entry>TGTTGCAACAACACACTCTTGGGTCCCCAAAAGAAATCGATCCATTTTAAACACGAGCCAAAGAGGGATACTTGAAGATG</entry></row><row><entry>AGCAAATGTACCAAAGGTGCTGCAATTTATTTGAAAAATTCTTCCCAAGTAGCTCATACAGAAGACCAGTTGGAATATCC</entry></row><row><entry>AGTATGGTAGAGGCTATGGTTTCAAGAGCCCGAATTGATGCACGGATTGATTTCGAATCTGGAAGGATAAAGAAAGAGGA</entry></row><row><entry>ATTCGCTGAGATCATGAAGACCTGTTCCACCATTGAAGACCTCAGACGGCAAAAATAGGGAATTTGGCTTGTCCTTCATG</entry></row><row><entry>AAAAAATGCCTTGTTTCTACT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;11&#x2003;(PB2,&#x2003;105p30)</entry></row><row><entry>AGCGAAAGCAGGTCAATTATATTCAATATGGAAAGAATAAAAGAGCTAAGGAATCTGATGTCACAATCTCGCACTCGCGA</entry></row><row><entry>GATACTTACCAAAACTACTGTAGACCACATGGCCATAATAAAGAAATACACATCAGGAAGACAGGAGAAAAACCCATCAC</entry></row><row><entry>TTAGGATGAAATGGATGATGGCAATGAAATACCCAATTACAGCTGATAAAAGGATAACGGAAATGATTCCTGAAAGAAAT</entry></row><row><entry>GAGCAAGGACAGACACTATGGAGTAAAGTGAATGATGCCGGATCAGACCGAGTGATGATATCACCCCTAGCTGTGACATG</entry></row><row><entry>GTGGAACAGAAATGGACCAGTGGCAAACACTATCCACTATCCAAAAATCTACAAAACTTACTTTGAAAAGGTTGAAAGGT</entry></row><row><entry>TAAAACATGGAACCTTTGGCCCTGTACACTTTAGAAACCAAGTCAAAATACGCCGAAGAGTCGACATAAATCCTGGTCAT</entry></row><row><entry>GCAGACCTCAGCGCCAAGGAGGCACAGGATGTAATTATGGAAGTTGTTTTCCCTAATGAAGTGGGAGCCAGAATACTAAC</entry></row><row><entry>ATCAGAATCGCAATTAACGATAACTAAGGAGAAAAAAGAGGAACTCCAGAATTGCAAAATTTCCCCTTTGATGGTTGCAT</entry></row><row><entry>ACATGTTAGAGAGGGAACTTGTCCGCAAAACAAGATTTCTCCCGGTTGCAGGTGGAACAAGCAGTGTGTACATTGAAGTT</entry></row><row><entry>TTGCATTTAACACAGGGGACATGCTGGGAGCAGATGTACACTCCAGGTGGGGAGGTGAGGAATGATGATGTTGATCAAAG</entry></row><row><entry>CCTAATTATTGCTGCTAGGAACATAGTGAGAAGAGCTGCAGTATCAGCAGATCCACTAGCATCTTTATTAGAAATGTGCC</entry></row><row><entry>ATAGCACACAGATTGGTGGAACAAGGATGGTGGATATTCTCAGGCAAAATCCAACAGAAGAACAAGCTGTGGACATATGC</entry></row><row><entry>AAAGCAGCAATGGGGCTGAGAATCAGTTCATCCTTCAGTTTTGGCGGATTCACATTTAAGAGAACAAGTGGATCGTCAGT</entry></row><row><entry>CAAAAGGGAGGAAGAAGTGCTAACGGGCAATCTGCAAACATTGAAGCTAACTGTGCATGAGGGATATGAAGAATTCACAA</entry></row><row><entry>TAGTTGGGAAAAAGGCAACAGCTATACTCAGAAAAGCAACCAGGAGATTGATTCAACTAATAGTGAGTGGAAGAGACGAA</entry></row><row><entry>CAGTCAATAGTCGAAGCAATAGTTGTAGCAATGGTATTCTCACAAGAAGATTGCATGGTAAAAGCGGTTAGAGGTGATCT</entry></row><row><entry>GAATTTCGTTAATAGAGCGAATCAGCGGTTGAATCCCATGCATCAACTTTTGAGACATTTTCAGAAGGATGCTAAAGTAC</entry></row><row><entry>TTTTCCTAAATTGGGGAATTGAACATATTGACAATGTGATGGGAATGATTGGGATATTACCTGATATGACTCCAAGTACC</entry></row><row><entry>GAGATGTCAATGAGAGGAGTGAGAGTCAGCAAAATGGGTGTAGATGAATACTCCAATGCTGAAAGGGTAGTGGTAAGCAT</entry></row><row><entry>TGACCGTTTTTTGAGGGTCCGGGACCAAAGAGGAAATGTATTACTGTCTCCAGAGGAAGTCAGTGAAACACAAGGAACAG</entry></row><row><entry>AGAAACTGACAATAACTTACTCTTCATCATTGATGTGGGAGATTAATGGCCCTGAGTCAGTGTTGATCAATACCTACCAA</entry></row><row><entry>TGGATCATCAGAAACTGGGAGACTGTTAAAATTCAGTGGTCTCAGAACCCTACAATGCTATACAATAAAATGGAATTTGA</entry></row><row><entry>GCCATTTCAATCTCTAGTCCCCAAGGCCATTAGAGGCCAATACAGTGGGTTTGTTAGAACTCTATTTCAACAAATGAGGG</entry></row><row><entry>ATGTGCTCGGGACCTTTGACACAACTCAGATAATAAAACTTCTTCCCTTTGCAGCCGCTCCACCAAAGCAAAGTAGAATG</entry></row><row><entry>CAATTCTCGTCATTAACTGTGAATGTGAGGGGATCAGGAATGAGAATACTTGTAAGGGGTAATTCTCCAGTATTCAACTA</entry></row><row><entry>CAACAAGACCACTAAGAGACTCACAATCCTCGGAAAGGATGCTGGCACTTTAACTGAAGACCCAGATGAAGGCACAGCTG</entry></row><row><entry>GAGTGGAATCTGCTGTTTTAAGGGGATTCCTCATTCTAGGCAAAGAAGATAGAAGATATGGGCCAGCATTAAGCATCAGT</entry></row><row><entry>GAATTGAGCAACCTTGCGAAAGGGGAGAAAGCTAATGTGCTAATTGGGCAAGGGGATGTAGTGTTGGTAATGAAACGAAA</entry></row><row><entry>ACGGGACTCTAGCATACTTACTGACAGCCAGACAGCGACCAAAAGAATTCGGATGGCCATCAATTAATTTCGAATAATTT</entry></row><row><entry>AAAAACGACCTTGTTTCTACT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;12&#x2003;(NP,&#x2003;105p30)</entry></row><row><entry>AGCAAAAGCAGGGTAGATAATCACTCACTGAGTGACATCAAAGTCATGGCGTCCCAAGGCACCAAACGGTCTTACGAACA</entry></row><row><entry>GATGGAGACTGATGGGGAACGCCAGAATGCAACTGAAATCAGAGCATCCGTCGGAAGAATGATTGGGGGAATTGGGCGAT</entry></row><row><entry>TCTACATCCAAATGTGCACCGAGCTTAAGCTCAATGATTATGAGGGACGACTGATCCAGAACAGCTTAACAATAGAGAGA</entry></row><row><entry>ATGGTGCTTTCTGCTTTTGATGAGAGGAGAAATAAATATCTGGAAGAACATCCCAGCGCAGGGAAAGATCCTAAGAAAAC</entry></row><row><entry>TGGAGGACCCATATACAAGAGAGTAGATGGAAAGTGGGTGAGGGAACTCGTCCTTTATGACAAAGAAGAAATAAGGCGGA</entry></row><row><entry>TTTGGCGCCAAGCCAACAATGGTGATGATGCAACAGCTGGTTTGACTCACATTATGATCTGGCATTCTAATTTGAATGAT</entry></row><row><entry>ACAACTTACCAGAGGACAAGAGCTCTTGTCCGCACCGGAATGGATCCCAGGATGTGCTCTTTGATGCAAGGTTCAACTCT</entry></row><row><entry>CCCTAGAAGATCTGGAGCAGCAGGCGCTGCAGTCAAAGGAGTTGGGACAATGGTATTGGAGTTAATCAGGATGATCAAAC</entry></row><row><entry>GTGGGATCAACGACCGAAACTTCTGGAGGGGTGAGAATGGGAGAAAAACAAGGATTGCTTATGAGAGAATGTGCAACATT</entry></row><row><entry>CTCAAAGGAAAATTTCAAACAGCTGCACAAAAAGCAATGATGGATCAAGTGAGAGAAAGCCGGAACCCAGGAAATGCTGA</entry></row><row><entry>GATCGAAGATCTCACTTTTCTGGCACGGTCTGCACTCATATTGAGAGGATCAGTTGCTCACAAGTCTTGCCTGCCTGCTT</entry></row><row><entry>GTGTGTATGGACCAGCCGTAGCCAGTGGGTATGACTTCGAAAAAGAGGGATACTCTTTGGTGGGAGTAGACCCTTTCAAA</entry></row><row><entry>CTGCTTCAAACCAGTCAGGTATACAGCCTAATTAGACCAAACGAGAATCCCGCACACAAGAGCCAGTTGGTGTGGATGGC</entry></row><row><entry>ATGCAATTCTGCTGCATTTGAAGATCTAAGAGTGTCAAGCTTCATCAGAGGGACAAGAGTACTTCCAAGGGGGAAGCTCT</entry></row><row><entry>CCACTAGAGGAGTACAAATTGCTTCAAATGAAAACATGGATGCTATTGTCTCAAGTACTCTTGAACTGAGAAGCAGATAC</entry></row><row><entry>TGGGCCATAAGAACCAGAAGTGGAGGGAACACCAATCAACAAAGGGCCTCTGCGGGCCAAATCAGCACACAACCTACGTT</entry></row><row><entry>TTCTGTGCAGAGAAACCTCCCATTTGACAAAACAACCATCATGGCAGCATTCACTGGGAATACAGAGGGAAGAACATCAG</entry></row><row><entry>ACATGCGGGCAGAAATCATAAAGATGATGGAAAGTGCAAGACCAGAAGAAGTGTCCTTCCAGGGACGGGGAGTCTTTGAG</entry></row><row><entry>CTCTCGGACGAAAGGGCAACGAACCCGATCGTGCCCTCCTTTGACATGAGTAATGAAGGATCTTATTTCTTCGGAGACAA</entry></row><row><entry>TGCAGAGGAGTACGACAATTAATGAAAAATACCCTTGTTTCTACT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;13&#x2003;(M,&#x2003;105p30)</entry></row><row><entry>AGCAAAAGCAGGTAGATATTGAAAGATGAGTCTTCTAACCGAGGTCGAAACGTACGTTCTCTCTATCGTCCCATCAGGCC</entry></row><row><entry>CCCTCAAAGCCGAGATCGCACAGAGACTTGAAGATGTATTTGCTGGAAAGAATACCGATCTTGAGGCTCTCATGGAATGG</entry></row><row><entry>CTAAAGACAAGACCAATCCTGTCACCTCTGACTAAGGGGATTTTAGGATTTGTGTTCACGCTCACCGTGCCCAGTGAGCG</entry></row><row><entry>AGGACTGCAGCGTAGACGCTTTGTCCAAAATGCCCTTAATGGGAATGGGGATCCAAATAATATGGACAAGGCTGTCAAAC</entry></row><row><entry>TGTATCGAAAGCTTAAGAGGGAGATAACATTCCATGGGGCCAAAGAAATAGCACTCAGTTATTCTGCTGGAGCACTTGCC</entry></row><row><entry>AGTTGTATGGGACTCATATACAACAGGATGGGGGCTGTGACCACCGAATCAGCATTTGGCCTTATATGTGCAACCTGTGA</entry></row><row><entry>ACAGATTGCCGACTCCCAGCATAAGTCTCATAGGCAAATGGTAACAACAACCAATCCATTAATAAGACATGAGAACAGAA</entry></row><row><entry>TGGTTCTGGCCAGCACTACAGCTAAGGCTATGGAGCAAATGGCTGGATCGAGTGAACAAGCAGCTGAGGCCATGGAGGTT</entry></row><row><entry>GCTAGTCAGGCCAGGCAGATGGTGCAGGCAATGAGAGCCATTGGGACTCATCCTAGCTCTAGCACTGGTCTGAAAAATGA</entry></row><row><entry>TCTCCTTGAAAATTTGCAGGCCTATCAGAAACGAATGGGGGTGCAGATGCAACGATTCAAGTGATCCTCTTGTTGTTGCC</entry></row><row><entry>GCAAGTATAATTGGGATTGTGCACCTGATATTGTGGATTATTGATCGCCTTTTTTCCAAAAGCATTTATCGTATTTTTAA</entry></row><row><entry>ACACGGTTTAAAAAGAGGGCCTTCTACGGAAGGAGTACCGGAGTCTATGAGGGAAGAATATCGAGAGGAACAGCAGAATG</entry></row><row><entry>CTGTGGATGCTGACGATGGTCATTTTGTCAGCATAGAGCTAGAGTAAAAAACTACCTTGTTTCTACT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;14&#x2003;(NS,&#x2003;105p30)</entry></row><row><entry>AGCAAAAGCAGGGTGGCAAAGACATAATGGATTCCCACACTGTGTCAAGCTTTCAGGTAGATTGTTTCCTTTGGCATGTC</entry></row><row><entry>CGCAAACAAGTTGCAGACCAAGATCTAGGCGATGCCCCCTTCCTTGATCGGCTTCGCCGAGATCAGAAGTCTCTAAAGGG</entry></row><row><entry>ACGAGGCAACACTCTCGGTCTGAACATCGAAACAGCCACTTGTGTTGGAAAGCAAATAGTAGAGAGGATTCTGAAAGAAG</entry></row><row><entry>AATCCGATGAGACATTTAGAATGACCATGGCCTCCGCACTTGCTTCGCGGTACCTAACTGACATGACTGTTGAAGAAATG</entry></row><row><entry>TCAAGGGACTGGTTCATGCTCATGCCCAAGCAGAAAGTGGCTGGCCCTCTTTGTGTCAGAATGGACCAGGCGATAATGGA</entry></row><row><entry>TAAGAACATCATACTGAAAGCGAACTTCAGTGTGATTTTTGACCGGTTGGAGAATCTGACATTACTAAGGGCTTTCACCG</entry></row><row><entry>AAGAGGGAGCAATTGTTGGCGAAATTTCACCATTGCCTTCTTTTCCAGGACATACTAATGAGGATGTCAAAAATGCAATT</entry></row><row><entry>GGGGTCCTCATCGGGGGACTTGAATGGAATGATAACACAGTTCGAGTCTCTGAAGCTCTACAGAGATTCGCTTGGAGAAG</entry></row><row><entry>CAGTAATGAGACTGGGGGACCTCCATTCACTACAACACAGAAACGGAAAATGGCGGGAACAATTAGGTCAGAAGTTTGAA</entry></row><row><entry>GAAATAAGATGGCTGATTGAAGAAGTGAGGCATAAATTGAAGACGACAGAGAGTAGTTTTGAACAAATAACATTTATGCA</entry></row><row><entry>AGCATTACAGCTATTGTTTGAAGTGGAACAAGAGATTAGAACGTTCTCGTTTCAGCTTATTTAATGATAAAAACACCCTT</entry></row><row><entry>GTTTCTACT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;15&#x2003;(HA,&#x2003;105p30)</entry></row><row><entry>AGCGAAAGCAGGGGAAAATAAAAGCAACCAAAATGAAAGTAAAACTACTGGTTCTGTTATGTACATTTACAGCTACATAT</entry></row><row><entry>GCAGACACAATATGTATAGGCTACCATGCCAACAACTCAACCGACACTGTTGACACAGTACTTGAGAAGAATGTAACAGT</entry></row><row><entry>GACACACTCTGTCAACCTACTTGAGGACAGTCACAATGGAAAACTATGTCTACTAAAAGGAATAGCCCCACTACAATTGG</entry></row><row><entry>GTAATTGCAGCGTTGCCGGATGGATCTTAGGAAACCCAGAATGCGAATTACTGATTTCCAAGGAATCATGGTCCTACATT</entry></row><row><entry>GTAGAAACACCAAATCCTGAGAATGGAACATGTTACCCAGGGTATTTCGCCGACTATGAGGAACTGAGGGAGCAATTGAG</entry></row><row><entry>TTCAGTATCTTCATTTGAAAGGTTCGAAATATTCCCCAAAGAGAGCTCATGGCCCAACCACACCGTAACCGGAGTATCAG</entry></row><row><entry>CATCATGCTCCCATAACGGGAAAAGCAGTTTTTACAGAAATTTGCTATGGCTGACGGGGAAGAATGGTTTGTACCCAAAC</entry></row><row><entry>CTGAGCAAGTCCTATGCAAACAACAAAGAGAAAGAAGTCCTTGTACTATGGGGTGTTCATCACCCGCCTAACATAGGGGA</entry></row><row><entry>CCAAAGGGCCCTCTATCATACAGAAAATGCTTATGTCTCTGTAGTGTCTTCACATTATAGCAGAAGATTCACCCCAGAAA</entry></row><row><entry>TAGCCAAAAGACCCAAGGTGAGAGACCAGGAAGGAAGAATCAACTACTACTGGACTCTGCTGGAACCCGGGGATACAATA</entry></row><row><entry>ATATTTGAGGCAAATGGAAATCTAATAGCGCCAAGGTATGCTTTCGCACTGAGTAGAGGCTTGGGATCAGGAATCATCAC</entry></row><row><entry>CTCAAATGCACCAATGGATGAATGTGATGCAAAGTGTCAAACACCTCAGGGAGCTATAAACAGCAGTCTTCCTTTCCAGA</entry></row><row><entry>ATGTACACCCAGTCACAATAGGAGAGTGTCCAAAGTATGTCAGGAGTGCAAAATTAAGGATGGTTACAGGACTAAGGAAC</entry></row><row><entry>ATCCCATCCATTCAATCCAGAGGTTTGTTTGGAGCAATTGCCGGTTTCATTGAAGGGGGGTGGACTGGAATGGTAGATGG</entry></row><row><entry>TTGGTATGGTTATCATCATCAGAATGAGCAAGGATCTGGGTATGCTGCAGATCAAAAAAGCACACAAAATGCCATTAACG</entry></row><row><entry>GGATTACAAACAAGGTGAATTCTGTAATTGAGAAAATGAACACTCAATTCACAGCTGTGGGCAAAGAATTCAACAAATTG</entry></row><row><entry>GAAAGAAGGATGGAAAACTTAAATAAAAAAGTTGATGATGGGTTTCTAGACATTTGGACCTATAATGCAGAATTGTTGGT</entry></row><row><entry>TCTACTGGAAAATGAAAGGACTTTGGATTTCCATGACTCCAACGTGAAGAATCTGTATGAGAAAGTAAAAAGCCAATTAA</entry></row><row><entry>AGAATAATGCCAAAGAAATAGGAAACGGGTGTTTTGAATTCTATCACAAGTGTAACGATGAATGCATGGAGAGTGTGAAA</entry></row><row><entry>AATGGAACTTATGACTATCCAAAATATTCCGAAGAATCAAAGTTAAACAGAGAGAAAATTGATGGAGTGAAATTGGAATC</entry></row><row><entry>AATGGGAGTCTATCAGATTCTGGCGATCTACTCAACAGTCGCCAGTTCCCTGGTTCTTTTGGTCTCCCTGGGGGCAATCA</entry></row><row><entry>GCTTCTGGATGTGTTCCAATGGGTCTTTGCAGTGTAGAATATGCATCTAAGACCAGAATTTCAGAAATATAAGGAAAAAC</entry></row><row><entry>ACCCTTGTTTCTACT</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;16&#x2003;(NA,&#x2003;105p30)</entry></row><row><entry>AGCAAAAGCAGGAGTTTAAAATGAATCCAAATCAAAAAATAATAACCATTGGATCAATCAGTATAGCAATCGGAATAATT</entry></row><row><entry>AGTCTAATGTTGCAAATAGGAAATATTATTTCAATATGGGCTAGTCACTCAATCCAAACTGGAAGTCAAAACCACACTGG</entry></row><row><entry>AATATGCAACCAAAAAATCATCACATATGAAAACAGCACCTGGGTGAATCACACATATGTTAATATTAACAACACTAATG</entry></row><row><entry>TTGTTGCTGGAAAGGACAAAACTTCAGTGACACTGGCCGGCAATTCATCTCTTTGTCCTATCAGTGGATGGGCTATATAC</entry></row><row><entry>ACAAAAGACAACAGCATAAGAATTGGCTCCAAAGGAGATGTTTTTGTCATAAGAGAACCTTTCATATCATGTTCTCACTT</entry></row><row><entry>GGAATGCAGAACCTTTTTTCTGACCCAAGGTGCTCTATTAAATGACAAACATTCAAATGGAACCGTTAAGGACAGAAGTC</entry></row><row><entry>CTTATAGGGCCTTAATGAGCTGTCCTCTAGGTGAAGCCCCGTCACCATACAATTCAAAGTTTGAATCAGTTGCATGGTCA</entry></row><row><entry>GCAAGCGCATGCCATGATGGCAAGGGCTGGTTAACAATCGGAATTTCTGGTCCAGACAATGGAGCTGTGGCTGTACTAAA</entry></row><row><entry>ATACAACGGAATAATAACTGAAACCATAAAAAGTTGGGAAAAGCGAATATTGAGAACACAAGAGTCTGAATGTGTTTGTG</entry></row><row><entry>TGAACGGGTCATGTTTCACCATAATGACCGATGGCCCGAGTAATGGGGCCGCCTCGTACAAAATCTTCAAGATCGAAAAG</entry></row><row><entry>GGGAAGGTTACTAAATCAACAGAGTTGAATGCACCCAATTTTCATTATGAGGAATGTTCCTGTTACCCAGACACTGGCAC</entry></row><row><entry>AGTGATGTGTGTATGCAGGGACAACTGGCATGGTTCAAATCGACCTTGGGTATCTTTTAATCAAAACTTGGATTATCAAA</entry></row><row><entry>TAGGATACATCTGCAGTGGAGTGTTCGGTGACAATCCGCGTCCCAAAGATGGGAAGGGCAGCTGTAATCCAGTGACTGTT</entry></row><row><entry>GATGGAGCAGACGGAGTTAAGGGGTTTTCATACAAATATGGTAATGGTGTTTGGATAGGAAGGACTAAAAGTAACAGACT</entry></row><row><entry>TAGAAAGGGGTTTGAGATGATTTGGGATCCTAATGGATGGACAGATACCGACAGTGATTTCTCAGTGAAACAGGATGTTG</entry></row><row><entry>TGGCAATAACTGATTGGTCAGGGTACAGCGGAAGTTTCGTCCAACATCCTGAGTTAACAGGATTGGACTGTATAAGACCT</entry></row><row><entry>TGCTTCTGGGTTGAGTTAGTCAGAGGACTGCCTAGAGAAAATACAACAATCTGGACTAGTGGGAGCAGCATTTCTTTTTG</entry></row><row><entry>TGGCGTTGATAGTGATACTGCAAATTGGTCTTGGCCAGACGGTGCTGAGTTGCCGTTCACCATTGACAAGTAGCTCGTTG</entry></row><row><entry>AAAAAAACTCCTTGTTTCTACT</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0032" level="1">REFERENCES</heading><p id="p-0229" num="0000"><ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0206">[1] Cobbin et al. (2013) <i>J. Virol. </i>87(10):5577-5585.</li>    <li id="ul0001-0002" num="0207">[2] Luytjes et al. (1989) <i>Cell </i>59(6):1107-1113.</li>    <li id="ul0001-0003" num="0208">[3] Enami et al. (1990) <i>PNAS </i>87(10):3802-3805.</li>    <li id="ul0001-0004" num="0209">[4] Fodor et al. (1999) <i>J. Virol. </i>73(11):9679-9682.</li>    <li id="ul0001-0005" num="0210">[5] Hoffmann et al. (2000) <i>PNAS </i>97(11):6108-6113.</li>    <li id="ul0001-0006" num="0211">[6] WO2009/000891</li>    <li id="ul0001-0007" num="0212">[7] WO2011/012999</li>    <li id="ul0001-0008" num="0213">[8] Verity et al. (2012) <i>Influenza Other Respir. Viruses </i>6(2): 101-109</li>    <li id="ul0001-0009" num="0214">[9] WO2010/133964</li>    <li id="ul0001-0010" num="0215">[10] Sambrook et al, Molecular Cloning: A Laboratory Manual, 2 ed., 1989, Cold Spring Harbor Press, Cold Spring Harbor, N. Y</li>    <li id="ul0001-0011" num="0216">[11] WO2011/145081</li>    <li id="ul0001-0012" num="0217">[12] Kistner et al. (1998) Vaccine 16:960-8.</li>    <li id="ul0001-0013" num="0218">[13] Kistner et al. (1999) Dev Biol Stand 98:101-110.</li>    <li id="ul0001-0014" num="0219">[14] Bruhl et al. (2000) Vaccine 19:1149-58.</li>    <li id="ul0001-0015" num="0220">[15] WO97/37000.</li>    <li id="ul0001-0016" num="0221">[16] Brands et al. (1999) Dev Biol Stand 98:93-100.</li>    <li id="ul0001-0017" num="0222">[17] Halperin et al. (2002) Vaccine 20:1240-7.</li>    <li id="ul0001-0018" num="0223">[18] Tree et al. (2001) Vaccine 19:3444-50.</li>    <li id="ul0001-0019" num="0224">[19] Pau et al. (2001) Vaccine 19:2716-21.</li>    <li id="ul0001-0020" num="0225">[20] http://www.atcc.org/</li>    <li id="ul0001-0021" num="0226">[21] http://locus.umdnj.edu/</li>    <li id="ul0001-0022" num="0227">[22] WO03/076601.</li>    <li id="ul0001-0023" num="0228">[23] WO2005/042728.</li>    <li id="ul0001-0024" num="0229">[24] WO03/043415.</li>    <li id="ul0001-0025" num="0230">[25] WO01/85938.</li>    <li id="ul0001-0026" num="0231">[26] WO2006/108846.</li>    <li id="ul0001-0027" num="0232">[27] EP-A-1260581 (WO01/64846).</li>    <li id="ul0001-0028" num="0233">[28] WO2006/071563.</li>    <li id="ul0001-0029" num="0234">[29] WO2005/113758.</li>    <li id="ul0001-0030" num="0235">[30] WO03/023021.</li>    <li id="ul0001-0031" num="0236">[31] WO03/023025.</li>    <li id="ul0001-0032" num="0237">[32] WO2006/027698.</li>    <li id="ul0001-0033" num="0238">[33] WO97/37001.</li>    <li id="ul0001-0034" num="0239">[34] EP-B-0870508.</li>    <li id="ul0001-0035" num="0240">[35] U.S. Pat. No. 5,948,410.</li>    <li id="ul0001-0036" num="0241">[36] WO2007/052163.</li>    <li id="ul0001-0037" num="0242">[37] WO02/28422.</li>    <li id="ul0001-0038" num="0243">[38] WO02/067983.</li>    <li id="ul0001-0039" num="0244">[39] WO02/074336.</li>    <li id="ul0001-0040" num="0245">[40] WO01/21151.</li>    <li id="ul0001-0041" num="0246">[41] WO02/097072.</li>    <li id="ul0001-0042" num="0247">[42] WO2005/113756.</li>    <li id="ul0001-0043" num="0248">[43] Huckriede et al. (2003) Methods Enzymol 373:74-91.</li>    <li id="ul0001-0044" num="0249">[44] Vaccines. (eds. Plotkins &#x26; Orenstein). 4th edition, 2004, ISBN: 0-7216-9688-0.</li>    <li id="ul0001-0045" num="0250">[45] Treanor et al. (1996) J Infect Dis 173:1467-70.</li>    <li id="ul0001-0046" num="0251">[46] Keitel et al. (1996) Clin Diagn Lab Immunol 3:507-10.</li>    <li id="ul0001-0047" num="0252">[47] Herlocher et al. (2004) J Infect Dis 190(9):1627-30.</li>    <li id="ul0001-0048" num="0253">[48] Le et al. (2005) Nature 437(7062):1108.</li>    <li id="ul0001-0049" num="0254">[49] WO2008/068631.</li>    <li id="ul0001-0050" num="0255">[50] Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th edition, ISBN: 0683306472.</li>    <li id="ul0001-0051" num="0256">[51] Banzhoff (2000) Immunology Letters 71:91-96.</li>    <li id="ul0001-0052" num="0257">[52] Nony et al. (2001) Vaccine 27:3645-51.</li>    <li id="ul0001-0053" num="0258">[53] WO90/14837</li>    <li id="ul0001-0054" num="0259">[54] Podda &#x26; Del Giudice (2003) Expert Rev Vaccines 2:197-203</li>    <li id="ul0001-0055" num="0260">[55] Podda (2001) Vaccine 19: 2673-2680</li>    <li id="ul0001-0056" num="0261">[56] Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell &#x26; Newman) Plenum Press 1995 (ISBN 0-306-44867-X)</li>    <li id="ul0001-0057" num="0262">[57] Vaccine Adjuvants: Preparation Methods and Research Protocols (Volume 42 of Methods in Molecular Medicine series). ISBN: 1-59259-083-7. Ed. O'Hagan</li>    <li id="ul0001-0058" num="0263">[58] WO 2008/043774</li>    <li id="ul0001-0059" num="0264">[59] US 2007/014805</li>    <li id="ul0001-0060" num="0265">[60] US 2007/0191314</li>    <li id="ul0001-0061" num="0266">[61] Fox et al. (2013) Vaccine 31:1633-1640</li>    <li id="ul0001-0062" num="0267">[62] Allison &#x26; Byars (1992) Res Immunol 143:519-25</li>    <li id="ul0001-0063" num="0268">[63] Hariharan et al. (1995) Cancer Res 55:3486-9</li>    <li id="ul0001-0064" num="0269">[64] Suli et al. (2004) Vaccine 22(25-26):3464-9</li>    <li id="ul0001-0065" num="0270">[65] WO 95/11700</li>    <li id="ul0001-0066" num="0271">[66] U.S. Pat. No. 6,080,725</li>    <li id="ul0001-0067" num="0272">[67] WO 2005/097181</li>    <li id="ul0001-0068" num="0273">[68] WO 2006/113373</li>    <li id="ul0001-0069" num="0274">[69] Han et al. (2005) Impact of Vitamin E on Immune Function and Infectious Diseases in the Aged at Nutrition, Immune functions and Health EuroConference, Paris, 9-10 Jun. 2005</li>    <li id="ul0001-0070" num="0275">[70] U.S. Pat. No. 6,630,161</li>    <li id="ul0001-0071" num="0276">[71] Potter &#x26; Oxford (1979) Br Med Bull 35: 69-75.</li>    <li id="ul0001-0072" num="0277">[72] Greenbaum et al. (2004) Vaccine 22:2566-77.</li>    <li id="ul0001-0073" num="0278">[73] Zurbriggen et al. (2003) Expert Rev Vaccines 2:295-304.</li>    <li id="ul0001-0074" num="0279">[74] Piascik (2003) J Am Pharm Assoc (Wash D.C.). 43:728-30.</li>    <li id="ul0001-0075" num="0280">[75] Mann et al. (2004) Vaccine 22:2425-9.</li>    <li id="ul0001-0076" num="0281">[76] Halperin et al. (1979) Am J Public Health 69:1247-50.</li>    <li id="ul0001-0077" num="0282">[77] Herbert et al. (1979) J Infect Dis 140:234-8.</li>    <li id="ul0001-0078" num="0283">[78] Chen et al. (2003) Vaccine 21:2830-6.</li>    <li id="ul0001-0079" num="0284">[79] Dormitzer et al. (2013) Sci Trans Med 5(185): 185ra68</li>    <li id="ul0001-0080" num="0285">[80] Hoffmann et al. (2002) Vaccine 20(25-26):3165-70.</li></ul></p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230000971A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><us-math idrefs="MATH-US-00001" nb-file="US20230000971A1-20230105-M00001.NB"><img id="EMI-M00001" he="6.01mm" wi="76.20mm" file="US20230000971A1-20230105-M00001.TIF" alt="embedded image " img-content="math" img-format="tif"/></us-math><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A method for generating reassortant influenza viruses comprising the steps of:<claim-text>(i) contacting a culture host with a parent influenza virus strain comprising a first hemagglutinin (HA) gene and a first neuraminidase (NA) gene;</claim-text><claim-text>(ii) introducing into the culture host one or more expression construct(s) comprising one or more influenza genes, wherein said influenza genes comprise a second HA gene or a second NA gene;</claim-text><claim-text>(iii) culturing the culture host in order to produce reassortant viruses; and</claim-text><claim-text>(iv) selecting for reassortant viruses that comprise the second HA gene or the second NA gene.</claim-text></claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising step (v) isolating a reassortant influenza virus comprising the second HA gene or the second NA gene.</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The method of <claim-ref idref="CLM-00002">claim 2</claim-ref>, wherein the isolated reassortant influenza virus is a 7:1 reassortant influenza virus.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the one or more influenza genes comprise a second HA gene and a second NA gene, and step (iv) comprises selecting for reassortant viruses that comprise the second HA gene and/or the second NA gene.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The method of <claim-ref idref="CLM-00004">claim 4</claim-ref>, further comprising step (v) isolating a reassortant influenza virus comprising (i) the second HA gene; and/or (ii) the second NA gene.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The method of <claim-ref idref="CLM-00004">claim 4</claim-ref>, wherein the isolated reassortant influenza virus is a 6:2 reassortant influenza virus.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The method of <claim-ref idref="CLM-00004">claim 4</claim-ref>, wherein the one or more influenza genes comprise a second PB1, PB2, PA, M, NS or NP, and step (iv) comprises selecting for reassortant viruses that comprise the second PB1, PB2, PA, M, NS or NP gene.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The method of <claim-ref idref="CLM-00007">claim 7</claim-ref>, further comprising the step (v) of isolating a reassortant influenza virus comprising (i) the second HA gene; and/or (ii) the second NA gene; and (iii) the second PB1, PB2, PA, M, NS or NP gene.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The method of <claim-ref idref="CLM-00008">claim 8</claim-ref>, wherein the isolated reassortant influenza virus is a 5:3 reassortant influenza virus.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The method of any preceding claim, wherein the one or more expression construct(s) comprise no more than seven, six, five, four or three influenza genes.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The method of any of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00006">6</claim-ref>, wherein the one or more expression construct(s) comprise no more than two influenza genes.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The method of any preceding claim, wherein the one or more expression construct(s) is one or more plasmid(s), one or more linear DNA molecule(s), or one or more RNA molecule(s).</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The method of <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein the one or expression construct(s) comprises a synthetic nucleic acid molecule, for example a synthetic DNA molecule or a synthetic RNA molecule.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. The method of any preceding claim, wherein the one or more expression construct(s) are bi-directional expression construct(s), wherein at least one gene is located between an upstream pol II promoter and a downstream non-endogenous pol I promoter.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. The method of any preceding claim, wherein the one or more expression construct(s) are introduced into the culture host at the same time as the culture host is contacted with the parent influenza virus strain.</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. The method of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00014">14</claim-ref>, wherein the one or more expression construct(s) are introduced into the culture host before or after the culture host is contacted with the parent influenza virus strain.</claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. The method of any preceding claim, comprising a step of separating reassortant influenza viruses from the culture host prior to step (iv).</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The method of any preceding claim, wherein step (iv) comprises negative selection against the first HA.</claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. The method of <claim-ref idref="CLM-00018">claim 18</claim-ref>, wherein the negative selection comprises contacting the culture host or the reassortant influenza viruses that have been separated from the culture host with one or more antibodies which are specific for the first HA.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. The method of <claim-ref idref="CLM-00018">claim 18</claim-ref> or <claim-ref idref="CLM-00019">19</claim-ref>, wherein the negative selection comprises contacting the culture host with an inhibitory agent that reduces or prevents the transcription and/or translation of the first HA.</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. The method of any preceding claim, wherein step (iv) comprises negative selection against the first NA.</claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. The method of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the negative selection comprises contacting the culture host or the reassortant influenza viruses that have been separated from the culture host with one or more antibodies which are specific for the first NA.</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. The method of <claim-ref idref="CLM-00021">claim 21</claim-ref> or <claim-ref idref="CLM-00022">22</claim-ref>, wherein the negative selection comprises contacting the culture host with an inhibitory agent that reduces or prevents the transcription and/or translation of the first NA.</claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. The method of any preceding claim, wherein step (iv) comprises positive selection for the second HA or the second NA.</claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. The method of <claim-ref idref="CLM-00024">claim 24</claim-ref>, wherein the positive selection comprises contacting the culture host or the reassortant influenza viruses that have been separated from the culture host with one or more antibodies which are specific for the second HA or the second NA.</claim-text></claim><claim id="CLM-00026" num="00026"><claim-text><b>26</b>. The method of any of <claim-ref idref="CLM-00017">claims 17</claim-ref>-<claim-ref idref="CLM-00025">25</claim-ref>, wherein step (iv) comprises three or fewer selection steps.</claim-text></claim><claim id="CLM-00027" num="00027"><claim-text><b>27</b>. The method of any <claim-ref idref="CLM-00002">claims 2</claim-ref>-<claim-ref idref="CLM-00003">3</claim-ref>, <claim-ref idref="CLM-00005">5</claim-ref>-<claim-ref idref="CLM-00006">6</claim-ref> or <claim-ref idref="CLM-00008">8</claim-ref>-<claim-ref idref="CLM-00026">26</claim-ref>, wherein the isolation of the reassortant virus comprises a limited dilution step and/or a plaque isolation step.</claim-text></claim><claim id="CLM-00028" num="00028"><claim-text><b>28</b>. The method of any of <claim-ref idref="CLM-00002">claims 2</claim-ref>-<claim-ref idref="CLM-00003">3</claim-ref>, <claim-ref idref="CLM-00005">5</claim-ref>-<claim-ref idref="CLM-00006">6</claim-ref> or <claim-ref idref="CLM-00008">8</claim-ref>-<claim-ref idref="CLM-00027">27</claim-ref>, further comprising the step (vi) of purifying the virus obtained in step (v).</claim-text></claim><claim id="CLM-00029" num="00029"><claim-text><b>29</b>. The method of any preceding claim, wherein the second HA gene comprises one or more modifications relative to the wild-type influenza virus from which the second HA gene is derived.</claim-text></claim><claim id="CLM-00030" num="00030"><claim-text><b>30</b>. The method of <claim-ref idref="CLM-00029">claim 29</claim-ref>, wherein the modification of the second HA gene is the deletion of a polybasic cleavage site.</claim-text></claim><claim id="CLM-00031" num="00031"><claim-text><b>31</b>. The method of any preceding claim, wherein the reassortant influenza virus produced or isolated is less virulent than the wild-type influenza virus from which the second HA gene or second NA gene is derived.</claim-text></claim><claim id="CLM-00032" num="00032"><claim-text><b>32</b>. The method of any preceding claim, wherein the culture host is an embryonated avian egg.</claim-text></claim><claim id="CLM-00033" num="00033"><claim-text><b>33</b>. The method of any of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00031">31</claim-ref>, wherein the culture host is a mammalian cell or an avian cell.</claim-text></claim><claim id="CLM-00034" num="00034"><claim-text><b>34</b>. The method of <claim-ref idref="CLM-00033">claim 33</claim-ref>, wherein the culture host is an MDCK, Vero, PerC6, CEF or EB66 cell.</claim-text></claim><claim id="CLM-00035" num="00035"><claim-text><b>35</b>. The method of <claim-ref idref="CLM-00034">claim 34</claim-ref>, wherein the cell grows adherently.</claim-text></claim><claim id="CLM-00036" num="00036"><claim-text><b>36</b>. The method of <claim-ref idref="CLM-00034">claim 34</claim-ref>, wherein the cell grows in suspension.</claim-text></claim><claim id="CLM-00037" num="00037"><claim-text><b>37</b>. The method of <claim-ref idref="CLM-00036">claim 36</claim-ref>, wherein the MDCK cell is of the cell line MDCK 33016 (DSM ACC2219).</claim-text></claim><claim id="CLM-00038" num="00038"><claim-text><b>38</b>. The method of any preceding claim, wherein the reassortant influenza virus is an influenza A virus or an influenza B virus.</claim-text></claim><claim id="CLM-00039" num="00039"><claim-text><b>39</b>. A population of reassortant influenza viruses produced by the method of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>, <claim-ref idref="CLM-00004">4</claim-ref>, <claim-ref idref="CLM-00007">7</claim-ref>, <claim-ref idref="CLM-00010">10</claim-ref>-<claim-ref idref="CLM-00026">26</claim-ref> or <claim-ref idref="CLM-00029">29</claim-ref>-<claim-ref idref="CLM-00032">32</claim-ref>.</claim-text></claim><claim id="CLM-00040" num="00040"><claim-text><b>40</b>. An isolated reassortant influenza virus produced by the method of any one of <claim-ref idref="CLM-00002">claims 2</claim-ref>-<claim-ref idref="CLM-00003">3</claim-ref>, <claim-ref idref="CLM-00005">5</claim-ref>-<claim-ref idref="CLM-00006">6</claim-ref> or <claim-ref idref="CLM-00008">8</claim-ref>-<claim-ref idref="CLM-00038">38</claim-ref>.</claim-text></claim><claim id="CLM-00041" num="00041"><claim-text><b>41</b>. A method of preparing a vaccine, comprising the steps of (a) preparing a reassortant influenza virus by the method of any of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00038">38</claim-ref>, and (b) preparing a vaccine from the reassortant influenza virus.</claim-text></claim><claim id="CLM-00042" num="00042"><claim-text><b>42</b>. A vaccine produced by the method of <claim-ref idref="CLM-00041">claim 41</claim-ref>.</claim-text></claim></claims></us-patent-application>